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ABSTRACT

DESIGN AND SYNTHESIS OF PYRIMIDINE BASED FUSED HETEROCYCLICS IN THE
POTENTIAL TREATMENT OF CANCER AND OPPORTUNISTIC INFECTION

By
Farhana Islam
August 2020

Dissertation supervised by Dr. Aleem Gangjee
This dissertation designates an introduction, background and research progress in the areas
of agents designed as (a) inhibitors of microtubule polymerization and multiple receptor tyrosine
kinase (RTK) for potential treatment of cancer; (b) selective Pneumocystis jirovecii dihydrofolate
reductase (pjDHFR) inhibitors for pneumocystis pneumonia (PCP) infection and (c) substrates for
tumor-targeted therapy for cancer.
Dose-limiting toxicities of clinically used agents and development of resistance are two
significant limitations in cancer chemotherapy. Microtubule targeting agents (MTAs) are a
structurally diverse set of compounds that disrupt microtubule dynamics and exert their anticancer
effect. Combination chemotherapy with antiangiogenic agents and microtubule targeting agents
has shown an advantage against both these drawbacks. Single agents with dual antiangiogenic
activity and cytotoxicity would afford a therapy that circumvents pharmacokinetic problems of
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multiple agents, avoid drug-drug interactions, lower the drug dose, decrease overlapping toxicities,
and delay or prevent tumor cell resistance. The work in this dissertation reflects the progress of
fused pyrimidines, aimed to inhibit tubulin polymerization as well as act as antiangiogenic agents
which inhibit one or more of the receptor tyrosine kinases (RTKs)- vascular endothelial growth
factor receptor-2 (VEGFR2), platelet derived growth factor receptor-β (PDGFRβ) and epidermal
growth factor receptor (EGFR), using molecular modeling studies. This work also reviews the
synthesis of bicyclic and tricyclic thieno[2,3-d]pyrimidines and pyrazolo[4,3-d]pyrimidines and
discusses novel synthetic strategies for substituted thieno[2,3-d]pyrimidines and pyrazolo[4,3d]pyrimidines.
Pneumocystis pneumonia (PCP) is a form of pneumonia that is caused by the yeast-like
fungus Pneumocystis jirovecii. The current treatment involving the use of a combination of
trimethoprim and sulfamethoxazole is limited by drug resistance, treatment failures and adverse
side effects. Newer drugs are critically needed for patients, unresponsive or resistant to this
treatment. Dihydrofolate reductase (DHFR) is an essential enzyme that provides folate cofactor
for DNA, RNA, and methionine biosynthesis. Hence, selectively inhibiting pjDHFR is an
important strategy for effective treatment of infection by the pathogen. Structure-based design,
using pjDHFR homology model and through the identification of amino acid differences between
pjDHFR and hDHFR active sites, has been presented in the text. Novel synthetic strategies were
developed for efficient synthesis of 6-(arylthio)pyrido[2,3-d]pyrimidine-2,4-diamines.
Three specialized folate transport systems exist in mammalian cells that include the
reduced folate carrier (RFC), folate receptors (FRs) α and β, and the proton-coupled folate
transporter (PCFT). Among several targeting strategies for cancer cells, selectively targeting
through PCFT and FRs, over RFC have been successfully investigated. To avoid dose-limiting
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toxicities, the next valid step in the field is to carry out a structure-based drug design to gain
selectivity for PCFT and/or FRs transport over RFC. Drug discoveries in these areas become
challenging in the absence of X-ray crystal structures for PCFT and RFC. PMX, the most widely
used antifolate, has three disadvantages: (i) transport by RFC; (ii) dependence on its
polyglutamylation for potency; and (iii) development of resistance due to mutagenesis in the target
enzyme (thymidylate synthase). This dissertation focuses on the development of substitutedpyrazolo[4,3-d]pyrimidines and pyrrolo[2,3-d]pyrimidines to combat the above-mentioned
drawbacks of PMX, using the X-ray crystal structures of intracellular targets and transporters and
using the basic principles of scaffold hopping and bioisosteric replacements. The work described
herein discusses our efforts to obtain agents with inhibition of two or more intracellular targets to
inhibit de novo purine biosynthesis. Synthetic efforts for the development of pyrazolo[4,3d]pyrimidines with different linkers have been discussed.
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Scheme 7
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Scheme 10
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Scheme 11
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xxvii

59

Scheme 12

Synthesis of 2-alkyl-4-oxo-pyrrolo[3,2-d]pyrimidines from

60

ethyl 3-amino-5substituted-1H-pyrrole-2-carboxylate
Scheme 13

Synthesis of 3H-pyrrolo[3,2-d]pyrimidin-4(5H)-one from ethyl 3-

60

amino-1H-pyrrole-2-carboxylate
Scheme 14

Synthesis of 2-sulfanyl-4-oxo-pyrrolo[3,2-d]pyrimidines from ethyl

61

3-amino-1H-pyrrole-2-carboxylate
Scheme 15

Synthesis of 2,4-dichloro pyrazolo[4,3-d]pyrimidines from methyl-

61

pyrazolo-carboxylic acids 55
Scheme 16

Synthesis of pyrazolo[4,3-d]pyrimidines from 4-amino-3-methyl-1H- 62
pyrazole-5-carboxamide) with thiourea.

Scheme 17

Synthesis of 7-hydroxypyrazolo[4,3-d]pyrimidine from 4-amino-1H- 62
pyrazole-5-carboxamide with formamide.

Scheme 18

Synthesis of 3-methyl-7-thioxo-1,4,6,7-tetrahydro-5H-pyrazolo[4,3- 63
d]pyrimidin-5-one from 4-amino-3methyl-1H-pyrazole-5carbothioamide with urea.

Scheme 19

Synthesis of pyrazolo[4,3-d] pyrimidinedione from 5-carbamoyl-1H- 63
pyrazole-4-carbonyl azide.

Scheme 20

Synthesis of pyrazolo[4,3-d]pyrimidine from 4-nitro-1H-pyrazole-5- 64
carboxamide.

Scheme 21

Synthesis of pyrazolo[4,3-d]pyrimidine from ethyl 4-amino-1-(4-

65

methoxyphenyl)-1H-pyrazole-3-carboxylate and 1,1,1triethoxyethane
Scheme 22
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I. BIOCHEMICAL REVIEW

A.1. Single agents with combination chemotherapy and multiple RTK inhibitory potential
A.1.1. Microtubules
A.1.1.1 Microtubule structure
Microtubules are crucial components of the cytoskeleton and are involved in critical
cellular processes including cell division, trafficking, signaling and migration. 1

Figure 1: Structure of microtubules: αβ-tubulin heterodimers assemble into protofilaments. 2
Tubulin dimers polymerize to form microtubules and consist of 13 linear protofilaments
assembled around a hollow core.3 Tubulin is globular protein and consists of five distinct families,
the alpha (α), beta (β), gamma (γ), delta (δ), epsilon (ε) and zeta (ζ). At a macroscopic level the
1

diameter of the hollow tube is ~25 nm. The α-tubulin and β-tubulin are important members of the
tubulin family that build the microtubule (Figure 1).3 These tubulin dimers associate longitudinally
to form protofilaments.1, 4 Lateral assembly of protofilaments form the microtubule, which can be
further elongated or shortened by single α- and β-tubulin heterodimers (Figure 1). 5

Figure 2. Structure, polymerization and depolymerization of microtubules. 5
At a critical concentration, where these dimers are present above the specific concentration,
polymerization takes place and by the addition of dimer, this process is accelerated. However,
microtubules possess a crucial feature of polarity, which is mandatory for its biological function.
Therefore, in a protofilament, one end has the α subunits exposed. In contrast, the other end has
the β subunits exposed, these ends designated as (α) and (β) ends, respectively (Figure 1). 1 The βtubulin subunit is exposed at the more dynamic plus-end of the microtubule, which typically
extends toward the cell periphery. The microtubule minus-end is less dynamic and in cells, is
commonly anchored at the centrosome-containing microtubule organizing center (MTOC)
2

adjacent to the nucleus which is exposed to the α tubulin. Both the α- and β-tubulin subunits bind
GTP (Figure 2); however, only the nucleotide on β-tubulin is hydrolyzed and exchanged. At the
site of (-) polarity, GTP molecule binds irreversibly and at the (+) end, GTP molecules bind
reversibly.1, 4 Microtubules undergo dynamic growth and shrinkage (Figure 2). During growth
(polymerization), α and β monomer ends are bound by GTP. During shrinkage (depolymerization),
the GTP bound at β tubulin end is hydrolyzed to GDP. The GDP-bound β tubulin at the tip causes
disassembly of the microtubule. The switch from growth to shrinkage is called a catastrophe. On
the contrary, the switch from shrinkage to growth is called rescue. 4

A.1.1.2 Microtubule Targeting Agents (MTAs)
Molecules binding to tubulin and interrupting tubulin dynamics are recognized as
microtubule targeting agents (MTAs) and have been used clinically as single agents or in
combinatorial regimens for the effective treatment of leukemia, lymphoma, and various solid
tumors.3
(a) Classification of MTAs:
Classification based on their effects on microtubule stability:6
(i) Microtubule-destabilizing agents/ Microtubule depolymerizers: These microtubule
destabilizers initiate microtubule depolymerization, leading to microtubule disassembly and a
decrease in microtubule density. These include natural products such as the vinca alkaloids,
cryptophycins, halichondrins, estramustine, colchicine and its analogs and combretastatines.

3

ii) Microtubule-stabilizing agents/ Microtubule polymerizers: These microtubule
stabilizers promote the polymerization of tubulin, thereby increasing the density of microtubules.
These include paclitaxel, docetaxel, epothilones and discodermolide.

Figure 3. Tubulin binding sites and representative agents of microtubule-targeted drugs. 3, 4

Classification based on binding domains of tubulin:3
Additionally, six groups of distinct classes of microtubule-binding agents are classified
based on their binding domain (Figure 3).3, 4 Two tubulin-binding sites have been identified as
microtubule polymerizers, Taxane7 and Laulimalide site8, 9. Four tubulin-binding sites have been
identified for microtubule depolymerizers: the vinca site,10 the colchicine site,11, 12 the maytansine
site,13 and, more recently, the pironetin site.14, 15 The binding sites are the following:

4

1)

Taxanes site agents:

Figure 4. Representative taxanes
Paclitaxel (Figure 4) was the first microtubule stabilizer identified.7 Paclitaxel and its
derivatives and most MTAs that increase microtubule polymerization, such as the epothilones,
discodermolide, eleutherobin, and sarcodictyins, bind to the Taxol-binding site. 16, 17 Ixabepilone,
which belongs to the Epothilone class of paclitaxel-site binders, was approved for the treatment of
drug-refractory metastatic breast cancer in 2007.16, 18 All the agents bind to a pocket of β-tubulin
located on the luminal side of microtubules (Figure 3). Paclitaxel is suggested to bind by diffusing
through pores in the microtubule lattice. Binding of paclitaxel stabilizes the microtubule by

5

inducing a conformational change in β-tubulin that increases its affinity for adjacent tubulin
molecules.16
2. Laulimalide/Peloruside agents:9

Figure 5. Structure of Laulimalide and Peloruside A.
Laulimalide and peloruside A (Figure 5), are a sponge-derived natural product that induces
tubulin hyper assembly.9 Laulimalide/peloruside site, are targeted by the named natural products.
They have a unique binding site located on two adjacent β-tubulin units between tubulin
protofilaments (Figure 3).19 The binding causes the bridging of two adjacent β-tubulin across the
protofilaments.

3) The Vinca site agents:

Figure 6. Representative structure of Vinca alkaloids

6

Noble and Charles Thomas Beer were the first to identify vinca alkaloid from
Catharanthus roseus (basionym Vinca rosea) family Apocynaceae in 1950. This class includes
the Vinca alkaloids (Figure 6): vincristine, vinblastine, vinorelbine , vinflumine and vindesine.
They have been widely used in cancer chemotherapy for leukemia, lymphomas and non-smallcell
lung cancer.20 The effect of such alkaloids can be concentration-dependent. At low concentrations,
vinblastine inhibits microtubule assembly and depolymerization of microtubules, whereas at
higher concentrations, vinblastine causes tubulin assembly. The Vinca alkaloids bind to the βsubunit of soluble tubulin heterodimers at a region commonly referred to as the Vinca-binding
domain (Figure 3).18, 20 Other MTAs such as the cryptophycins, halichondrins and dolastatins also
bind at the same site.

4) Colchicine site agents12:

Figure 7. Colchicine and combretastatin
One of the most potent anti-mitotic agent which gained the attention of medicinal chemists
and cancer biologists is combretastatin A-4 (CA-4, Figure 7).21 Colchicine binding site inhibitors
have been extensively studied and many of them have entered clinical trials, including 2methoxyestradiol, combretastatin A-4 phosphate (CA-4P, Figure 7) (fosbretabulin), the
combretastain CA-1P prodrug (OXi4503), AVE8062 ((2S)-2-Amino-3-hydroxy-N-[2-methoxy-

7

5-[(Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl]propenamide),

CKD-516

((S)-N-(4-(3-(1H-

1,2,4-triazol-1-yl)-4-(3,4,5-trimethoxybenzoyl)phenyl)thiazol-2-yl)-2-amino-3methylbutanamide

hydrochloride),

BNC105P

(sodium

6-methoxy-2-methyl-3-(3,4,5-

trimethoxybenzoyl)benzofuran-7-yl phosphate), ABT-751 (N-[2-(4-hydroxyanilino)pyridin-3-yl]4-methoxybenzenesulfonamide),

CYT-

997

(1-ethyl-3-[2-methoxy-4-[5-methyl-4-[[(1S)-1-

pyridin-3-ylbutyl]amino]pyrimidin-2-yl]phenyl]urea), ZD6126 (Phosphoric acid mono-(5acetylamino-9,10,11-trimethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-3-yl) ester), plinabulin
(NPI-2358)

((3Z,6Z)-3-benzylidene-6-[(5-tert-butyl-1H-imidazol-4-yl)methylidene]piperazine-

2,5-dione),

MN-029

(methyl

N-[6-[4-[[(2S)-2-aminopropanoyl]amino]phenyl]sulfanyl-1H-

benzimidazol-2-yl]carbamate).13,14,22 Colchicine binding site agents include podophyllotoxin,
combretastatin and flavonols. Colchicine is not used clinically in cancer treatment due to its
toxicity at doses that produce antimitotic effects.12 Colchicine binds to soluble tubulin at a distinct
site referred to as the colchicine binding site. CA4P (Fosbretabulin) is under extensive
investigation for platinum-resistant ovarian cancer, neuroendocrine tumors (NETs), hepatocellular
carcinoma, and gastric cancer.23, 24 The colchicine binding site is on β-tubulin at the interface
between α- and β- tubulins (Figure 3).18

5) Maytansine site agents:
The maytansine site (Figure 3) on tubulin has been discovered only very recently. 13, 25 It is
a unique site on β-tubulin that is located at the longitudinal tubulin–tubulin interface in
microtubules, which readily explains the microtubule-destabilizing effects of maytansine-site
ligands. Three distinctly different ligands that target the maytansine site have been described:
maytansine, PM060184 26 and rhizoxin13 (Figure 8).
8

Figure 8. Structure of Maytansine, Rhizoxin and PM-060184
Maytansine (Figure 8) has been successfully incorporated into the ADC trastuzumab
emtansine, which is approved for the treatment of breast cancer. 27 PM060184 is in phase II clinical
development for the treatment of breast cancers (clinicaltrials.gov), while rhizoxin had reached
phase II, before being discontinued for reasons that are poorly understood. 28

6) Pironetin site agents:

Figure 9: Structure of Pironetin

9

Pironetin (Figure 9) is the only natural product crystallographically characterized to bind
solely to α-tubulin. It was initially known as PA-48153C and was isolated concurrently from the
fermentation broth and cell paste of Streptomyces prunicolor.29, 30 Pironetin displays potent in vitro
activity against cell lines both sensitive and resistant to current first-line therapeutics 31-33
Importantly, pironetin is cancer-cell specific, as it was inactive against normal human lung
fibroblasts (IMR90) that displayed normal cell-cycle bias and no indications of apoptosis
following treatment.34 Furthermore, pironetin is not a P-glycoprotein (Pgp) substrate. 35

A.1.1.3 Role and Functions of MTAs:
MTAs’ biological functions are due to their effects in polymerization dynamics.
A.1.1.3.1 Mitosis as a target:20
Microtubules are ideal targets for anticancer drugs because of their pivotal role in mitosis, 36
and have long been recognized as “anti-mitotic agents”.37 MTAs can either increase or decrease
polymerization at different concentrations. The effect of mitotic arrest is due to an aberrant spindle
formation.36 Both these effects cause cell-cycle arrest and cell death through apoptosis at the
cellular level.36 Based on MTAs’ success as anti-mitotic agents, inhibitors targeting several mitotic
kinases (Polo-like kinase, Aurora Kinase A and Aurora Kinase B) have been developed. 38
Nevertheless, they did not show success in clinical trials. The hypothesis that MTAs target only
mitosis has since been questioned and is supported by the findings that human tumors (sensitive
to MTAs) in vivo do not divide as fast as in vitro tumor cells. As a result, other effects of MTAs
in tumors are being investigated in addition to mitosis.

10

A.1.1.3.2 Interphase as a target:39

Figure 10. Diverse anticancer interphase activities of MTAs.40
Literature precedence suggests that MTAs act primarily on interphase cells. 40 The
microtubule is responsible for various functions at the interphase (Figure 10), namely: (a)
centrosome clustering; (b) induction of voltage-dependent anion channel opening with release of
Ca2+ and cytochrome c; (c) disruption of delivery of mRNA along interphase microtubule tracks;
(d) induction of mRNA release from polysomes; (e) improvement of major histocompatibility
complex (MHC) class I expression; increased activation of (f) dendritic cells, (g) cytotoxic T
lymphocytes and (h) macrophages; (i) impede vesicular traffic to the cell front; (j) blocked timely
endocytosis; (k) interfere with transcription factor transport by motors to the nucleus with (l) upor down-regulation of tumor suppressor or oncogenes, respectively. The major dose-limiting
toxicity, neurotoxicity, is because of the activity of MTAs on the interphase of the non-dividing
neurons. However, the most important factors (Figure 10) responsible for cell death is yet to be
11

determined. Because there are a number of mechanisms by which MTAs operate, as illustrated in
Figure 10, the chemotherapeutics work in the interphase are responsible for cancer cell death by
prompting “thousand cuts” on the cancer cell. 40 Knowledge of these targets and to identify the
differences in interphases of normal and cancer cells are currently underway. 40

A.1.1.3.3 Vascular disruption:41, 42
The tumor vasculature is an attractive target for cancer therapy because their survival and
the main route for metastatic spread require oxygen and nutrients by the vasculature. 43 Tumor
vessels are tortuous, strikingly heterogeneous and are an important feature of cancer. 44 Multiple
factors, including the specific organ and tissue in which the tumor arises, the composition of tumorassociated stromal cells, as well as the nature, diversity and relative abundance of pro- and antiangiogenic mediators control the nature of tumors. 45 Combretastatin analogs are recognized as
vascular disrupting agents (VDAs).46 The tumor-VDA effects are seen well below the maximum
tolerated dose of the combretastatins’.43 Tumor-VDA effects have advantages in solid tumors
which have different vasculature of endothelial cells and pericytes than normal cells. 47 Tumor cells
are more permeable than normal cells because of the absence of vascular smooth muscle cells. 47
Solid stress also compresses lymphatic vessels, further elevating interstitial fluid pressure and
exacerbating the reduced blood flow caused by vessel leakiness. Endothelial cells rely on the
tubulin cytoskeleton to maintain cell shape.48 Tumor-VDAs can cause rapid disruption of blood
supply to solid tumors by disruption of vascular endothelial-cadherin at the junction. 47 This
changes the cell shape change, decreased blood flow to the tumor cells and vasoconstriction,
causing tumor ischemia and cell death.47
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Figure 11. Differences between tumor-VDAs and antiangiogenic agents.49 (Modified from ref. 49)
The cytotoxic effect of vascular disruption is different from the cytostatic effect of antiangiogenic agents (Figure 11).49 VDAs present an alternative way to target tumor blood vessels.
Unlike anti-angiogenic drugs, VDAs damage established tumor blood vessels. 50 Tumor-VDAs
cause tumor necrosis at the core of the tumor. Anti-angiogenic agents target neovascularization,
prevent tumor growth and limit the tumors’ metastatic potential and thus their greatest effect is on
the periphery of the tumor. Tumor-VDA effect and antiangiogenic effect have distinct profiles,
offering potential for their use in combination.47 Compared to single agents, combination of tumorVDA and antiangiogenic agent have produced delayed tumor growth in preclinical studies. 47

A.1.1.4 MTAs Resistance Mechanism:
The microtubule has been recognized as an effective target for the treatment of human
malignancies.3 MTAs constitute a large group of chemically diverse compounds and are widely
13

used in the clinic for treatment of various types.51 However, despite the success, the clinical use of
MTAs is often hampered by the acquisition of resistance.52, 53 Cancer cells employ several distinct
types of mechanisms to develop resistance to anti-microtubular drugs. 53 Efflux via the membrane
efflux pump of the ATP binding cassette (ABC) family is the primary mechanism of resistance
towards MTAs.54,

55

Pglycoprotein (Pgp), a product of a multidrug resistant gene (MDR1 or

ABCB1) is responsible for the efflux of MTAs.52 The potency of paclitaxel was reduced 800-fold
in Pgp-overexpressing SK-OV-3 MDR-1-6/6 cell line, compared to the parental cell lines. 56 Pgp
substrates cannot enter the CNS when drugs are administered orally. As a result, agents that are
less susceptible to efflux by Pgp could possess a novel pharmacodynamic and pharmacokinetic
profile.55 Microtubules are accumulated with more than 13 diverse isotypes of α and β tubulins.
Among them, increased levels of βIII-tubulin are related with reduced rate of responses to taxanes
in tumors of lung, breast and ovary.57,

58

Contrary to the effect of βIII-tubulin with taxanes,

epothilones are indifferent to the expression of βIII-tubulin. 55

A.1.2 Angiogenesis
Angiogenesis is the formation of new blood vessels, which involves the migration, growth,
and differentiation of endothelial cells, which line the inside wall of blood vessels (Figure 12). 59
Angiogenesis occurs during tumor development depending on changing tissue requirements. 60
Blood vessels and stromal components respond to pro- and anti-angiogenic factors. However, in
cancer, as the tumor grows, it obtains its blood supply. 61 To achieve this, the tumor tilts the balance
towards pro-angiogenic factors to drive vascular growth by attracting and activating cells from
within the microenvironment of the tumor.62
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Figure 12. (a–e) Angiogenic “switch” from dormant cells to tumor vasculature.62
When a tumor grows beyond 2 mm3, it requires nutrients and oxygen for maintenance and
growth. This phenomenon initiates the process of acquiring additional blood supply; and the
process of angiogenic switching (from the release of anti-angiogenic factors to proangiogenic
factors) in a tumor starts to develop (Figure 12).63 By releasing cytokines and growth factors, tumor
cells exploit their microenvironment. These include vascular endothelial growth factor (VEGF),
platelet-derived endothelial growth factor (PDGF) and epidermal growth factor (EGF), which
promote endothelial cell proliferation/migration.63-65 The new blood vessels grow and infiltrate the
tumor to provide oxygen and nutrients to the growing tumor, leading to tumor progression and
metastases.66 This process leads to a leaky tumor vasculature with irregular blood flow which
makes it different from the normal tissue vasculature.67
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Judah Folkman proposed the treatment of cancer by blocking angiogenesis nearly 45 years
ago.68 Multiple anti-angiogenic agents has since been approved by the FDA as single agents or in
combination with other cytotoxic drugs. Most notable of these are receptor tyrosine kinase
inhibitors which are involved in the process of angiogenesis.69

A.1.2.1 Receptor Tyrosine Kinase (RTKs):
Tyrosine kinases (TKs) play vital roles in diverse biological processes like growth,
differentiation, metabolism and apoptosis in response to external and internal stimuli. 70,71 TK can
be divided into non-receptor TKs and receptor TKs (RTKs) where non-receptor TKs carry out
intracellular communication and RTKs are involved in signal transduction. RTKs have three major
parts: extracellular N-terminal domain, a transmembrane domain, and an intracellular C-terminal
domain, which has the kinase activity.72 The kinase domain has a ATP-binding site between the
N- and C-terminal lobes.

Figure 13. ATP binding site in RTK.72-74 (Modified from ref. 72-74)
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Figure 14. RTK signaling.75
Additionally, the ATP binding domain can be classified into the adenine region, sugar
region and phosphate binding region (Figure 13). The C-terminal lobe forms an activation loop
and has aspartic acid, phenylalanine and glycine, which is abbreviated as the “DFG” motif.
Dimerization

(homodimerization

or

heterodimerization)

and

subsequent

auto-

phosphorylation of the tyrosine residues occurs upon binding growth factor on the extracellular
domain of RTKs (Figure 14).75 The phosphorylations are tightly monitored and regulated under
normal physiological conditions which is responsible for triggering a cascade of downstream cell
signaling pathways. These pathways are highly dysregulated in cancer cells and inhibition of these
can thus offer a key therapeutic strategy for the treatment of cancer. ,76, 77
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Figure 15. Representative small molecule RTK inhibitors
(a)

Epidermal growth factor receptor (EGFR):78 There are eleven members and

four EGFR family receptors in the EGF family.79 EGFR overexpression leads to an increased
tumor cell proliferation, survival and invasiveness. 80,79 EGFR signaling inhibition has been shown
to promote selective apoptosis in tumor endothelial cells. 81 Some examples of approved EGFR
inhibitors are erlotinib (Tarceva®) (Figure 15) for locally advanced or metastatic non-small cell
lung cancer,82 gefitinib (Iressa®) (Figure 15) for metastatic non-small cell lung cancer,83 and
afatinib (Gilotrif®) (Figure 15) for squamous non-small cell lung cancer.84
(b)

Vascular endothelial growth factor receptor (VEGFR):85 The vascular

endothelial growth factor (VEGF) and its receptor (VEGFR) play significant roles in cancer. 86 The
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VEGFR family consists of three related RTKs- VEGFR-1, VEGFR-2 and VEGFR-3. The VEGF
family has five members- VEGF-A, VEGF-B, VEGF-C, VEGF-D and placental derived growth
factor (P1GF). VEGF-A is the principal facilitator of the tumor angiogenesis and signals through
VEGFR-2, which is the primary VEGF signaling receptor. VEGFR inhibitors are bevacizumab
(Avastin®) for colorectal cancer82, sunitinib (Sutent®) (Figure 15) for metastatic pancreatic
neuroendocrine tumors87 and sorafenib (Nexavar®) (Figure 15)

for advanced renal cell

carcinoma.88
(c)

Platelet-derived growth factor receptors (PDGFR):89 The third most important

factor involved in angiogenesis is the PDGFR. The PDGF has four members- PDGF-A, PDGF-B,
PDGF-C and PDGF-D, which bind to receptors PDGFRα and PDGFRβ. The receptor PDGFRα
signaling controls the development of several organs such as the lung, intestine, kidney, bones,
and neuroprotective tissues. PDGFRβ signaling regulates hematopoiesis and blood vessel
formation.90 PDGFs recruit pericytes and smooth muscle cells and promote the maturation and
stability of the vasculature. Approved PDGFR inhibitor is imatinib (Gleevec®) (Figure 15) for
chronic myeloid leukemia.91
Resistance and severe toxicities are the two major problems associated with the use of RTK
inhibitors as anti-angiogenic agents.44 Acquired and inherent resistance are frequently observed in
preclinical and clinical settings.91-93 Bleeding, hypertension and fatigue are also common toxicities
of RTK inhibitors.92 Resistance to anti-VEGF therapy, a non-VEGF could be responsible for
angiogenesis signals in tumors. Thus, a combination approach targeting different angiogenesis
signaling mechanisms could be highly effective. Additionally, synergism was observed in
signaling by fibroblast growth factor-2 (FGF-2) and PDGF-BB in tumor growth and metastasis. 93
Numerous small-molecules function as single agents with multi-RTK inhibitory potential. Axitinib
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(Inlyta®) is approved for renal cell carcinoma which inhibits VEGFR, PDGFR and c-KIT. 94
Vandetanib (Caprelsa®) is approved for the advanced medullary thyroid cancer which inhibits
VEGFR2 and EGFR.95 Nindetanib (Ofev®) is approved for non-small cell lung cancer which
inhibits VEGFR, FGRF and PDGFR.96 These clinically successful RTK inhibitors validate the
development of single agents as multi-RTK inhibitors.

A.1.3 Anti-angiogenic agents and MTAs as a combination chemotherapy
Combination therapy, combines two or more therapeutic agents, is a mainstay in cancer
therapy.97 Combination therapy could circumvent pharmacokinetic problems of multiple agents,
avoid drug-drug interactions, and could be used at lower doses to minimize toxicities and tumor
cell resistance than two or more agents dosed separately in combination chemotherapy. 98 The
combination therapy has several advantages: increased patient compliance, emergence of an
additive or synergistic interaction of the combined drugs, prevention of resistance, reduction of
drug dosage with a consequence of diminished toxicity. 99,100 Inhibition of a single target or
pathway is known to be of limited benefit to a cancer patient. Thus, combination therapy can
provide an effective technique to combat resistance and target tumor heterogeneity. 101
A.1.3.1 Vessel normalization for cancer
MTAs, which are cytotoxic agents, kill cancer cells directly, whereas cytostatic agents like
antiangiogenic agents kill cancer cells indirectly by the deprivation of nutrients and oxygen. 99 A
combination of cytotoxic drug with antiangiogenic agents showed clinical success in the treatment
of cancer.101 Instead of blocking the delivery of cytotoxic drug to the tumor, the anti-angiogenic
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therapy has shown to enhance its effect. Jain and coworkers102 established the “vascular
normalization” hypothesis based on this observation.

Figure 16. Schematic of changes in tumor vasculature during the course of anti-angiogenic
therapy. a, Normal vasculature, composed of mature vessels and maintained by the perfect balance
of pro- and anti-angiogenic molecules, might not change during the course of anti-angiogenic
therapy. b, Abnormal tumor vasculature, composed largely of immature vessels with increased
permeability, vessel diameter, vessel length, vessel density, tortuosity and interstitial fluid
pressure, compromises the delivery of therapeutics and nutrients. c, Judiciously applied direct or
indirect antiangiogenic therapies might prune immature vessels, leading to more normalized tumor
vasculature. This network should be more efficient for the delivery of therapeutics and nutrients.
d, Rapid pruning of, or coagulation in, tumor vasculature might reduce the vasculature to the point
that it is inadequate to support tumor growth and might lead to tumor dormancy. This is the
ultimate goal of anti-angiogenic/anti-vascular therapy. 102
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Cancer cells have a hostile tumor microenvironment, disorganized blood vessels, which
are leaky and tortuous (Figure 16).102 This conditions produce spatial heterogeneity in blood flow,
low pH, increased interstitial fluid pressure and hypoxia.103 The blood flow heterogeneity
decreases the delivery of cytotoxic drug. Acidic pH decreases activity of immune cells and hypoxia
renders cells resistant to radiotherapy.104 An anti-angiogenic therapy can cause a transient increase
in vascular patency, decrease in interstitial fluid pressure and hypoxia. The tumor angiogenic
signal obstruction results in pruning of the immature blood vessels and remodeling of the
vasculature. It thus normalizes the tumor blood vessels and improves blood flow, oxygen supply,
and drug delivery to the tumor.

Figure 17. Proposed effect of drug dose and schedule on vascular normalization of tumor. 61

Under physiological conditions, the blood vessels have normal structure and function
because of a balance of the signals downstream of the proangiogenic molecules (e.g., VEGF and
Ang2) and antiangiogenic molecules (e.g., sVEGFR1, thrombospondins, and semaphorins). 61 In
contrast, under pathological conditions, tumor vessels are structurally and functionally abnormal
because of an imbalance between pro- and antiangiogenic signals. This creates an abnormal
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microenvironment in tumors, characterized by hypoxia, acidosis, and elevated fluid pressure, that
fuels tumor progression and treatment resistance via multiple mechanisms as shown in Figure 17. 61
Inhibiting proangiogenic signaling or enhancing antiangiogenic signaling can prune some
abnormal vessels and remodel the rest, resulting in a normalized vasculature. 44 Depending on the
extent of normalization versus pruning, tumor perfusion/oxygenation may increase, remain
unchanged, or decrease. Some tumors might be intrinsically resistant to a given AA agent, and
others may switch to nonsprouting mechanisms of vessels recruitment that are refractory to the
given AA agent and continue to make abnormal vessels again.44, 61 (B) The window of increased
perfusion from vascular normalization depends on the dose and potency of antiangiogenic
therapy.61 High doses may cause excessive pruning of tumor vessels, resulting in a shorter window,
and may starve a tumor of oxygen and other nutrients. High doses may also increase toxicity,
including some fatal.61 The tumor vasculature normalization is limited to a fixed time after the
antiangiogenic therapy is administered. This is defined as the “vascular normalization window”
(Figure 17).105 This window is short-lived and delivery of cytotoxic drugs in this time duration can
provide synergistic effect. Successful chemotherapy treatment requires lateral dosing, scheduling,
sequencing and studying the tumor vasculature. To optimize the efficacy and reduce the negative
side-effects of combination of cytotoxic drug and anti-angiogenic agent, careful consideration is
mandatory.44
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A.1.3.2 Combination of vascular disrupting agents and anti-angiogenic agents 106
The VDAs target the existing tumor vasculature leading to central necrosis of the tumor. This
leaves viable, proliferating cells at the periphery.107 These proliferating cells at the periphery can
cause metastasis and thus limit the use of tumor-VDAs as monotherapy. As anti-angiogenic agents
target the periphery, this phenomenon warrants the use of a combination therapy of VDAs with
anti-angiogenic agents.44

A.1.3.3 Multitargeted agents with MTA and RTK inhibitory potential

The multi-targeted drugs have much more potential and defined as rationally designed
single chemical entities capable of selectively targeting two or more biological targets or
processes.108, 109. Multitargeted drugs have numerous advantages over combination chemotherapy,
which includes (i) predictable pharmacodynamic and pharmacokinetic effects; (ii) improved
patient compliance; and (iii) presence of multiple entities (in one agent) with multiple effects
simultaneously.108 Combination chemotherapy entails a very careful selection of scheduling,
which can be avoided during the design of a multitargeted drug. 99 Drug delivery to the tumor can
be improved via the surviving vasculature, while administrating a cytotoxic agent during the
transient phase of tumor vasculature ‘‘normalization”.44 Dosing separate antiangiogenic and
cytotoxic agents might miss the timing window of the transient normalization in combination
chemotherapy. Single molecular entities with both antiangiogenic and cytotoxic features allow the
cytotoxicity to be established as soon as the antiangiogenic effect and vasculature normalization
occur.99
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In phase III clinical trial, Docetaxel (MTA) plus nintedanib (VEGFR, PDGFR and FGFR
inhibitor) versus docetaxel plus placebo in patients in non-small-cell lung cancer (LUME-Lung 1)
displayed an increase in overall survival of 10.9 months for the drug combination, compared to
7.9 months for docetaxel monotherapy.110 The clinical evidence prompted further investigation
into the combination therapy of MTAs with multi-RTK inhibitors.

Figure 18. Reported 7-benzyl-N-(substituted)-pyrrolo[3,2-d]pyrimidin-4-amine as single agents
acting as MTAs, along with inhibitors of VEGFR-2, PDGFRβ and EGFR. 99

Pavana et al. .99 reported 7-benzyl-N-(substituted)-pyrrolo[3,2-d]pyrimidin-4-amines 1-3
(Figure 18). These compounds act as a multitargeted single agents with MTAs and VEGFR-2,
PDGFRβ and EGFR inhibition. Compound 2 displayed excellent inhibition across all the four
targets among the three compounds. It has an IC50 of 480 ± 8 nM in inhibiting tubulin assembly.
The IC50 against VEGFR-2, PDGFRβ and EGFR was 33 ± 5.0 nM, 2.3 ± 0.3 nM and 10.3 ± 1.7
nM respectively.99 Compound 2 also significantly reduced tumor growth in 4T1 cells (mouse
mammary carcinoma), compared to paclitaxel.
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Figure 19. Reported 5-methyl-furo[2,3-d]pyrimidines as single agents acting as MTAs, along with
inhibitors of VEGFR-2, PDGFRβ and EGFR.111
Devambatla et al. reported 5-methyl-furo[2,3-d]pyrimidines 4-6 (Figure 19) as
multitargeted single agents acting as MTAs, along with inhibitors of VEGFR-2, PDGFRβ and
EGFR. Compounds 4-6 displayed nanomolar inhibition of EGFR kinase. Compounds 4-6 inhibited
VEGFR-2 and PDGFR-β kinases better than or equal to the standard sunitinib. Gangjee and
coworkers111,

112

have further reported 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as

multitargeted single agents that inhibit VEGFR-2, PDGFRβ and EGFR, along with tubulin
assembly. These studies attest to the rationale of designing compounds with anti-angiogenic and
MTA potential to produce combination chemotherapy as single agents.

A.2. Selective pjDHFR inhibitors

A.2.1. Pneumocystis jirovecii and pneumocystis pneumonia Infection
Pneumocystis pneumonia (PCP) is a form of pneumonia that is caused by the yeast-like
fungus Pneumocystis jirovecii (pj).113 Pj is an opportunistic pathogen that causes severe pulmonary
infection in immune compromised hosts.114 PCP commonly occurs in patients with human
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immunodeficiency virus (HIV) infection. PCP can occur in patients without HIV, including those
who have undergone organ transplantation, chemotherapy, and/or high-dose corticosteroid
therapy.115 If left untreated, PCP is almost always fatal. Even when treated, the mortality rate is
10%. In the USA, 9% of HIV infected patients and 1% of organ transplant recipients develop PCP
infection.116,117, 118 It is an atypical fungus, which differs from other fungi in the fungi family due
to the presence of cholesterol, instead of ergosterol, in its cell membrane. The species affecting
humans is unique than the species affecting other animals such as rats and mice and the infection
is host-specific. The infection from rats, when transfected to mice, does not proliferate, whereas
the infection from rats to other rats causes severe infection. 119 The infection remains under control
in the healthy immune system of an individual. PCP presents itself when the patients’ CD4 count
is below 200 cells/mm.120, 121 Although PCP prophylaxis and antiretroviral therapy (ART) has
changed the face of the HIV/AIDS epidemic, the incidences of HIV cases persist due to
nonadherence to the medication, toxicity to the medications, emergence of drug-resistant HIV
strains, late diagnosis of HIV and the rise of the number of cases in developing countries. 122, 123
The mortality rates of PCP range from 10% to 20% among HIV infected patients, while it is 30%–
60% among the non-HIV population. Thus, PCP continues to be a significant public health
concern. In the US, 9% of hospitalized HIV/AIDS and 1% of organ transplant patients develop
PCP infection.124 In these patients, the mortality rate is from 5-40% while being treated for PCP
and approaches 100% if left untreated.124
For past few decades, the first-line therapy for both the prophylaxis and the treatment for
PCP is Sulfamethoxazole/trimethoprim (SMX/TMP) combination (co-trimoxazole) (Figure 20). 125
This combination synergistically blocks folic acid synthesis, since TMP is a selective, but weak
inhibitor of dihydrofolate reductase (DHFR),126 while SMX is an inhibitor of dihydropteroate
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synthase (DHPS).127 The low activity of TMP against DHFR is amplified by SMX, in the treatment
regimen. The efficacy, low cost and activity in variety of infections has drove cotrimoxazole to be
used indiscriminately. Due to the widespread use, there are mutations in the DHPS locus of pj
encoding DHPS as the cause of TMP/SMX resistant strains of PCP.127-130

Figure 20. Clinical and non-clinical agents for the treatment for PCP.
Clinical and non-clinical mutations have also been reported in DHFR after treatment or
prophylaxis using DHFR inhibitors.131-135 Due to such resistant strains or toxicity/allergy by SMX
(Figure 20) , treatment failure and discontinuation of co-trimoxazole occurs in several cases have
been repo rted.136-140 Treatment failure to TMP/SMX has enabled TMP-dapsone or clindamycinprimaquine as the second-line treatment in mild to moderate PCP. This thaerpy leads to low
efficacy and often lethal side-effects.141-144 Piritrexim (PTX, Figure 20) and trimetrexate (TMQ,
Figure 20) are potent, but non-selective inhibitors of DHFR, which cause dose-limiting
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toxicities.141, 145, 146 These agents, combined with leucovorin had high costs, drug toxicities, drug
interactions and lack of efficacy.147 New drugs for the treatment of PCP are critically needed for
patients that do not respond to first line treatment as well the inevitable recurrence of resistance,.
A.2.2. DHFR

Figure 21. Reaction catalyzed by DHFR31
DHFR is an enzyme catalyzes the reduction of dihydrofolate to tetrahydrofolate (THF),
using NADPH as an electron donor, and can be converted to the kinds of tetrahydrofolate cofactors
used in 1-carbon transfer (C1 metabolism) chemistry (Figure 21).

148, 149

DHFR is considered as

an important drug target for several human diseases- protozoal, bacterial, fungal infections, and
autoimmune diseases.150 Folate metabolism (C1 metabolism) has been studied for decades as a
target in chemotherapy.151 Thymidine is synthesized by eukaryotic organisms via the thymidylate
cycle, which consists of enzymes: (a) Serine hydroxymethyltransferase (SHMT); (b) DHFR; and
(c) Thymidylate synthase (TS). DHFR catalyzes the NADPH-dependent reduction of 7,829

dihydrofolate to the 5,6,7,8-tetrahydrofolate (THF) (Figure 21). The THF then acts via 5,10methylene THF as a cofactor in the conversion of deoxyuridine monophosphate (dUMP) to
deoxythymidine monophosphate (dTMP), catalyzed by TS. Inhibition of TS and/or DHFR causes
disruption in DNA, RNA and protein synthesis of the organism and eventually leads to death. As
a result, TS or DHFR inhibition causes “thymineless death” and which is a proven concept and
drug discovery methodology for several antimalarial, antiprotozoal and antimicrobial agents. 11

A.2.3. hDHFR, pcDHFR and pjDHFR
Pneumocystis is an unusual host-specific fungus that takes advantage of a weakened
immune system.152 Pneumocystis carinii DHFR (pcDHFR) was presumed to be the causative
species of PCP infection in humans and thus far, most of the drugs synthesized and evaluated for
PCP infections were tested against pcDHFR.126, 153 On the other hand, pc however is a distinct
species that infects rats, different from pj, responsible for human infections.134 There is a 38%
amino acid sequence difference in the pcDHFR and pjDHFR.113 Therefore, drugs assessed and
studied against the surrogate pcDHFR in-vitro, may not translate into activity in the treatment of
PCP infection in humans.154 Additionally, due to a lack of crystal structure information for
pjDHFR the rational design of pjDHFR inhibitors is hindered. The inability to grow the pj
organism outside the human lungs impedes the drug discovery process. Therefore, there is an
unmet need to develop a tissue culture for in vitro studies or an animal model for in vivo evaluation
of the synthesized compounds for pjDHFR enzyme.
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Table 1. Recombinant DHFR from pjDHFR and human DHFRs’ (hDHFR) inhibitory
Concentrations (IC50, in nM) against and Selectivity Ratios 154

a

pjDHFR (IC50, in nM)

hDHFR (IC50, in nM)

h/pj

7

2.4

52

21

8

2.5

5.6

2

9

4.2

150

35

TMP

120

32200

268

PTX

1.6

3.0

2

TMQ

2.1

2.6

1

These assays were carried out at 37 °C under 18 μM dihydrofolic acid concentration. The

standard error of the means for these values is 12% or less than the mean value.
Gangjee and coworkers154 reported pyrido[2,3-d]pyrimidines 7-9 as selective and
potent pjDHFR inhibitors (Table 1). Cody et al.155 reported the X-ray co-crystal structures of
9 with pcDHFR and hDHFR (PDB: 4IXE and 4QJC, respectively) to exemplify the
interactions that defines the enhanced selectivity and potency. The crystal structures of 7-9
were reported as ternary complexes with either hDHFR or native pcDHFR. 155 The hDHFR9-NADPH ternary complex superposed with of pcDHFR-9-NADPH ternary complex crystal
structure (Figure 22) discloses the differences and the binding geometry of 9 in pcDHFR and
hDHFR.155 In hDHFR cocrystal structure (PDB:4QJC) with ligand 9 (cyan), the scaffold
pyrido[2,3-d]pyrimidine is stabilized by a π-π stacking interaction with Phe31. The protonated
N1 and 2-NH2 form an ionic bond with Glu30. The 4-NH2 forms hydrogen bond interaction
between the backbone carbonyls of Ile7 and Val115. The side chain trifluorophenyl ring is
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oriented in the pocket formed by Asp21, Ser59, Pro61 and Asn64. The N6-CH3 group is
positioned towards Val115 side chain.

Figure 22. Superimposition of X-ray co-crystal structures of active sites of hDHFR (PDB: 4QJC,
1.62 Å) and pcDHFR (PDB: 4IXE, 1.54 Å).155 The hDHFR amino acid residues are displayed in
pink, ligand N6-methyl-N6-(3,4,5-trifluorophenyl)pyrido[2,3-d]pyrimidine2,4,6-triamine 9 is
displayed in cyan and the NADPH in yellow. The pcDHFR amino acid residues are displayed in
grey, ligand N6-methyl-N6-(3,4,5-trifluorophenyl)pyrido[2,3d]pyrimidine-2,4,6-triamine 9 is
displayed in magenta and the NADPH in tan color. The visualization was in Schrӧdinger Maestro
2020-1.156
In the pcDHFR co-crystal structure (PDB:4IXE) with ligand 9 (magenta) the
protonated N1 and 2-NH2 form an ionic bond with Glu32. The 4-NH2 forms hydrogen bonding
interaction between the backbone carbonyls of Ile10 and Ile123. The side chain
trifluorophenyl ring is placed in the pocket formed by Ser24, Ser64, Pro66 and Phe69. The
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N6-CH3 group is oriented towards the Ile123 side chain. The amino acids that are different
between the active sites of pcDHFR and hDHFR are indicated in Figure 22.

Figure 23. Sequence alignment of hDHFR (186 residues), pcDHFR and pjDHFR (both 206
residues). Mutational sites are underlined and in red while key active site residues are numbered
and colored cyan Reproduced with permission of the International Union of Crystallography from
ref.155 Copyright 2015 International Union of Crystallography.
Cody et al.135 investigated the variability in pcDHFR, pjDHFR and hDHFR enzyme
sequences. Residues seem to impact the active site (as seen in Figure 23) are described. In the
hDHFR enzyme, these residues are Gln and Asn; in pcDHFR enzyme, these are Lys and Phe and
in pjDHFR enzyme are Ser and Ser. Structural data for inhibitor binding to hDHFR and pcDHFR
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reveal that the residues interact with inhibitors and that inhibitors have been designed in the past
to specifically target these residues.134, 149, 157
Table 2. Kinetic constants (Ki) of TMP against pjDHFR, pcDHFR, and wild type and mutant
hDHFR.135

Enzyme

Ki (nM)

hDHFR

5200 ± 700 (n = 4)

pcDHFR

800 ± 300 (n = 7)

pjDHFR

43 ± 5 (n = 14)

hDHFR Q35S

1800 ± 100 (n = 3)

hDHFR N64S

170 ± 0.5 (n = 2)

hDHFR Q35S/N64S

1200 ± 100 (n = 4)

TMP is safe in PCP infection and is comparatively inactive against hDHFR (Table 2) which
is used as a potent pcDHFR and pjDHFR inhibitor.158 The importance of the positions in hDHFR
was illustrated by evaluating the Ki of TMP against wild type and mutants of hDHFR (Table 2).
The Q35S mutant hDHFR shows a 3-fold reduction in Ki for TMP, compared to hDHFR. The
N64S mutant displays a 31-fold reduction in Ki compared to hDHFR. The Q35S/N64S double
mutant displays a 4-fold reduction in Ki compared to hDHFR. Thus, pjDHFR over hDHFR
selectivity can be achieved by rational design of compounds targeting the different amino acid
residues in hDHFR and pjDHFR enzymes.
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A. 3. Multitargeting single agents that target tumors via cellular uptake by Folate receptors
and/or Proton-Coupled Folate Transporter and inhibit de novo purine nucleotide
biosynthesis
A.3.1 Folates

Figure 24. Physiologically important folates
Folate belongs to water-soluble B-vitamin and enzymatic cofactor that is necessary for the
synthesis of purine and thymidine nucleotides.159 Folic acid can be described as the parent structure
of folates (Figure 24). The group encompasses various oxidized forms of folic acid with
substitutions at N5 and/or N10, and the presence of γ-linked glutamyl residues (2-8). Reduced
folates (e.g. 5-methyltetrahydrofolate) are cofactors in the biosynthesis of purines and pyrimidines.
Mammalian cells do not have the enzymatic machinery to create folates de novo, thus, folates are
gained from dietary sources in mammals.160 Folates are hydrophilic and anionic structures that
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cannot cross biological membranes by passive diffusion. As a result, for the absorption of folic
acid several sophisticated transport systems are required. 160

Figure 25. Physiological role of folates in the cytosol.161

A.3.2 Physiological roles of Folates
Folates are essential cofactors and play a key role in cellular one-carbon C1 transfer
reactions (Figure 25).162,

163

The reduced cofactor 10-formyl-THF is used in the purine

biosynthesis in the cytosol,.162, 164 The enzyme glycinamide ribonucleotide formyltransferase
(GARFTase) utilizes 10-formyl-THF for the development of the imidazole ring of purines. 164
5-Aminoimidazole-4-carboxamide ribonucleotide formyltransferase (AICARFTase) enzyme,
uses 10-formyl-THF to synthesize inosin-5ˊ-monophosphate (IMP). 164 On the other hand,
5,10-methylene THF acts as a co-factor in reactions catalyzed by thymidylate synthase
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(TS).162, 165 The conversion of 2ˊ-deoxyuridine monophosphate (dUMP) to 2ˊdeoxythymidine
monophosphate (dTMP) is catalyzed by TS and the reaction generates DHF. 165 The DHF is
recycled into THF by the enzyme dihydrofolate reductase (DHFR), which is profusely
expressed in the cytosol.117 Another form of folic acid, 5-CH3-THF synthesized by Methylene
Tetrahydrofolate Reductase (MTHFR) from 5,10-methyleneTHF in the cytosol acts as a
cofactor for the reaction catalyzed by Methionine Synthase (MS).118 MS causes the conversion
of cysteine to methionine, which later conjugates with Adenosine Triphosphate (ATP) to form
S-Adenosyl-Methionine (SAM). SAM aids as a methyl group donor for several methylation
reactions on DNA, RNA, histones and neurotransmitters, and thus can cause an increase or
decrease in transcription and translation of proteins, such as tumor suppressor genes or
promoter genes.166

Figure 26. The physiological role of the mitochondrial folates. 167
Transport of THF cofactor into mitochondria from the cytosol occurs via mitochondrial
folate transporter (MFT/SLC25A32).168, 169 THF is used mainly in the biosynthesis of formate and
glycine in the mitochondria (Figure 26). For various cellular synthetic reactions the intermediate
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folic acid derivatives are transported to the cytosol.170 Around 40% of the folate ares accumulated
by mitochondria in the cell.170, 171 DNA synthesis, DNA repair, DNA methylation, can be affected
by abnormalities in the nucleotide biosynthesis, methylation reactions, glycine biosynthesis. This
can cause genomic instability of the cellular system, potentially leading to cell death. 172 The
reactions 1, 3, 4, and 5 in both the mitochondria and cytoplasm are illustrated in Figure 26.
Reaction 2 is limited only to the mitochondria. The enzymes involved are Serine
hydroxymethyltransferase

(SHMT)

(1);

glycine

oxidase

complex

(2);

5,10-

methylenetetrahydrofolate dehydrogenase (MTHF) (3); methenyltetrahydrofolate cyclohydrolase
(MDMC ) (4); and formyltetrahydrofolate synthetase (FTHFS) (5).

A.3.3 Transport of cellular folate
A.3.3.1 Transporters for folate influx

Figure 27. Intracellular and extracellular transport of (anti)folates.162
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(a) Reduced Folate Carrier (RFC, SLC19A1):162
RFC (Figure 27) is a group of transport proteins that is part of the major facilitator
superfamily (MFS) of the transporter, specifically solute carrier (SLC) family of facilitative
carriers.173 The protein has 12 hydrophobic transmembrane domains (TMD) with a short
hydrophilic N-terminus and long hydrophilic C-terminus in the cytosol.174 RFC is a 591- amino
acid transmembrane protein with a molecular mass of approximately 85 kDa. 174 There is no ATP
binding site domain in RFC and thus, its transport is not ATP-driven. 174 It is a bidirectional
antiporter that exchanges adenosine nucleotides, thiamine monophosphate and thiamine
pyrophosphate (which are stored intracellularly). The transport of folates is uphill into the cell by
the antiporter due to low concentration of folates inside the cell. 175 RFC has a higher affinity for
reduced folates (Km = 1-3 µM) and lower affinity for oxidized folates like folic acid (Km =200400 µM).176 RFC is ubiquitously expressed in normal and malignant cells in humans. The cancer
cells are present in bone marrow, breast, lung, heart, small intestine and lymphocytes. 177-179
(b) Proton-Coupled Folate Transporter (PCFT, SLC46A1):
PCFT (Figure 27) is abundantly expressed in human tumors and is active under pH
conditions associated with the tumor microenvironment. 180 It is a unidirectional symporter that
transports folates with protons into the cells. 181 In the upper small intestine, the concentration of
protons is high due to the activity of Na+/H+ exchanger and the high extracellular H+ concentration
acts as the driving force for the PCFT symport into the cell.182 PCFT functions optimally at pH
5.5.181 As the pH increases the activity of the transporter decreases. 181 Unlike RFC, PCFT has an
equal affinity for both folic acid and reduced folates.182, 183 PCFT has 12 TMDs and both of its N-
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and C-termini are present in the cytosol.181 The amino acid similarity between PCFT and RFC is
14%.184 The X-ray crystal structures for PCFT and RFC have not yet been resolved, which makes
the binding interactions and the drug design challenging.
(c) Folate receptors (FRα, FRβ, FRγ):162
Folate receptors and transporters and one-carbon metabolism play essential roles in the
treatment of cancer.185 FRs are glycoproteins with high affinity for folates and are encoded by
three different loci of FRα, FRβ, and FRγ. There is 70-80% amino acid homology among the FRs
and have 245-257 amino acid residues.186 FRα and FRβ are glycosylphosphatidylinositol (GPI)anchored cell surface glycoproteins and FRγ is a secretory protein. 186 The FRα and β uptake is
receptor-mediated endocytosis.187 FRα is expressed in epithelial cells of uterus, placenta, choroid
plexus, retina and kidney. Moreover, it is expressed in cancers of epithelial origin- adenocarcinoma
of ovary, cervix, uterus, kidney, lung, breast, bladder and pancreas. 186, 188, 189 The expression of
FRβ is in placenta, thymus, spleen, and malignancies of myelomonocytic origin. 186

Figure 28. X-ray co-crystal structure of FRα with AGF183 (Pink) (PDB: 5IZQ, 3.6Å)190
visualized using Schrӧdinger Maestro 2020-1. 156
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The X-ray crystal structures of FRα and FRβ have been resolved which demonstrates the
co-crystal structure of a known antifolate AGF183 displayed in Figure 28.179, 190 The 2-amino-4oxo pyrimidine motif is commonly observed across folates and antifolates. The 2-NH 2 forms an
ion-dipole interaction with the Asp81 side chain. The 3-NH interacts with the side chain of Ser174
via hydrogen bond interactions. The 4-oxo forms a hydrogen bond with the side chain of Arg103.
The pyrrolo[2,3-d]pyrimidine scaffold is stabilized by π-π stacking interactions with Tyr85 and
Trp171. The L-glutamate side chain extends into a pocket composed of hydrophilic side chains.
The α-COOH forms ion-dipole interactions with the Trp140 side chain and backbone NHs of
Trp138 and Gly137. The γ-COOH forms ionic interactions with Lys136 and ion-dipole
interactions with side chains of the Trp102 and Gln100.

Figure 29. X-ray co-crystal structure of FRβ with Pemetrexed (PMX, green) (PDB: 4KN2, 2.6
Å)141 visualized Schrӧdinger Maestro 2020-1.156
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The co-crystal structure of FRβ with MTX has been resolved, which is visualized in Figure
29. The stabilization of the 2,4-diamino scaffold is observed by π-π stacking interactions with
Tyr101 and Trp187. The 2-NH2 forms hydrogen bonding interactions with Ser190 side chain and
the 4-NH2 forms ion-dipole interaction with Asp97 side chain. The phenyl linker is also stabilized
by π-π stacking interactions with Phe78 and Trp118. The L-glutamyl NH forms a hydrogen
bonding interaction with His151 backbone. The anionic side is oriented in a solvent exposed
pocket. The α-COOH forms ion-dipole interactions with Trp154 and Trp156 side chain and
backbone NH of Gly153. The γCOOH forms ionic interactions with Arg152 and ion-dipole
interactions with side chains of Trp118 and Gln116.

A.3.3.2 Transporters for efflux of folates
In humans several ABC transporters exist where multidrug resistance proteins (MRP),
MRP1-5 are capable of exporting folate derivatives.191 Another exporter of folates is breast cancer
resistance protein (BRCP/ABCG2).192 Overexpression of these transporters in cancer cells can
mediate the removal of (anti)folates from the cell.
A.3.3.3 Folates retention in the cell
Folates undergo folylpolyglutamylation following the uptake and this process is catalyzed
by the enzyme folylpoly-γ-glutamate synthetase (FPGS).193 It catalyzes sequential addition of
multiple equivalent of glutamic acid to the γ-carboxyl chain of the folate cofactors. As a result,
there is an increased intracellular retention of these polyanions. There are two forms of FPGS:
cytosolic and mitochondrial forms.167 Polyglutamylated folates are recognized as a much better
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substrates for various folate-dependent enzymes.194 Folylpolyglutamylation process can be
inverted by the enzyme γ-glutamyl hydrolase (GGH), which catalyze the hydrolysis of the γglutamyl tail of polyglutamylated folates.195

C.3.4 Antifolates and their clinical uses

Figure 30. Clinically used antifolates

For over 60 years, antifolates have served important therapeutic roles as anticancer,
antimicrobial and immunomodulatory agents.196 Aminopterin, the first antifolate, was well-known
for cancer therapy.197 Aminopterin was replaced with methotrexate (MTX) in the 1950s due to its
low therapeutic index.198 MTX is a DHFR inhibitor, which is taken up by cells via PCFT but
mainly by RFC transport (Figure 26).162 Raltitrexate (RTX) (Tomudex®) (Figure 30) is a potent
inhibitor of TS (Ki = 62 nM) and is transported into cells by RFC and FRα. 199, 200 When compared
to the monoglutamylated form the polyglutamylated form of RTX increases the inhibition for TS
by 100-fold. PMX (Alimta®) (Figure 30) is a TS inhibitor and is an excellent substrate for FPGS.
The pentaglutamylated form of PMX displays an 84-fold increase in potency for TS, compared to
the monoglutamylated form.201, 202 Pemetrexed (PMX) (Alimta®) was introduced in the market for
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treatment of mesothelioma and non-small cell lung cancer in 2004. 82, 203 The pentaglutamylated
form of PMX also shows moderate potency against GARFTase and AICARFTase enzymes, the
monoglutamylated form is inactive against these two targets. 201 As a result, TS is the primary target
for PMX. Pralatrexate (PDX) (Folotyn®) (Figure 30) is a DHFR inhibitor with an intracellular
uptake through RFC.82, 203 In patients it has been approved with peripheral T-cell lymphoma. 82, 203
As a main mechanism of entry into the cell all the clinically used folates utilize RFC
transport.196 These compounds cause dose-limiting toxicities (severe myelosuppression) due to
their ubiquitous expression in RFC.204, 205 They do not have inherent selectivity for cancer cells.
Polyglutamylation decreases when the concentration of intracellular folates (e.g., 5-formyl-THF)
increases. As a result, when the concentration of intracellular folates increases the activity of PMX
will decrease.Moreover, PMX-resistant cancers have been identified which were developed due
mutagenesis in the FPGS active site.206-208 Since polyglutamylation is responsible for increased
potency, loss of FPGS activity can lead to drug-resistant cancer cell lines. 207 Several studies have
displayed reduced activity of such FPGS-dependent antifolates in cancer cell lines. These cell lines
have low FPGS activity or have mutated FPGS incapable of binding to the antifolate. 206,
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Decreased activity of antifolates is observed with an increase in GGH activity which can cause
resistance.209 Resistance can also be developed by the overexpression and mutations in the active
site of DHFR or TS.206-208
There is a critical need to develop agents where drug resistance and dose-limiting toxicities
can be circumvented by (a) increased selectivity for transport via PCFT or FRs over RFC to
eradicate or decrease dose-limiting toxicities; (b) ability to target two or more intracellular
enzymes to decrease the development of resistance; and (c) absence of dependence on FPGS for
activity against intracellular targets. Dies et al. .210 and Wang et al.211 report 6-substituted
44

pyrrolo[2,3-d]pyrimidines with selectivity for transport through PCFT and FRs over RFC. These
compounds showed potent GARFTase (inhibit purine synthesis) inhibition. This inhibition in
GARFTase are mainly due to their monoglutamylated form and do not depend on FPGS.
A.3.5 Inhibition of de novo purine synthesis

Figure 31. De novo purine nucleotide biosynthesis pathway.212 (Modified from ref 212)
Purines, a coenzyme A (coA,) serve as building blocks of DNA and RNA, and as a
component of ATP, cyclic adenosine monophosphate (cAMP), nicotinamide adenine dinucleotide
(NAD).196 The synthesis of purines can occur through de novo synthetic pathway or salvage
pathway.184 The de novo synthetic pathway is a 10-step folate-dependent pathway (from
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phosphoribosyl pyrophosphate (PRPP) to AMP) (Figure 31). 184 Free purine bases, which are
derived from the turnover of nucleotides or from the diet, can be attached to PRPP to form purine
nucleoside monophosphates. There are two types of phosphoribosyl transferases: adenine
phosphoribosyl

transferase

(APRT)

for

AMP

formation

and

hypoxanthine-guanine

phosphoribosyl transferase (HGPRT) for IMP and GMP formation. 162 Many enzymes required for
salvages pathways get co-deleted in cancer cells and cancer cells remain dependent on the de novo
synthesis for obtaining purines.213 Further, methylthioadenosine phosphorylase (MTAP), another
salvage enzyme that releases adenine from methylthioadenosine is abundantly expressed in normal
tissues and is co-deleted with CDKN2A in many tumors. 214-216

Table 3. GARFTase inhibition constants (Ki)210

X

n

Ar

Ki (nM)

AGF23 NH 4

1,4-phenyl

17 ± 3

AGF50 S

1,4-phenyl

1067 ± 271

AGF71 NH 4

2,5-thiophenyl

22 ± 3

AGF94 NH 3

2,5-thiophenyl

68 ± 11

4
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(a) GARFTase
Gangjee and coworkers have published 6-substituted pyrrolo[2,3-d]pyrimidines which
displayed GARFTase inhibition (Table 3).210,

211, 217

The reported compounds showed potent

inhibition of GARFTase in their monoglutamylated form. 210

Figure 32. X-ray co-crystal structure of GARFTase and antifolate AGF150 (PDB: 4ZZ1, 1.35
Å).211 AGF150 is displayed in green and the substrate GAR is displayed in yellow. The co-crystal
structure was visualized Schrӧdinger Maestro 2020-1.156
The X-ray co-crystal structure of GARFTase and antifolate AGF150 (PDB: 4ZZ1, 1.35 Å)
(Figure 32) can illustrate the binding mode of antifolates in GARFTase can be visualized by
studying.211 The N1 of the pyrrolo[2,3-d]pyrimidine scaffold forms a hydrogen bond with NH of
the backbone of Leu899. The 2-NH2 shows a hydrogen bond with backbone NHs of Ala947 and
Glu948. The 3-NH also forms a hydrogen bond with the backbone NH of Ala947. The 4-oxo forms
hydrogen bond with backbone NH of Asp951. The glutamate side chain is oriented in a solvent-
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exposed pocket. The α-COOH forms an ionic bond with Arg871 and an ion-dipole interaction with
the backbone NH of Ile898.
(b) AICARFTase
Adenine phosphoribosyl transferase (APRT) and adenosine kinase (AK) metabolize 5Aminoimidazole-4-carboxamide (AICA) and AICAR to AICAR monophosphate (ZMP). 184 Thus,
this can circumvent the reaction catalyzed by GARFTase. Moran and coworkers 218 reported an
interesting find on the effect of PMX on AICARFTase. Inhibition of AICARFTase causes
accumulation of its substrate- AICAR (ZMP). The accumulated ZMP causes activation of AMPdependent protein kinase (AMPK), the activation of AMPK causes inhibition of the mechanistic
target of rapamycin (mTOR) as well as direct phosphorylation of the raptor component of
mammalian target of rapamycin complex (mTORC1 complex). Thus, it inhibits cell growth
through two distinct pathways.

Figure 33. X-ray co-crystal structure of AICARFTase with bicyclic classical antifolate compound
(PDB: 1P4R, 2.55 Å).219 The ligand and AICAR are displayed in cyan and magenta color,
respectively. The co-crystal structure was Schrӧdinger Maestro 2020-1. 156
48

To illuminates the binding mode of compounds in AICARFTase the X-ray cocrystal
structure of AICARFTase with a bicyclic classical antifolate has been revealed (Figure 33). 219
Stabilization of the bicyclic scaffold occurs by π-π stacking interaction with Phe544. The 2-NH 2
displays hydrogen bond with the backbone carbonyl of Asn489 and an ion-dipole interaction with
the side chain of Asp546. The 3-NH also displays ion-dipole interaction with the side chain of
Asp546. The 4-oxo group forms a hydrogen bond with the side chain of Asn547. The sulfone in
the linker shows hydrogen bonding interaction with backbone NH of Arg541, the side chain of
Asn431 and an ion-dipole interaction with Lys266. The glutamate side chain is oriented in a
hydrophilic, solvent-exposed pocket.

Figure 34. 5-substituted pyrrolo[2,3-d]pyrimidine compounds 10-13 with inhibitory activity
against GARFTase and AICARFTase.220, 221
The 5-substituted pyrrolo[2,3d]pyrimidines 10-13 were reported by Gangjee and
coworkers220, 221 (Figure 34), which exhibited inhibition of both GARFTase and AICARFTase.
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This dual inhibition attacks the purine biosynthetic pathway at two distinct sites and could
overcome tumor resistance developed at a single site. Such a multitarget agent will be effective for
drug-resistant tumors and will be advantageous in anti-folate drug discovery.
A.3.6 Inhibitors of serine hydroxymethyl transferase enzyme
One-carbon metabolism incorporates a broad range of biosynthetic reactions that can occur
in the cytoplasm and the mitochondria.222 These are essential for maintaining cellular homeostasis
and supports multiple physiological functions.222, 223 The reactions include biosynthesis (purines
and thymidine), amino acid homeostasis (glycine, serine, and methionine), epigenetic
maintenance, and redox defense.222, 224 One carbon metabolic reactions are compartmentalized in
both eukaryotic cells and across organs.222 Mitochondrial 1C reactions are crucial, both for
producing 1C units that are exported to the cytosol and for making additional products, including
glycine and NADPH.222 Serine is a key metabolic source for producing one-carbon (1C) units in
mammalian cells.222 Two serine hydroxymethyl transferase (SHMT) enzymes, SHMT1 and
SHMT2, break down serine into glycine and methylene-tetrahydrofolate (THF) in the cytosol and
mitochondria, respectively.225 The latter serine catabolite feeds into cellular 1C pool, and either
directly participates in thymidine synthesis or indirectly in purine or methionine synthesis after its
oxidative or reductive conversion to formyl- or methyl-THF. 226 Because the 1C-derived products
are key anabolic building blocks, sustaining the 1C pool is vital for cellular proliferation and is
required for a number of physiological and pathophysiological processes ranging from stem cell
renewal to cancer progression.227 Consistent with their critical roles in supporting cell
proliferation, SHMTs are highly active in many rapidly-growing cancer cells and are important
molecular targets for cancer intervention.222, 228
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Figure 35. C1 metabolism is compartmentalized in the cytosol and mitochondria. 229, 230 (Modified
from 229 and 230)
Th entry of folates to the cell through the plasma membrane is facilitated by folate
transporters, PCFT, RFC and mitochondria via SLC25A32 (Figure 35). One carbon units
incorporated in various folate metabolism cofactors are primarily derived from serine catabolism
occurring in mitochondria.

222

Thus, serine catabolism plays an indispensable role in cancer

growth.222, 224 Serine is catabolized in mitochondria and synthesized in the cytosol by a set of
enzymes that allow not only for parallel metabolic processes but also for a complete
oxidative/reductive cycle.222 In mitochondria, serine is metabolized to formate via three enzymes:
a) SHMT2, b) methylene tetrahydrofolate dehydrogenase 2 (MTHFD2), and c) methylene
tetrahydrofolate dehydrogenase 1 like (MTHFD1L). In the cytosol, serine is synthesized via a)
methylene tetrahydrofolate dehydrogenase 1 (MTHFD1) and b) SHMT1. The cycle that
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catabolizes serine in mitochondria and synthesizes serine in cytosol is thermodynamically driven
by the difference in electrochemical potential between NADH (NADPH) and cytosolic NADPH.
There is a continuous need for 1C supply in rapidly proliferating cells such as cancer cells
which results in the overexpression of SHMT2 and MTHFD2.231-233 The 1C unit generated from
the serine catabolism in the mitochondria is exported to cytosol as formate. 222, 224 The MTHFD1
incorporates the formate into the THF to form 10-formylTHF. Subsequently, by a series of
reactions catalyzed by GARFTase, AICARFTase and thymidylate synthase (TS), the 1C unit is
used for nucleotide synthesis.224, 234 SHMT2 (or MTHFD2) knockout (KO) cells are viable and
tumorigenic (albeit with decreased growth rates) in nutrient-rich conditions, as the reversal of
cytosolic SHMT1 (serine-to-glycine) provides sufficient C1 units to sustain some level of de novo
nucleotide biosynthesis.224 Additionally, SHMT1 does not generate sufficient glycine for protein,
nucleotide and glutathione biosynthesis, rendering both SHMT2 and MTHFD2 KO cells as glycine
auxotrophs.222 Simultaneous inhibition of cytosolic and mitochondrial SHMT enzyme is necessary
to achieve the cytotoxic effect. Gangjee and coworkers, 229, 230 have recently reported pyrrolo[3,2d]pyrimidine antifolates which inhibit both SHMT1 and SHMT2 along with de novo purine
biosynthesis pathway and are transported selectively into tumor cell. This resulted in outstanding
in vivo efficacy in a pancreatic cancer model. These compounds are exciting prototypes for dualtargeting mitochondrial and cytosolic C1 metabolism for cancer, with significant promise for
overcoming resistance to current anticancer therapies.
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II. CHEMICAL REVIEW

The chemistry related to the work carried out is reviewed in this section and includes
synthetic approaches to the following heterocyclic ring systems:
B.1. Thieno[2,3-d]pyrimidines
B.2. Pyrrolo[3,2-d]pyrimidines
B.3. Pyrazolo[4,3-d]pyrimidines
B.4. Pyrido[2,3-d]pyrimidines
B.5. Pyrrolo[2,3-d]pyrimidines
B.6 Name Reactions

B.1. Synthesis of thieno[2,3-d]pyrimidines
Scheme 1. Retro-synthetic analysis of thieno[2,3-d]pyrimidines

The synthetic strategy for the construction of thieno[2,3-d]pyrimidines includes two categories
(Scheme 1):

1. From thiophene precursors (Route A)
2. From pyrimidine precursors (Route B)
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1. From thiophene precursors (Route A)

1.1 Condensation to obtain 2-amino-5,6-disubstituted thieno[2,3-d]pyrimidines

Scheme 2. Synthesis of thieno[2,3-d]pyrimidine 18

Reagents and conditions: a) DMSO2, 140 oC
2-Amino-5,6-disubstituted thieno[2,3-d]pyrimidines 18 (Scheme 2) were reported to be
synthesized via cyclocondenation of appropriate thiophenes 14-16 with an amidine derivatives
17a-17b,235 which can be guanidine (R = NH2) or chloroformamidine hydrochloride (R = Cl). The
nature of the X substitution in thiophene 14-16 determines the substitution pattern at 4-position (Y
at the C4-position) in 18; when X = CN, COOR or CHO, the cyclization reaction affords 18 with
Y = NH2, OH or H respectively.

Scheme 3. Synthesis of thieno[2,3-d]pyrimidine from formamide.

Reagents and conditions: a) 170o C, 12h236
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The synthesis of thieno[2,3-d]pyrimidin-4(3H)-one 21 (Scheme 3) was reported by Fyfe et
al.,236 from methyl 2-aminothiophene-3-carboxylate (19) and formamide 20 at 170 °C under a
nitrogen atmosphere.

Scheme 4. Synthesis of thieno[2,3-d]pyrimidine from thioamide.

Reagents and conditions: a) Microwave irradiation237
The thioamide 23 and amino-thiophene-carboxylates 22 were used as starting materials for
the construction of thieno[2,3-d]pyrimidin-4-amines 24a-24e following literature method (Scheme
4).237 The thioamide 23 can be synthesized from the corresponding amide by reaction with
Lawesson’s reagent.237 In this context, the preparation of thienopyrimidin-4-ones, which usually
requires very vigorous reaction conditions and prolonged reaction times, can be achieved starting
from the corresponding thioamides 23, amino-thiophene-carboxylates 22 as hydrochlorides,
without solvent and under microwave irradiation. In a typical general procedure, twenty 4 mL open
vials containing a homogenized mixture of the corresponding thioamide 23 (3 mmol) and aminothiophene-carboxylates 22, as hydrochlorides (1 mmol), were inserted into a Teflon disc and
irradiated at 550 Watt power for 3.5 minutes.237
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Scheme 5. Synthesis of thieno[2,3-d]pyrimidine from nitrile and HCl gas.

Reagents and conditions: a) HCl (gas), Dioxane, r.t., 2-3 h.

Synthesis of 27 were described by Shishoo et al.,238 (Scheme 5) which involves bubbling
dry HCl gas through a stirred solution of 25 and the corresponding nitrile 26 in dioxane at room
temperature for 2–3 hours (until saturation). Then stirring the mixture was done at room
temperature for a further 12 h period. This procedure yielded the corresponding thieno
pyrimidinones 27, which were simply isolated and purified by trituration with diethyl ether. 237
Scheme 6. Synthesis of thieno[2,3-d]pyrimidine from chloroacetonitrile

Reagents and conditions: a) sulfur, morpholine, ethyl cyanoacetate, rt, 18 h (b) chloroacetonitrile,
HCl (g), 50 °C to reflux, 4−24 h236

An equimolar mixture of powdered sulfur and morpholine was stirred until total dissolution
of the sulfur (Scheme 6). Ethyl cyanoacetate and butan-2-one 28 were added to the reactional
mixture, which was stirred at room temperature for 18 h to get cyclized ethyl 2-amino-4,556

dimethylthiophene-3-carboxylate 29. Compound 30 was synthesized by reacting 29 and
chloroacetonitrile in 1,4-dioxane and heated to 50 °C, and passed with dry HCl gas until the
starting material was disappeared in 3−24 h or a precipitate is formed. 236

Scheme 7. Synthesis of thieno[2,3-d]pyrimidine from urea.

Reagents and conditions: a) 170 oC, 2 h.
Ishikawa and coworkers239 reported a novel synthesis of 2-amino-4-phenyl substituted
thieno[2,3-d]pyrimidines 33 where the condensation of aminocarbonyl thiophenes 31 and urea 32
was done to afford thieno[2,3-d]pyrimidine 33 (Scheme 7).

Scheme 8. Synthesis of 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one from
formamide.

Reagents and conditions: a) formamide, 170 °C, 12 h 236
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Ethyl-2-amino-4,5,6,7-tetrahydrobenzothiophene-3-carboxylate (34) (Scheme 8) was
taken up in formamide and heated to 170 °C under a nitrogen atmosphere to obtain 5,6,7,8tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one 35.236
Scheme 9. Synthesis of 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one from
chloroacetonitrile

Reagents and conditions: a) morpholine, rt, 12h b) chloroacetonitrile, 1,4-dioxane, HCl(g) (Kipp’s
apparatus), 50°C, 2 h236
Sulfur 37 and morpholine was stirred until total dissolution of the sulfur (Scheme 9).
Cyclohexanone 36 and ethyl cyanoacetate 38 were added to the reactional mixture, which was
stirred

at

room

temperature

for

∼12

h

to

get

cyclized

ethyl

2-amino-4,5,6,7-

tetrahydrobenzo[b]thiophene-3-carboxylate 34. Compound 39 was synthesized by reacting 34 and
chloroacetonitrile in 1,4-dioxane and heated to 50 °C, and passed with dry HCl gas (Kipṕs
apparatus) until the starting material was disappeared in 3−24 h or a precipitate formed. 236

B.2. Synthesis of pyrrolo[3,2-d]pyrimidines

Elliott et al.,240 published a method (Scheme 10) of synthesizing 7-Substituted Pyrrolo[3,2d]pyrimidine 45. Aldehydes 40 and 3,3-dimethoxypropionitrile were mixed together and added to
a solution of NaOMe in MeOH to synthesize 41 followed by treatment with 6N HCl to deprotect
the acetal group and provide 42 (Scheme 12). Catalytic hydrogenation of 42 in MeOH followed
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by condensation of the resulting 43 with diethylamino malonate gave the required enamine 44. On
treatment with NaOMe in MeOH at room temperature, 44 was smoothly converted to 45. Removal
of the MeOH and addition of water gave essentially pure pyrrole (45a) in 57% yield, and thus, this
sequence obviated the need for purification by column chromatography. Other pyrroles (45b-45i)
behaved similarly.
Scheme 10. Synthesis of 7-Substituted pyrrolo[3,2-d]pyrimidine from aldehydes and 3,3dimethoxypropionitrile.

Reagents and conditions: a) NCCH2CH(OCH3)2, NaOMe; b) 6 N HCl; c) H2, Pd/ C; d)
H2NCH(COOEt)2; e) NaOMe, MeOH.
Scheme 11. Synthesis of pyrrolo[3,2-d]pyrimidines from methyl pyrrole 2-carboxylate and acid
chlorides.

Reagents and conditions: a) AlCl3, appropriate acid chloride, DCM, 0 oC- r.t., 16 h; b) F3CCOOH,
Et3SiH, r.t., overnight
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Regioselective Friedel-Crafts acylation241 of commercially available methyl pyrrole 2carboxylate (46) using the appropriate acid chlorides and aluminium trichloride gave methyl esters
47 in 63-74% yields. Reduction242 of 47 with Et3SiH and F3CCOOH yielded 48 (Scheme 11).

Scheme 12. Synthesis of 2-alkyl-4-oxo-pyrrolo[3,2-d]pyrimidines from ethyl 3-amino5substituted-1H-pyrrole-2-carboxylate

Reagents and conditions: a) (i) Alkylnitrile, HCl(g); (ii) NaOH, EtOH
Pyrrolo[3,2-d]pyrimidines 50 with 2-alkyl substituents are obtained by treatment of 5substituted pyrrole 49 (Scheme 12) with an alkyl nitriles in anhydrous hydrochloric acid followed
by heating with sodium hydroxide.243 For R = methyl, the yield was 53%.
Scheme 13. Synthesis of 3H-pyrrolo[3,2-d]pyrimidin-4(5H)-one from ethyl 3-amino-1H-pyrrole2-carboxylate

Reagents and conditions: a) formamidine acetate, EtOH
Pyrrolo[3,2-d]pyrimidines with 2-H 52 are obtained by cyclocondensation of substituted
ethyl 3-amino-1H-pyrrole-2-carboxylate 51 (Scheme 13) with formamidine acetate in refluxing
ethanol.244
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Scheme 14. Synthesis of 2-sulfanyl-4-oxo-pyrrolo[3,2-d]pyrimidines from ethyl 3-amino-1Hpyrrole-2-carboxylate

Reagents and conditions: a) S=C=NCOOC 2H5, HCl; b) aq. NaOH
Pyrrolo[3,2-d]pyrimidine 54 with 2-sulfanyl substituent can be obtained by treatment of
2-amino-6-phenyl-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one 53 (Scheme 14) with an ethyl
isothiocyanatoformate and hydrochloric acid in benzene at reflux followed by heating with
aqueous sodium hydroxide.245

B.3. Pyrazolo[4,3-d]pyrimidines
Scheme 15. Synthesis of 2,4-dichloro pyrazolo[4,3-d]pyrimidines from methyl-pyrazolocarboxylic acids 55

Reagents and conditions: a) (i) fuming HNO3, H2SO4, 0°C, (ii) SOCl2, NH4OH, 0°C to r.t., (iii)
10% Pd/C, EtOH, 60 psi H2, over all 46-51% yield; b) CDI, ACN, reflux, 98%; c) POCl 3, N,Ndiethylaniline, 130°C, 60-72%.246
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The pyrazolo intermediates 56a and 56b (Scheme 15) were prepared following a literature
method246 from readily available 1-methyl-1H-pyrazole-5-carboxylic acid 55a and 1,3-dimethyl1H-pyrazole-5-carboxylic acid 55b, respectively. Pyrimidinediones 57a-57b were synthesized by
treating 56a-56b and CDI in reflux condition in ACN. Chlorination was done by treatment of 57a57b with phosphoryl chloride in the presence of N, N-diethylaniline to provide dichloropyrimidines
58a-58b in 60-72% yield (Scheme 15).

Scheme 16. Synthesis of pyrazolo[4,3-d]pyrimidines from 4-amino-3-methyl-1H-pyrazole-5carboxamide with thiourea.

Reagents and conditions: a) 190-210 oC
Robins et al.247 (Scheme 16) accomplished the desired product 61 by the cyclization of 4amino-3-methyl-1H-pyrazole-5-carboxamide 59 with thiourea 60 under reflux conditions.
Scheme 17. Synthesis of 7-hydroxypyrazolo[4,3-d]pyrimidine from 4-amino-1H-pyrazole-5carboxamide with formamide.

Reagents and conditions: a) H2O, 1h.
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Robins et al.,248 treated 4-amino-1H-pyrazole-5-carboxamide 62 with formamide 63 under
boiling conditions to afford 7-hydroxypyrazolo[4,3-d]pyrimidine 64 as a target molecule (Scheme
17).

Scheme 18. Synthesis of 3-methyl-7-thioxo-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-d]pyrimidin-5one from 4-amino-3methyl-1H-pyrazole-5-carbothioamide with urea.

Reagents and conditions: a) reflux
Long and co-workers249 introduced a fusion reaction by ring annulation of 4-amino3methyl-1H-pyrazole-5-carbothioamide 65 with urea 66 to achieve 3-methyl-7-thioxo-1,4,6,7tetrahydro-5H-pyrazolo[4,3-d]pyrimidin-5-one 67 (Scheme 18).

Scheme 19. Synthesis of pyrazolo[4,3-d] pyrimidinedione from 5-carbamoyl-1H-pyrazole-4carbonyl azide.

Reagents and conditions: a) toluene, reflux
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Curtius rearrangement249 was carried out in boiling toluene to generate pyrazolo[4,3-d]
pyrimidinedione 69 as a final compound (Scheme 19) from 5-carbamoyl-1H-pyrazole-4-carbonyl
azide 68.

Scheme 20. Synthesis of pyrazolo[4,3-d]pyrimidine from 4-nitro-1H-pyrazole-5-carboxamide.

Reagents and conditions: a) DBAD/Ph 3P; b) H2, Pd/C; c) CDI; d) POCl3

Tollefson and co-workers250 carried out a Mitsunobu reaction (Scheme 20) of the alkoxy
ethanol (71) with 4-nitro-1H-pyrazole-5-carboxamide (70) to afford the N-alkylated pyrazole (72).
The nitro group in compound 72 was reduced to the amine 73 via hydrogenation. Cyclization of
compound 73 to the dione 75 was accomplished by reaction with carbonyldiimidazole (CDI, 74).
Finally,

chlorination

of

75

using

phosphorus

pyrazolopyrimidine dichloride 76.
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oxychloride

afforded

the

required

Scheme 21. Synthesis of pyrazolo[4,3-d]pyrimidine from ethyl 4-amino-1-(4-methoxyphenyl)1H-pyrazole-3-carboxylate and 1,1,1-triethoxyethane

Reagents and conditions: a) NH4OAc, MW.
Lenzi et al.251 attempted the cyclization reaction of ethyl 4-amino-1-(4-methoxyphenyl)1H-pyrazole-3-carboxylate 77 with 1,1,1-triethoxyethane 78 in presence of ammonium acetate to
afford 79 under microwave irradiation conditions (Scheme 21).

Scheme 22. Synthesis of pyrazolo[4,3-d]pyrimidine with potassium hydroxide or potassium tertbutoxide.

Reagents and conditions: a) KOH, EtOH or t-BuOK, THF
Brantenko and co-workers252 attempted intramolecular cyclization reaction of 80 by
treating with potassium hydroxide in EtOH or potassium tert-butoxide in THF to afford 81
(Scheme 22).
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Scheme 23. Synthesis of pyrazolo[4,3-d]pyrimidine from 4-amino-1-phenyl-1H-pyrazole-3carbonitrile and ethyl (E)-3-(4-methoxyphenyl)acrylimidate hydrochloride.

Reagents and conditions: a) NH4OAc, MW, 150 oC
Squarcialupi et al.,253 reacted 4-amino-1-phenyl-1H-pyrazole-3-carbonitrile (82) with
ethyl (E)-3-(4-methoxyphenyl)acrylimidate hydrochloride 83 to attain 84 in presence of
ammonium acetate under microwave conditions (Scheme 23).

Scheme 24. Synthesis of pyrazolo[4,3-d]pyrimidine from 6-(bromomethyl)-1,3-dimethyl-5nitropyrimidine-2,4(1H, 3H)dione and methylamine.

Reagents and conditions: a) EtOH, reflux, 4h.
Senda et al.,254 have accomplished the desired molecule 87 by reacting 6-(bromomethyl)1,3-dimethyl-5-nitropyrimidine-2,4 (1H, 3H) dione 85 with methylamine 86 in ethanol under
reflux conditions (Scheme 24).
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B.4. Pyrido[2,3-d]pyrimidines
Scheme 25. Synthesis of pyrido[2,3-d]pyrimidines from 2,4,6-triaminopyrimidine and
bromomalondialdehyde

Reagents and conditions: a) (i) BrCH(CHO)2, HCl, EtOH, 30 min; (ii) PivCl, pyridine, reflux; b)
p-Toluidine, Pd2dba3, LiHMDS, X-Phos, toluene, 100 oC
Gangjee et al.,154 reported method of synthesizing pyrido[2,3-d]pyrimidine from 2,4,6triaminopyrimidine 88 and bromomalondialdehyde in acidic conditions (Scheme 25). A further
protection of the 2,4-diamino-6-bromopyrido[2,3-d]pyrimidine 89 with the pivaloyl group
increased solubility and facilitated purification of the final compound. Under these conditions, bis
pivaloyl derivative 89 was obtained in a global yield of 39%. Buchwald−Hartwig aminations of
89 afforded 90 in 56-93% yields.

Scheme 26. Synthesis of pyrido[2,3-d]pyrimidines from pyrido dimethyl amidine and substituted
phenyl sulfanyl aniline.

Reagents and conditions: a) AcOH, reflux.
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Krueger et al.255 investigated the synthesis pyrimidine derivatives in Scheme 26. The
isopropyl pyrido[2,3-d] pyrimidine analog 93 was constructed by cyclization of pyrido dimethyl
amidine 91 with the substituted phenyl sulfanyl aniline 92 in moderate yield 10-54%.

Scheme 27. Synthesis of pyrido[2,3-d]pyrimidines from 4-aminopyrimidine-5-carbaldehyde.

Reagents and conditions: a) K2CO3, acetone, r.t.
Rao group256 investigated the synthesis of 7-substituted pyrido[2,3-d]pyrimidines in
Scheme 27. The 7-substituted pyrido[2,3-d] pyrimidine 96, easily obtained from 4aminopyrimidine-5-carbaldehyde 94 and various aromatic or heteroaromatic ketones 95, in 7885% yield.

Scheme 28. Synthesis of pyrido[2,3-d]pyrimidines from 2,4,6-triaminopyrimidine and β-ketoester.

Reagents and conditions: a) NMP, 180 oC, 47%; b) (i) (COCl)2, DMF, 70%; (ii) HCO2Na, 5%
Pd/C, 97%; (iii) NIS, TFA, 70%
Rosowsky et al.,257 described the synthesis of pyrido[2,3-d]pyrimidine 98 (Scheme 28)
which was achieved by reaction of 2,4,6-triaminopyridine 88 and β-ketoester 97, affording 98 in
47% yield. Derivative 99 obtained from 98 via a sequence of reactions described in Scheme 34.
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Scheme 29. Synthesis of pyrido[2,3-d]pyrimidines from 2-amino-3-cyano-4trifluoromethyl-6phenyl-pyridine and guanidine, thiourea, and urea.

Reagents and conditions: a) guanidine/thiourea/urea, C 2H5ONa/EtOH, reflux 48–50 h.258
Chandrasekaran et al.,258 reported a method of synthesizing substituted pyrido[2,3d]pyrimidines (Scheme 29) from the precursor 2-amino-3-cyano-4trifluoromethyl-6-phenylpyridine 100 on a cyclocondensation reaction with guanidine, thiourea, and urea under basic
conditions (sodium ethoxide) which resulted in the formation of 101, 102, and 103, respectively.

Scheme 30. Synthesis of pyrido[2,3-d]pyrimidines from 3-amino-2-methylacrylaldehyde and
pyrimidine-2,4,6-triamine

Reagents and conditions: a) Glacial acetic acid, piperidine acetate 259
Gangjee et al.,259 reported the synthesis of 6-methylpyrido[2,3-d]pyrimidine-2,4-diamine
in depicted in Scheme 30. To a solution of 2,4,6-triaminopyrimidine 88 in glacial acetic acid
containing catalytic amount of piperidine acetate was added to powdered 3-amino-2methylacrylaldehyde 104 at 60 oC. The mixture was refluxed and after the reaction the solution
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was neutralized to pH 7 with concentrated ammonium hydroxide which afforded a yellow
precipitate of 105.
Scheme 31. Synthesis of pyrido[2,3-d]pyrimidines from 2-nitromalonaldehyde and
pyrimidine-2,4,6-triamine

Reagents and conditions: a) (i) HCl, EtOH, reflux, 10 min; (ii) NH4OH, H2O, neutralized; b) H2,
Ni, rt, 35 psi; c) AcOH
Gangjee et al.,260 reported method of synthesizing pyrido[2,3-d]pyrimidine (Scheme 31) from 2nitromalonaldehyde

106

and

pyrimidine-2,4,6-triamine

88.

In

acidic

condition

2-

nitromalonaldehyde 106 and pyrimidine-2,4,6-triamine 88 were refluxed in EtOH. In situ
reduction of 107 with Raney Ni afforded the amino intermediate 108 which was condensed without
isolation with benzaldehydes 109 to afford the target compounds 110 in 50 – 58% yield.
B.5. Synthesis of pyrrolo[2,3-d]pyrimidines
Scheme 32. Synthesis of pyrrolo[2,3-d]pyrimidines from 6-amino-2- (dimethylamino)pyrimidin-4(3H)-one

Reagents and conditions: a) n-butanol, reflux
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Gangjee et al.261 reported the synthesis of 115 (Scheme 32) by the condensation of an
aqueous solution of α-chloroacetone 111 in presence of NaOAc in 70% yield. Linz et al.262 also
reported

the

synthesis

of

a

series

of

pyrrolo[2,3-d]pyrimidines

from

6-amino-2-

(dimethylamino)pyrimidin-4(3H)-ones 112 (Scheme 32). Compound 112 on treatment with αchloroacetone 113 or α-chloroacetaldehyde 114 provided the corresponding pyrrolo[2,3d]pyrimidines 115 or 116 in 68% and 75% yields respectively.

Scheme 33. Synthesis of pyrrolo[2,3-d]pyrimidines using Fisher-Indole reaction

Reagents and conditions: a) methyl 4-(4-oxopentyl)benzoate, 2-methoxyethanol; b) Ph2O

Taylor et al.263 synthesized methyl 4-(2-(2-amino-6-methyl-4-oxo-4,7-dihydro- 3Hpyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzoate 119 (Scheme 33) by a Fisher-Indole approach. Reaction
of 2-amino-6-hydrazinylpyrimidin-4(3H)-one, 117 with one equivalent of methyl 4-(4oxopentyl)benzoate in 2-methoxyethanol under reflux afforded the requisite intermediate 118, methyl
(Z)-4-(4-(2-(2-amino-6-oxo-1,6-dihydropyrimidin-4-

yl)hydrazineylidene)pentyl)benzoate.

The

cyclization was accomplished by thermolysis of 118 in refluxing diphenyl ether to regioselectivity
afford the pyrrolo[2,3-d]pyrimidine 119.
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Scheme 34. Synthesis of 2-amino-pyrrolo[2,3-d]pyrimidines from 4-substituted 2,6- diamino
pyrimidines

Reagents and conditions: a) DMF, 60°C, 4 d
Khalaf et al.264 synthesized pyrrolopyrimidines 122-123 (Scheme 34) where pyrimidine
substrate, 2,6-diamino-4-oxo 120 were reacted with diaryl bromoketones 121 with DMF at 60 oC.

Scheme 35. Synthesis of 2-amino-pyrrolo[2,3-d]pyrimidines from 2-bromo-1,1- diethoxyethane

Reagents and conditions: a) malononitrile, K2CO3, DMF, 50°C, 17–18 h; (b) thiourea, potassium tertbutoxide, EtOH, reflux, 16–17 h; r.t., 1–2 h; (c) 5 N HCl, H2O, 10 N NaOH, 50°C, 50 min
El-Gamal and Oh265 synthesized the intermediate 2-(2,2-diethoxyethyl)malononitrile 127
(Scheme 35) from 2-bromo-1,1-diethoxyethane 124 with malononitrile by heating in N,Ndimethylformamide (DMF) in the presence of base K2CO3. Synthesis of 4,6-diamino-5-(2,2diethoxyethyl)pyrimidine-2-thiolate 126 was carried out by refluxing the geminal dicyano 125 with
thiourea in the presence of a stronger base potassium tert-butoxide. Cyclization to 126 could be
achieved by neutralization of the thiol potassium salt 125 using 5 N aqueous HCl followed by heating
with 10 N aqueous NaOH to afford 7H-pyrrolo[2,3-d] pyrimidin-4-amine 127.
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Scheme 36. Synthesis of pyrrolo[2,3-d]pyrimidines from 4-chloro-5-iodo-2,6-dimethylpyrimidine

Reagents and conditions: a) Pd(OAc)2; b) PdCl2; c) NaN3; d) heat or UV
Kondo and coworkers266 reported the synthesis of pyrrolo[2,3-d]pyrimidine 133 via a
photoinduced or thermal cyclization of 4-azidopyrimidines 132 containing an olefinic
functionality at the 5-position (Scheme 36). Intermediates 132 were in turn obtained by a palladium
catalyzed cross-coupling between the 4-chloro-5-iodo-2,6-dimethylpyrimidine 128 and
appropriate stannanes 130 or alkene 129, followed by nucleophilic displacement of the 4-chloro
in pyrimidine 131 with sodium azide.
Scheme 37. Synthesis of pyrrolo[2,3-d]pyrimidines from 2,6-diaminopyrimidin-4(3H)-one

Reagents and conditions: a) aq. ClCH2CHO. DMA, r.t.; b) MeOH; c) PivCl, 90 oC, d) POCl3, CH3CN,
reflux, e) NIS, THF, r.t.; f) K2CO3, DMF, r.t.
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Shi et al.267 reported the synthesis started with 2,6-diaminopyrimidin-4-ol 134 (Scheme 37) in
which treatment of 134 with aqueous chloroacetaldehyde provided the pyrrolo[2,3-d]pyrimidine 135
(42%). By performing this cyclization in the presence of N,N-dimethylacetamide (DMA) as opposed
to DMF, the desired product precipitated out as a 1:1 DMA complex, which facilitated its production
on kilogram scale. The DMA was then easily removed by recrystallization from MeOH (95%).
Protection of the amino group with PivCl gave amide 137 (93%). Deoxychlorination was best achieved
with a complex mixture of products upon sequential treatment with POCl3 and NIS. However, cleaving
the pivaloyl group proved to be a difficult operation. After extensive experimentation, we found that
the pivaloyl group could be efficiently removed if 138 was first alkylated with the commercially
available chloromethylpyridine 140 to get 141 (80%).
B.6 Name reactions
The chemistry related to the present work will be reviewed and includes
B.6.1. Gewald reaction.
B.6.2. Sonogashira coupling.
B.6.3. Ullmann coupling.

B.6.1 Gewald reaction
Scheme 38. A general model of the Gewald reaction.

Reagents and conditions: a) base
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Gewald reaction (Scheme 38) is a multi-component condensation reaction between sulfur,
an α-methylene carbonyl compound and an α-cyanoester in the presence of morpholine as catalyst
to give 2-aminothiophenes.268 The Gewald reaction is the most convergent and well-established
approach for the preparation of multiple substituted 2-aminothiophenes.

Scheme 39. The proposed mechanism of the Gewald reaction.

Reagents and conditions: a) base; b) S8, base
The reaction mechanism of the Gewald reaction has been recently elucidated as shown in
Scheme 39, the first step is a Knoevenagel condensation between the α-methylene carbonyl
compound 148 and an α-cyanoester 144 to produce intermediate 149. Through an unknown
mechanism, intermediate 150 reacts with elemental sulfur to afford intermediate 151, which is
further converted to 2-aminothiophenes 153 via cyclization and tautomerization.
New procedures of the Gewald reactions have been developed under solvent free
conditions. In 2014, Shearouse et al.269 reported the solvent-free synthesis of 2-aminothiophenes
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(R = H, Br, NO2, etc.) via Gewald reaction. A one-step one-pot method for conducting the Gewald
synthesis in presence of base catalyst was discovered.

B.6.2 Sonogashira coupling

Scheme 40. A general model for Sonogashira cross-coupling.

Reagents and conditions: a) Pd(0) or Pd(II) (cat)/ligand, Cu(I)-salt (cat)/base/solvent

In 1975, Sonogashira et al.270 reported the synthesis of symmetrically substituted alkynes
via a coupling reaction between acetylene gas and aryl iodides or vinyl bromides in the presence
of catalytic amounts of Pd(PPh3)Cl2 and CuI under mild conditions. Thus, the copper-palladium
catalyzed coupling of terminal alkynes with aryl and vinyl halides to give alkynes is called the
Sonogashira cross-coupling (Scheme 40). Typically, two catalysts, a zerovalent palladium
complex and a halide salt of copper(I), are necessary for the reaction. The reaction also requires
basic medium to neutralize the hydrogen halide produced as the byproduct of this coupling
reaction. The reactivity order of the aryl and vinyl halides is I ≈ OTf > Br >> Cl.
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Scheme 41. Mechanism of Sonogashira cross-coupling. Modified from Negishi, E. and Anastasia,
L.271

Sonogashira cross-coupling is believed to involve oxidative addition-reductive elimination
pathway (Scheme 41), although the mechanism is not clearly understood.

Scheme 42. Synthesis of N-(7-benzyl-4-methyl-5-(phenylethynyl)-7Hpyrrolo[2,3-d]pyrimidin-2yl)-N-pivaloylpivalamide 164.

Reagents and conditions: a) Phenylacetylene, Et3N, tetrakis(triphenylphosphine) palladium (0),
CuI, r.t., DCM
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In 2007, Gangjee et al.272 reported the synthesis of N-(7-benzyl-4-methyl-5(phenylethynyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)-N-pivaloylpivalamide 164 (Scheme 42) from
N-(7-benzyl-5-iodo-4-methyl-7H-pyrrolo[2,3-d]pyrimidin-2-yl)-N103 pivaloylpivalamide and
phenylacetylene

163

via

a

Sonogashira

cross-coupling

in

the

presence

of

tetrakis(triphenylphosphine)palladium(0) and CuI as catalysts in dichloromethane.

B.6.3 Ulman coupling

Scheme 43. A general model for Ullmann coupling.

Reagents and conditions: a) Cu (I) orCu (II) (cat), ligand/base/solvent

Ullmann-coupling is the copper-catalyzed nucleophilic aromatic substitution between
various nucleophiles with aryl halides (Scheme 43).273 The Ullmann coupling involves the
formation of a C-O, C-N and C-S bond by the reaction between an aryl halide with phenol, aniline
and thiophenol. Typically, Ullmann coupling requires harsh reaction conditions including high
temperatures (> 200 oC), strong bases, and long reaction times. In addition, the classical Ullmann
reaction is limited to electron deficient aryl halides and can only affords moderate yields. The
application of modern variants of the Ullmann reaction employing palladium and nickel have
widened the substrate scope of the reaction and rendered reaction conditions more mild. 274
Although the reaction mechanism of the Ullmann reaction has been extensively studied, the exact
mechanistic pathway is unknown.345 According to radical scavenger experiments and electron spin
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resonance, radical mechanisms have been ruled out. Although the exact nature (oxidation state) of
the Cu-intermediate is not known, the reaction is proposed to involve the formation of an
organocopper compound (RCuX), which reacts with the other aryl reactant in a nucleophilic
aromatic substitution.
Scheme 44. Synthesis of thioether 170

Palomo et al.275 have reported the formation of a C-S bond via Ullmann coupling (Scheme
44) at lower temperature (80-110 oC) with high yield (80-94%).

Scheme 45. Synthesis of thioether 173 under microwave assisted Ullmann coupling condition.

Reagents and conditions: a) NiCl2PPh3, K2CO3, NMP, µW, 195 oC, 1-6h, 67-89%
Microwave assisted organic synthesis has been widely used in organic synthesis, resulting
in faster and cleaner reactions. In 2010, Chen and coworkers 276 reported Nickle catalyzed Ullmann
coupling (Scheme 45).
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III. STATEMENT OF THE PROBLEM

The present section deals with the design and molecular modeling studies of compounds in the
following four areas:
C.1. Combination chemotherapy potential in single agents
1) 2, 4-substituted thieno[2,3-d]pyrimidines
2) 2, 4, 5- and 6-substituted thieno[2,3-d]pyrimidines
3) 4- and 7-substituted pyrrolo[3,2-d]pyrimidines
C.2. Inhibition of tubulin
1) 2- and 4-substituted 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine
2) 2, 4- and 5-substituted pyrazolo[4,3-d]pyrimidines
C.3. Selective pjDHFR inhibitors
1) 6-(arylthio)pyrido[2,3-d]pyrimidine-2,4-diamines
C.4. Folate receptors (FRs) and/or Proton-Coupled Folate Transporter (PCFT) targeted
(cytosolic and/or mitochondrial) one carbon (1C) metabolism inhibitors
1) N1-substituted 5-amino-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-ones
2) N2-substituted 5-amino- 2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-ones
3) 6-substituted 2-amino-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-ones
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C.1. Combination chemotherapy potential in single agents
Angiogenesis is the process for revascularization where new blood vessels form from preexisting ones.277 Although angiogenesis is essential in physiological processes such as wound
healing, it also participates in pathological conditions known as angiogenesis-dependent diseases.
Angiogenesis is a hallmark of various diseases, including cancers, as tumors depend on a constant
supply of oxygen and nutrients to grow.278 To grow beyond 2–3 mm in size, solid tumors depend
on angiogenesis to meet their demand for nutrients, oxygen and proteolytic enzymes. 279 It is an
elaborate multistep process and is tightly regulated by a balance between proangiogenic and
antiangiogenic factors.61 Hypoxia or low oxygen tension is the primary factor in the induction of
angiogenesis where tumors secrete pro-angiogenic growth factors such as VEGF (Vascular
endothelial growth factor), PDGF (Platelet-derived growth factor), and EGF (Epidermal growth
factor).280 These growth factors bind to their respective receptor tyrosine kinases (RTKs) such as
VEGFR, PDGFR-β, and EGFR and stimulate the process of angiogenesis resulting in tumor
growth, survival and metastases.279, 281 RTKs are the enzymes that catalyze the transfer of the γphosphate of ATP to tyrosine residues of protein substrates. RTK families are overexpressed in
cancer cells.282
Antiangiogenic agents (AA) have been identified as a relatively new treatment for
cancer.278, 282, 283 Consequently, multi-RTK inhibition in cancer chemotherapy has emerged as a
promising approach and its validity has been highlighted by the approval of several multi-RTK
inhibitors including sorafenib (inhibits VEGFR-2, VEGFR-3, PDGFR-β, and Raf kinase) and
sunitinib (inhibits VEGFRs, PDGFRs and c-kit).284 However, the antiangiogenic treatment only
prevents blood supply to the tumor but does not destroy cancer cells. Additionally, RTK inhibitors
that function by inhibition of a single RTK are prone to resistance by numerous mechanisms
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including redundant pathways, point mutations in the ATP-binding site and upregulation of
additional RTKs.282, 283 Also, such single agents could afford synergic effects as anti-tubulin effects
can exert their cytotoxic effect as soon as or even during transient tumor vasculature normalization
caused by the antiangiogenic component.61 Additionally, the lack of long-term therapeutic efficacy
is prevalent with the current RTK inhibitors.285, 286 Furthermore, antiangiogenic agents causing
vascular regression could increase intra tumoral hypoxia.287 This might induce radio-resistance,
chemo-resistance, and even anti-angiogenesis resistance since many pro-angiogenic molecules and
factors contributing to tumor aggression are mainly released by tumor cells within hypoxic
regions.288 Therefore, antiangiogenic agents need to be combined with radiotherapy and/or
chemotherapy to provide effective treatment to achieve additive or synergistic effects in cancer
treatment.289, 290
Yoshizawa et al.291 have reported enhanced tumor penetration and in vivo antitumor activity
of cytotoxic paclitaxel in combination with the VEGFR2 inhibitor semaxanib in Colon-26 solid
tumor-bearing mice. Tumors treatment with semaxanib contained significantly smaller hypoxic
regions compared with the nontreated control group, suggesting that structural normalization of
the tumor vasculature resulted in an improvement in tumor vessel functions, including oxygen
supply. Immunostaining for endothelial cells and pericytes showed that the treatment with
semaxanib enhanced the pericyte coverage of the tumor vasculature. Treatment with semaxanib
increased the distribution of paclitaxel in the core region of the tumor, hence decreasing the ratio
of their peripheral distribution. These results suggest that the structural and functional
normalization of the tumor vasculature by the treatment with semaxanib to reach the deeper regions
within tumor tissues leads to a more potent antitumor activity of paclitaxel. This strategy of
utilizing the VEGFR2 inhibition based vascular normalization phase to enhance blood supply and
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the delivery of cytotoxic agents may also address the problem of dose-limiting toxicities as there
is decreased peripheral distribution of the cytotoxic agent. 291
The highly dynamic microtubules (MTs) play an essential role in mitosis and cell division. 6
Microtubule targeting agents (MTAs) are highly effective drugs used for the treatment of solid
tumors and hematological malignancies and one of the most significant drug classes for cancer
chemotherapy.3, 6 Tubulin binding agents such as paclitaxel and Vinca alkaloids are widely used
to treat solid tumors and hematological malignancies.6, 20 Antiangiogenic agents and cytotoxic
agents in combination chemotherapy are more effective in cancer treatment than either agent
alone.111,

289, 292

Single agents with dual antiangiogenic and cytotoxic activities significantly

diminished tumor growth, tumor metastasis and angiogenesis and are superior to docetaxel and
sunitinib in xenograft mice models, remarkably without any toxicity. 293, 294 Such single agents with
multiple mechanisms of action are commonly referred to as designed multiple ligands and show
superior pharmacokinetic (PK), pharmacodynamic (PD) and safety profile compared to multiple
drugs administered in combination.295,

296

These agents could potentially avoid drug-drug

interactions associated with two or more agents. 296-298 In addition, they could prevent or delay the
emergence of resistance and toxicities.296, 298 Most significantly, single agents with dual cytotoxic
and antiangiogenic activities simultaneously target proliferating tumor cells and the tumor
vasculature. The molecule that acts simultaneously on multiple targets displays superior efficacy
against advanced-stage diseases compared to compounds with high specificity for a single
target.295 Thus, the cytotoxic component of these agents need not be as potent as conventional
chemotherapeutic agents. Dosing of such an antiangiogenic agent with comparatively lower
cytotoxic activity would mimic metronomic chemotherapy, which utilizes more frequent and lowdose administrations of cytotoxic agents compared with conventional chemotherapy. 299 Several
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clinical trials attest to the safety and efficacy of using antiangiogenic agents such as sunitinib and
sorafenib with metronomic doses of cytotoxic agents.300-303 Such single agents with multi-targeting
potential offer other advantages such as decreased cost and increased patient compliance 297, which
can play a major part in the clinical success of therapy.
RTK-overexpressing endothelial cells are targeted by the antiangiogenic component of
multi-targeted single agents targets and therefore, is typically targeted to tumor cells under normal
circumstances.61 On the other hand, the cytotoxic component interferes with tumor cell division
with less selectivity over rapidly dividing normal cells present in bone marrow, hair and cells lining
the mouth and gut.304 Therefore, a fundamental challenge in developing single agents with a
cytotoxic component is that the cytotoxic component should only eradicate tumor cells that are
compromised via the antiangiogenic effect but should not cause toxicity to normal cells. 111, 293 As
a result, dose-limiting toxicities associated with cytotoxic agents could be avoided as the cytotoxic
component of these single agents need not be as potent as conventional chemotherapeutic agents.
Decreased tumor growth, tumor metastasis and angiogenesis in xenograft mice models are
observed with single agents with dual antiangiogenic and cytotoxic activities without any
toxicity.111, 293, 294 The antiangiogenic effects of these compounds were due to inhibition of RTKs
and the cytotoxic effects were due to inhibition of tubulin.111, 293 In these project studies, inhibition
of VEGFR-2, PDGFR-β and EGFR were chosen as the targets for the antiangiogenic effects
because of their crucial role in tumor angiogenesis. Moreover, the successful clinical and
preclinical combinations of tubulin inhibitors like paclitaxel with antiangiogenic agents 305 were
also an essential factor in selecting tubulin as the potential cytotoxic targets.
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C.1.1. Design of 2-, 4- substituted thieno[2,3-d]pyrimidines

Figure 36: Structure of compounds 174-181.
Table 4: Effects of 174-181 on cell proliferation, microtubule depolymerization and RTK
inhibition.

IC50 ± SD

EC50 (nM) Kinase inhibition IC50 (nM)

(MDA-MB-

A-10 cells

EGFR

VEGFR-2

PDGFR-β

435) nM

a

174

96.6±5.3

1200

29.5 ± 3.1

182.3 ± 20.6

250.2±43.0

175

42.7±3.2

230

49.2 ± 5.1

80.6 ± 8.2

140.9±19.2

176

7.0 ± 2.7

27

192.3± 6.2

1052.3±98.3

404 ± 61.5

177

3.4 ± 0.9

8

28.5 ± 3.9

216.1±18.6

266.8±35.4

178

183 ± 3.4

5800

-

-

-

179

>10 µM

>40 µM

-

-

-

180

198 ± 23

8000

-

-

-

181

61.5 ± 5.6

807

-

-

-

CA4

4.4± 0.46a

9.8a

-

Sunitiniba

-

-

172±19.4

18.9 ±2.7

83.1±10.1

Erlotiniba

-

-

1.2 ± 0.2a

124.7± 18.2a

NDb

Results previously published.111 b ND: Not determined.
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Gangjee et al.306 published pyrrolo[3,2-d]pyrimidines 174-175 (Figure 36) that are watersoluble colchicine site microtubule depolymerizing agents with sub micromolar potency against
cellular proliferation. Compound 174 showed 2-digit nanomolar (GI50) inhibitor of 8 tumor cell
lines in the NCI 60 cell line.306 Compounds 174-175 exhibited VEGFR-2, PDGFR-β, and EGFR
kinase inhibitory activities (Table 4) and also displayed impressive activities against both Pgp- and
βIII-tubulin-overexpressing cancer cell lines.293
Gangjee and coworkers307, 308 also reported thieno[3,2-d]pyrimidines 176-177 (Figure 36)
as single agents acting as MTAs, along with inhibitors of VEGFR-2, PDGFR-β and EGFR (Table
4). Compounds 176-177 were designed as isosteric replacement or scaffold hopping of compounds
174-175. Compounds 176-177 showed remarkable activities against both Pgp- and βIII-tubulinoverexpressing cancer cell lines (Table 4). Compounds 176 and 177 with the thieno[3,2d]pyrimidine scaffold are 14- and 12-fold better in cell proliferation activity than the pyrrolo[3,2d]pyrimidine scaffold containing compounds 174 and 175, respectively. There is significant 44and 29-fold improvement of microtubule depolymerizing activity for compounds 176 and 177
compared to 174 and 175, respectively. Compound 177 is 2-fold better than compound 175 in
EGFR kinase inhibitory activity.
On the other hand, compounds 178-181 (Figure 36), were designed as MTA and RTK
inhibitors to explore the SAR of the pyrrolo[2,3-d]pyrimidine scaffold.56 Compound 178 was
tested in the preclinical screening program of the National Cancer Institute in its 60-cancer-cellline panel, and found to inhibit the proliferation of most of the cancer cell lines with a GI 50 in the
nanomolar range.309, 309, 310 Compound 178 was discovered to be a colchicine site binding and also
to overcome the two most clinically relevant tumor resistance mechanisms that limit the activity
of microtubule targeting agents: overexpression of Pgp311, 312 and βIII-tubulin.313-317 Gangjee and
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coworkers318 reported pyrrolo[2,3-d]pyrimidines 180 where isosteric replacement of the oxygen
atom of the 4’-OCH3 of 178 with a sulfur moiety generated 180 to determine the nature of
heteroatom substitution to

hydrogen bond (HB) strength.319 Conformational analysis via

molecular modeling and 1H NMR studies of 178 and 179 suggested that the methyl group at the
4-position of the aniline nitrogen of 178 restricted the free rotation of bond “a” as well as bond
“b” (Figure 36) and thus restricts the conformation of the aniline ring in 179.320 Incorporation of
tetrahydroquinoline rings as in 181 further restrict the “b”- bond. Compound 181 showed 3- and
7-fold better potency compared to 178 in the antiproliferative effect in MDA-MB-435 cells and
microtubule depolymerizing assays in A-10 cells, respectively (Table 4). Compound 180 displayed
comparable potency to 178. Compound 179 was inactive towards both assays.56 Unfortunately, for
compounds 178-181, the biological evaluation of several RTK-overexpressing cancer cell lines
showed poor RTK inhibitory activities.318

Figure 37: Rationale for designing 182
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Figure 38: Series I

Compounds containing the thieno[3,2-d]pyrimidine scaffold displayed extraordinary
improvement in inhibition of cell proliferation and microtubule depolymerization activity
compared to pyrrolo[3,2-d]pyrimidine. The kinase inhibitory activities were better (EGFR) or
comparable. On the other hand, compounds with pyrrolo[2,3-d]pyrimidines were moderately
active against cell proliferation and microtubule depolymerization compared to 174-177.318 These
attributes prompted the design of thieno[2,3-d]pyrimidine derivatives 182-185 (Series I, Figure 37
and 38) as isosteres of the pyrrolo[2,3-d]pyrimidines 178-181 and as regioisomer of the thieno[3,2d]pyrimidines 176-177 to exhibit inhibitory activity as MTAs and activities against several RTKs
such as VEGFR2,321-323 PDGFRβ,323 EGFR.324 The thieno[2,3-d]pyrimidine is a promising
scaffold with a broad spectrum of biological activities with diverging profiles of
pharmacodynamics.325 Thienopyrimidine-based EGFR inhibitors are well known in the
literature.325, 326
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Figure 39: Superimposition of the docked pose of 178 (green) and colchicine (pink) in tubulin
(PDB ID: 6BS2). 327
To better understand the binding of proposed compounds 182-185 in the colchicine binding
site and the potential significance of thieno[2,3-d]pyrimidine compounds, all the compounds 182185 and the lead compound 178 were docked in Schrodinger Maestro156 using the X-ray crystal
structure of tubulin (PDB code: 6BS2, 2.65 Å).327 Multiple low energy conformations were
obtained from the docking analysis. As representative examples, Figure 39 shows the docked
conformation of 178 (green) superimposed on the co-crystallized ligand, colchicine (pink). The
pyrrolo[2,3-d]pyrimidine scaffold of 178 forms hydrophobic interactions with Alaβ314, Alaβ352
and Ileβ368 and occupies the region where the A ring of colchicine binds. The N1 of the
pyrrolo[2,3-d]pyrimidine makes a water-mediated hydrogen bond with the backbone of Cysβ239.
The N4-CH3 interacts with the Leuβ253 and Leuβ250 through hydrophobic interactions. The
oxygen atom of the 4ˊ-methoxyphenyl group lies within the pocket that consists of polar residues
like Lysβ350, Asnβ256, and Thrβ312. Additionally, the 2-methyl group creates hydrophobic
interaction with Leuβ240 and Leuβ246. The docked score of 178 was -9.96 kcal/mol.
89

O
H 3C

N
4

3

5

N
2

H3 C

N

1

7N

6

H
178
O

H 3C

CH3

N
4

3

5

N

2

H3 C

CH3

N

1

7S

6

182

Figure 40: Superimposition of the docked pose of 178 (cyan) and 182 (pink) in tubulin (PDB ID:
6BS2).327
Compounds 182-185 displayed similar binding to 178 to the colchicine binding site of
tubulin. Proposed compounds 182-185 showed docked scores that were better than 178 (-9.96
kcal/mol) in tubulin, suggesting an improvement in their binding compared to 178. The docked
scores were in a range of -10.12 to -11.49 kcal/mol. As a representative example, Figure 40 shows
the docked conformation of 182 (pink) superimposed with lead 178 (cyan). Compared to the
pyrrole ring in the lead 178, the thiophene ring in the thieno[2,3-d]pyrimidine scaffold of 182 is
much more amenable to the hydrophobic pocket of Alaβ352, Alaβ314, Alaβ315, Ileβ368 and
Ileβ316. The rest of the molecule interacts similarly to the lead 178. The docked score for 182 is
-11.49 kcal/mol which is better than the lead 178 (-9.96 kcal/mol)
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Figure 41: Superimposition of the docked pose of gefitinib (green) and 182 (pink) in EGFR (PDB
ID: 4WKQ).328

Proposed compounds 182-185 were also docked in the X-ray crystal structure of EGFR cocrystallized with gefitinib (PDB ID: 4WKQ).328 Figure 41 displays docking analysis of 182 in the
EGFR binding site as a representative of compounds from Series I. The thieno[2,3-d]pyrimidine
scaffold of 182 forms hydrophobic interactions with Val726. The oxygen of 4ˊ-methoxyphenyl
group forms water-mediated hydrogen bond with Thr854. The phenyl ring makes hydrophobic
interactions with Val845 and Leu844. The N-1 and N-3 make hydrogen bond with CSX-797. The
mode of binding of 182 is similar to compounds 183-185, in series I. The docked scores of 182185 are -9.15, -8.36, -9.02, -9.28 kcal/mol, respectively, which are better than the docked score of
gefitinib (-8.76 kcal/mol).
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A

B

Figure 42A: Superimposition of the docked pose of axitinib (green) and 182 (pink) in VEGFR-2
(PDB ID: 4AG8).329 42B: Docked pose of 182 (pink) in the crystal structure of homology model
PDGFR-β.294
Figure 42A shows the docked conformation of 182 (pink) superimposed on the cocrystallized ligand, axitinib (green) in the crystal structure of VEGFR-2.329 The thieno[2,3d]pyrimidine scaffold of 182 is stabilized by the hydrophobic interactions with Leu889, Val899
Val914 and Val916. The N3 of 182 makes hydrogen bond with the backbone of Cys1045. The N4CH3 is oriented towards the hydrophobic pocket formed by the Leu1035 and Phe1047. The bestdocked pose of 182 had docked score of -13.21 kcal/mol, which is better than the gefitinib docking
score -12.02 kcal/mol. All of the proposed compounds in the Series I also displayed docked scores
within 1 kcal/mol of -13.21 kcal/mol in VEGFR-2, indicating these compounds should have
VEGFR-2 activity.
The docked conformations of 182 (pink) in our validated homology model294 of PDGFR-β
indicated that the thieno[2,3-d]pyrimidine scaffold of 182 forms hydrophobic interactions with
Ala713, Ala764 and Ile766 (Figure 42B). The 4′-methoxyphenyl group is oriented to the pocket
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formed by Cys843 and Lys762. The thiophene ring in 182 is oriented to the hydrophobic pocket
lined by Ile766. This suggests that a thieno[2,3-d]pyrimidine would lead to a considerable increase
in the PDGFR-β activity. The best-docked poses of 182 had docked scores of –8.30 kcal/mol. All
the proposed compounds in the Series I also displayed docked scores within 1 kcal/mol of -8.30
kcal/mol in PDGFR-β, suggesting that these analogs would have good PDGFR-β inhibitory
activity.

Figure 43: Cyclopenta[d]pyrimidines 186-187 and thieno[3,2-d]pyrimidines 176 and 188 with
MTA and RTK activity
Table 5: Effects of 176, 186-188 on cell proliferation, microtubule depolymerization and RTK
inhibition.

IC50±SD

EC50±

SD Kinase inhibition IC50 (nM)

(MDA-MB-

(A-10 cells)

435) nM

nM

186

7.0 ±0.7

187

EGFR

VEGFR2

PDGFRβ

25.9

ND

ND

ND

2.8± 0.2

4.5

ND

ND

ND

176

7.0 ± 2.7

27

192.3± 6.2

1052.3± 8.3

404±61.5

188

1.7 ± 0.2

3

50.3± 7.1

1048.4± 8.3

250.3±41.8

CA4

4.4 ± 0.46

9.8

ND

ND

ND

Sunitiniba

-

-

172.1±9.4

18.9 ± 2.7

83.1 ± 10.1

Erlotiniba

-

-

1.2 ± 0.2

124.7±18.2

NDb

a: published data111
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Gangjee and coworkers319 also designed and evaluated the 5′-methoxynapthalene
cyclopenta[d]pyrimidine (187), variation of the 4′-methoxyphenyl cyclopenta[d]pyrimidine (186),
which showed excellent MTA activities (Figure 43 and Table 5). Compound 187 displayed a ~3fold improvement in antiproliferative effect, compared to 186 and was 2-fold better than the
standard CA-4. Similarly, with the thieno[3,2-d]pyrimidine series 188 showed 4- and 3-fold
improvement in antiproliferative effects than 176 and CA-4, respectively.308 Compound 188 is 9and 3-fold better with regard to microtubule depolymerizing effects than 176 and CA-4,
respectively. Additionally, 188 was tested for inhibition against EGFR, VEGFR-2 and PDGFR-β
kinases that are overexpressed by tumor cells (Table 5). Compound 188 revealed 4- and 2-fold
better activities in EGFR and PDGFRβ kinase assays than 176.308 The improvements in activities
of 187 and 188 compared to 186 and 176, could be attributed to their bulkier naphthyl group, which
improves their binding in the colchicine binding site in tubulin and respective kinases.

Figure 44: Series II
Series II (Compound 189, Figure 44) with a thieno[2,3-d]pyrimidine ring was designed as
bioisosteric analog of 187 and a regio analog of 188. The 5′-methoxy naphthalene group of 187189 mimics the 4′-methoxyphenyl group of 182 (Figure 38). Proposed compound 189 displayed
docked score (-12.04 kcal/mol) higher than compound 187 (-11.49 kcal/mol) and 188 (-11.66
kcal/mol) in tubulin, suggesting an improvement in their binding compared to 187 and 188.
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Figure 45. Cyclopenta[d]pyrimidines and thieno[3,2-d]pyrimidines 190-195 with MTA activity
Table 6: Antiproliferative and microtubule depolymerization activity of 190-195
IC50 ± SD in MDA-435 Cells EC50 for Microtubule Depolymerization in A·10
(nM)

Cells (nM)

190

50.4 ± 2.4

691

191

16.7±0.8

110

192

60.4

319

193

36.9

200

194

9.8±0.9

21

195

3.8 ± 0.3

22

CA-4

4.4 ± 0.46

9.8

Gangjee and coworkers 308, 330 designed compounds 190-195 (Figure 45) as analogs of 186
and 176, respectively. Exploration of 2-position was attempted by removing the methyl group from
186 and 176 to afford 190 and 192, respectively. Compounds 191 and 193 were generated by
incorporating an amino group at the 2-position to explore the importance of a 2-amino and
hydrogen bond (if any) with corresponding amino acids at the colchicine site and RTK binding
sites. Compounds 191 and 193 were 3- and 2-fold better than the corresponding 2-H compounds
190 and 192, respectively, in the antiproliferative assay (Table 6). Additionally, 191 and 193 were
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6- and 1.5-fold better in potency regarding microtubule depolymerizing activity than 190 and 192,
respectively. Conformationally restricted analogs of 190 and 192, by restricting the rotation around
the “b” bond generated 194 and 195, respectively (Figure 45). Conformationally restricted analogs
194 and 195 were 5- and 16-fold better in antiproliferative assay in MDA-435 cells and 32- and
14-fold better in potency in microtubule depolymerization activity, respectively than 190 and
192.308, 330

Figure 46: Series III
Compounds 196-197 were designed as bioisosteric analogs of 190-191 and regioisomers
of 192-193 (Series III, Figure 46). Compounds 198-199, which are conformationally restricted
analogs of 196-197, were designed by restricting the rotation of the “b” bond.

Figure 47. N-(4′-methoxyphenyl)-N-methylquinazolin-4-amine 200-203 with MTA activity.
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Table 7: Antiproliferative and microtubule depolymerization activity of 200-203
IC50 ± SD in MDA-435 EC50

R

Cells (nM)

(nM)

Microtubule

Depolymerization in A·10 Cells (nM)

200

CH3

1.7 ± 0.1

2.12

201

Cl

0.6 ± 0.1

2

202

CH3

1.1 ± 0.2

3

203

Cl

0.7 ± 0.2

2

4.4 ± 0.46

9.8

CA-4

for

Compound 200 (Figure 47) was reported as a potent inducer of apoptosis, binding at the
colchicine site and an inhibitor of tubulin polymerization (EC50 T47D=2 ± 0.1 nM). 331 Compound
201 with a chloro substitution at the 2-position were synthesized by Gangjee and coworkers, 332
demonstrated 3-fold better antiproliferative activities than 200 (Table 7). Restriction around the
“b” bond on 200 and 201 generated compounds 202 and 203, respectively, which showed
comparable antiproliferative activities toward MDA-435 tumor cells.

Table 8: In silico pKa and cLogP of 200-203333
R

pKa

cLogP

200

CH3

6.7

2.02

201

Cl

3.3

3.73

202

CH3

6.66

2.89

203

Cl

3.22

3.79

cLogP and pKa were calculated using ACD labs pKa predictor.333

97

Comparison of the pKa of protonated N1 and cLogP for 2-H compounds (200, 202) and 2Cl compounds (201, 203) suggests that 2-Cl substitution increases the cLogP and decreases the
pKa (Table 8). The increased cLogP (increased lipophilicity) could increase the passive diffusion
of the compounds. Additionally, decreased pKa will decrease ionization of the compound at
physiological pH.334 Both of these effects could increase the intracellular concentration of the
compounds with a 2-Cl, compared to the lead compounds with a 2-CH 3.

Figure 48: Series IV

Literature precedence shows bioisosteric replacement of the quinazolin-4(3H)-one scaffold
by thieno[2,3-d]pyrimidin-4(3H)-one ring.325 Hence, bioisosteric replacement of the quinazoline
core with a thieno[2,3-d]pyrimidine could be explored toward finding more active molecules for
the development of anticancer agents. Thus, compounds 204-205 (Series IV, Figure 48) with 2-Cl
derivatives of 2-CH3 analogs 182 and 185 (Figure 38, series I) were designed. Compounds 204205 are bioisosteric analogs of the quinazoline derivatives 201 and 203, respectively.
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C.1.2. Design of 2-, 4-, 5- and 6-substituted thieno[2,3-d]pyrimidines
C.1.2.1 Design of 5-methylated thieno[2,3-d]pyrimidin-4-amine

Figure 49. Pyrrolo[3,2-d]pyrimidines 206-217 with MTA activity
Table 9: Antiproliferative and microtubule depolymerization activity of 206-217
No.

IC50 ± SD (nM) EC50 (nM)

No

IC50

±

SD EC50 (nM)

(nM)
206

96.6 ± 5.3

1200

213

ND

>10000

207

193 ± 39

5700

214

9.2 ± 1.8

78

208

18.3 ± 5.0

309

215

21.0 ± 3.6

39.2

209

4.3 ± 0.3

7.4

216

30.5 ± 0.8

76.5

210

13.4 ± 0.5

27.5

217

4.1 ± 0.1

3.31

211

1.3 ± 0.0

1.48

CA-4

4.4 ± 0.46

9.8

212

42.7 ± 3.2

233.1

Gangjee and coworkers335, published compounds 209-211 and 215-217 (Figure 49) as
analogs of 206-208 and 212-214, respectively, which incorporate an additional CH3 group at 5position. There could be two effects of this 5-CH3 group: (i) it could allow additional hydrophobic
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interactions with the targets, and (ii) restricts the rotation around the N-phenyl bond (bonds “a”
and “b”), thus providing conformational rigidity which could increase potency (Figure 49). 335 Low
energy conformations of the proposed compounds were generated using Schrӧdinger Maestro 156,
and the number of conformations within 5 kcal/mol obtained for 206 and 209 were 14 and 9,
respectively. Thus, 209, the N5-CH3 analog of 206, displays a lower number of conformations due
to conformational restriction across bonds “a” and “b”. This 5-CH 3 moiety led to an increase in
anti-proliferative activity by 22-,14- and 14-fold in 209, 210, and 211 compared to compounds
206, 207 and 208, respectively (Table 9). The microtubule depolymerization activities of 209, 210,
and 211 were better than 206, 207, and 208 by 162-, 207-, and 208-fold, respectively. Compounds
212-214 and 215-217 were designed as conformationally restricted analogs of 206-208 and 209211, respectively, by further restricting the “b” bond. These analogs also inhibited of EGFR,
VEGFR-2, and PDGFR-β kinases. Thus, they could inhibit four distinct targets and were single
agents with combination chemotherapy and multiple RTK inhibitory potential. These attributes
make them ideal as leads for the design of inhibitory multitargeted agents- VEFGR-2, PDGFR-β,
EGFR and microtubule assembly.

Figure 50: Series V
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Based on the improved activities of the 5-methylated analogs of pyrrolo[3,2-d]pyrimidines,
the 5-methylated thieno[2,3-d]pyrimidines 218-220 and 221-223 (Series V, Figure 50) were
designed using scaffold hopping with 209-211 and 215-217 (Figure 49), respectively. Compound
218 contains a 5-CH3 will restricts the rotation of both bonds “a” and “b” in compound 182 (Figure
50). Low energy conformations of 182 and the proposed compound 218 were generated using
Schrӧdinger Maestro156 and the number of conformations within 5 kcal/mol obtained for the
compounds are 12 and 9. Compounds 218-223 with a 5-CH3, displayed a lower number of
conformations due to conformational restriction across bonds a and b. The design of compounds
221-223 has two purposes: (i) incorporation of methyl group at the 5-position in 185, 199 and 205;
(ii) conformationally restricted analogs of 218-220, to improve potency.

C.1.2.2 Design of 5,6-dimethylated thieno[2,3-d]pyrimidin-4-amine

Figure 51: Compound 224 with a thieno[2,3-d]pyrimidine scaffold
Shyyka et al.336 reported various thieno[2,3-d]pyrimidines, which showed remarkable
anticancer activity. Compound 224 (Figure 51), 2-(benzylamino)-5,6-dimethylthieno[2,3d]pyrimidin-4(3H)-one was found to be the most active compound among thieno[2,3d]pyrimidine-4(3H)- ones which possessed cytotoxic activity on almost all cancer cell lines with
mean growth inhibition of 51.01%, where the most sensitive was the melanoma cell line MDAMB-435 with GP (Growth Percent) -31.02%. On the other hand, compound 182 (Figure 38)
showed potent RTK and tubulin inhibition.307 The most commonly used strategy in the design of
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multitargeted agents is the hybrid drug design which involves incorporating structural elements
from different compounds that bind to their respective targets.293, 337 If the pharmacophores for the
respective targets overlap, the common structural features of the lead compounds can be "merged"
resulting in a multitargeted single agent.338

Figure 52: Hybrid structure of 225 from lead compounds 224 and 182.

Figure 53: Series VI
Compound 225 (Figure 52) was designed as a hybrid structure of 182 and 224 with RTK
and tubulin inhibition that would afford an analog as a single agent with dual antiangiogenic and
cytotoxic activities. Proposed compounds 226-229 (Series VI, Figure 53,) are the direct analog of
225. In compound 226, isosteric replacement of the 4′-OCH3 with 4′-SCH3 was done by
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incorporating sulfur in place of oxygen at 4′-position. Compounds 227-228 were designed as
conformationally flexible molecule of 225 and 226. Compounds 225 and 226 are designed by
restricting bond “a” by incorporating a methyl group at the N4-position of 227 and 228. Successful
binding to a protein requires a molecule to adopt a bioactive conformation. 339 By limiting the
number of conformations available to the unbound molecule, there is a lower entropic cost when
the molecule binds.339 Conformational constrained molecules 225 and 226 will enhance the
binding affinity to its intended target protein by reducing the conformational entropic costs upon
binding compared to 227 and 228. Compound 229 was designed as a conformationally restricted
analogs of 225 by further restricting the “b” bond by incorporating a 7-methoxy-3,4-dihydro-2Hbenzo[b][1,4]oxazine to explore hydrogen bond acceptor (HBA) ability (if any) of the compound.
A

B

Figure 54A: Docked pose of 225 (pink) in colchicine binding site in tubulin (PDB ID: 6BS2).327
Figure 54B: Superimposition of docked poses of 225 (pink) and gefitinib (green) in EGFR crystal
structure (PDB ID: 4WKQ).328
Proposed compounds 225-229 were docked in the colchicine binding site in the X-ray
crystal structure of tubulin (PDB code: 6BS2, 2.65 Å). 327 Multiple low energy conformations were
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obtained on docking. As representative examples, Figure 54A shows the docked conformation of
225 (pink) where the thieno[2,3-d]pyrimidine scaffold of 225 forms hydrophobic interactions with
Ileβ316, and Ileβ368. Additionally, the 5- and 6-methyl groups are positioned towards the
hydrophobic residues Metβ257, Alaβ314, and Alaβ352. The N1 of the thieno[2,3-d]pyrimidine
makes water-mediated hydrogen bond with Cysβ239. The N4-CH3 interacts with Leuβ246,
Alaβ248 and Leuβ253 through hydrophobic interactions. The oxygen atom of the 4ˊmethoxyphenyl group lies within the pocket that consists of polar residues like Lysβ350, Asnβ256,
and Thrβ312. Moreover, the 2-methyl group creates hydrophobic interactions with Leuβ240,
Alaβ248 and Leuβ250. The docked score of 225 was -12.22 kcal/mol, better than the lead 182 (11.49 kcal/mol).
Docking analysis compounds 225-229 were done in the X-ray crystal structure of EGFR
co-crystallized with gefitinib (PDB ID: 4WKQ).340 Figure 54B reveals the superimposed docking
pose of 225 where the thieno[2,3-d]pyrimidine scaffold of 225 forms hydrophobic interactions
with Leu718, Val726 and Gly719. The oxygen of 4ˊ-methoxyphenyl group forms water-mediated
hydrogen bond with Thr854. The phenyl ring makes hydrophobic interaction with Leu844. The
N-1 and N-3 make hydrogen bond with CSX-797. Compounds 225-229 have similar binding pose
to 182. The docked scores of 225 is -9.20 kcal/mol, slightly better than its desmethyl analog 182
(-9.15 kcal/mol).
Figure 55A shows the docked conformation of 225 (pink) superimposed on the cocrystallized ligand, axitinib (green) in the crystal structure of VEGFR-2. 329 The thieno[2,3d]pyrimidine scaffold of 225 is stabilized by hydrophobic interactions with Leu889, Val848,
Val914, and Val916. The N-3 of 225 makes hydrogen bond interaction with the backbone of
Cys1045. The N4-CH3 is oriented towards the hydrophobic pocket formed by Leu1035 and
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Phe1047. The best-docked pose of 225 had a docked score of -13.46 kcal/mol better than its
desmethyl analog 182 (-13.21 kcal/mol).

A

B

Figure 55A: Superimposition of the docked poses of 225 (pink) and axitinib (green) VEGFR-2
(PDB ID: 4AG8)329 and 55B. Superimposition of the docked poses of 225 (pink) and axitinib
(green) in the homology model of PDGFR-β.294
The docked conformations of 225 (pink) in our validated homology model294 of PDGFRβ indicated that the thieno[2,3-d]pyrimidine scaffold of 182 forms hydrophobic interactions with
Ala713, Ala764 and Ile766 (Figure 55B). The 4′-methoxyphenyl group is oriented in the pocket
formed by Cys843, Leu715 and Lys762. The thiophene ring with methyl at 5-and 6-position in
225 is oriented in the hydrophobic pocket lined by Ile766, Ala764, and Ala713. Thus, the idea of
proposing methyl groups at 5- and 6-positions of thieno[2,3-d]pyrimidine would lead to a
considerable increase in the PDGFR-β activity. The best-docked poses of 225 had a docked score
of –8.38 kcal/mol, similar to its desmethyl analog (-8.30 kcal/mol). All the proposed compounds
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in this series also displayed docked scores within 1 kcal/mol of -7.25 kcal/mol in PDGFR-β,
suggesting that these analogs would have good PDGFR-β inhibitory activity.

C.1.3. Design of 4- and 7-substituted pyrrolo[3,2-d]pyrimidines

Figure 56: Pyrrolo[3,2-d]pyrimidines 206-207 and 230-231.
Table: 10: EGFR, VEGFR-2, PDGFR-β kinase activities of compounds 206-207 and 230-231.
IC50 (nM) ± SD
EGFR

VEGFR-2

PDGFR-β

MDA-MB-

Microtubule

435 IC50

depolymerizat

(nM) ± SD

ion EC50 (nM)

206

29.5±3.1

182.3±20.6

250.2±43.0

96.6 ± 5.3

1200

230

23.6±5.8

21.3±3.2

>200

328 ± 42

6100

231

1.1 ±0.2

27.3 ± 5.1

8.1 ± 0.91

ND

ND

207

19.2±1.9

132.6±221

223.2±4.8

193 ± 39

5700

CA-4

-

-

-

4.4 ± 0.46

9.8

Sunitinib

172.1±9.4

18.9±2.7

83.1±10.1

Erlotinib

1.2±0.2

124.7±18.2

ND

Gangjee and coworkers293,

341

reported compounds 206-207 and 230-231 (Figure 56)

containing the pyrrolo[3,2-d]pyrimidine scaffold. Compounds 206-207 acted as MTAs293 and
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showed RTK inhibition (Table 10). On the other hand, compounds 230-231 with a benzyl ring at
the 7-position showed better activity in VEGFR-2 kinase (compounds 230-231 are 6-fold better
than 206 in VEGFR-2) and comparable potency in EGFR and PDGFR-β. Compound 207 with no
substitution at the 2-position were designed was designed to explore the effect of substituents in
this position regarding antitubulin activity and showed 1.5-fold improvement in EGFR and
VEGFR-2 activity compared to 206.

Figure 57: Series VII
Compound 232 (Series VII, Figure 57) was synthesized towards the goal of identifying
single agents with RTK and tubulin inhibitory activities in the same structure. Incorporation of a
2-H group on 230-231 scaffold would explore the effect of 7-benzyl substituted pyrrolo[3,2d]pyrimidines without any substituents in the 2-position and would also evaluate the importance
of the 2-CH3 and 2-NH2 substituents in 230 and 231, respectively.

C.2. Inhibition of tubulin
Tubulin binding agents disrupt microtubule dynamics leading to mitotic arrest and cell death. 342
Tubulin binding agents such as taxanes and vinca alkaloids are widely used for the treatment of solid
tumors and hematological malignancies.343 However, the enormous clinical success of taxanes and
vinca alkaloids has been compromised by two primary mechanisms of tumor resistance:
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Overexpression of Pgp and the expression of the βIII-tubulin. Pgp overexpression is clinically observed
in many tumor cell lines, particularly in patients who have received prior chemotherapy. 3
Overexpression of Pgp resulted in poor response to taxol-based chemotherapy in patients with nonsmall cell lung cancer. The use of Pgp inhibitors in overcoming Pgp-mediated resistance was not
successful due to intolerable side effects. Tubulin binding agents that are not substrates for Pgp (e.g.
epothilones) represent a viable alternative strategy for circumventing Pgp-mediated resistance. Such
agents would be extremely useful for patients that develop resistance due to Pgp overexpression. 1, 3, 6
The expression of βIII-tubulin is involved in clinical resistance to taxanes and vinca alkaloids
in non-small cell lung, breast, ovarian, and gastric cancers.1, 3, 6, 344, 345 Colchicine-site binding agents
were not susceptible to βIII-tubulin mediated resistance,346 which demonstrates the importance of
developing anti-cancer drugs binding to the colchicine-site. Although there are no colchicine-site
agents in the clinic, several agents, including CA4P (Fosbretabulin®)347 and CA1P (OXi4503)348 are
currently in phase 1 and 2 clinical trials. The development of tubulin-binding agents that are less
sensitive to Pgp and/or βIII-tubulin mediated resistance could result in a broader spectrum of antitumor
activity and improved rates of survival.

C.2.1 Design of 2- and 4-substituted 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine

Figure 58: Compounds 233 with MTA activity
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Figure 59: Series VIII
Tricyclic 5,6,7,8-tetrahydrobenzofuro[2,3-d]pyrimidines with general structures 233
(Figure 58) have been reported by Gangjee and coworkers.349 Compound 233 displayed 23.3±1.9
and 61 nM inhibition in antiproliferative and microtubule depolymerization assays, respectively.
It was of interest to identify the structural features of the tricyclic 5,6,7,8-tetrahydrobenzofuro[2,3d]pyrimidines that contribute to antitubulin activity. Hence, isosteric replacement of 5,6,7,8tetrahydrobenzofuro[2,3-d]pyrimidine in compound 233 was carried out to afford compound 234
(Series VIII, Figure 59) as a potential inhibitor of tubulin.

Figure 60. Cyclopenta[d]pyrimidines 186 and 235 with MTA activity
Gangjee and coworkers319 designed and evaluated the cyclopenta[d]pyrimidines 186 and
235, possessing significant MTA activities (Figure 60). It was noted that the replacement of a 4′methoxyphenyl with 4′-methylthiophenyl lead to an improvement in the tubulin assembly
inhibition by 3-fold.319
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Figure 61: Series IX

Series IX (Compound 69, Figure 61) was designed as the 4′-thiomethylphenyl analog of
234. The methoxy group of the lead 234 is positioned near Thrα179; thus, 236 was designed in an
attempt to study the effect of replacement of the oxygen in 234 with sulfur at the 4′-position. It has
been widely known that acceptor (or donor) strengths correlate with affinity, leading to valuable
insights into the SAR for given scaffolds.350 Different hydrogen bond acceptors (HBA) can help
design molecules with better overall properties, as developing a high-affinity inhibitor involves
finding a delicate balance between intermolecular interactions and the unfavorable desolvation
penalty suffered when a ligand binds to an enzyme or receptor.319 The strength of HBA based on
pKBHX database is as follows: dimethylsulfide (0.12) and ether (1.11). 351 Based on this data,
compound 236 is designed to engage Thrα179 in the tubulin colchicine binding site with a watermediated hydrogen bond. Sulfides are considered as mild HBA and these compounds will also
offer insights into the optimum HBA strength.352 The entropic penalty of sulfide is considerably
less than that of an ether despite sulfide being a weak HBA,which can lead to an improved affinity
for the sulfide over the ether.353 Proposed compound 236 displayed a docking score lower than 11.56 kcal/mol in tubulin, suggesting an improvement in its binding over that of 234 (-11.19
kcal/mol).
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Figure 62. Cyclopenta[d]pyrimidines 187 and 237 with MTA activity

Gangjee and coworkers319, 354 also designed and evaluated 187 and 237 as microtubule
targeting agents (Figure 62). Replacement of the 4′-methoxyaniline in 186 (Figure 60) with a 6methoxytetrahydroquinoline (237, Figure 62) restricts the rotation of the unsaturated ring of
quinoline across N4-phenyl bond by restricting the “b” bond. Compound 187 was designed by
varying the 4′-methoxyphenyl in cyclopenta[d]pyrimidines (186) to a 5-methoxynapthalene (187).
Both compounds 187 and 237 showed excellent MTA activities.319 Compound 237 showed a 1.5fold improvement in the antiproliferative effect compared to 186. Compound 187 displayed a 3fold improvement in antiproliferative effect, compared to 186 and was 2-fold better than the
standard CA-4.319 This was attributed to the increased binding of the bulkier compounds 187 and
237 to the colchicine binding site in tubulin.

Figure 63: Series X
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Series X (compounds 238-240, Figure 63) were designed as analogs of 234 (Figure 59).
Restriction of the “b” bond of 234 were carried out following Gangjee and coworkers 319 to generate
compound 238. The 5′-methoxy naphthalene compound 239 mimics the 4′-methoxyphenyl group
of the lead 234. The oxygen can interact with the Thrα179 of tubulin through a water-mediated
hydrogen bond. Compound 240 a N4-H analog is proposed as more flexible analog of 239.
Proposed compounds 238-240 displayed a docked score in a range of -10.56 to -11.68 kcal/mol in
the tubulin-binding site of colchicine.

Figure 64. Pyrimido[4,5-b]indole 241-243 with MTA activity

Table: 11. Antiproliferative and microtubule depolymerization activities of 241-243.
Comp.

MDA-MB-435

EC50 for microtubule Inhibition

IC50 ± SD (nM) depolymerization
(nM)

of Inhibition

tubulin assembly colchicine binding
IC50 ±SD (µM)

(% inhibition ± SD)
at 5 µM

241

33.9 ± 3.4

130

1.2 ± 0.04

67 ± 5

242

14.7 ± 1.5

130

1.4 ± 0.007

84 ± 0.5

243

130 ± 7.8

1200

2.3 ± 0.4

62 ± 4

CA-4

4.4 ± 0.46

9.8

1.0 ± 0.09

99 ± 0.2
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of

Gangjee and coworkers320 reported the tricyclic pyrimido[4,5-b]indoles 241-243 (Figure 64),
which vary the substitution at the 2-position. Compounds 241-243 were evaluated as tubulin inhibitors
and as agents that can overcome Pgp and βIII-tubulin mediated drug resistance. These compounds have
radiolabeled colchicine displacement values between 62-84% at 5 µM concentration (Table 11).

Figure 65: Series XI
The combination of multiple aromatic rings has significant implications for “drug-like”
properties, and simple, planar structures are often associated with poor physicochemical profiles
and toxicity.355 Drug candidates show a higher success rate with one or more Sp3 hybridized
carbon atoms than “flat” molecules, because of low aqueous solubility of purely aromatic
compounds.356 One of the limitations of MTAs, particularly the taxoids, is their poor water
solubility.357 Thus, water-soluble microtubule targeted agents are highly desired, and an enormous
effort continues to chemically modify and/or formulate analogs of these agents to increase their
water solubility. Increasing ‘aromatic proportion’ in a molecule has a detrimental effect on
solubility.358, 359 On the other hand, the fraction of Sp3 hybridized carbon atoms (Fsp3), in other
words, the fraction of carbon atoms that are saturated correlates with water solubility. 356 Based on
this hypothesis, we replaced the unsaturated aromatic ring in the lead compounds 241-243 to
design

compounds

244-248

(Series

XI,

Figure

65)

with

the

5,6,7,8-

tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine scaffold in an attempt to both probe the water
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solubility as well as the ring interactions with the hydrophobic pocket. These compounds are direct
analogs of 234 (Figure 59) with variations at the 2-position. It was of interest to observe the
isosteric effect of replacement of the 2-CH3 in 234, 236, and 238 (Figure 59, 61, 63) with 2-NH2
to generate compounds 244, 245, and 246, respectively.
A

B

Figure 66A: Docked pose of 244 (magenta) in the colchicine binding site of tubulin. Figure 66B:
Docked pose of 247 (cyan) in colchicine binding site of tubulin (PDB ID: 6BS2)327
The 2-NH2 group in the lead compound 242 and the designed compounds 244-246 is
oriented towards the solvent and polar residues. As a representative example, in Figures 66A, in
the docked pose of the 2-NH2 of proposed compound 244 is oriented towards the solvent and polar
residues Asp249 and Lys252. To further improve the potency, the 2-NH 2 in compound 244-246
was removed to generate compound 247-248 to explore the importance of a 2-NH2 and hydrogen
bond (if any) with corresponding amino acids at the colchicine site. These two compounds (247
and 248) will determine the importance of any polar group like NH 2 at the 2-position and/or any
hydrophobic interactions at the colchicine site.
To better understand the binding of the proposed tricyclic ring compounds, proposed
compounds 234, 236, 238-240 and 244-248 were docked in the colchicine binding site in the X114

ray crystal structure of tubulin (PDB ID: 6BS2, 2.65 Å).327 Docking resulted in multiple low energy
conformations. Figure 66A and Figure 66B show the docked conformation of lead compound 244
(magenta) and 247 (cyan) in the colchicine site, respectively. The thieno[2,3-d]pyrimidine portion
of the scaffold of 244 and 247 form hydrophobic interactions with Ileβ316, Leuβ253, Ileβ368 and
Cysβ239 of tubulin. The cyclohexene part of the scaffold creates hydrophobic interactions with
Alaβ352, Leuβ246, Alaβ314, and Ileβ368. The N1 of the thieno[2,3-d]pyrimidine portion makes
water-mediated hydrogen bond with Cysβ239. The N4-CH3 interacts with Leuβ253 through
hydrophobic interactions. The oxygen atom of the 4ˊ-methoxyphenyl group lies within the pocket
that consists of polar residues like Lysβ350 and Asnβ256. The 2-NH 2 group resides in the pocket
with polar residues Aspβ249 and Lysβ252. Docked scores of 244 and 247 were -12.23 and -12.24
kcal/mol, respectively. All the proposed compounds in this series also displayed a docked scores
within 1 kcal/mol difference of -12.24 kcal/mol in tubulin, which is similar to the natural ligand
colchicine (-13.28 kcal/mol) suggesting that these analogs would have good MTA inhibitory
activity.

C.2.2 Design of 2-, 4- and 5-substituted pyrazolo[4,3-d]pyrimidines

Figure 67: Compounds 211, 217, and 249-250 with MTA activity
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Gangjee and coworkers353 reported compounds 211 and

217 (Figure 67) as a potent

microtubule depolymerizing agent. They were discovered to be a colchicine-site binding agents
and to overcome Pgp and βIII-tubulin mediated drug resistance clinically observed with paclitaxel
and vinca alkaloids. Banerjee et al.327 reported compounds 249-250 (Figure 67) where the purine
and isoxazolo[5,4-d]pyrimidine rings are bioisosteric replacement of the pyrrolo[3,2-d]pyrimidine
ring in compounds 211 and 217. Compounds 249 and 250 showed direct binding to the colchicine
site in tubulin and significantly inhibited tumor growth in an A375 melanoma xenograft model.
These compounds overcame clinically relevant multidrug resistance in a paclitaxel-resistant PC3/TxR prostate cancer xenograft model. Furthermore, the 5-methyl group would also act to
sterically restrict the number of conformations and render the possibility of getting bioactive
conformation.335 Such conformational restriction has been reported in MTA drug design to provide
conformation (s) more conducive to colchicine binding. 320
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Figure 68: Series XII
Compounds 251-253 (Series XII, Figure 68) with a unique pyrazolo[4,3-d]pyrimidine
scaffold were designed as a bioisosteric replacement of all three rings (purine, isoxazolo[5,4d]pyrimidine, pyrrolo[3,2-d]pyrimidine, Figure 67). As shown in Figure 68, the bioactive
conformations of 251 and 253 are determined by three rotatable single bonds: 7-position C-N bond
(bond a), 1′-position C-N bond (bond b), and 4′-position C-O bond (bond c). Based on prior
literature reports,320, 335, 346 conformational analysis via molecular modeling and 1H NMR studies
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suggested that the methyl group on the N4-aniline nitrogen restricted the free rotation of bond “a”
as well as bond “b” and thus restricts the conformation of the anilino ring in 211 and 217.
Successful binding to a protein requires a molecule to adopt a bioactive conformation. 360 By limiting the number of conformations available to the unbound molecule, there is a lower entropic cost
when the molecule binds.339 Therefore, investigation of conformationally restricted analog 251,
where restriction of “a” bond was carried out by incorporating a N7-CH3 group on 252. Compound
253, the 1,2,3,4-tetrahydroquinoline derivative was designed from 252, by further restricting bond
“b.”

cO
H3 C
3N

Cl

b
N
a 4

CH 3

CH3
N 5
6

2 N
1

7

211
cO
b
N
a 7 1 CH3
N
6N
2
N
Cl 5 N
3

CH 3

H3 C

4

251

Figure 69: Superimposition of the docked pose of 211 (cyan) and 251 (pink) in the colchicine
binding site in the X-ray crystal structure of tubulin (PDB ID: 6BS2, 2.65 Å). 327
Proposed compounds were docked in the colchicine binding site in the X-ray crystal
structure of tubulin (PDB ID: 6BS2, 2.65 Å)327 to investigate the binding mode. Docking resulted
in multiple low energy conformations. Figure 69 illustrates the docked conformation of lead
compound 211 (cyan) and 251 (magenta) in the colchicine site. The pyrazolo[4,3-d]pyrimidine
scaffold of 251 forms hydrophobic interactions with Ileβ316, Alaβ314, Alaβ352 and Cysβ239. The
N1-CH3 of pyrazolo[4,3-d]pyrimidine interacts with Metβ257 and Alaβ314. Water mediated
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hydrogen bond interaction with Cysβ239 was observed with the N4 of the pyrazolo[4,3d]pyrimidine. The N7-CH3 interacts with Leuβ253 and Leuβ246 through hydrophobic interactions.
The oxygen atom of the 4′-methoxyphenyl group lies within the pocket consisting of polar residues
like Asnβ256, Thrβ312 and Asnβ348. The 5-Cl group resides in the pocket with hydrophobic
residues Leuβ240 and Ala2β48. Docking score of 251 was -11.28 kcal/mol, which is better than
the docking score of lead compound 211 (-10.95 kcal/mol).

Figure 70: Cyclopenta[d]pyrimidines 186 and 254-256 with MTA activity

The concept homologation has been adapted and used in medicinal chemistry as an
important strategy for molecular modification.8 Gangjee et al.330 reported 186 and 254-256 (Figure
70) as potent microtubule targeting agents. Compounds 255 and 256 were designed by increasing
the chain length at 4′-position by replacing 4′-OCH3 in 186 and 254 to 4′-OCH2CH3, respectively.

Figure 71: Series XIII
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The homologation and branching of the 4′-OMe (251, Figure 64)) to a 4′-OCH2CH3 (257)
and 4′-OCH(CH3)2 (258) were designed to allow these groups to better penetrate the hydrophobic
pocket in the colchicine site (Series XIII, Figure 71).

Figure 72: Pyrrolo[3,2-d]pyrimidines 211, 259-260 with MTA activity

Gangjee and coworkers353 reported 211 and 259-260 containing pyrrolo[3,2-d]pyrimidines
with chlorine at 2-position (Figure 72). In compound 259 the 5′-methoxynapthalene variation of
the 4′-methoxyphenyl (211) was designed, which showed 22.6- and 50 nM antiproliferative and
microtubule depolymerization activity, respectively. A comparative activity was observed for the
sulfur analog 260, which was designed with the sulfur as a bio-isosteric replacement of the oxygen
on the phenyl ring on 211. Sulfides can mimic the HBA ability of the ether oxygen with decreased
desolvation penalty.319

Figure 73: Series XIV
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Compounds 261-263 (Series XIV, Figure 73) were designed to explore the impact of
electron density and hydrogen bond ability on the N7-phenyl ring. Compound 261, the 5′methoxynapthalene variation of the 4′-methoxyphenyl in the pyrazolo[4,3-d]pyrimidine 251
(Figure 68) was designed to evaluate the additional hydrophobic group and electronics effect on
the N7-substitution. The distance and the nature of heteroatom substitution affects the hydrogen
bond (HB) strength.319 Thus, it was of interest to isosterically replace the oxygen atom of the 4′OCH3 of 251 (Figure 68) with a sulfur moiety to design 262. Compound 263 with 3'-fluorine group
was designed to evaluate the contribution of meta-electron-withdrawing moieties on biological
activity. All the proposed compounds in this series also displayed docked scores within 1 kcal/mol
of -9.38 kcal/mol in tubulin, suggesting that these analogs would have good MTA inhibitory
activity.

C.3. Selective pjDHFR inhibitors

Pneumocystis organisms characterize a large group of species of atypical fungi with
universal distribution, with specificity for a specific mammalian host. 135 Targeting Pneumocystis
jirovecii DHFR (pjDHFR) is one of the most efficient strategies to treat PCP infection. 149 DHFR
enzyme catalyzes the reduction of 7,8 dihydrofolate to the 5,6,7,8-tetrahydrofolate and inhibits
with thymidylate biosynthesis and consequently DNA synthesis, as well as the inhibition of folate
dependent formyl transferases causing inhibition of purine synthesis. 126 Disruption in DNA, RNA
and protein synthesis and death of the organism are caused by these inhibition. Pneumocystis
infection is host-species specific infection. Most of the drugs were tested against Pneumocystis
carinii DHFR (pcDHFR), which was presumed to be the causative species of PCP infection in
humans.126, 153 P. carinii is responsible for human infections infecting rats and is different from
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P. jirovecii. Development of the homology model for pjDHFR and isolation of pjDHFR, provided
the amino-acid sequence differences between pjDHFR and pcDHFR, as well as human DHFR
(hDHFR). The difference in amino acid sequence of the DHFR of P. carinii (pcDHFR) is 38%
when compared to the DHFR of P. jirovecii (pjDHFR).113 The superimposition of the active site
of pcDHFR and pjDHFR displays the amino acid differences present in the active sites of the two
enzymes and emphasizes the challenges of designing and evaluating activity against the surrogate
pcDHFR as inhibitors of pjDHFR. Therefore, drugs evaluated against the surrogate pcDHFR invitro may not translate into potent activity for the treatment of PCP infection in humans. 134
Isolated pjDHFR113 has been used to evaluate clinically used agents such as TMP
(trimethoprim), PTX (piritrexim) and novel DHFR inhibitors. 134, 154 Selectivity ratio (IC50 hDHFR/
IC50 pjDHFR) measurement of the agent for pjDHFR over hDHFR can be calculated from the
inhibition of hDHFR compared with pjDHFR. Due to low selectivity for pjDHFR over hDHFR
compounds, such as PTX and TMQ (trimetrexate) are much toxic, and this explains the reason for
their discontinuation for the treatment of opportunistic infections. The selectivity of TMP for
pjDHFR over hDHFR is 266-fold and is an aspect that contributes to its clinical success in PCP
treatment. Potency for pjDHFR is highly desirable besides the selectivity. TMP is a poor inhibitor
of pjDHFR and lacks in vivo efficacy as a single agent against parasitic infections and must be
used with Sulfamethoxazole (SMX). A long-term goal of Gangjee and coworkers are to provide
analogs with excellent potency along with high selectivity for pjDHFR. Such agents could be used
alone as well as with sulfonamides and other drugs for the treatment of PCP infections in humans.

Due to the lack of an X-ray crystal structure of pjDHFR the design of pjDHFR inhibitors
became very challenging. However, homology models can be used with refinement to model
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pjDHFR in the absence of crystal structures.154, 155 Therefore, along with known hDHFR X-ray
crystal structures,155 pjDHFR homology models can be used to design and develop potent and
selective pjDHFR inhibitors. Another most important challenge in the discovery and development
of inhibitors of pjDHFR is the inability to grow the organism outside the human lung. As a result,
with the synthesized compounds it is difficult to develop a tissue culture for in vitro studies or an
animal model for in vivo evaluation. Isolation and use of the pjDHFR enzyme is presently the only
direct indicator that a compound could be effective (or ineffective) in the treatment of PCP
infection in humans.
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Figure 74. X-ray crystal of hDHFR published with pyrido[2,3-d]pyrimidine 264.154
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hDHFR

pjDHFR

Val115

Ile123

Ile60

Leu65

Ser 59

Ser 64

Phe 31

Met 33

Figure 75. Superimposition of active sites of hDHFR and pjDHFR. The pairs of amino acid
residues shown are the residues that are different. The cyan ribbon and pink ribbon represent the
active site and major amino acid difference in hDHFR (PDB: 4QJC, 1.62 Å) 155 and pjDHFR
(homology model)154, respectively.
Table 12: Differences in amino acids between hDHFR and pjDHFR
hDHFR

pjDHFR

Val 115

Ile123

Ile 60

Leu 65

Ser 59

Ser 64

Phe 31

Met 33

The X-ray crystal of hDHFR is published with a pyrido[2,3-d]pyrimidine 264 (Figure
74).154,

155

The amino acids of hDHFR and the homology model sequence of pjDHFR were

superimposed on the hDHFR X-ray crystal published with pyrido[2,3-d]pyrimidines in order to
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study the differences in the active site of hDHFR and the pjDHFR (Figure 75). 154, 155 The amino
acids are quite distinct that constitute the active site of pjDHFR and hDHFR (Table 12). The
hDHFR active site contains Phe31, Ile60, and Val115, whereas the active site of pjDHFR contains
Met33, Leu65, and Ile123. Occupying the same location in the active sites, such as Met33 (in
pjDHFR) vs. Phe31 (in hDHFR) and Ile 123 (in pjDHFR) vs. Val115 (in hDHFR), possess varied
shapes, sizes and electronic properties.155 Such differences can be exploited for the design and
development of inhibitors to provide potency and selectivity for pjDHFR over hDHFR.

C.3.1. Design of N6-substituted pyrido[2,3-d]pyrimidine-2,4-diamines
Table 13. Inhibition Concentrations (IC50) against pjDHFR and hDHFR and selectivity
ratios of pyrido[2,3-d]pyrimidines with NH-substitution at 6-position.154

Comp. R

pjDHFR

hDHFR (nM)

(nM)

Selectivity Ratios
[hDHFR/pjDHFR]

265

H

300

190

1

266

4ˊ-CH3

620

2100

3

267

4ˊ-OCH3

400

3650

9

268

2ˊ,3ˊ-(CH)4

250

2100

8

269

3ˊ,4ˊ-(CH)4

400

2200

5

TMP

92

24500

266

PTX

41

2

0.05
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Gangjee et al.154 published 6-substituted pyrido[2,3-d]pyrimidine compounds 265-269
(Table 13). Isosteric replacement were carried out with NH at 6-position with the -CH 2 moiety in
PTX. Different electron-donating, electron-withdrawing and bulky substituents on the phenyl side
chain were introduced to explore the SAR of this novel series of compounds. Compounds 265-269
displayed moderate potency for pjDHFR, but none of them were significantly selective for
pjDHFR over hDHFR greater than 9-fold.
A

B

Figure 76A. Docked pose of 265 (purple) in the crystal structure of hDHFR (PDB: 4QJC, 1.62 Å,
amino acids are depicted as light blue).154 76B. Docked pose of 265 (purple) in the homology
model of pjDHFR (amino acids are depicted as light pink). 154

Docking analysis of 265-269 was performed in hDHFR and homology model of
pjDHFR.154 In the X-ray crystal structure of hDHFR (Figure 76 A), the pyrido[2,3-d]pyrimidine
scaffold of 265 stacked amid the Phe31, Phe34 and Leu22. The 2-NH2 makes ion-dipole
interaction with Glu30 and water-mediated hydrogen bond with Thr136 and Phe134. The 4-NH 2
makes a hydrogen bond with the backbone of Ile7. The N1-H of the pyrido[2,3-d]pyrimidine
makes ion-dipole interaction with Glu30. The side chain phenyl ring makes hydrophobic
interactions with Pro61, Ile60 and Leu67. In the homology model of pjDHFR (Figure 76 B), the
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pyrido[2,3-d]pyrimidine scaffold of 265 stacked between the Phe36, Leu25 and Ala12. The 2-NH2
and N1-H make ion-dipole interaction with Thr144 and Asp32. The 4-NH 2 makes a hydrogen bond
with the backbone of Val11. The side chain phenyl ring makes hydrophobic interactions with
Pro66 and Leu65.361

Table 14. Inhibition Concentrations (IC50) against pjDHFR and hDHFR and selectivity Ratios
pyrido[2,3-d]pyrimidines with N6-CH3 substitution.154, 362

Comp.

R

pjDHFR

hDHFR

Selectivity Ratios

(nM)

(nM)

[hDHFR/pjDHFR]

270

H

2.2

57

26

271

4ˊ-CH3

2.4

32

13

272

4ˊ-OCH3

1.9

12

6.6

264

2ˊ,3ˊ-(CH)4

2.5

5.6

2.2

TMP

92

24500

266

PTX

41

2

0.05

126

A

B

Figure 77A. Docked pose of 270 (yellow) in the crystal structure of hDHFR (PDB: 4QJC, 1.62
Å).154 77B. Docked pose of 270 (yellow) in the homology model of pjDHFR.154

Gangjee et al.154 reported the 6-substituted pyrido[2,3-d]pyrimidine compounds 264, 270272 (Table 14). These compounds were designed by incorporating a N6-methyl group on 265-269.
This methyl group was predicted to interact with Ile123 of pjDHFR and not with the shorter amino
acid Val115 in hDHFR and thus confer both potency and selectivity for pjDHFR (Figure 77A and
77B) over hDHFR. Compounds 264, 270-272 (Table 10) displayed moderate potency and some
had better selectivity for pjDHFR than compounds 265- 269.
In hDHFR (Figure 74, 75), the corresponding Val115, being shorter by one carbon, may
not interact with the N6-methyl group. This should improve selectivity as well as the potency of
these compounds against pjDHFR over hDHFR. Further, the N6-methyl group restricts the number
of possible conformations of the side chain phenyl group, therefore perhaps contributing to
increased potency and selectivity.361 Compounds 264, 270-272 with the N6-methyl group are also
more lipophilic than the corresponding N6−H analogs 265-269, thus, improving hydrophobicity
and perhaps the cell penetration.361 Compounds 264, 270-272 with the N6-methyl group with
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various electron-donating, electron-withdrawing, and bulky hydrophobic substituents were
designed to explore the SAR and to afford potent and selective inhibitors for pjDHFR. 154

Table 15. Inhibition concentrations (IC50) against pjDHFR and hDHFR and Selectivity Ratios of
pyrido[3,2-d]pyrimidines with S-substitution at 6-position.353

#

X

R

pjDHFR (nM)

hDHFR (nM)

Selectivity Ratios
[hDHFR/pjDHFR]

273

NH

H

112

1526

13

274

NH

4ˊ-OCH3

239

2459

10

275

NH

2ˊ,3ˊ-(CH)4

112

1098

10

276

NH

3ˊ,4ˊ-(CH)4

275

3185

12

277

S

3ˊ-OCH3

0.96

450

469

278

S

2ˊ,3ˊ-(CH)4

0.031

0.526

17

279

S

3ˊ,4ˊ-(CH)4

0.061

4.12

67

280

S

4ˊ-NO2

2.48

258

104

281

S

H

9.6

226

15

TMP -

-

92

24500

266

-

-

41

2

0.05

PTX
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Gangjee and coworkers353 reported pyrido[3,2-d]pyrimidines with N6-H-substitution (273276). Biological evaluation of 273-276 with NH linker at the 6-positon of the pyrido[3,2d]pyrimidine scaffold displayed moderate potency and selectivity for pjDHFR (Table 15). A
comparison of active sites of pjDHFR and hDHFR discloses several amino acid differences that
could be exploited to gain potent and selective pjDHFR inhibitors (Figure 75). For instance,
Met33/Phe31 in pjDHFR/hDHFR can affect binding due to their distinct steric and electronic
properties. Isosteric replacement of the 6-position nitrogen with sulfur afforded 277-281 to further
potentiate the activity for pjDHFR. Compounds 278 and 279, showed 3600 and 4500-fold better
potency in pjDHFR, than their 6-NH analogs 275 and 276, respectively. Compounds 278 and 279
are 1.7 and 6-fold more selective than 275 and 276, respectively. Compared to the lead analog,
sulfur linked analogs could change the bond angle, distance, and electronics of the side chain aryl
group and cause a steric clash with Phe31 in hDHFR, whereas they appropriately fit with Met33
in pjDHFR and provide selectivity in pjDHFR over hDHFR. 353
Table 16. Bond angles and bond distance for C-X-C angle and C-X bond measured with
Schrödinger Maestro.156

Entry

X

C-X Bond distance (Å)

C-X-C Bond angle (⁰)

273

NH

1.41

132.8

281

S

1.76

100.6
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Gangjee and coworkers353 reported bond angles and bond distances of the energy
minimized conformations for representative analogs of 6-substituted pyrido[3,2-d]pyrimidines 273
and 281 using Schrödinger Maestro.156 The increased C-S bond length and reduced C-S-C bond
angle (Table 16) compared to the C-N bond length and C-N-C bond angle will increase the
probability of a steric clash between the side chain aryl ring and the Phe31 in hDHFR (Figure 40).
Compounds containing sulfur at the 6-position will thus decrease binding with hDHFR. On the
other hand, the active site of pjDHFR has a flexible Met33 side chain (Figure 40) in place of Phe31
(hDHFR) and is anticipated to avoid the steric clash with the 6-substituted sulfur linked pyrido[3,2d]pyrimidines and improve selectivity in pjDHFR over hDHFR. Additionally, the S-linker at 6position is expected to have less hydrophobic interaction with the shorter amino acid Val115 in
hDHFR compared to Ile123 in pjDHFR and improves selectivity and potency in pjDHFR over
hDHFR. This phenomenon was observed in compounds 277-281 in the docking study.

Figure 78: Series XV
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Scaffold hopping has been widely applied by medicinal chemists to discover novel
compounds.363 Compound 282 (Series XV, Figure 78) was designed as a hybrid of the 6-NHsubstituted pyrido[2,3-d]pyrimidine 265 and the 6-S-substituted pyrido[3,2-d]pyrimidine 281.
Isosteric replacement of NH- to S at the 6-position of the pyrido[2,3-d]pyrimidine (Table 9,
compounds 265-269) will generate the first compound 282 with a 6-S-substituted pyrido[2,3d]pyrimidine scaffold. Compound 282 can also represent a regioisomer of the 6-S-substituted
pyrido[3,2-d]pyrimidine 281.
A

B

Figure 79: A. Docked pose of 282 (green) in the crystal structure of hDHFR (PDB: 4QJC, 1.62
Å).154 79B. Docked pose of 282 (green) in the homology model of pjDHFR.154

To validate the hypothesis, we docked 282 in hDHFR (Figure 79 A) and the homology
model of pjDHFR (Figure 79 B). In hDHFR the pyrido[2,3-d]pyrimidine scaffold of 282 is stacked
amid Phe31, Phe34, and Leu22. Ion-dipole interactions were observed between the 2-NH 2 and N1of the pyrido[2,3-d]pyrimidine with Glu30. Additionally, water-mediated hydrogen bond with
Thr136 and Phe134 was observed with the 2-NH2 of 282. The 4-NH2 makes a hydrogen bond with
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the backbone of Ile7. The side chain phenyl ring makes hydrophobic interactions with Pro61, Ile60,
and Leu67. The S-linker is expected to have less hydrophobic interaction with the shorter amino
acid Val115 in hDHFR. The docked pose for 265 and 282 generated a docking score of-8.45
kcal/mol and -8.74 kcal/mol, respectively in hDHFR. In the homology model of pjDHFR, the
pyrido[2,3-d]pyrimidine scaffold of 282 lies between the Phe36, Leu25, and Ala12. The 2-NH2
and 4-NH2 make ion-dipole interactions with Asp32. The 4-NH2 makes a hydrogen bond with the
backbone of Thr144. The side chain phenyl ring moves upwards and makes hydrophobic
interactions with Phe36, Ile123, and Leu65. Sulfur is a bulkier linker compared to NH in the lead
265, and changes the angle compared to NH. The C-S-C angle of 282 and C-N-C angle of 265
were 100.5o and 131.1o, respectively (measured in Schrodinger Maestro).156 This decreased angle
in 282 compared to 265 brings the side chain closer to Met33 in pjDHFR and produces a steric
clash with Phe31 in hDHFR. Thus 282 is hypothesized to have greater selectivity for pjDHFR than
hDHFR. The docked pose for 265 and 282 generated a docking score of-10.35 kcal/mol and -10.68
kcal/mol, respectively in pjDHFR.

Figure 80: Series XVI
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Compounds 283-287 (Series XVI, Figure 80) were designed as analogs of 282 with the
pyrido[2,3-d]pyrimidine scaffold. Effects of electron-donating and electron-withdrawing groups
are expected to determine the optimum electronics required for potency and selectivity for
pjDHFR. Compounds 283-285 are anticipated to provide a structure-activity relationship through
electron-donating groups (inductive and resonance). Compounds 286-287 were predicted to
provide a structure-activity relationship through electron-withdrawing groups like fluorine and OCF3 through inductive effects. All the proposed compounds displayed favorable docked scores
for pjDHFR over hDHFR and were better than 265 and 281.

Figure 81: Leads pyrido[2,3-d]pyrimidines.
Gangjee et al.154 reported pyrido[2,3-d]pyrimidines 265 (Figure 81).154 The potency of 265
against pjDHFR was IC50 300 nM and the selectivity over hDHFR was 1 (Table 13). To address
the issue of selectivity, substituents with varying steric bulk and lipophilicity were probed at the
6-position. Compound 268 (Figure 81) was designed with a naphthyl group at the 6-position.
Compound 268 showed better potency against pjDHFR (IC50 = 250 nM) and had the advantage of
significantly enhanced selectivity over compound 265 (selectivity of 268 was 8). Due to the larger
size of the naphthyl group in 268, the side chains of these proposed compounds were expected to
sterically clash with the side chain Phe31 in hDHFR. This clash is avoided in pjDHFR, since the
pjDHFR enzyme has a flexible Met33 residue instead of Phe31 (in hDHFR) at this position.
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Figure 82: Series XVII
Compounds 288-289 (Series XVII, Figure 82) were designed as analogs of 282. Compound
288 is designed by an isosteric replacement of NH- of 268 to S-linked analog. Compound 289 is a
regioisomer of 288, where the different orientations of the naphthyl groups on both 288 and 289
will suggest the different interactions with the amino acids in hDHFR and pjDHFR. The bulkier
size of the naphthyl groups in 288-289 are predicted to sterically clash with the side chain Phe31,
in hDHFR. This clash should be avoided as before in compounds 282-287 in pjDHFR, since the
pjDHFR enzyme active site has a flexible Met33. Additionally, compounds 288-289 should
evaluate the influence of electron-withdrawing groups on the side chain aryl group and its effect
on potency and selectivity towards pjDHFR inhibition.
A

B

Figure 83: A. Docked pose of 289 (green) in the crystal structure of hDHFR (PDB: 4QJC, 1.62
Å).154 83B. Docked pose of 289 (green) in the homology model of pjDHFR.154
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To validate the hypothesis compounds 288-289 were docked in hDHFR and the homology
model of pjDHFR (Figure 83). In both the target, compounds 288-289 displayed similar
interactions like 282 (Figure 79) and 268. The S-linker decreases the angle C-S-C in 288 compared
to C-N-C in 268 and this creates a steric clash with Phe31 in hDHFR (Figure 83A), which is absent
in pjDHFR (Figure 83B). The docked pose for 288 and 289 generated a docking score of -9.22, 9.15 kcal/mol and -10.86, -10.72 kcal/mol, respectively in hDHFR and pjDHFR. All of the
proposed compounds in the Series XV-XVII displayed docked scores within 1 kcal/mol of -10.86
kcal/mol in pjDHFR, indicating these compounds should have excellent pjDHFR activity.

C.4. Folate receptors (FRs) and/or Proton-Coupled Folate Transporter (PCFT) targeted
(cytosolic and/or mitochondrial) one carbon (1C) metabolism inhibitors
C.4.1. Design of N1-substituted 5-amino-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-ones
Proliferating tumor cells have unique metabolic requirements. 364 These requirements are
characterized by improved cell-autonomous nutrient uptake and a reorganization of metabolic
pathways are needed for cell growth and division to support the biosynthesis of macromolecules. 187
This includes the folate-dependent de novo synthesis of purine nucleotides and thymidylate. Folate
receptors (FRs) mediate uptake of folates into cells by receptor-mediated endocytosis, whereas,
the reduced folate carrier (RFC) and proton-coupled folate transporter (PCFT) are facilitative
folate transporters.185, 365 FRα and FRβ, as well as PCFT are narrowly expressed in tissues where
they perform specialized functions such as in the proximal tubules of the kidney where FRα
contributes to reabsorption of folate from the urine.184, 186 Notably, FRs in normal tissues are either
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inaccessible to circulating folates (e.g., FRα in renal tubules) or are nonfunctional (FRβ in
thymus).186 The PCFT is required for intestinal absorption of folates and folate transport from
blood to cerebrospinal fluid across the choroid plexus.366 PCFT is expressed in the upper
gastrointestinal tract where it functions as the major transporter for dietary folates at acidic
pH.181,367, 368 While PCFT is expressed in a number of other normal tissues (e.g., liver, kidney), 184
it shows maximum activity at an acidic pH (pH < 7, optimum at pH 5−5.5),369 thus limiting PCFT
mediated folate transport in most normal tissues. Several solid tumors (e.g., ovarian, non-small
cell lung cancer) express PCFT, often together with FRα. 211, 370, 371 In tumors, FRα is accessible to
the circulation. Thus selective tumor targeting via PCFT and/or FRs is an attractive approach for
development of antitumor antifolates.372 PCFT is active at the acidic pH typically associated with
the tumor microenvironment, which provides additional tumor selectivity. 184 FRβ is expressed in
hematologic malignancies such as acute myeloid leukemia186 and in white blood cells of the
myeloid lineage186 including tumor-associated macrophages (TAMs).373 374 Based on the different
patterns of expression and functions of FRs, RFC, and PCFT in tumors and normal tissues, it is
possible to design agents with tumor selective targeting. Folic acid-vindesine conjugate
(vintafolide) was internalized by FRs and its cleavage intracellularly releases the cytotoxic vinca
alkaloid.375 Another folic acidtubulysin conjugate was in phase I clinical trials. 376 In addition small
molecule

N-[4-[2propyn-1-yl[(6S)-4,6,7,8-tetrahydro-2-(hydroxymethyl)-4-oxo-

3Hcyclopenta[g]quinazolin-6-yl]amino]benzoyl]-L-γ-glutamyl-D-glutamic acid (ONX0801) has
substrate selectivity for RFs over RFC and has TS as its intracellular target. 377 The principal aim
is to design agents with transporter specificity and cytotoxic abilities, which does not require an
intracellular cleavage mechanism to release the cytotoxic component as in to the conjugates
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previously developed. Premature cleavage (before reaching the tumor) of the cytotoxic vinca
alkaloids or tubulysin results in unacceptable toxicities and consequent failure in clinical trials.
Cancer cells become dependent on one-carbon metabolism to support purine and
thymidylate synthesis to sustain their proliferation. 378 Reprogramming of energy metabolism is a
hallmark in cancer development.379 Serine hydroxymethyltransferase (SHMT) catalyzes the
reversible

conversion

of

L-serine

and

tetrahydrofolate

to

glycine

and

5,10-

methylenetetrahydrofolate.380 This enzyme plays a pivotal role in one-carbon metabolism. It is
involved in tumor cell metabolic reprogramming and is a recognized target of chemotherapy
intervention.380 Folate-dependent one-carbon (C1) metabolism is situated in the mitochondria and
cytosol and is a source of critical metabolites for proliferating tumors. Mitochondrial C1
metabolism, including serine hydroxymethyltransferase 2 (SHMT2), generates glycine for de novo
purine nucleotide and glutathione biosynthesis. 222 It is an important source of NADPH, ATP, and
formate, which affords C1 units as 10-formyl-tetrahydrofolate and 5,10-methylenetetrahydrofolate for nucleotide biosynthesis in the cytosol. In cancer cells, serine is the major
source of one-carbon units. In mitochondria, serine catabolic enzymes including SHMT2, 5, 10methylene THF dehydrogenase 2 (MTHFD2) and 10-formyl-THF synthetase (reverse)
(MTHFD1L) generate glycine and one-carbon units (i.e. formate) to sustain one carbon dependent
nucleotide and amino acid biosynthesis in cytosol. The resynthesis of 10-formyl THF from formate
in the cytosol is carried out by the trifunctional enzyme MTHFD1. The 10-formyl THF is utilized
for purine nucleotide biosynthesis and can be further converted by MTHFD1 to 5,10-methylene
THF for TS and SHMT1.
Comparison of mRNA profiles of 1,454 metabolic enzymes across 1,981 tumors spanning
19 cancer types identified SHMT2 and MTHFD2 as the most consistently overexpressed
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enzymes.233 Metabolomic analysis of 219 extracellular metabolites from the NCI-60 cancer cell
lines showed that glycine metabolism strongly correlated with cancer cell proliferation. 381 Thus,
mitochondrial one-carbon metabolism has been implicated as critical for the malignant
phenotype.233, 381-384 These findings, combined with a functional shortage of amino acids (e.g.,
glycine) in tumors, suggested a therapeutic opportunity for SHMT2 targeting in cancer.

Table 17. IC50 Values (nM) for 5-Substituted Pyrrolo[2,3-d]pyrimidine Classical Antifolates in
RFC-, PCFT-, and FR-Expressing CHO Cell Lines.190, 221 Growth inhibition assays: IC50 Values
(nM) for 5-Substituted Pyrrolo[2,3d]pyrimidines in KB human tumor sublines (expressing RFC,
FRα, and PCFT) and protection study results by added metabolites. 190, 221

hRFC
PC43-10

PMX 12 ± 1.1

hFRα
R2

RT16

216±8.7 114 ± 31

hPCFT
RT16
(+FA)

R2/hPCFT R2
4
(VC)

KB
IC50
nM
461 ± 62 120.5±16.8 >1000 6.00 ± 0.6

KB
(+Thd/Ade
/AICA)
Thd/Ade

290

68.8 ± 21.2 >1000

72.0± 27.1 >1000

329 ± 61

>1000 49.5± 13.2 Ade

291

56.6 ± 5.8

8.6 ± 2.1

840 ± 90

>1000 12.7 ± 5.4 Ade

292

196.4 ± 55 >1000

33.5 ± 2.5 >1000

>1000

>1000 17.3 ± 8.9 Ade/AICA

293

>1000

>1000

>1000

>1000 >1000

>1000

>1000

>1000

>1000
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Gangjee and coworkers221 synthesized 5-substituted pyrrolo[2,3-d] pyrimidine agents 290293, as dual-acting inhibitors of glycinamide ribonucleotide formyltransferase (GARFTase) and
5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase (AICARFTase) in de novo
purine nucleotide biosynthesis (Table 17). These compounds were substrates for FRs, PCFT, and
RFC. Despite the moderate transporter activity via FRs and PCFT, 290-292 were not tumor cell
specific. PMX (Table 17) has significant uptake through RFC, which is its major limitations with
respect to a dose limiting toxicity.

Table 18. IC50 Values (nM) for 5-Substituted Pyrrolo[3,2-d]pyrimidine in RFC-, PCFT-, and FRExpressing Cell Lines and KB human tumor sublines (expressing RFC, FRα, and PCFT).

R2

RFC

FRα

FRβ

PCFT

PC43-10

RT16

D4

R2/hPCFT4

KB

294

>1000

43

50

1.59

25.2

6.7

295

>1000

516

2.13

1.29

309

6.8

296

>1000

>1000

26.6

6.3

327

6.3

PMX

894(93)

138(13)

42(9)

60(8)

13.2(2.4)

68 (12)
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Table 19. IC50 values for cell-free enzyme inhibition by pyrrolo[3,2-d]pyrimidine inhibitors.
Results are shown as mean IC50 values (± standard deviations), corresponding to the concentrations
that inhibit growth by 50%, from at least four biological replicates. IC 50 values represent the
interpolated concentrations of drug at which growth of 50% of cells was inhibited relative to
vehicle-treated control cells. ND denotes “not determined.”

In vitro enzyme assays [Ki (µM)]
GARFTase

AICARFTase

SHMT2

SHMT1

294

ND

13.31 (3.16)

0.63 (0.29)

0.90 (0.06)

PMX

5.19 (1.63)

0.88 (0.56)

ND

ND

Table 20. IC50 values for anti-proliferative activity toward engineered CHO and human tumor cell
lines, and cell-free enzyme inhibition by pyrrolo[3,2-d]pyrimidine inhibitors. Proliferation
inhibition assays were performed using human tumor cell lines, including HCT116 (colon cancer),
H460 (lung cancer), and MIA PaCa-2 (pancreatic cancer). Results are shown as mean IC 50 values
(± standard deviations), corresponding to the concentrations that inhibit growth by 50%, from at
least four biological replicates. IC50 values represent the interpolated concentrations of drug at
which growth of 50% of cells was inhibited relative to vehicle-treated control cells.

In vitro enzyme assays [Ki (nM)]
HCT116

HCT116 SHMT2 KO

H460

MIA PaCa-2

294

2266(450)

108(66)

461(163)

3664(721)

PMX

293(81)

333(40)

165(59)

281(23)
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Dual inhibition in the purine synthesis pathway is beneficial as the tumor cell cannot
survive under conditions where resistance occurs developed to one of the targets. Past efforts on
discovery and development of dual inhibition in the purine synthesis pathway have focused on
developing agents to achieve: (i) transporter-specificity; (ii) dual inhibition of GARFTase and
AICARFTase; and (iii) increased KB tumor cell inhibition. To investigate the contribution of the
7-NH moiety in 290-293 on the uptake and intracellular target inhibition, it was of interest to
design compounds based on a novel scaffold. Gangjee and coworkers 229, 230 have recently reported
5-substituted pyrrolo[3,2-d]pyrimidines 294-296 (Table 18-20). These are regio analogs of the 5substituted pyrrolo[2,3-d]pyrimidines 290-292. The proposed compounds evaluated the
importance of a hydrogen bond donor at the 7-position in compounds 290-293. Compounds 294296 inhibit cytosolic purine biosynthetic enzymes, GARFTase and/or AICARFTase, and C1
metabolism at SHMT1 and SHMT2 (Table 19).230 In vitro antitumor efficacy was established with
the lead compound 294 toward lung, colon, and pancreatic cancer cells (Table 20).229, 230 These
discoveries established novel drug prototypes and structure-activity relationships for further
development of multitargeted antitumor agents.
C.4.1.1 Rationale for the design of pyrazolo[4,3-d]pyrimidines

Figure 84: A, B, C: Representation of the general structure of pyrroles, pyrazoles and pyridines;
D: Representation of pyrazole structure, emphasizing the properties of the ring nitrogen atoms.
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The pyrazolo[4,3-d]pyrimidine scaffold, an isostere of adenine, is an important drug-like
scaffold, and its derivatives have shown a myriad of therapeutic applications including antiinflammatory, anticancer, and anti-infectious effects. 249, 385 The pyrazole (Figure 84B) is a fivemembered aromatic ring structure containing two vicinal nitrogen atoms. It has an acidic pyrrolelike nitrogen (Figure 84A) with a lone pair of electrons involved in aromaticity and a basic sp2hybridized pyridine-like nitrogen (Figure 84C), and three carbon atoms. Given the nature of the
nitrogen, N-unsubstituted pyrazoles demonstrate amphoteric properties, acting as both acids and
bases.386 While the acidic pyrrole-like NH group donates its proton, the basic pyridine-like
nitrogen has the ability to accept protons even more readily. Nevertheless, substitutions on the ring
can modulate these properties.386 Pyrazolo[4,3-d]pyrimidine, which is an isostere of purines, has
acquired considerable importance due to its diverse, facile and general synthetic methodologies
with great medicinal importance.249 Rosowsky et al.387 reported (4-(2-(2-amino-6-oxo-6,9-dihydro1H-purin-8-yl)ethyl)benzoyl)-L-glutamic acid analog with purine scaffold with potent biological
activity as antifolates. Compounds 290-292 with 5-substituted pyrrolo[2,3-d]pyrimidine and 294296 with 5-substituted pyrrolo[3,2-d]pyrimidine are excellent lead analogs for further structure
optimization for improvement in multitargeted inhibition of GARFTase, and/or AICARFTase,
and/or SHMT; along with selective transport by FRs and/or PCFT over RFC.

Figure 85: Series XVIII
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Compounds 297-298 (Series XVIII, Figure 85) with a pyrazolo[4,3-d]pyrimidine scaffold
was designed to probe the isosteric replacement of C-2 (Figure 84A) in the pyrrole ring to N-2
(Figure 84 B) in the pyrazole to determine the importance of the electronics in the five-membered
ring. In compound 297-298, the acidic pyrrole-like N1-H group is alkylated, and the basic pyridinelike nitrogen N-2 has the ability to act as hydrogen bond acceptor (HBA) (Figure 84D, 85). The
proposed compound 297-298 will evaluate the importance of HBA at the N-2 position and
additional nitrogen atom at the 2-position in 297-298 will help to understand the role of the fused
pyrazolo[4,3-d]pyrimidine ring system in anti-folate drug design.
To understand the binding of these compounds in transporters and intracellular targets,
molecular modeling studies of 290-298 were carried out in the crystal structures for FRs,190, 388
GARFTase,211 AICARFTase,219 SHMT2389 using Schrödinger Maestro 2020.156

OOC

COO
O

HN

O
4

5 N

OOC
COO
HN

3

NH

6

N 2 NH2

7

O

1

295

2

N

1

7

O

3

6

NH

N

N 5 NH 2
4

298

Figure 86. Molecular modeling with human FRα (PDB ID: 5IZQ):190 Superimposition of docked
poses of 295 (magenta) and 298 (green).
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The docked scores of the proposed compounds in all the four targets (FRα, FRβ,
GARFTase, AICARFTase, and SHMT2) were similar to that obtained for their respective lead
compounds (±1.2 kcal/mol).

Figure 86 depicts the binding mode of 295 and 298 in the active site of FRα. For both
compounds, the 2-NH2 of 295 and 5-NH2 of 298 form a hydrogen bond with Asp81. The 4-oxo of
295 and 7-oxo of 298 interacts with the side chains of Arg103 and Arg106 via hydrogen bond. The
scaffolds are stabilized by a π–π stacking interaction with Tyr85 and Trp171. The acidic groups
are in the proximity of hydrophilic amino acid residues. The α-COOH forms an ion-dipole
interaction with Trp140 and the γ-COOH forms salt bridge with Lys136, and ion-dipole
interactions with Trp102 and Gln100. The docked scores for 295 and 298 in FRα were -15.11 and
-15.22 kcal/mol, respectively. This suggests that 298 would display a FRα transport similar to 295.
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Figure 87. Molecular modeling with human FRβ (PDB ID: 4KN2).388 Superimposition of docked
poses of 295 (magenta) and 298 (green).
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Figure 87 demonstrates the molecular modeling of 295 (magenta) and 298 (green) in FRβ.
The scaffold is stabilized by π–π stacking interactions with Trp187 and Tyr101. The 2-NH 2 295
and 5-NH2 of 298 interact via ionic bonds with Asp97. The 4-oxo group of 295 and 7-oxo of 298
interacts via a hydrogen bond with the Arg119 side chain. The 3-NH of 295 and 6-NH of 298 make
a water mediated hydrogen bond with Arg122. The α-COOH forms an ion-dipole interaction with
Trp156 and the γ-COOH forms ionic interaction with backbone of Arg152, and ion-dipole
interaction with Trp118. The docked scores for 295 and 298 in FRβ were -15.24 and -15.38
kcal/mol, respectively. This suggests that 295 would display similar affinity as 298 in transport via
FRβ.
A

B

Figure 88. A. Molecular modeling of 295 (magenta) with human GARFTase (PDB ID: 4ZZI)
88. B. Molecular modeling of 298 (green) with human GARFTase (PDB ID: 4ZZI)

Figure 88 show the molecular modeling of 295 (magenta) and 298 (green) in GARFTase.
The 4-oxo of 295 and 7-oxo of 298 make hydrogen bonds with the backbone of the Asp951. The
2-NH2 of 295 and 5-NH2 of 298 make hydrogen bonds with the backbone of Leu899 and Glu948.
The acidic groups extend to a solvent exposed pocket, where the α-COOH interacts via an ionic
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interaction with Arg871 and the γ-COOH with Arg897 and Lys844 via water molecules. The
docked scores for 295 and 298 in GARFTase were -14.28 and -14.33 kcal/mol, respectively.
A

B

Figure 89. A. Molecular modeling of 295 (magenta) with human AICARFTase (PDB ID: 1P4R)219
89. B. Molecular modeling of 298 (green) with human AICARFTase (PDB ID: 1P4R).219

Figure 89 shows the molecular modeling of 295 (magenta) and 298 (green) in
AICARFTase. Similar hydrogen bonds were observed with the scaffolds of 295 and 298 in the
active site. The 2- NH2 of 295 and 5-NH2 of 298 hydrogen bond interaction with the Asn489 and
an ion-dipole interaction with the Asp546. The 4-oxo of 295 and 7-oxo of 298 hydrogen bonds
with Asn547. The scaffold is stabilized by a π–π stacking interactions with Phe544. The acidic
functional groups for 295 and 298 show different orientations. For 295, the α-COOH forms an iondipole interaction with Ser565 and the backbone of Ala566. The γ-COOH of 131 is exposed to the
solvent area. On the other hand, the α-COOH of 298 forms hydrogen bond with water, and γCOOH is exposed to the solvent. The docked scores for 295 and 298 in AICARFTase were -10.76
and -10.68 kcal/mol, respectively.
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Figure 90: Superposition of docked poses of 5-CHO-THF (yellow) and 295 (magenta) in the
SHMT2 folate bonding site (PDB ID: 5V7I)389
The natural cofactor 5-CHO-THF can be used to determine the binding requirements at the
SHMT2 binding site. To determine the structural requirements for binding to the SHMT2 at folate
binding site, 5-CHO-THF and 295 (pyrrolo[3,2-d]pyrimidine) were docked in the recently
published SHMT2 crystal structure.389 Figure 90 shows the docked pose of 5-CHO-THF (yellow)
and 295 in the SHMT2 binding site. The folate active site is located at the interface of chain A
(pink) and chain B (purple) and consists of a cavity at the bottom with a narrow channel opening
into the solvent-exposed region. The pteridine ring of 5-CHO-THF binds to the cavity and the
para-amino benzoyl (PABA) ring binds to the narrow channel lined by Tyr176 of chain B and
Tyr105 of chain A. The α-COOH makes a salt bridge with Lys181 (chain B) whereas the γ-COOH
makes an ion-dipole interaction with Ser178 (chain B). The docked pose reveals a conformation
with the pteridine ring orthogonal to the PABA ring. Based on the docked pose of 5-CHO-THF, it
147

was hypothesized that, relative to the PABA ring, an orthogonal conformation of the scaffold is
favorable to bind to the SHMT2 binding site. The docked score of 5-CHO-THF in SHMT2 was 10.42 kcal/mol.
Figure 90 shows the superposition of 295 and 5-CHO-THF in the SHMT2 binding site
where the pyrrolo[3,2-d]pyrimidine scaffold binds deeper into the pocket similar to 5-CHO-THF.
This allows the phenyl side chain of 295 to make π–π interactions with Tyr176 (chain B) and
Tyr105 (chain A). The α-COOH group make salt bridges with Lys181 (chain B) and γ-COOH
penetrates the solvent area. The docked pose of the 5-substituted pyrrolo[2,3-d]pyrimidine analog
291 does not bind deep into the SHMT2 binding pocket as the 5-CHO-THF (Figure not shown).
Compound 295 (-9.93 kcal/mol) showed a better docked score than 291 (-8.21 kcal/mol).
Moreover, 295 displayed the orthogonal conformation similar to 5-CHO-THF. This suggests that
compounds with the pyrrolo[3,2-d]pyrimidine scaffold would be a better inhibitor of SHMT2 than
those with the pyrrolo[2,3-d]pyrimidine.
Compound 298 (Figure 85: Series XVIII) with a pyrazolo[4,3-d]pyrimidine was designed
to probe the effect of an isosteric replacement of C-2 in a pyrrolo[3,2-d]pyrimidines 294-296 to
N-2. The proposed compound 298 will evaluate the importance of HBA at the N-2-position and
the additional nitrogen atom at the 2-position will help to determine the binding of the
pyrazolo[4,3-d]pyrimidine ring system in the SHMT2 binding site.
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A

B

Figure 91: A: Molecular modeling studies of 295 (magenta) in the SHMT2 folate bonding site
(PDB ID: 5V7I); 91. B: Molecular modeling studies of 298 (green) in the SHMT2 bonding site
(PDB ID: 5V7I).389

To better understand the binding of 295 and 298 with the folate SHMT2 binding site, both
the compounds were docked in the SHMT2 binding site (PDB ID: 5V7I) 389 (Figure 91). The 2NH2 and 3-NH of 295 make hydrogen bonds with the backbone of Pro167 (chain B). The 5-NH2
and 6-NH of 298 make hydrogen bonds with the backbone of Gly170 (chain B). The α- and γCOOH groups make salt bridges with Lys181 (chain B) and Lys103 (chain A), respectively. The
docked score of 295 and 298 in the SHMT2 folate binding site were -9.93 and -10.55 kcal/mol,
respectively.
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Figure 92: Superposition of docked poses of 5-CHO-THF (yellow), 295 (magenta) and 298
(green) in the SHMT2 folate bonding site (PDB ID: 5V7I). 389
Docked poses of the 5-CHO-THF (yellow), 295 (magenta), and 298 (green) were
superposed (Figure 92). Both compounds 295 and 298 with a side chain phenyl ring can mimic
the orthogonal conformation of 5-CHO-THF. This unique feature of the pyrrolo[3,2-d]pyrimidine
and pyrazolo[4,3-d]pyrimidine scaffold could be the reason that 295 and 298 can bind into the
cavity of the SHMT2 binding site. Therefore the pyrazolo[4,3-d]pyrimidine scaffold offers a
unique opportunity to develop dual one-carbon metabolism inhibitors with inhibition of cytosolic
de novo purine biosynthesis enzymes and the mitochondrial SHMT2 enzyme. Such compounds
with selective transport via FRs and/or PCFT over RFC can achieve targeted tumor therapy with
multiple enzyme inhibitions that would eliminate or decrease dose-limiting toxicity and would
circumvent or delay the development of tumor resistance.
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Figure 93. Superposition of docked pose of 298 in the crystal structures of FRα190 (cyan), FRβ 388
(orange), GARFTase 211 (green), AICARFTase219 (grey) and SHMT2 (magenta).389
The docking studies of 298 in the targets FRα, FRβ, GARFTase, AICARFTase, and
SHMT2 (Figures 86-89 and 92) displayed different conformational preferences of the side chain
linker with reference to the pyrazolo[4,3-d]pyrimidine scaffold. Superimposition of the scaffold of
the docked poses of 298 were carried out in the crystal structures for FRs, GARFTase,
AICARFTase and SHMT2 that enabled visualization of these relative side chain conformations
(Figure 93). In reference to the scaffold, the side chains extend at different angles to bind to a
particular active site. It emphasizes the importance of the necessity of a flexible linker, with a
specific length to obtain optimal activity at all four targets to preserve the multitargeted attributes
of these agents.
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C.4.2. Design of N2-substituted 5-amino- 2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-ones
Table 21. IC50 Values (nM) for 6-Substituted Pyrrolo[2,3-d]pyrimidine Classical Antifolates in
RFC-, PCFT-, and FR-Expressing Cell Lines.

Compound

R2

>1000
>1000
894(93)

299
300
PMX

RFC

FRα

FRβ

PCFT

PC43-10

RT16

D4

R2/hPCFT4

649(38)
>1000
138(13)

6.3(1.6)
6.3(1.6)
42(9)

5.6(1.2)
10(2)
60(8)

23.0(3.3)
213(28)
13.2(2.4)

Table 22: Growth inhibition assays: IC50 Values (nM) for 6-Substituted Pyrrolo[2,3-d]pyrimidines
in KB human tumor sublines (expressing RFC, FRα, and PCFT) and protection study results by
added metabolites.

KB
299
300
PMX

KB
(+Thd/Ade/AICA)
Ade/AICA
Ade/AICA
Thd/Ade

1.7(0.4)
1.9(0.7)
68 (12)

Gangjee et al.390 reported novel 6-substituted classical pyrrolo[2,3-d]pyrimidines 299-300
as cytotoxic antifolates with varying lengths of the carbon bridge (Table 21-22) and are
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characterized by having selective FRα and FRβ transport over RFC. The three- and four-carbon
bridged analogs 299 and 300 were active toward FR-expressing human tumors (KB and IGROV1)
and the cytotoxicity was primarily due to potent inhibition of GARFTase, the first folate-dependent
reaction in de novo purine nucleotide biosynthesis. The three-carbon pyrrolo[2,3-d]pyrimidine
derivative, 299 (Table 21), was subsequently reported to also be a substrate for PCFT, thus
providing an additional means of tumor-targeting. 391

Figure 94: Series XIX
In an attempt to optimize the structure for selective transport by FR and/or PCFT, and
GARFTase inhibitory activity, the pyrazolo[4,3-d]pyrimidines 301-302 with N-2 substitutions
with the three- and four-carbon bridge analogs (Series XIX, Figure 94) were designed by selecting
6-substituted pyrrolo[2,3-d]pyrimidines 299-300 as the lead compounds and scaffold hopping
approach.

To understand the binding of these compounds in transporters and intracellular targets,
molecular modeling studies of 299-302 were carried out in crystal structures of FRs,190,

388

GARFTase,211 AICARFTase219 and SHMT2389 using Schrödinger Maestro.156 The docked scores
of the proposed compounds in all the five targets (FRα, FRβ, GARFTase, AICARFTase, SHMT2)
were similar to that obtained for their respective lead compounds (±1.0 kcal/mol).
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A

B

Figure 95. A: Molecular modeling of docked pose of 300 (violet) with human FRα ; 95. B:
Molecular modeling of docked poses 302 (orange) with human FRα (PDB ID: 5IZQ)190
A

B

Figure 96. A: Molecular modeling of docked pose of 300 (cyan) with human FRβ ; 96. B.
Molecular modeling of docked pose of 302 (orange) with human FRβ (PDB ID: 4KN2)388
Figure 95 depicts the binding mode of 300 and 302 in the active site of FRα. The 2-NH2 of
300 and 5-NH2 of 302 hydrogen bond interactions with Asp81. The 4-oxo of 300 and 7-oxo of 302
makes ion-dipole interactions with Arg103 and Arg106. The 3-NH of 300 and 6-NH of 302 make
a water mediated hydrogen bond with Arg106. Amino acids Tyr85 and Trp171 stabilize both the
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scaffold. In compound 302 the α-COOH forms a salt bridge with Lys136, and the γ-COOH forms
an ion-dipole interaction with Trp140. The docked scores for 300 and 302 in FRα were -15.16 and
-15.32 kcal/mol, respectively. This suggests that 302 would display a transport similar to 300 via
FRα.

Figure 96 demonstrates the molecular modeling studies of 300 and 302 in FRβ. The
scaffold is stabilized by π–π stacking interaction with Trp187 and Tyr101. The 2-NH 2 of 300, 5NH2 of 302 and 4-oxo of 300, 7-oxo of 302 of both the compounds’ hydrogen bond with Asp97
and Arg119, respectively. The 3-NH of 300 and 6-NH of 302 make a water mediated hydrogen
bond with Arg122. The α-COOH forms an ion-dipole interaction with Trp156 and the γ-COOH
forms ionic interactions with Arg152 and an ion-dipole interaction with Gln116. The docked
scores for 300 and 302 in FRβ were -14.15 and -14.86 kcal/mol, respectively. This suggest that
302 would display transport similar to 300 via FRβ.

A

B

Figure 97: A: Molecular modeling of 300 (cyan) with human GARFTase; 97. B: Molecular
modeling of 302 (orange) with human GARFTase (PDB ID: 4ZZI) .211 5′-phosphoribosylglycinamide (GAR) depicted in yellow.
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Figure 97 shows the molecular modeling studies of 300 and 302 in GARFTase. Scaffolds
for both compounds display similar hydrogen-bonding interactions in the active site. The 2-NH 2
of 300 and 5-NH2 of 302 hydrogen bonds with the backbone of Leu899 and Glu948. The 4-oxo of
300 and 7-oxo of 302 group hydrogen bonds with Asp951. The acidic functional groups are
extended in a solvent-exposed pocket, where the α-COOH interacts via an ionic bonding with the
Arg871 and the γ-COOH ionic bonds to Arg897 and Lys844 via water. The docked scores for 300
and 302 in GARFTase were -14.60 and -14.68 kcal/mol, respectively.
A

B

Figure 98. A: Molecular modeling of 300 (cyan) with human AICARFTase; 98. B. Molecular
modeling of 302 (orange) with human AICARFTase (PDB ID: 1P4R)219

Figure 98 shows the molecular modeling of 300 and 302 in AICARFTase. The 2- NH2 of
300 and 5-NH2 of 302 form an ion-dipole interaction with Asp546. The 4-oxo of 300 and 7-oxo
of 302 form a hydrogen bond with Asn547. The scaffold is stabilized by a π–π stacking interaction
with Phe544. For 302, the α-COOH interacts via an ion-dipole interaction with Ser565 and the
backbone of Ala566 and the γ-COOH is exposed to the solvent area. The docked scores for 300
and 302 in AICARFTase were -10.43 and -10.59 kcal/mol, respectively.
156

Figure 99: Superposition of docked poses of 298 (green) and 302 (magenta) in the SHMT2 folate
binding site (PDB ID: 5V7I).389

Figure 100: Superposition of docked poses of 5-CHO-THF (cyan), 298 (green) and 302 (magenta)
in the SHMT2 folate bonding site (PDB ID: 5V7I).389
Side chain phenyl ring attach to the N-1 of 298 (N-1 substituted pyrazolo[4,3-d]pyrimidine)
can mimic the orthogonal conformation of 5-CHO-THF (Figure 99, 100) for attachment to
SHMT2. The side chain phenyl ring at the N-2 of 302 (N-2 substituted pyrazolo[4,3-d]pyrimidine)
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is unable to adopt the same conformation (Figure 99, 100) at SHMT2. Superimposition of the
docked poses of 5-CHO-THF (cyan), 298 (green), and 302 (magenta) clearly show the difference
(Figure 100). This unique feature of the N-1 substituted pyrazolo[4,3-d]pyrimidine scaffold could
be the reason that the proposed compound 298 can bind to the cavity of the SHMT2 binding site
and 302 cannot position itself in the cavity of SHMT2 as the natural 5-CHO-THF. The docked
scores of 298, 302, and 5-CHO-THF in SHMT2, are -10.55, -9.48, and -10.42 kcal/mol,
respectively.
C.4.3. Design of 6-substituted 2-amino-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-ones
Table 23. IC50 Values (nM) in RFC-, PCFT-, and FR-Expressing Cell Line and in KB human
tumor sublines (expressing RFC, FRα, and PCFT).190

R2

RFC

FRα

FRβ

PCFT

KB

KB
(+Thd/Ade

PC43-

RT16

D4

10

/AICA)

R2/hPCF
T4

300

>1000

>1000

6.3(1.6)

10(2)

213(28)

1.9(0.7)

Ade/AICA

303

>1000

>1000

4.6 (1.3)

5.6(1.4)

>1000

2.5(0.64)

Ade/AICA

304

>1000

>1000

0.58(0.12)

1.6(0.44)

23(2)

0.59

Ade/AICA

PMX

894(93) 138(13)

42(9)

60 (8)

13.2(2.4)

68 (12)

Thd/Ade
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Table 24. Distances and bond angle variations measured for energy-minimized conformations of
300 (X =CH2) and 303 (X=O) predicted by Schrodinger Maestro.156

X

C-X Bond distance (Å)

C-X-C Bond angle (⁰)

300

CH2

1.52

112.8

303

O

1.38

119.4

Gangjee and coworkers390 reported compound 300 (Table 23) which showed selective
PCFT and FRs cellular uptake over RFC and inhibited GARFTase, resulting in cytotoxicity and
inhibition of tumor cell proliferation. Golani et al.190 reported the 6-substituted pyrrolo[2,3d]pyrimidine 303 (Table 23) with a four-atom chain linker as transporter-specific inhibitors of
GARFTase. Compound 303 was designed with a heteroatom “O” vicinal to the phenyl ring. The
design is based on the natural substrate for GARFTase (10-CHO-THF), which has a -CH 2N- twoatom bridge on a 6,6- pteridine system. The analog 303 with an oxygen hetero atom linker showed
comparable potency with 300 toward KB human tumor cells. Compound 303 displayed 1.5- and
2-fold better activities in FRα-expressing RT16 cells and FRβ expressing D4 cells, respectively
than the lead analog 300. Anti-proliferative activities toward PCFT- (R2/PCFT4) expressing cells
were undetectable for 303 compared to 300. The improvement in activity in FRα-expressing RT16
cells and FRβ expressing D4 cells for 303 was attributed to chain length variation (due to varying
C-X bond distances) and C-X-C bond angles. The bond lengths of C-X follow the trend: C-O < CCH2.156 The C-X-C bond angle follows the trend: C-CH2-C <C-O-C (Table 24).156 Thus, replacing
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the benzylic CH2 in 300 with an oxygen in 303 decreases the bond length and increase the bond
angle, which allows a different conformation of the side-chain phenyl ring to better accommodate
in the active site of FRα and FRβ. These structural alterations could impact transport specificity
and GARFTase inhibition, and it was of interest to determine how these variations would affect
biological activity.392
Compound 304 (Table 23) with a fluorine at the 2ؘ′-position of 300 was designed and
reported by Ravindra et al.393 Introduction of a fluorine can have direct (amphipathic character,
resulting in polar and hydrophobic interactions) or indirect (metabolism, lipophilicity, changes in
acidity and basicity, etc.) effects on the lead molecules.393 The 2′-fluoro substitution in 304
dramatically increased antiproliferative activity mediated through all three transporters, with the
most significant impact (11- and 9-fold, respectively) on the FRα and PCFT-expressing CHO cell
lines compared to 300. Compounds 304 also inhibited the proliferation of IGROV1 and A2780
epithelial ovarian cancer cells; in IGROV1 cells with knockdown of FRα. 393 Compound 304 also
inhibited GRAFTase, a key enzyme in the de novo purine biosynthesis pathway. 393

Figure 101. Series XX
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Compound 305 (Series XX, Figure 101) was designed as analog of 303 and 304. Based on
the biological evaluations of 300 and 303-304 (Table 19), compound 305 was designed to evaluate
and compare the effects of replacing the benzylic 11-CH2 of 304 with an oxygen to compare its
effects towards improving selectivity in FRα, FRβ and PCFT over RFC.
A

B

Figure 102. A. Molecular modeling studies of docked poses of 304 (pink) and 305 (green) with
human FRα (PDB ID: 5IZQ)190 ; 102. B. Molecular modeling studies of docked poses of 304 (pink)
and 305 (green) with human FRβ (PDB ID: 4KN2)388

Figure 102A depicts the binding mode of 304 and 305 in the active site of FRα. For both
compounds, the 2-NH2 forms a hydrogen bond with Asp81. The 4-oxo makes ion-dipole
interactions with Arg103 and Arg106. The 3-NH makes a water mediated hydrogen bond with
Arg106. Amino acids Tyr175 and Trp171 stabilize the scaffold. The α-COOH forms an ion-dipole
interaction with Trp140 and the γ-COOH forms a salt bridge with Lys136 and ion-dipole
interaction with Trp102. The docked scores for 304 and 305 in FRα were -15.22 and -15.16
kcal/mol, respectively. This suggests that 305 would display transport similar to 304 via FRα.
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Figure 102B demonstrates the molecular modeling of 304 and 305 in FRβ. The scaffold is
stabilized by π–π stacking interactions with Trp187 and Tyr101. The 2-NH2 group of both
compounds’ hydrogen bond with Asp97. The 4-oxo makes ion-dipole interactions with Arg119
and Arg122. The 3NH makes a water mediated hydrogen bond with Arg122. The α-COOH forms
ion-dipole interaction with Trp156 and the γ-COOH forms ionic interaction with the backbone of
Arg119 and an ion dipole interaction with Trp118. The docked scores for 304 and 305 in FRβ were
-15.11 and -15.10 kcal/mol, respectively. This would suggest that 305 would display similar
transport through FRβ.
A

B

Figure 103. A. Molecular modeling studies of docked pose of 304 (pink) with human GARFTase;
211

103. B. Molecular modeling studies of docked pose of 305 (green) with human GARFTase. 5′-

phosphoribosyl-glycinamide (GAR) depicted in yellow.
Figures 103A and 103B show the molecular modeling of 304 and 305 in GARFTase,
respectively. Scaffolds for both compounds display similar hydrogen-bond interactions in the
active site. The 4-oxo of both the compounds interact with the backbone of the Asp951. The 2NH2 for both the compounds make hydrogen bonds with the backbone of Leu899 and Glu948. The
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3-NH makes a hydrogen bond with the backbone of Ala947. The N1 of the scaffold makes a
hydrogen bond with the backbone of Ile898. The 5′-phosphoribosyl-glycinamide (GAR) depicted
in yellow makes hydrogen bond with the oxygen of 305 (Figure 103B). This type of interaction is
absent of 304 with -CH2- the C-11 position. The acidic functional groups are extended to a solventexposed pocket, where the α-COOH interacts via an ionic bonding with Arg871 and γ-COOH with
the Arg897 and Lys844 via a water molecule. The docked scores for 304 and 305 in GARFTase
were -15.12 and -15.38 kcal/mol, respectively.
A

B

Figure 104. A. Molecular modeling of docked pose of 304 (pink) with human AICARFTase;
104. B. Molecular modeling of docked pose 305 (green) with human AICARFTase (PDB ID:
1P4R)219
Figures 104A and 104B show the molecular modeling of 304 and 305 in AICARFTase,
respectively. Scaffolds of 304 and 305 display similar hydrogen bond with the active site. The 2NH2 forms a hydrogen bond interaction with Asn489 and an ion-dipole interaction with Asp546.
The 4-oxo forms a hydrogen bond interaction with Asn547. The 3-NH makes an ion dipole
interaction with Asp546. The scaffolds are stabilized by a π–π stacking interaction with Phe544
and Phe315. The acidic functional groups for 304 and 305 show different orientations. For 304,
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the α-COOH makes ion-dipole interactions with a water molecule and the γ-COOH makes an ionic
interaction with Lys357. On the other hand, the α-COOH of 305 forms an ion-dipole interaction
with water molecule and the γ-COOH is exposed to the solvent. The docked scores for 304 and
305 in AICARFTase were -11.16 and -11.29 kcal/mol, respectively.

Figure 105: Superposition of the scaffold docked pose of 305 in crystal structures of FRα190
(cyan), FRβ 388 (orange), GARFTase 211 (green) and AICARFTase219 (grey).
The docking studies of 305 in the targets (Figures 102-104) displayed different
conformational preferences of the side chain linker in reference to the pyrrolo[2,3-d]pyrimidine
scaffold. Superimposition of the docked poses of 305 was carried out in the crystal structures for
FRs, GARFTase, and AICARFTase enabled visualization of these conformations (Figure 105). In
reference to the scaffold, the side chains extend at different angles to bind to a particular active
site. It emphasizes the importance of the necessity of a flexible linker, with a specific length to
obtain optimal activity at all four targets.
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IV. CHEMICAL DISCUSSION
The present section deals with the development of synthesis for compounds in the following four
areas:
D.1. Synthesis of agents with combination chemotherapy potential in single agents
4)

2, 4-disubstituted thieno[2,3-d]pyrimidines

5)

2, 4, 5- and 6-substituted thieno[2,3-d]pyrimidines

6)

4, 7-disubstituted pyrrolo[3,2-d]pyrimidines

D.2. Synthesis of single agents with tubulin inhibition.
3) 2, 4-disubstituted 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine
4) 2, 4, 5-trisubstituted pyrazolo[3,2-d]pyrimidines
D.3. Synthesis of selective pjDHFR inhibitors
2) 6-(arylthio)pyrido[2,3-d]pyrimidine-2,4-diamines
D.4. Synthesis of single agents with Folate Receptors (FRs) and/or Proton-Coupled Folate
Transporter (PCFT) targeted (cytosolic and/or mitochondrial) one carbon (1C) metabolism
inhibitors
4) N1-substituted 5-amino-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-ones
5) N2-substituted 5-amino- 2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-ones
6) 6-substituted 2-amino-3,7-dihydro-4 -pyrrolo[2,3-d]pyrimidin-4-ones
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D.1. Synthesis of agents with combination chemotherapy potential in single agents
D.1.1: Synthesis of 2-, 4-, 5- and 6-substituted thieno[2,3-d]pyrimidines

Scheme 46. Synthesis of intermediate 308

Reagents and conditions: a) HCl (g), 30 mins, CH3CN, rt, 2 h; b) POCl3, 12-24 h; c) POCl3,
pyridine, toluene, reflux, 12h.
The synthesis of the bicyclic thieno[2,3-d]pyrimidine 307 (Scheme 46) was accomplished
by the treatment of commercially available ethyl 2-aminothiophene-3-carboxylate 306 with
acetonitrile under acidic condition.293 To synthesize 4-chloro-2-methylthieno[2,3-d]pyrimidine
308, chlorinating agent POCl3 was added to 307 at reflux for 12-24 h. The reaction was cooled,
excess chlorinating agent was evaporated and neutralized with the ammonia solution, and the
mixture was filtered. During work up, the 4-chloro product 308 converted back to the 4-oxo
product 307 (confirmed by 1H NMR). Other chlorinating agents like thionyl chloride (SOCl 2)394
or phosphorus pentachloride (PCl5)395, or a mixture of POCl3 and PCl5396 were attempted to convert
307 to 308. In all of these cases, where these chemicals were utilized as both chlorinating agents
and solvents, the excess of the solvent removal and the work-up process was very tedious.
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Table 25: Chlorination conditions to covert 307 to 308
No.

Chlorinating agents

Base

Status of reaction/yields%

1.
2.
3.

POCl3
POCl3
POCl3

Et3N
Pyridine
DIPEA

45
62
40

4.

POCl3

DBU

55

Sun et al.397 reported a method where nitrogen containing aromatic heterocyclic analogs
were efficiently prepared from the corresponding hydroxylated precursors under low-solvent
conditions with equimolar or less chlorinating reagents. Arnott et al.398 also described methods for
chlorination of 4-quinazolones using POCl3. This high yielding protocol allows successful
preparations of multigram and kilogram quantities of critical synthetic intermediates. The
chlorination reaction was attempted at reflux with POCl 3 (1 eq.) and with several different
combinations of solvents (dioxane, acetonitrile, toluene) and bases (1 eq.) (Table 25). Optimized
results were obtained at reflux for 12 h with POCl 3 (1 eq.) and pyridine (1 eq.) in toluene to afford
308 in 62% yield.
Scheme 47. Synthesis of target compounds 182-184.

Reagents and conditions: a) anilines, isopropanol, 1 drop of HCl, microwave, 120 ⁰C, 6 h; b)
sodium hydride, iodomethane, DMF, r.t., 2 h.
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To afford a nucleophilic aromatic substitution reaction,309 308 was heated in a microwave
reactor at 120 oC with 4-methoxyaniline or 4-(methylthio)aniline to afford 183 and 184a,
respectively (Scheme 47). The N4-methylation was carried out using the published procedure 346
with sodium hydride and iodomethane in DMF with 183 and 184a to afford 182 and 184 in 78%,
and 52% yield, respectively.
Scheme 48. Synthesis of target compound 185

Reagents and conditions: a) 6-methoxy-1,2,3,4-tetrahydroquinoline, 1 drop HCl, isopropanol, 120
o

C, microwave, 6 h.
Following

the

reported

methylthieno[2,3-d]pyrimidine

185

method,293
(Scheme

4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)-248)

was

synthesized

using

4-chloro-2-

methylthieno[2,3-d]pyrimidine 308 and 6-methoxy-1,2,3,4- tetrahydroquinoline with a drop of HCl
in isopropanol at 120 ⁰C in a microwave reactor for 6 h (76% yield).

Scheme 49. Synthesis of the target compound 189

Reagents and conditions: a) 6-aminonaphthalen-1-ol, isopropanol, 1 drop HCl, microwave, 120
o

C, 8 h; b) sodium hydride, iodomethane, DMF, r.t., 2 h.
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Intermediate 308 and 6-aminonaphthalen-1-ol were dissolved in isopropanol and heated in
a microwave reactor at 120 oC using the reported method293 followed by methylation of the N4-H
and 5’-OH with sodium hydride and iodomethane in DMF solution to afford 189 in 48% yield over
two steps (Scheme 49).346
Scheme 50. Synthesis of target compound 196

Reagents and conditions:
a)

4-methoxy-N-methylaniline, isopropanol, 1 drop of HCl, microwave, 120 ⁰C, 6 h.
The synthesis of N-(4-methoxyphenyl)-N-methylthieno[2,3-d]pyrimidin-4-amine 196

(Scheme 50) was carried out with the reported SNAr reaction399 in isopropanol with treatment of
commercially available 4-chlorothieno[2,3-d]pyrimidine 309, 1 drop of HCl and 4-methoxy-Nmethylaniline in a microwave reactor for 6 h (60% yield).
Scheme 51. Synthesis of target compound 198

Reagents and conditions: a) 6-methoxy-1,2,3,4-tetrahydroquinoline, 1 drop of HCl, isopropanol,
microwave, 120 ⁰C, 8 h.

169

Commercially available 4-chlorothieno[2,3-d]pyrimidine 309 was treated with 1 drop of
HCl followed by the addition of 6-methoxy-1,2,3,4-tetrahydroquinoline and heated in a microwave
reactor to afford 4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)thieno[2,3-d]pyrimidine 198 in 58%
yield (Scheme 51).

Scheme 52. Synthesis of intermediate 311

Reagents and conditions: a) Chloroformamidine hydrochloride, methyl sulfone, 140 oC, 4 h; b)
Piv2O, reflux, 2 h; c) POCl3, pyridine, toluene, reflux, 10 h
Commercially available ethyl 2-aminothiophene-3-carboxylate 306 was cyclized to 2aminothieno[2,3-d]pyrimidin-4(3H)-one 310 with chloroformamidine hydrochloride in dimethyl
sulfone (Scheme 52). Intermediate 310 was protected with pivalic anhydride and chlorinated with
POCl3 and pyridine in toluene to afford the crucial intermediate 311 (49% over two steps).

Scheme 53. Synthesis of target compound 197

Reagents and conditions: a) 4-methoxy-N-methylaniline, isopropanol, 1 drop HCl, reflux, 12 h.;
b) 1 N NaOH, reflux, 2 h.
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For the synthesis of N4-(4-methoxyphenyl)-N4-methylthieno[2,3-d]pyrimidine-2,4diamine 197 (Scheme 53), the displacement method was followed in the first step as previously
reported400 by treating 311 with 4-methoxy-N-methylaniline at reflux condition for 12 h. The
pivaloyl protected intermediate was deprotected with 1 N NaOH and heated to reflux for 2 h to
obtain 197 in 48% yield over two steps.

Scheme 54. Synthesis of target compound 199

Reagents and conditions: a) 6-methoxy-1,2,3,4-tetrahydroquinoline, isopropanol, 1 drop of HCl,
reflux, 8 h.; b) 1 N NaOH, reflux, 2 h.

For the synthesis of 4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)thieno[2,3-d]pyrimidin2-amine 199 (Scheme 54), the displacement method as previously reported by Gangjee and coworkers353 was followed where 311 was treated with 1 drop of HCl and 6-methoxy-1,2,3,4tetrahydroquinoline in isopropanol at reflux condition for 12 h. To crude reaction was added 1 N
NaOH solution and maintained at reflux for 2 h to obtain 199 in 40% in two steps.
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Scheme 55. Synthesis of the compound 204

Reagents and conditions: a) 4-methoxy-N-methylaniline, isopropanol, r.t., 48 h.

Commercially available 2,4-dichlorothieno[2,3-d]pyrimidine 312 was reacted with 4methoxy-N-methylaniline at r.t. for 48 h in acetonitrile in order to synthesize 2-chloro-N-(4methoxyphenyl)-N-methylthieno[2,3-d]pyrimidin-4-amine 204 in 38% yield following the
reported procedure by Shah and Gangjee353 (Scheme 55).
Scheme 56. Synthesis of compound 205

Reagents and conditions: a) 6-methoxy-1,2,3,4-tetrahydroquinoline, isopropanol, r.t., 48 h.
Commercially available 2,4-dichlorothieno[2,3-d]pyrimidine 312 was reacted with 6methoxy-1,2,3,4-tetrahydroquinoline at r.t. for 48 h in order to synthesize 2-chloro-4-(6-methoxy3,4-dihydroquinolin-1(2H)-yl)thieno[2,3-d]pyrimidine 205 in 35% yield following the reported
procedure by Shah and Gangjee353 (Scheme 56).
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D.1.2: Synthesis of 2, 4, 5- and 6-substituted thieno[2,3-d]pyrimidines
Scheme 57. Synthesis of target compound 218

Reagents and conditions: a) HCl (g) 30 mins, CH3CN, rt, 1 h; b) POCl3, pyridine, toluene, reflux,
12 h, c) 4-methoxy-N-methylaniline, isopropanol, 1 drop of HCl, reflux, 12 h
The synthesis of 2,5-dimethylthieno[2,3-d]pyrimidin-4(3H)-one 314 (Scheme 57) was
accomplished by the treatment of commercially available ethyl 2-amino-4-methylthiophene-3carboxylate 313 with acetonitrile under acidic conditions.293 Chlorination of 314 with POCl3 and
pyridine in toluene afforded the intermediate 4-chloro-2,5-dimethylthieno[2,3-d]pyrimidine 315a.
Nucleophilic aromatic substitution reaction309 of the intermediate 315a with 4-methoxy-Nmethylaniline in isopropanol with 1 drop of HCl afforded 218 in 62% yield.

Scheme 58. Synthesis of target compound 221

Reagents and conditions: a) 6-methoxy-1,2,3,4-tetrahydroquinoline, isopropanol, 1 drop of HCl
reflux, 6 h.

173

Intermediate 315a was subjected to a SNAr displacement with

6-methoxy-1,2,3,4-

tetrahydroquinoline using the published procedure401 to synthesize 4-(6-methoxy-3,4dihydroquinolin-1(2H)-yl)-2,5-dimethylthieno[2,3-d]pyrimidine 221 in 60% yield (Scheme 58).
Scheme 59. Synthesis of target compounds 219-220

Reagents and conditions: a) 4-methoxy-N-methylaniline, isopropanol, 1 drop of HCl, r.t., 18-24 h.
Commercially available 2,4-dichloro-5-methylthieno[2,3-d]pyrimidine 315b and 4-chloro5-methylthieno[2,3-d]pyrimidin-2-amine 315c were displaced with 4-methoxy-N-methylaniline
following the reported procedure by Shah and Gangjee353 at r.t. for 18-24 h to generate 2-chloroN-(4-methoxyphenyl)-N,5-dimethylthieno[2,3-d]pyrimidin-4-amine
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and

N4-(4-

methoxyphenyl)-N4,5-dimethylthieno[2,3-d]pyrimidine-2,4-diamine 220 in 48% and 45% yield,
respectively (Scheme 59).
Scheme 60. Synthesis of target compounds 222-223

Reagents and conditions: a) 6-methoxy-1,2,3,4-tetrahydroquinoline, isopropanol, 1 drop of HCl,
r.t., 18-24 h
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Commercially available 2,4-dichloro-5-methylthieno[2,3-d]pyrimidine 315b and 4-chloro5-methylthieno[2,3-d]pyrimidin-2-amine

315c

were

displaced

with

6-methoxy-1,2,3,4-

tetrahydroquinoline following the reported procedure by Shah and Gangjee 353 and at r.t. for 18-24
h

to

generate

d]pyrimidine
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2-chloro-4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)-5-methylthieno[2,3and

4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)-5-methylthieno[2,3-

d]pyrimidin-2-amine 223 in 45% and 40% yield, respectively (Scheme 60).
Scheme 61. Synthesis of target compounds 225, 226a, 226 and 227

Reagents and conditions: a) HCl (g) 30 min, CH3CN, rt, 1 h; b) POCl3, pyridine, toluene, reflux,
12 h, c) anilines, isopropanol, 1 drop of HCl, reflux, 12 h, d) iodomethane, NaH, DMF, rt, 2 h.

The synthesis of 2,5,6-trimethylthieno[2,3-d]pyrimidin-4(3H)-one 317 (Scheme 61) was
accomplished by treatment of commercially available ethyl 2-amino-4,5-dimethylthiophene-3carboxylate 316 with acetonitrile under acidic conditions.293 Chlorination of 317 with POCl3 and
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pyridine in toluene afforded 4-chloro-2,5,6-trimethylthieno[2,3-d]pyrimidine 318. Nucleophilic
aromatic substitution reactions309 of the intermediate 318 with 4-methoxyaniline and 4(methylthio)aniline in isopropanol with 1 drop of HCl afforded 227 and 228, respectively.
Synthesis of N-(4-methoxyphenyl)-N,2,5-trimethylthieno[2,3-d]pyrimidin-4-amine (225)

and

N,2,5,6-tetramethyl-N-(4-(methylthio)phenyl)thieno[2,3-d]pyrimidin-4-amine (226) were carried
out by treatment of 227 and 228 with sodium hydride in DMF at room temperature followed by
dropwise addition of iodomethane for 2 h in 69% and 36% yield, respectively.

Scheme 62. Synthesis of target compounds 229

Reagents and conditions: a) 7-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazine, isopropanol, 1 drop
of HCl, reflux, 8 h.

Intermediate 318 was subjected to SNAr displacement with 7-methoxy-3,4-dihydro-2Hbenzo[b][1,4]oxazine using a published procedure401 to synthesize 7-methoxy-4-(2,5,6trimethylthieno[2,3-d]pyrimidin-4-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazine 229 in 58% yield
(Scheme 62).
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D.1.3. Synthesis of 4,7-disubstituted pyrrolo[3,2-d]pyrimidine
Scheme 63. Synthesis of the target compound 232

Reagents and conditions: a) 3,3-dimethoxypropanenitrile, CH 3ONa, CH3OH, r.t., overnight; b) 6N
HCl, r.t., 30 mins; c) H2, Pd/C 50 psi, r.t., 3 h; d) diethylamino malonate, CH3COONa, CH3OH,
r.t., 16 h; e) CH3ONa, CH3OH r.t., 12 h, reflux, 3 h; f) formamide, µW, 170 oC, 12 h; g) POCl3,
pyridine, toluene, reflux, 4 h; h) 4-methoxy-N-methylaniline, isopropanol, 1 drop of HCl, reflux,
3 h.
Key intermediate methyl 3-amino-4-benzyl-1H-pyrrole-2-carboxylate 323 (Scheme 63)
was synthesized following the reported procedure by Elliott et al.240 A mixture of benzaldehyde
319 and 3,3-dimethoxypropionitrile was added to a solution of NaOMe in MeOH to afford 2(dimethoxymethyl)-3-phenylacrylonitrile 320. This was followed by the addition of 6N HCl to
deprotect the acetal and provide 2-formyl-3-phenylacrylonitrile 321.240 Catalytic reduction240 of
321 to 2-benzyl-3-oxopropanenitrile 322, followed by cyclization of 322 with diethylamino
malonate and CH3COONa in methanol provided the key intermediate methyl 3-amino-4-benzyl177

1H-pyrrole-2-carboxylate 323. Cyclization320 of 323 with formamide produced 7-benzyl-5Hpyrrolo[3,2-d]pyrimidin-4-ol 324. This was then subjected to chlorination reaction 320 with POCl3
to

obtain

7-benzyl-4-chloro-5H-pyrrolo[3,2-d]pyrimidine

325.

Nucleophilic

aromatic293

substitution with 325 and 4-methoxy-N-methylaniline in isopropanol gave the final compound 232
in 72% yield.
D.2. Synthesis of single agents with tubulin inhibition.
D.2.1. Synthesis of 2,4-disubstituted 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidines.
Scheme 64: Retrosynthetic analysis to 2,4-substituted 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3d]pyrimidine.

From a retrosynthetic point of view (Scheme 64), the general strategy was envisioned for
the synthesis of 2,4-disubstituted 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidines. The
tricyclic 328 could be derived from 329, which in turn could be synthesized from 330. Synthesis
of 330 could be attempted from the commercially available 4-cyclohexanone 331, sulfur 332, and
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ethyl cyanoacetate 333 through the Gewald reaction402 and cyclization. Thus, 4-chloro-2-methyl5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine 328 is the key intermediate for the synthesis
of 2- and 4-substituted 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidines. Attempt of N4methylation from 326 with iodomethane and nucleophilic aromatic substitution (SNAr) from 327
could be accomplished from variety of anilines.

Scheme 65. Synthesis of target compounds 234 and 236.

Reagents and conditions: a) S8, ethyl cyanoacetate, morpholine, EtOH, 60 oC, 12 h; b) CH3CN,
HCl (g), 30 min, r.t.; overnight; c) POCl3, pyridine, toluene, reflux, 6 h.; d) anilines, isopropanol,
1-2 drops of HCl, reflux, 4-8 h.; e) sodium hydride, iodomethane, DMF, r.t., 2 h.

Commercially available cyclohexanone 331 and sulfur in ethanol were treated with ethyl
cyanoacetate, followed by the dropwise addition of morpholine to obtain 330 (Scheme 65).403 The
synthesis of the tricyclic thieno[2,3-d]pyrimidine 329 was accomplished by bubbling hydrochloric
acid293,

404

in 330 in acetonitrile. The 2-methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3179

d]pyrimidin-4(3H)-one 329 was then chlorinated with phosphorus oxychloride and pyridine in
toluene to generate 4-chloro-2-methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine 328..
Nucleophilic aromatic substitution293 of 328 using 4-methoxyaniline and 4-(methylthio)aniline in
isopropanol with 1 drop of HCl afforded 334 and 335 in 40 and 41% yield, respectively. The N4methylation405 was carried out using sodium hydride and iodomethane with 334 and 335 to afford
234 and 236 in 68% and 70% yield, respectively.

Scheme 66. Synthesis of target compound 238

Reagents and conditions: a) 6-methoxy-1,2,3,4-tetrahydroquinoline, 1 drop of HCl, isopropanol,
reflux, 6 h.

To a solution of isopropanol and 328, 1 drop of HCl and 6-methoxy-1,2,3,4tetrahydroquinoline were added and the mixture kept at reflux to provide the synthesis of 238
(Scheme 66) in 55% yield.293
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Scheme 67. Synthesis of target compounds 239-240

Reagents and conditions: a) 6-aminonaphthalen-1-ol, 1 drop of HCl, isopropanol, reflux, 8h; b)
sodium hydride, iodomethane, DMF, r.t. 2 h
To a solution of isopropanol and
aminonaphthalen-1-ol

and

kept

328 was added with 1 drop of HCl and 6at

reflux

to

afford

6-((2-methyl-5,6,7,8-

tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)amino)naphthalen-1-ol 240 in 71% yield
(Scheme 67).293 Methylation4,405 of N4-H and 5’-OH of 240 was carried out using sodium hydride
and iodomethane in DMF to afford N-(5-methoxynaphthalen-2-yl)-N,2-dimethyl-5,6,7,8tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-amine 239 in 57% yield.
Scheme 68. Synthesis of target compounds 244 and 245.

Reagents and conditions: a) chloroformamidine hydrochloride, DMSO 2, 140 oC, 4 h; b) Piv2O,
reflux, 2 h; c) POCl3, pyridine, toluene, reflux, 4 h; d) i) 1-2 drops of HCl, isopropanol, anilines,
reflux, 6-8 h; ii) 1N NaOH, reflux 2 h.
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Using

the

reported

procedure,320

the

synthesis

of

2-amino-5,6,7,8-

tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one 336 was initiated by cyclization of 330
with chlorformamidine hydrochloride in dimethyl sulfone at 140 oC (Scheme 68). The amino
group of 336 was protected using pivalic anhydride to afford N-(4-oxo-3,4,5,6,7,8hexahydrobenzo[4,5]thieno[2,3-d]pyrimidin-2-yl)pivalamide 337. Chlorination of 337 was carried
out with phosphorus oxychloride, pyridine in toluene to generate N-(4-chloro-5,6,7,8tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-2-yl)pivalamide
procedure,

320

SNAr

reaction

using

338.

Following

N-methyl-4-methoxyaniline

and

a

reported

N-methyl-4-

(methylthio)aniline in isopropanol under reflux condition followed by deprotection of the pivalate
group with 1N NaOH under reflux afforded N4-(4-methoxyphenyl)-N4-methyl-5,6,7,8tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine-2,4-diamine

244

and

N4-methyl-N4-(4-

(methylthio)phenyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine-2,4-diamine

245

in

56% and 48% yield, respectively.
Scheme 69. Synthesis of target compound 246

Reagents and conditions: a) 1 drop of HCl, isopropanol, 6-methoxy-1,2,3,4-tetrahydroquinoline,
reflux, 8 h; ii) NaOH, reflux 1h.
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To a solution of the intermediate 338 in isopropanol, 1 drop of HCl, and 6-methoxy-1,2,3,4tetrahydroquinoline were added and the mixture was kept at reflux. This was followed by pivalate
deprotection with 1N NaOH at reflux to afford 4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-2-amine 246 in 42% yield (Scheme 69).

Scheme 70. Synthesis of target compounds 247 and 248.

Reagents and conditions: a) Formamide, 180 oC, µW, 12 h; b) POCl3, pyridine, toluene, reflux, 8
h; c) 1-2 drops of HCl, isopropanol, aniline, reflux, 6 h.

Following a reported procedure402 intermediate 330 was cyclocondensed with formamide
in

a

microwave

reactor

at

180

o

C

for

12

h

to

afford

tricyclic

5,6,7,8-

tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one 339 (Scheme 70). Chlorination of 339
with

phosphorus

oxychloride

and

pyridine

in

toluene

generated

4-chloro-5,6,7,8-

tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine 340 which was then subjected to SNAr reaction using
the appropriate anilines in isopropanol at reflux to afford 247 and 248 in 68% and 70% yield,
respectively.
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D.2.2: Synthesis of 2,4,5-trisubstituted pyrazolo[3,2-d]pyrimidines

Scheme 71. Attempted synthesis of the intermediate 342a

Reagents and conditions: a) Methylation agents, K2CO3, solvent, r.t., 12-24 h.

Table 26: Reaction optimization with various methylation agents at different solvents with
K2CO3 base at r.t. for 12-24 h.

Attempts

Methylation agents

Solvent

342a (%Yield)

342b (%Yield)

1

dimethyl sulphate

MeOH

25

50

2

dimethyl sulphate

DMF

28

52

3

dimethyl sulphate

Acetone

4

methyl tosylate

MeOH

26

52

5

methyl tosylate

DMF

30

54

6

MeI

MeOH

28

50

7

MeI

DMF

35

55
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342a inseparable

The synthesis of the intermediate 342a (Scheme 71) was initiated from commercially
available methyl 4-nitro-1H-pyrazole-5-carboxylate 341. Initially both the regioisomers 342a and
342b formation was observed. In addition, the decreased isomer 342a was obtained in as one half
as much as the isomer 342b. The reaction was thus attempted in several different solvents with
various methylation agents, with temperature variations from r.t. to higher temperatures and at
different time intervals (Table 26).406, 407 The most efficient yield of 342a was with methyl iodide
in the presence of K2CO3 in DMF, at r.t. This provided desired regioisomer 342a in 35% yield and
the other isomer in 55% yield. The isomers 342a and 342b were separated via column
chromatography and were structurally characterized by 1H NMR and NOESY spectroscopy.

D.2.2.1: 1H NMR Evidence for the structure of compounds 342a and 342b:

Figure 106: NOESY NMR of intermediate 342a
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Figure 107: NOESY NMR of intermediate 342b

N1-methylation of the pyrazole scaffold 341, generated as anticipated two regioisomers
342a and 342b. It is well known that alkylation of unsymmetrically substituted pyrazole
derivatives usually provides mixtures of both possible N1-alkylated products.407 The
regiochemical identification of the methylated intermediates 342a and 342b was carried out by 1H
NMR407 and NOESY spectroscopy (Figure 106 and 107). In the 1H NMR (only δ values are
included, spectra not shown), the chemical shifts of N1-CH3 protons for 342a and 342b occurred
as singlets at 4.02 and 3.95 ppm, respectively. It is noteworthy that the presence of the adjacent
C5-carboxylate to the N1-CH3 in compound 342a caused the N1-CH3 protons of 342a to shift
~0.07 ppm downfield than the N1-CH3 of 342b. The initial studies involved NMR and NOESY
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(Nuclear Overhauser Enhancement Exchange Spectroscopy) which is one of the most direct ways
to determine spatial proton-proton/proton-heteronucleus/heteronucleus-heteronucleus correlations
within a molecule in the range of up to 5 Å or less.408 Intermediate 342a, can be identified as the
methyl 1-methyl-4-nitro -1H-pyrazole-5-carboxylate regioisomer as no strong NOE correlation
was observed between the H3 proton and the N1-CH3 protons (Figure 106). However, the
regioisomeric 342b regioisomer, the methyl 1-methyl-4-nitro -1H-pyrazole-3-carboxylate showed
characteristic NOE correlation between H5 proton and N1-CH3 protons (Figure 107). The observed
H5 proton and N1-CH3 cross peak (δ 8.95, 3.95) was dominated by scalar coupling effects, with
evidence of only a NOE coupling proton contributing to it in 342b. This establishes the structure
of 342b. For 342a the H3 proton occurs at δ 8.36 and for 342b the H5 proton occurs at δ 8.95. The
probable deshielding effects of the H5 proton in 342b is due to the direct electron attracting effect
of the C-5. Literature precedence on 1H NMR407, crystal structure407 and the 2D-NMR from our
studies confirms the structure of the regioisomers 342a and 342b as depicted in Scheme 71.

Scheme 72. Synthesis of target compound 251.

Reagents and conditions: a) 10% Pd/C, H2, MeOH, 40 psi, 1 h; b) urea, 180 oC, 2 h; c) POCl3,
pyridine, toluene, 4 h, reflux, d) 4-methoxy-N-methylaniline, acetonitrile, reflux, 12 h.
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Reduction of the nitro group385 of 342a, yielded 343 (Scheme 72), which was
cyclocondensed with urea407 followed by chlorination with POCl3 and pyridine in toluene to
provide

the

key

intermediate

5,7-dichloro-1-methyl-1H-pyrazolo[4,3-d]pyrimidine

344.

Nucleophilic aromatic substitution335 of 344 was carried out using 4-methoxy-N-methylaniline to
provide 5-chloro-N-(4-methoxyphenyl)-N,1-dimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-amine 251
in 38% yield.
Scheme 73. Synthesis of target compound 252

Reagents and conditions: a) 4-methoxyaniline, acetonitrile, reflux, 8 h.
Nucleophilic aromatic substitution335 of 344 with 4-methoxyaniline to provide 5-chloro-N(4-methoxyphenyl)-1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-amine (252) in 45% yield (Scheme
73).

D.2.2.2: 1H NMR Evidence for Conformational Restriction in Compounds 251 and 252:
1

H-NMR studies were carried out to confirm that the SNAr reaction occurred

regiospecifically at the 7-position of 344 in Scheme 72 and Scheme 73 to generate 251 and 252,
respectively. Comparing the chemical shift positions of the protons at the N1-CH3 for 251 with the
chemical shift of the protons at the N1-CH3 for 252, it was observed that the protons after the
displacement are shielded by 1.30 ppm in compound 251 (Figure 108). Such a shielding effect
attributed to the anisotropy of the phenyl ring of the aniline is only possible if the S NAr
188

displacement occurred at the 7-position of 344. Similar anisotropic effects of the phenyl ring have
been previously reported by Shah et al.335 in pyrolo[3,2-d]pyrimidine analogs.

Figure 108: Possible explanation of the phenyl ring orientation in compound 251

The 1H NMR spectra of the N7-H analog 252 and N7-CH3 analog 251 in DMSO-d6 afforded
additional information related to the conformational restriction in 251 (Figure 108). For 251, the
“N1-CH3” protons appeared at δ 3.04, whereas for 252 they were significantly deshielded at δ 4.35
ppm. This shielding of the “N1-CH3” protons in 251 was attributed to a diamagnetic anisotropic
effect in 251 arising from the proximity of the N7-phenyl ring as shown in Figure 108 (more
favored anti- conformation for 251 on the basis of the N7-CH3 and the N1-CH3 groups). The steric
bulk of the N7-CH3 and/or steric clash of the N7-CH3 and the N1-CH3 groups in 251 restricts the
conformation and positions the N7-phenyl group on top of the N1-CH3 moiety resulting in the
observed shielding effect, in the 1H NMR, on the N1-CH3 group in 251 as compared to that in 252.
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This shielding effect of the phenyl group on the N1-CH3 group (δ ≈ 1.20) was also observed for
other the N7-CH3 analogs.

Scheme 74. Synthesis of target compound 253

Reagents and conditions:
a) 6-methoxy-1,2,3,4-tetrahydroquinoline, acetonitrile, reflux, 12h

Nucleophilic aromatic substitution of 344 was carried out with 6-methoxy-1,2,3,4tetrahydroquinoline in acetonitrile to provide 1-(5-chloro-1-methyl-1H-pyrazolo[4,3-d]pyrimidin7-yl)-6-methoxy-1,2,3,4-tetrahydroquinoline 253 in 40% yield (Scheme 74).

Scheme 75. Synthesis of target compounds 257, 258 and 262

Reagents and conditions: a) Anilines, acetonitrile, reflux, 10-12 h
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Nucleophilic aromatic substitution of 344 was done using 4-ethoxy-N-methylaniline, 4isopropoxy-N-methylaniline,

N-methyl-4-(methylthio)aniline,

and

N-methyl-4-

(trifluoromethoxy)aniline in acetonitrile to provided 257, 258 and 262 in 36-42% yield (Scheme
75).
Scheme 76. Synthesis of target compound 261

Reagents and conditions: a) 5-methoxy-N-methylnaphthalen-2-amine, acetonitrile, reflux, 8 h

Nucleophilic aromatic substitution of 344 with 5-methoxy-N-methylnaphthalen-2-amine
in acetonitrile at reflux provided 5-chloro-N-(5-methoxynaphthalen-2-yl)-N,1-dimethyl-1Hpyrazolo[4,3-d]pyrimidin-7-amine 261 in 40% yield (Scheme 76).
Scheme 77. Synthesis of target compound 263

Reagents and conditions: a) Anilines, acetonitrile, reflux, 12 h.
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To synthesize the final compound 263, nucleophilic aromatic substitution of 344 was done
using 3-fluoro-4-methoxy-N-methylaniline in acetonitrile at reflux for 12 h to obtain 5-chloro-N(3-fluoro-4-methoxyphenyl)-N,1-dimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-amine 263 46% yield
(Scheme 77).

D.3. Synthesis of 6-(arylthio)pyrido[2,3-d]pyrimidine-2,4-diamines as selective pjDHFR.
Scheme 78: Attempted synthesis of 348

Reagents and conditions: a) Acetic acid, NBS, CH 3CN, reflux, overnight; b) Benzenethiol 347,
Cs2CO3, ACN, MW, 80 oC, 12 h.
The initial approach for the synthesis of 282 (Scheme 78) was bromination of 2aminonicotinonitrile 345 via NBS in acetonitrile at reflux overnight.121 The next step was to
append this key intermediate 346 with various arylthiols (benzenethiol 347 for 348). García et
al.409 reported a reaction of aryl thiol and the corresponding halo arylpyridine with Cs 2CO3 as a
base under microwave conditions. The structure of 346 was confirmed by investigating the
coupling constants (J) of the protons [1H NMR (500 MHz, DMSO-d6) δ 8.22 (d, J = 2.6 Hz, 1H),
8.07 (d, J = 2.6 Hz, 1H), 7.12 (s, 2H, exch., 2-NH2).] The coupling constants match the
characteristic J constants for meta coupling between aromatic protons.410 The reaction did not yield
any product after 12 h at 80 oC. At higher temperature (100 oC) debromination occurs and presence
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of 345 was observed from both TLC and 1H NMR [1H NMR (400 MHz, DMSO-d6) δ 8.20 (dd, J
= 4.8, 2.0 Hz, 1H), 7.86 (dd, J = 7.6, 2.0 Hz, 1H), 6.90 (s, 2H, exch., 2-NH2), 6.64 (dd, J = 7.6, 4.8
Hz, 1H).] The reason for the failure of the reaction could be the low nucleophilicity of 346 as the
5-bromo position is para to the amino group which might feed electrons and decrease the
electrophilicity of 346. Protection of 2-amine group of 346 with pivalic anhydride was carried out
to improve the electrophilicity of 346 and then the procedure of García et al.409 was followed to
synthesize 348. This attempt was unsuccessful as well.

Scheme 79: Attempted synthesis of 282

Reagents and conditions: a) guanidine hydrochloride, NaOMe, MeOH, reflux, 12h; b) pivalic
anhydride, reflux, 4h; c) acetic acid, NBS, CH3CN, reflux, overnight; d) benzenethiol, Cs2CO3,
ACN, MW, 80 oC, 12 h; e) 1N NaOH, reflux 1 h.

Next, an alternative method was devised to synthesize 282 (Scheme 79), following a
published procedure.411 Cyclization with guanidine hydrochloride with 2-aminonicotinonitrile 345
in refluxing methanol, afforded the 2,4-diaminopyrido[2,3-d]pyrimidines 349, which was
protected using pivalic anhydride to afford N,N'-(pyrido[2,3-d]pyrimidine-2,4-diyl)bis(2,2dimethylpropanamide) 350.411 Following Scheme 78, 350 was attempted to brominate to generate
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N,N'-(6-bromopyrido[2,3-d]pyrimidine-2,4-diyl)bis(2,2-dimethylpropanamide)

(351).412

Unfortunately, the brominating reaction did not occur. The probable reason for this failure of the
brominating reaction could be bulk at the 2- and, 4-positions which hinder the access bromine at
6-position. Failure of the above method led to the exploration of an alternative strategy that
involved a coupling reaction to give 348 with the appropriate arylthiols using the “Ullmann
coupling reaction”.

The Ullmann reaction or Ullmann coupling is a coupling reaction between aryl halides,
and aromatic thiols catalyzed by copper.413 In Scheme 80, Table 27, various Ullman coupling
conditions414, 415 were attempted to synthesize 348, using 2-amino-5-bromonicotinonitrile (346)
and benzenethiol 347 with and/or without copper iodide. The classical Ullmann reaction requires
harsh reaction conditions.413 Thus, all the reactions attempted in Table 27 were at high
temperatures (80-100oC) and in a high boiling point solvent (DMF).413 In the first case (Table 27),
K2CO3 was used according to the published procedure of Ullman coupimg. 416 Unfortunately, with
K2CO3, the coupling of 346 and 347 was unsuccessful. Uyeda et al.415 used various bases for
example, Cs2CO3, NaOtBu, and KOtBu along with copper iodide. Unfortunately, copper catalyzed
reactions with different bases failed to afford 348 (Table 27). Next, various ligands like 2,2’bipyridine,417 1,10-phenanthroline,417, 418 L-proline,419 and 2-picolinic acid420, 421 were used along
with copper iodide in DMF as solvent using a time range of 12-24 h. (Table 27). While monitoring
the reaction via TLC, at higher temperature (100 oC) debrominated product 345 was observed from
both TLC and 1H NMR [1H NMR (400 MHz, DMSO-d6) δ 8.20 (dd, J = 4.8, 2.0 Hz, 1H), 7.86
(dd, J = 7.6, 2.0 Hz, 1H), 6.90 (s, 2H, exch., 2-NH 2), 6.64 (dd, J = 7.6, 4.8 Hz, 1H).]
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Scheme 80: Ullmann coupling reaction: optimization to generate 348

Table: 27 Ullmann coupling: optimization of reaction conditions to generate 348 in DMF.
Attempt

Base

no

Cu

Ligand

Temperature Reaction
(oC)

source

1.416

K2CO3

-

-

80, 100

No reaction

2.415

K2CO3

CuI

-

80, 100

No reaction

3.415

Cs2CO3

CuI

-

80, 100

No reaction

4.415

NaOBu-t

CuI

-

80, 100

No reaction

5.

KOtBu

CuI

-

80, 100

No reaction

6.

Cs2CO3

CuI

80, 100

No reaction

7.

Cs2CO3

CuI

80, 100

No reaction

8.

Cs2CO3

CuI

80, 100

No reaction

9.

Cs2CO3

CuI

80, 100

No reaction
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Scheme 81: Attempted synthesis of 348 and 282
Copper(I) iodide/ligand-catalyzed arylation of thiophenols:
NC
H2N

a
N

NC
H2N

345

I

b

N
353 (72%)

NC
H2N

NH2

S

c

N

S

N

H2N

N

N
282 (40%)

348
o

Reagents and conditions: a) NIS, CH3CN, 80 C, overnight; b) Table 28 conditions; c)
Chloroformamidine HCl, DMSO2, 140 oC, 2h.

Table 28: Optimization of reaction conditions to generate 348 with CuI in DMF.
Base

Ligand

1.

Cs2CO3

Temperature
(oC)
100

Time (h)

Reaction yield %

12

40

2.

Cs2CO3

100

12

45

3.

Cs2CO3

100

12

52

4.

Cs2CO3

100

12

65

As at temperature 100 oC debromination of some of 346 was observed in Scheme 80, thus,
starting material 346 with aryl bromine at 5-position was replaced with aryl iodide (353). Aryl
iodide is often more successful than aryl bromide in many cases of Ullman coupling reaction. 422
and the reaction could be conducted at lower temperatures. 420 Method previously described in
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Scheme 78, was utilized to synthesize 2-amino-5-iodonicotinonitrile 353, where, Niodosuccinamide (NIS) was treated portion wise with 2-aminonicotinonitrile 345 in acetonitrile at
80 °C.414 The structure of 353 was confirmed by investigating the coupling constants (J) of the
protons [1H NMR (400 MHz, DMSO-d6) δ 8.35 (d, J = 2.3 Hz, 1H), 8.19 (d, J = 2.3 Hz, 1H), 7.11
(s, 2H, exch., 2-NH2)]. The coupling constants match the characteristic J constants for meta
coupling between aromatic protons.410 Several ligands and Cs2CO3 as a base were used (Table 28)
which gave success with the Ullmann coupling reaction to generate 348 at different yields (4065%). The best yield 65% was observed in DMF at 100 oC for 12 h with ligand 2-picolinic acid
and the base Cs2CO3.
Scheme 82: Synthesis of the target compounds 283-289

Reagents and conditions: a) Arylthiols, Cs2CO3, CuI, picolinic acid, DMF, 100 oC, 12-24 h; c)
Chloroformamidine HCl, DMSO2, 140 oC, 2-4 h
To synthesize the target compounds 283-289, (Scheme 82) various arylthiols were treated
with Cs2CO3 in a solution of DMF, followed by the addition of 2-amino-5-iodonicotinonitrile 353,
CuI and 2-picolinic acid420, 421. The mixture was stirred at 100 oC for 12-24 h to give 354-360.
Intermediates 354-360 without further purification were cyclized to the target compounds 283-289
with the treatment of 354-360 with chloroformamidine HCl in DMSO2, at 140 oC for 2-4 h to
afford the final compounds 283-289 in 36-64% yields.
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D.4. Folate receptors (FRs) and/or Proton-Coupled Folate Transporter (PCFT) targeted
(cytosolic and/or mitochondrial) one carbon (1C) metabolism inhibitors
D.4.1. Synthesis of N1-substituted 5-amino-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-ones
Scheme 83. Synthesis of the intermediate compounds 368-369.

Reagents and conditions: a) PdCl2, Ph3P, TEA, CuI, ACN, µW, 100 °C, 1 h; b) H2, Pd/C, MeOH,
rt, 12 h; c) TEA, MsCl, DCM, 0 oC, 3 h; d) NaI, acetone, reflux, 12 h.
Synthesis of the intermediate compounds 368-369 (Scheme 83) started with a palladiumcatalyzed Sonogashira coupling of methyl 4-iodobenzoate 361 with the appropriate alkynes 362363 to afford 364-365 in 84-86% yield. Catalytic hydrogenation of 364-365 afforded the saturated
alcohols 366-367 in 81-83% yield.211 The alcohols 366-367 were converted to the corresponding
mesylate derivatives using mesyl chloride and triethylamine at 0 ⁰C.423 The mesylate derivatives
were not purified and, after workup, were converted to the corresponding iodides 368-369 using
the Finkelstein reaction in 69-71% yield.424
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Scheme 84. Synthesis of the intermediate compounds 370 and 371.

Reagents and conditions: a) Methyl 4-nitro-1H-pyrazole-5-carboxylate 374, DMF, K2CO3, r.t., 12
h.
A literature search revealed that there were no reported synthetic procedures for the
intermediates 370 and 371 (Scheme 84). The synthetic method of alkylation utilized in this study
was sparked by the reported synthesis of a new series of 7-aminopyrazolo[4,3-d]pyrimidine
derivatives from the Colotta group.406 To a solution of DMF, methyl 4-nitro-1H-pyrazole-5carboxylate 374 was added, followed by addition of K2CO3 and 4-atom chain iodide intermediate
369 at room temperature (Scheme 84). After 4 h, the reaction was not complete and starting
material remained (TLC). Longer reaction time (12 h) resulted in complete consumption of the 4nitro-1H-pyrazole-5-carboxylate. Initially, the 4-atom chain intermediates 370 and 371 were
inseparable on TLC as well as column chromatography as both regioisomers had close polarity
and Rf values. Repeated column chromatography (5X) was attempted to isolate intermediate 370
from 371. Finally, methyl 1-(4-(4-(methoxycarbonyl)phenyl)butyl)-4-nitro-1H-pyrazole-5carboxylate 370 and methyl 1-(4-(4-(methoxycarbonyl)phenyl)butyl)-4-nitro-1H-pyrazole-3carboxylate 371 were isolated in 32 and 64% yield, respectively.
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Figure 109: 1HNMR of 370 and 371

Figure 110: X-ray crystal structure of molecule 371. A-C: Cell plot in different view along a-c. D:
Final crystal structure of 371 (X-ray crystal structure by Charles E. Dann III).

Intermediates 370 and 371 were characterized by 1H NMR spectroscopy. The 1H NMR
spectrum displayed a distinguishable peak for the regioisomers 370 and 371. For the analog 370
the H3 proton appears at δ 8.41 and for the analog 371 the H5 proton appears at δ 9.02 (Figure
109). Additionally, X-ray crystallography enabled the identification of the molecular structure of
the regioisomers 371 (Figure 110).
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Scheme 85. Synthesis of intermediate compounds 372 and 373

Table 29: Optimization of reaction in DMF with various bases, temperature and time range of 424h.
Bases

Temp
o
( C)
rt

50

Partial conversion: Mixture of 372, 373 and 374 were observed in
TLC.
Reaction incomplete: Mixture of 368, 372, 373 and 374 were observed
TLC.
Multiple products observed in TLC.

80

Multiple products observed in TLC.

100

Multiple products observed in TLC.

0
K2CO3

rt
0
Cs2CO3

NaH

Status of reactions

Partial conversion: Mixture of 372, 373 and 374 were observed in
TLC.
Reaction incomplete: Mixture of 368, 372, 373 and 374 were observed
TLC.

50

Multiple products observed in TLC.

80

Multiple products observed in TLC.

100

Multiple products observed in TLC.

rt

Major spot was 373 (TLC).

50

Major spot was 373 (TLC).
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Following Scheme 84, to a solution of DMF, methyl 4-nitro-1H-pyrazole-5-carboxylate
374 was added K2CO3 and the 3-atom chain iodide intermediate 368 at room temperature. With
this base, unfortunately, the intermediate 372 was inseparable from the intermediate 373, even
after repeated column chromatography (5X) separation attempts, the separation was unsuccessful.
Several different bases and temperature conditions (Table 29) were attempted to improve the yield
of 372 and thus enable a separation of 372 from 373. DMF was selected as the solvent and the
TLC monitoring was carried out every hour over a 4-24 h reaction time range.
The reactions were attempted in different bases, for example, K 2CO3, Cs2CO3, and NaH
(Table 29). Different temperatures; 0 oC, room temperature, 50 oC, 80 oC, and 100 oC were used
with bases K2CO3 and Cs2CO3. For NaH two temperatures were used: room temperature and 50
o

C. The base NaH yielded 373 as a major product. As Cs2CO3 has a relatively high solubility in

DMF and appears to act as a good base,425 it was chosen as the base at room temperature in a
solution of DMF and methyl 4-nitro-1H-pyrazole-5-carboxylate 374. To this stirred mixture was
added 368 under anhydrous conditions at room temperature. This afforded the 3-atom chain methyl
1-(3-(4-(methoxycarbonyl)phenyl)propyl)-4-nitro-1H-pyrazole-5-carboxylate 372 and methyl 1(3-(4-(methoxycarbonyl)phenyl)propyl)-4-nitro-1H-pyrazole-3-carboxylate 373, in 25 and 70%
yields, respectively.
Table 30: Solvent effect on the reaction on Scheme 85 (Reaction conditions and reagents: Cs2CO3,
r.t., 12h).
Solvent

Intermediates

Yields (%)

DMF

372
373
372
373
372
373

25
70
28
70
35
66

Acetone
Acetonitrile
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Since DMF requires high temperature for preparing a plug with silica for column
chromatography, various solvents other than DMF were used for example acetone and acetonitrile.
To further improve the yield of 372, the reaction in Scheme 85 was optimized with different
solvents: acetone and acetonitrile (Table 30). Intermediates 372 and 373 were separated
successfully based on the slightly improved yield (35%) of 372 and 66% yield of 373 via column
chromatography.
Scheme 86: Synthesis of target compound 298.

Reagents and conditions: a) 10% Pd/C, H2 , 45 psi, 30 mins; b) 1,3-bis(methoxycarbonyl)-2methyl-2-thiopseudourea, MeOH, CH3COOH, r.t., 16 h; c) NaOMe, MeOH, rt, 12 h; d) 1N NaOH,
50 oC, 3 h; e) 2-chloro-4,6-dimethoxy-1,3,5-triazine, NMM, diethyl L-glutamate; f) 1N NaOH, r.t.,
1 h.
Intermediates 372 and 370 were directly subjected to catalytic reduction426 to afford 375
and 376, respectively (Scheme 86). Condensation of 375-376 with, 1,3-bis(methoxycarbonyl)-2methyl-2-thiopseudourea with acetic acid as catalyst and MeOH yielded the cyclized products 377203

378, respectively in 40-48% yield over two steps. The hydrolysis427 of the protecting group was
carried out in 378 in situ with aqueous sodium hydroxide at 50 °C to afford the 2-amino-4-oxopyrazolo[4,3-d]pyrimidine intermediates followed by conversion of the free acids to the
corresponding L-glutamic acid diethyl ester 380. Peptide coupling with L-glutamic acid diethyl
ester hydrochloride using 2-chloro-4,6-dimethoxy-l,3,5-triazine393 followed by hydrolysis393 with
aqueous 1N NaOH at room temperature, and acidification with 1 N HCl, in the cold, afforded the
target compound 298. Compounds 379 and 297 were not characterized and requires further
characterization.
D.4.2. Synthesis of N2-substituted 5-amino- 2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7ones
Scheme 87: Synthesis of target compounds 301-302
O
O
O
H3C

O
O

O2N

CH3

a
N
N

O

H3C

n
373
371

O
O
O

H2N

n
1
2

O

b,c

N
N

O

n
O

n
381 1 (73%)
382 2 (76%)
O

d,e

N
H

O
HN
H2N

N

n
N
N
N
H n
383 1 (42% two steps)
384 2 (49% two steps)
O

f

O

n

H2N

n

N
H

O

N

N
N

OH

OH

O

HN

N
N

N

HN

O

O

O

CH3
O

CH3

O

n
n

385 1 (62%)
386 2 (64%)

301 1 (58%)
302 2 (62%)

Reagents and conditions: a) 10% Pd/C, H2 , 45 psi, 2 h; b) 1,3-bis(methoxycarbonyl)-2-methyl-2thiopseudourea, MeOH, CH3COOH, r.t., 16 h; c) NaOMe, MeOH, rt, 12 h; d) 1N NaOH, 50 oC, 6
h; e) 2-chloro-4,6-dimethoxy-1,3,5-triazine, NMM, diethyl L-glutamate; f) 1N NaOH, r.t., 2 h.
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Intermediates 373 and 371 (Scheme 87) were directly subjected to catalytic reduction426 to
generate

the

2-amino

derivatives

381-382.

Condensation

of

381-382

with

1,3-

bis(methoxycarbonyl)-2-methyl-2-thiopseudourea with acetic acid and MeOH gave the cyclized
products 383-384 in 42-49% over two steps. The hydrolysis427 of the protecting groups in 383-384
were carried out in situ with aqueous sodium hydroxide at 50 °C followed by conversion of free
acids to the corresponding L-glutamic acid diethyl esters via peptide coupling reaction with Lglutamic acid diethyl ester hydrochloride using 2-chloro-4,6-dimethoxy-l,3,5-triazine 393 followed
by chromatographic purification to afford the coupled products 385-386 in 62-64% yields.
Hydrolysis393 of 385-386 with aqueous 1N NaOH at room temperature, followed by acidification
with 1 N HCl, in the cold, afforded target compounds 301-302 in 58-62% yields.

D.4.3. Synthesis of 6-substituted 2-amino-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-ones
From a retrosynthetic point of view (Scheme 88), two general strategies were envisioned
for the synthesis of target compound (4-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3d]pyrimidin-6-yl)propoxy)-2-fluorobenzoyl)-L-glutamic acid 305. From the first strategy (Route
A) it was anticipated that the key intermediate methyl 4-(3-(2-amino-4-oxo-4,7-dihydro-3Hpyrrolo[2,3-d]pyrimidin-6-yl)propoxy)-2-fluorobenzoate 389 could be synthesized via a
nucleophilic displacement of 391 with 390. Intermediate 391 could be synthesized from 392 which
in turn could be obtained by cyclocondensation of 2,6-diaminopyrimidin-4(3H)-one 393 with ethyl
5-chloro-4-oxopentanoate 394.

205

Scheme 88. Retro synthetic route A and B for 305.

From the retrosynthetic analysis depicted in route B, (Scheme 88), the desired key
intermediate methyl 4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)ethoxy)2-fluorobenzoate 389 could also be synthesized from 2,6-dimethyl-4-chloro-furo[2,3d]pyrimidine 392 via a coupling reaction of 392 with different halogen containing fluro benzoates
395a-395b.
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Scheme 89: Synthesis of intermediate 389 for target compound 305.

Reagents and conditions: a) NaOAc, H2O, reflux, 16 h; b) LiEt3BH, THF, 0 oC, 1h; c) Mesyl
chloride or tosyl chloride, Et3N, DCM, 0 oC, 2h; d) Table 31
Table 31: Reaction optimization for 389 in DMF.
Base

Temp (oC)

Time (h)

Status

1

K2CO3

80, 100, 120, 140

6-24

No reaction

2

Cs2CO3

80, 100, 120, 140

6-24

No reaction

Gangjee and coworkers190 reported a methodology that could be adopted for the synthesis
of the key intermediate 389. The 6-substituted pyrrolo[2,3-d]pyrimidine 396 (Scheme 89) was
synthesized by condensation of 2,6-diaminopyrimidin-4(3H)-one 393 with ethyl 5-chloro-4oxopentanoate 394. Reduction of the ester group of 396 to the alcohol 2-amino-6-(3hydroxypropyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 392 and subsequent mesylation of
the alcohol gave 391a. Nucleophilic displacement with methyl 2-fluoro-4-hydroxybenzoate 390
with 391a was attempted in several different bases, for example, K2CO3 or Cs2CO3, at different
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temperatures (80-140 oC) and time intervals (6-24 h) (Table 31). This was unsuccessful. Tosylation
of the alcohol 392 gave 391b which was subjected to nucleophilic displacement with methyl 2fluoro-4-hydroxybenzoate 390 with K2CO3 or Cs2CO3, at different temperatures. It was anticipated
that increasing the electrophilicity with a tosyl group in 391b would improve the nucleophilic
displacement with 390. Unfortunately, all attempts at this nucleophilic displacement using a
variety of reaction conditions with different bases, electrophiles, time and temperature variations
were unsuccessful.
Scheme 90: Synthesis of intermediate 389 for target compound 305.

CuI, 1, 10-phelanthroline, DMF, Cs2CO3, 110-150 oC

a)

Table 32: Attempted reaction conditions for the synthesis of intermediate 389 in DMF at
110-150 oC for 12-24 h.
Mol% CuI

Mol% 1,10-phelanthroline

Reaction status

1

10

20

No reaction

2

20

20

No reaction

3

30

30

No reaction

The failure of the previous strategy prompted the investigation of an alternate method.
Buchwald and coworkers418 reported the coupling of aryl halides and aliphatic alcohols with
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catalytic amount of copper iodide and 1,10-phelanthroline as the ligand (Table 32). In Scheme 90,
coupling of 392 with 395a and 395b with different mol% of copper iodide and 1,10-phelanthroline
were attempted. However, unlike Buchwald and coworkers418 reported procedures the coupling
with various halides did not afford the corresponding key intermediate 389 but gave instead the
starting materials.
Scheme 91. Retro synthetic scheme for target 305 by route C.

Failure of the above method led the exploration of a new alternative retrosynthetic strategy
(Scheme 91, Route C) that involved the diazomethane reaction for the synthesis of key
intermediate 389. From route C, it was anticipated that the nucleophilic substitution reaction of
390 with 399 would afford the carboxylic acid 398. Carboxylic acid 398 can be converted to the
acyl chloride using oxalyl chloride followed by reaction with diazomethane to afford the αdiazoketone compound. The α-diazoketo compound can then be converted to the α-bromoketone
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397 using HBr. Cyclo-condensation of 397 with 2,6-diamino-3H-pyrimidin-4-one, 393,
hydrolysis, L-glutamate peptide coupling, and saponification would afford the desired compound
305.
Scheme 92: Synthesis of target compound 305.

Reagents and conditions: a) Cs2CO3, TBAI, DMF, 2h, 100 °C; b) CF3COOH, DCM; r.t., 2 h; c)
Oxalyl chloride, DCM, reflux, 2.5 h; d) Diazomethane, (CH3CH2)2O, r.t., 1.5 h; e) 48% HBr in
water, 80 °C, 2 h; f) 2,6-diaminopyrimidin-4(3H)-one, DMF, r.t., 3 days; g) 1N NaOH, MeOH,
rt, 2 h; h) 2-chloro-4,6-dimethoxy-1,3,5-triazine, N-methylmorpholine, DMF, rt, 12 h; i) 1N
NaOH, MeOH, rt,1 h.
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The synthesis of the key intermediate 389 was accomplished as indicated in Scheme 92.
Protected carboxylic acid 400 was obtained via a nucleophilic substitution of alkyl bromide 399
with compound 390. Deprotection of the tert-butyl ester with trifluoroacetic acid yielded 398 in
88%yield. The carboxylic acid 398 was then converted to the acid chloride 401, and immediately
reacted with diazomethane followed by 48% HBr in water to give the corresponding αbromomethyl ketone 403. Condensation of 2,6-diamino-3H-pyrimidin-4-one 393 with 403 in
DMF at room temperature for 3 days afforded the 2-amino-4-oxo-6-substituted-pyrrolo[2,3d]pyrimidine 389 in 21% yield over three steps. Hydrolysis of 389 gave the corresponding free
acid 387. Subsequent coupling with L-glutamate 388, using 2-chloro-4,6-dimethoxy-1,3,5-triazine
as the activating agent afforded the diester 404. Hydrolysis of 404 with aqueous 1N NaOH at room
temperature, followed by acidification with 1 N HCl, in the cold, gave the target compound 305 in
55% yield.

211

V. EXPERIMENTAL
Rotary evaporator at reduced pressure was used to carry out all evaporations. Analytical
samples were dried in vacuo in a CHEM-DRY drying apparatus over P 2O5 at 50 °C. Melting
points were determined either using a MEL-TEMP, II melting point apparatus with FLUKE
51 K/J electronic thermometer or using an MPA100 OptiMelt automated melting point system
and are uncorrected. Thin-layer chromatography (TLC) was performed on Whatman ® PE SIL
G/UV254 flexible silica gel plates or Sorbtech Silica G TLC plates of thickness 200 μm
w/UV254 and the spots were visualized under 254 and 365 nm ultraviolet illumination.
Proportions of solvents used for TLC are by volume. All analytical samples were
homogeneous on TLC in at least two different solvent systems. Flash chromatography was
carried out on the CombiFlash® Rf 200 (Teledyne ISCO) automated flash chromatography
system with pre-packed RediSep® Rf normal-phase flash columns (230 to 400 meshes) of
diverse sizes were used. Column chromatography was performed on the silica gel (70 to 230
meshes, Fisher Scientific) column. The amount (weight) of silica gel for column
chromatography was in the range of 50-100 times the amount (weight) of the crude
compounds being separated. Nuclear magnetic resonance spectra for proton ( 1H NMR) were
recorded on the Bruker Avance II 400 (400 MHz) or Bruker Avance II 500 (500 MHz) NMR
Spectrometer with TopSpin processing software. Acquired FIDs were analyzed using
MestReC 3.2 or MestReNova 9.0.The chemical shift values (δ) are expressed in, (parts per
million) relative to tetramethylsilane as an internal standard: s, singlet; d, doublet; dd, doublet
of doublet; t, triplet; q, quartet; m, multiplet; br, broad singlet; td, triplet of doublet; dt, doublet
of triplet; quin, quintet; exch., exchangeable using D 2O. Elemental analyses were performed
by Atlantic Microlab, Inc., Norcross, GA. Element compositions are within ± 0.4% of the
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calculated values. Fractional moles of water or organic solvents frequently found in some
analytical samples could not be prevented despite 24 to 48 hours of drying in vacuo and were
confirmed where possible by their presence in the 1H NMR spectra. Mass spectrum data were
acquired on an Advion expression® CMS system using the ESI probe. HPLC data were
acquired on ThermoFisher Scientific UltiMate TM 3000 HPLC system.

4-chloro-2-methylthieno[2,3-d]pyrimidine (308)
Commercially available ethyl 2-aminothiophene-3-carboxylate 306 (5.0 g, 29.20 mmol) was
dissolved in 25 mL of acetonitrile and hydrogen chloride gas was bubbled through the solution
for 30 mins. The mixture was stirred at room temperature for overnight. The solvent was
evaporated under reduced pressure. The residue was dissolved in 10 mL distilled water and
treated with ammonia in water solution which generated light yellow precipitate. The
precipitate was collected by filtration to afford 2.18 g (13.14 mmol, 45%) of 2methylthieno[2,3-d]pyrimidin-4(3H)-one 307 as a light yellow solid. TLC Rf = 0.21 (CHCl3:
MeOH, 20:1); mp, 208-209 °C (lit.428 210 °C). Without further characterization of 307,
chlorination of 307 (2.0 g, 12.03 mmol) was carried out using of POCl3 (1.13 mL, 12.03
mmol) and pyridine (0.96 mL, 12.03 mmol) and refluxed for 12 hours in toluene. The solvent
was evaporated and cooled in an ice bath followed by neutralization with ammonia in water
solution. Yellow precipitate was formed and was collected by filtration to afford 308 as yellow
solid (1.38 g, 62% yield). TLC Rf = 0.40 (Hexane: EtOAc, 10:1); mp, 91.6-92.5 °C (lit. 428 93
°C); 1H NMR (400 MHz, DMSO-d6) δ 8.01 (d, J = 6.0 Hz, 1H, Ar), 7.51 (d, J = 6.0 Hz, 1H,
Ar), 2.71 (s, 3H, 2-CH3). The 1H-NMR matched the 1H-NMR reported in the literature.428
This compound was used for the next reaction without further characterization.

213

General method for synthesis of 182-185 and 189
Intermediate 308 (0.20 g, 1.08 mmol) and equivalent anilines were dissolved in 10-12 ml
isopropanol and heated in a microwave reactor at 120 oC for 6-10 hours. The solvent was
evaporated in vacuo, silica gel was added to make a plug and flash chromatography was
carried out using ethyl acetate-hexane as eluent. The fractions containing the required
compound were evaporated under reduced pressure to afford the target compounds.

N-(4-methoxyphenyl)- 2-methylthieno[2,3-d]pyrimidin-4-amine (183)
Compound 308 (200 mg, 1.08 mmol) was dissolved in isopropanol (10 mL) followed by addition
of 1 drop of HCl and reacted with 4-methoxyaniline (133.40 mg, 1.08 mmol) at microwave
condition at 120 oC for 6 h. The reaction mixture was cooled, and silica gel was added to the
solvent mixture and plug was prepared. A flash column chromatographic separation was
performed using ethyl acetate-hexane as eluent to afford intermediate 183 as a white solid (182.22
mg, 62% yield). TLC Rf = 0.27 (CHCl3: MeOH, 20:1); mp, 138-139.6 oC; 1H NMR (400 MHz,
DMSO-d6) δ 9.55 (s, 1H, exch., N4-H), 7.85 (d, J = 8.8 Hz, 2H, Ar), 7.81 (d, J = 6.0 Hz, 1H, Ar),
7.60 (d, J = 6.0 Hz, 1H, Ar), 7.30 (d, J = 8.8 Hz, 2H, Ar), 3.80 (s, 3H, -OCH3), 2.48 (s, 3H, 2CH3). Anal. Calcd. for C14H13N3OS 0.26 (CH3)2CHOH. 0.35 HCl: C, 59.21; H, 5.19; N, 14.00; S,
10.69. Found: C, 59.25; H, 4.95; N, 14.04; S, 10.45.

N-(4-methoxyphenyl)-N,2-dimethylthieno[2,3-d]pyrimidin-4-amine (182):
A solution of 183 (150 mg, 0.552 mmol) in DMF (10 ml) followed by addition of portion wise
sodium hydride (60 % dispersion in mineral oil) (22.11 mg, 0.552 mmol). The reaction was stirred
at room temperature for 10 mins and then iodomethane (0.04 mL, 0.663 mmol) dissolved in 5 mL
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of DMF was added drop wise to the suspension. The reaction was stirred for 2 hours at room
temperature. Silica gel was added to the solvent mixture and plug was prepared. A flash column
chromatographic separation was performed using ethyl acetate hexane as eluent to afford 182 as a
white solid (123 mg, 78% yield). TLC Rf = 0.44 (Hexane: EtOAc, 3:1); mp, 155.3-157 oC; : 1H
NMR (400 MHz, DMSO-d6) δ 7.31 (d, J = 8.8 Hz, 2H, Ar), 7.15 (d, J = 6.2 Hz, 1H, Ar), 7.07 (d,
J = 8.8 Hz, 2H, Ar), 5.45 (d, J = 6.2 Hz, 1H, Ar), 3.83 (s, 3H, -OCH3 ), 3.49 (s, 3H, -N4CH3), 2.53
(s, 3H, 2-CH3). Anal. Calcd. for C15H15N3OS: C, 63.13; H, 5.29; N, 14.73; S, 11.23. Found: C,
63.43; H, 5.40; N, 14.83; S, 11.15.

N,2-dimethyl-N-(4-(methylthio) phenyl)thieno[2,3-d]pyrimidin-4-amine (184):
Compound 308 (200 mg, 1.08 mmol) was dissolved in isopropanol (10 mL) followed by
addition of 1 drop of HCl and reacted with 4-(methylthio)aniline (180.96 mg, 1.30 mmol) at
microwave condition at 120 oC for 8 h to afford 184a. Crude 184a (150 mg, 0.521 mmol)
without further characterization was dissolved in DMF (10 ml) followed by portion wise
addition of sodium hydride (60% dispersed in mineral oil) (20.87 mg, 0.521 mmol). The
reaction was stirred at room temperature for 10 mins and then iodomethane (0.039 mL, 0.626
mmol) dissolved in 5 mL of DMF was added drop wise to the suspension. The reaction was
stirred for 2 hours at room temperature. Silica gel was added to the solvent mixture and plug
was prepared. A flash column chromatographic separation was performed using ethyl acetate
hexane as eluent to afford 184 as a white solid (81 mg, 52% yield in two steps). TLC Rf = 0.5
(Hexane: EtOAc, 3:1); mp, 153.2-155 oC; 1H NMR (500 MHz, DMSO-d6) δ 7.38 (d, J = 8.7
Hz, 2H, Ar), 7.32 (d, J = 8.7 Hz, 2H, Ar), 7.21 (d, J = 6.2 Hz, 1H, Ar), 5.57 (d, J = 6.1 Hz,
1H, Ar), 3.50 (s, 3H, -N4CH3), 2.54 (s, 3H, -CH3 ), 2.53 (s, 3H, -CH3). Anal. Calcd. for
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C15H15N3S2: C, 59.77; H, 5.02; N, 13.94; S, 21.28. Found: C, 60.00; H, 4.97; N, 13.93; S,
21.01.

4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)-2-methylthieno[2,3-d]pyrimidine (185)
To a solution of 308 (200 mg, 1.08 mmol) in isopropanol (10 mL), 1 drop of HCl was added,
followed by addition of 6-methoxy-1,2,3,4-tetrahydroquinoline (194.48 mg, 1.19 mmol) at
microwave condition at 120 oC for 6 h. The reaction mixture was cooled to r.t., and silica gel
(500 mg) was added, and the solvent was removed under reduced pressure. Purification was
performed by column chromatography using hexane and ethyl acetate in a ratio of 10:1 to
give an off-white solid as 185 in 76% yield. (256 mg). TLC Rf = 0.38 (Hexane: EtOAC, 3:1);
mp 195-196.8 oC; 1H NMR (400 MHz, DMSO-d6) δ 7.35 (d, J = 6.1 Hz, 1H, Ar), 6.91 (d, J
= 8.8 Hz, 1H, Ar), 6.89 (d, J = 3.0 Hz, 1H, Ar), 6.70 (dd, J = 8.8 Hz, J =3.0 Hz, 1H, Ar), 6.27
(d, J = 6.2 Hz, 1H, Ar), 3.97 (t, J = 6.5 Hz, 2H, -CH2-), 3.76 (s, 3H, -OCH3), 2.75 (t, J = 6.5
Hz, 2H, -CH2-), 2.54 (s, 3H, 2-CH3), 1.99-190 (m, 2H, -CH2-). Anal. Calcd. for C17H17N3OS:
C, 65.57; H, 5.50; N, 13.49; S, 10.29. Found: C, 65.62; H, 5.51; N, 13.26; S, 10.19.

N-(5-methoxynaphthalen-2-yl)-N,2-dimethylthieno[2,3-d]pyrimidin-4-amine (189)
To a solution of 308 (200 mg, 1.08 mmol) in isopropanol (10 mL), 1 drop of HCl was added,
followed by addition of 6-aminonaphthalen-1-ol (206.92 mg, 1.30 mmol) at microwave
condition at 120 oC for 8 h. The reaction mixture was cooled to rt, silica gel (500 mg) was
added, and the solvent was removed under reduced pressure. Purification was performed by
column chromatography using hexane and ethyl acetate (10:1) to give off-white solid. TLC
Rf = 0.28 (CHCl3: MeOH, 20:1). Crude (120 mg, 0.390 mmol) without further characterization
was dissolved in DMF (10 ml) followed by portion wise addition of sodium hydride (60%
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dispersed in mineral oil) (15.61 mg, 0.390 mmol). The reaction was stirred at room
temperature for 10 mins and then iodomethane (0.03 mL, 0.468 mmol) dissolved in 5 mL of
DMF was added drop wise to the suspension. The reaction was stirred for 2 hours at room
temperature. Silica gel was added to the solvent mixture and plug was prepared. A flash
column chromatographic separation was performed using ethyl acetate hexane as eluent to
afford 189 as a white solid (104 mg, 48% yield). TLC Rf = 0.34 (Hexane: EtOAc, 3:1); mp,
206.2-207.8 oC; 1H NMR (400 MHz) (Me2SO-d6) δ 8.26 (d, J = 8.8 Hz, 1 H, Ar), 7.97 (d, J
= 2.3 Hz, 1 H, Ar), 7.80 (d, J = 5.5 Hz, 1 H, Ar), 7.55 (dd, J = 8.8, 2.3 Hz, 1 H, Ar), 7.51 –
7.48 (m, 2 H, Ar), 7.28 (d, J = 5.5 Hz, 1 H, Ar), 7.10 – 7.02 (m, 1 H, Ar), 3.99 (s, 3 H, -OCH 3),
3.61 (s, 3 H, -N4CH3), 2.52 (s, 3H, 2-CH3). Anal. Calcd. for C19H17N3OS: C, 68.03; H, 5.11;
N, 12.52; S, 9.56. Found: C, 68.25; H, 5.25; N, 12.41; S, 9.52.

N-(4-methoxyphenyl)-N-methylthieno[2,3-d]pyrimidin-4-amine (196)
Commercially available 4-chlorothieno[2,3-d]pyrimidine 309 (300 mg, 1.11 mmol) in
isopropanol (10 mL) was treated with 1 drop of HCl and 4-methoxy-N-methylaniline (183.08
mg, 1.33 mmol) at microwave condition at 120 oC for 6 hours. The reaction was cooled to
room temperature and silica gel was added to the solvent mixture and plug was prepared. A
flash column chromatographic separation was performed using ethyl acetate hexane as eluent
to afford 196 in 60% as yellow solid (247mg). TLC Rf = 0.41 (Hexane: EtOAc, 1:1); mp,
131.2-133.1 oC; 1H NMR (500 MHz, DMSO-d6) δ 8.52 (s, 1H, Ar), 7.34 (d, J = 9.0 Hz, 2H,
Ar), 7.29 (d, J = 6.2 Hz, 1H, Ar), 7.08 (d, J = 9.0 Hz, 2H, Ar), 5.52 (d, J = 6.2 Hz, 1H, Ar),
3.83 (s, 3H, -OCH3), 3.51 (s, 3H, -N4CH3). Anal. Calcd. for C15H15N3S2 C, 59.77; H, 5.02;
N, 13.94; S, 21.27. Found: C, 59.69; H, 5.00; N, 14.15; S, 21.33.
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4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)thieno[2,3-d]pyrimidine (198)
Commercially available 4-chlorothieno[2,3-d]pyrimidine 309 (300 mg, 1.11 mmol) in
isopropanol was treated with 1 drop of HCl and 6-methoxy-1,2,3,4-tetrahydroquinoline
(217.8 mg, 1.33 mmol) at microwave conditions at 120 oC for 8 hours. The reaction was
cooled to room temperature and silica gel was added to the solvent mixture and plug was
prepared. A flash column chromatographic separation was performed using ethyl acetate
hexane as eluent to afford 198 in 58% as yellow solid (255.7 mg). TLC Rf = 0.26 (Hexane:
EtOAc, 3:1); mp, 140.3-141.8 oC; 1H NMR (500 MHz, DMSO-d6) δ 8.48 (s, 1H, Ar), 7.31 (d,
J = 8.9 Hz, 1H, Ar), 7.29 (d, J = 3.0 Hz, 1H, Ar), 7.26 (d, J = 6.1 Hz, 1H, Ar), 7.02 (dd, J =
8.9 Hz, J =3.0 Hz, 1H, Ar), 5.62 (d, J = 6.1 Hz, 1H, Ar), 3.90 (t, J = 6.5 Hz, 2H, -CH2-), 3.78
(s, 3H, -OCH3), 2.71 (t, J = 6.5 Hz, 2H, -CH2-), 1.98-1.89 (m, 2H, -CH2-). Anal. Calcd. for
C16H15N3OS: C, 64.62; H, 5.08; N, 14.13; S, 10.78. Found: C, 64.61; H, 5.25; N, 14.13; S,
10.63.

N4-(4-methoxyphenyl)-N4-methylthieno[2,3-d]pyrimidine-2,4-diamine (197)
Methyl sulfone (15 g), commercially available ethyl 2-aminothiophene-3-carboxylate 306
(5.0 g, 29.20 mmol) and chloroformamidine hydrochloride (6.71 g, 58.41 mmol) were taken in
a round bottom flask. The reaction mixture was heated at 140 °C for 4 h. The reaction was
quenched with 100 mL water, cooled in an ice bath and was basified to pH 8.0 using an
aqueous NH4OH solution. The precipitate was collected by filtration, dried (using Na 2SO4)
and afforded 2.93 g (60% yield) of 2-aminothieno[2,3-d]pyrimidin-4(3H)-one 310 as a brown
solid. TLC Rf = 0.15 (MeOH: CHCl3:NH4OH, 1:5:0.5). Intermediate 310 (2.8 g, 16.75 mmol),
without further characterization, was added to a 250 mL round bottom flask and Piv 2O (34
mL, 167.48 mmol) was added. The reaction mixture was vigorously stirred at reflux condition.
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After 20 min, the reactant was completely dissolved, and, after 2 hours, the product was
precipitated. The crude product (2.95 g, 11.72 mmol, 70% yield) was not subjected to
separation efforts and was taken to the next step without any characterization. To a 100 mL
round bottom flask were added the crude 310 (2.93 g, 11.66 mmol), POCl3 (1.09 mL, 11.66
mmol) and pyridine (0.94 mL, 11.66 mmol). The reaction mixture was heated to reflux for 10
h. The POCl3 was evaporated, and the mixture was neutralized using an aqueous NH 4OH
solution to yield a precipitate. The precipitate 311 (2.20 g, 49% yield) was collected by
filtration, washed with water, dried and then dissolved in MeOH. The product N-(4chlorothieno[2,3-d]pyrimidin-2-yl)pivalamide 311 was not subjected to separation and the
precipitate crude was taken to the next step without any characterization. To a solution of 311
(300 mg, 1.11 mmol) in isopropanol (10 mL), 1 drop of HCl was added, followed by the
addition of 4-methoxy-N-methylaniline (183.03 mg, 1.33 mmol) under reflux condition for
12 hours. After cooling to r.t., 1 N NaOH solution (4 mL) was added and the reaction mixture
was heated to reflux for 2 hours. The reaction mixture was cooled to r.t., silica gel (500 mg)
was added, and the solvent was removed under reduced pressure. Purification was performed
by flash column chromatographic separation using ethyl acetate and hexane as eluent, and the
fractions containing the product (TLC) were pooled, evaporated to afford 152.7 mg (48% in
two steps) of 197 as a white solid. TLC Rf = 0.25 (Hexane: EtOAc, 1:1); mp 202.6 oC; 1H
NMR (400 MHz, DMSO-d6) δ 7.27 (d, J = 8.9 Hz, 2H, Ar), 7.05 (d, J = 8.9 Hz, 2H, Ar), 6.65
(s, J = 6.3 Hz, 1H, Ar), 6.28 (s, 2H, exch., 2-NH2), 5.29 (s, J = 6.3 Hz, 1H, Ar), 3.82 (s, 3H, OCH3), 3.49 (s, 3H, -N4-CH3). Anal. Calcd. for C14H14N4OS 0.06 CH3(CH2)4CH3: C, 59.17;
H, 5.13; N, 19.21; S, 10.99. Found: C, 58.82; H, 5.24; N, 18.90; S, 10.86.
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4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)thieno[2,3-d]pyrimidin-2-amine (199)
To a solution of 311 (300 mg, 1.11 mmol) in isopropanol (10 mL), 1 drop of HCl was added,
followed by addition of 6-methoxy-1,2,3,4-tetrahydroquinoline (235.98 mg, 1.45 mmol). The
reaction mixture was stirred for 8 hours at reflux condition. After cooling to rt, 1 N NaOH
solution (4 mL) was added and heated to reflux for 2 hours. The reaction mixture was cooled
to r.t., silica gel (500 mg) was added, and the solvent was removed under reduced pressure.
Purification was performed by flash column chromatographic separation using 5% MeOH in
CHCl3 as the eluent, and the fractions containing the product (TLC) were pooled, evaporated
to give a solid which was then washed with CHCl3 to afford 139 mg (40% in two steps) of
199 as white solid. TLC Rf = 0.55 (MeOH:CHCl3:NH4OH, 1:10:0.5); mp, 209-210 oC; 1H
NMR (400 MHz, DMSO-d6) δ 6.87 (d, J = 6.1 Hz, 1H, Ar), 6.85 (d, J = 8.9 Hz, 1H, Ar), 6.83
(d, J = 2.9 Hz, 1H, Ar), 6.69 (dd, J = 8.8 Hz, J =2.9 Hz, 1H, Ar), 6.38 (s, 2H, exch., 2-NH2),
6.10 (d, J = 6.1 Hz, 1H, Ar), 3.96 (t, J = 6.6 Hz, 2H, -CH2-), 3.75 (s, 3H, -OCH3), 2.78 (t, J =
6.5 Hz, 2H, -CH2-), 1.99-1.89 (m, 2H, -CH2-). Anal. Calcd. for C16H16N4OS 0.17 CH3OH :
C, 61.11; H, 5.29; N, 17.63; S, 10.09. Found: C, 61.09; H, 5.24; N, 17.63; S, 10.10.

2-chloro-N-(4-methoxyphenyl)-N-methylthieno[2,3-d]pyrimidin-4-amine (204)
Commercially available 2,4-dichlorothieno[2,3-d]pyrimidine 312 (400 mg, 1.95 mmol) in
isopropanol (10 mL) was treated with 4-methoxy-N-methylaniline (267.60 mg, 1.95 mmol)
and reacted for 48 hours at room temperature. Silica gel was added to the solvent mixture and
plug was prepared. A flash column chromatographic separation was performed using ethyl
acetate and hexane as eluent to afford 204 in 226.6 mg as pale-yellow solid (38% yield). TLC
Rf = 0.52 (Hexane: EtOAc, 3:1); mp, 156.7-159 oC; 1H NMR (400 MHz, DMSO-d6) δ 7.45
(d, J = 6.2 Hz, 1H, Ar), 7.15 (d, J = 8.8 Hz, 2H, Ar), 7.07 (d, J = 8.8 Hz, 2H, Ar), 6.22 (d, J
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= 6.2 Hz, 1H, Ar), 3.81 (s, 3H, -OCH3 ), 3.52 (s, 3H, -N4CH3). Anal. Calcd.

for

C14H12ClN3OS: C, 54.98; H, 3.95; Cl, 11.59; N, 13.74; S, 10.48. Found: C, 54.71; H, 4.02;
Cl, 11.37; N, 13.46; S, 10.44.

2-chloro-4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)thieno[2,3-d]pyrimidine (205)
Commercially available 2,4-dichlorothieno[2,3-d]pyrimidine 312 (400 mg, 1.95 mmol) in
isopropanol (10 mL) was treated with 6-methoxy-1,2,3,4-tetrahydroquinoline (318.39 mg,
1.95 mmol) and treated for 48 hours at room temperature. Silica gel was added to the solvent
mixture and plug was prepared. A flash column chromatographic separation was performed
using ethyl acetate hexane as eluent to afford 205 in 226 mg as pale-yellow solid (35% yield).
TLC Rf = 0.36 (Hexane: EtOAc, 3:1); mp, 168-169.8 oC; 1H NMR (400 MHz, DMSO-d6) δ
7.48 (d, J = 6.1 Hz, 1H, Ar), 7.06 (d, J = 8.7 Hz, 1H, Ar), 6.93 (d, J = 2.9 Hz, 1H, Ar), 6.74
(dd, J = 8.7 Hz, J =2.9 Hz, 1H, Ar), 6.28 (d, J = 6.1 Hz, 1H, Ar), 3.95 (t, J = 6.5 Hz, 2H, CH2-), 3.78 (s, 3H, -OCH3), 2.74 (t, J = 6.5 Hz, 2H, -CH2-), 1.98 – 1.87 (m, 2H, -CH2-). Anal.
Calcd. for C16H14ClN3OS 0.13 CH3(CH2)4CH3: C, 58.76; H, 4.65; Cl, 11.33; N, 12.24; S,
9.34. Found: C, 58.61; H, 4.55; Cl, 9.94; N, 12.36; S, 9.06.

4-chloro-2,5-dimethylthieno[2,3-d]pyrimidine (315a)
To a 50 mL flask were added commercially available ethyl 2-amino-4-methylthiophene-3carboxylate 313 (5.0 g, 26.99 mmol) and acetonitrile (20 mL). The resulting mixture was
stirred at room temperature to afford a clear solution. Anhydrous HCl gas was bubbled into
the solution for 30 mins until there was no further precipitation and then stirred for an
additional hour. The residue was dried and dissolved in 10 mL distilled water and treated with
ammonia in water solution to generate precipitate. The white precipitate was collected through
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filtration and washed with ether then dried over P 2O5 to afford 3.16 g of 314 (65% yield).
TLC Rf = 0.13 (Hexane: EtOAc, 3:1); mp, >250 oC (lit.404 263 oC); 1H NMR (400 MHz,
DMSO-d6) δ 12.27 (s, 1H, exch., -NH), 7.61 (s, 1H, Ar), 2.68 (s, 3H, 5-CH 3), 2.58 (s, 3H, 2CH3). Crude 314 (3.0 g, 16.65 mmol) without further characterization was dissolved in
toluene (30 mL) followed by addition of POCl3 (1.56 mL, 16.65 mmol), and pyridine (1.34
mL, 16.65 mmol). The resulting mixture was refluxed for 12 hours, and the solvent was
removed under reduced pressure to afford a dark residue. The solvent was evaporated and
neutralized with ammonia in water solution to generate light-yellow precipitate. The
precipitate was collected by filtration to afford crude 315a. Silica gel column chromatography
using hexane/EtOAc = 20:1 as the eluent was used to separate 315a. Fractions containing the
product (TLC) were combined and evaporated to afford 315a as a light-yellow solid (1.6 g,
48% yield); TLC Rf = 0.13 (Hexane: EtOAc, 3:1); mp, 252.5-253.6 oC; 1H NMR (400 MHz,
DMSO-d6) δ 7.21 (s, 1H, Ar), 2.45 (s, 3H, 5-CH3), 2.34 (s, 3H, 2-CH3). The 1H-NMR matched
the 1H-NMR reported in the literature.404 This compound was used for the next reaction
without further characterization.

N-(4-methoxyphenyl)-N,2,5- trimethylthieno[2,3-d]pyrimidin-4-amine (218)
Compound 315a (300 mg, 1.51 mmol) was dissolved in isopropanol (10 mL) followed by
addition of 1 drop of HCl and 4-methoxy-N-methylaniline (227.87 mg, 1.66 mmol). The
resulting mixture was refluxed for 12 hours. The reaction mixture was cooled, and silica gel
was added to the solvent mixture and plug was prepared. A flash column chromatographic
separation was performed using ethyl acetate-hexane as eluent to afford 218 as a white solid
(280 mg, 62% yield). TLC Rf = 0.56 (Hexane: EtOAc, 3:1) ); mp, 236-237.8 oC; 1H NMR
(400 MHz, DMSO-d6) δ 7.02 (s, 1H, Ar), 6.94 (d, J = 8.4 Hz, 2H, Ar), 6.86 (d, J = 8.4 Hz,
222

2H, Ar), 3.71 (s, 3H, -OCH3), 3.44 (s, 3H, -N4CH3), 2.58 (s, 3H, 2-CH3), 1.54 (s, 3H, 5-CH3).
Anal. Calcd. for C16H17N3OS: C, 64.19; H, 5.72; N, 14.03; S, 10.71. Found: C, 64.35; H,
5.73; N, 13.97; S, 10.60.

4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl) -2,5-dimethylthieno[2,3-d]pyrimidine (221)
Compound 315a (200 mg, 1.01 mmol) was dissolved in isopropanol followed by addition of
1 drop of HCl and 6-methoxy-1,2,3,4-tetrahydroquinoline (180.75 mg, 1.11 mmol). The
reaction mixture was stirred for 6 hours at reflux condition. The reaction mixture was cooled,
and silica gel was added to the solvent mixture and plug was prepared. A flash column
chromatographic separation was performed using hexane and EtOAc as eluent to afford 221
as a white solid (196.5 mg, 60% yield). TLC Rf = 0.36 (Hexane: EtOAc, 10:1) ); mp, 245.8247 oC; 1H NMR (400 MHz, DMSO-d6) δ 7.22 (s, 1H, Ar), 6.90 (d, J = 8.8 Hz, 1H, Ar), 6.85
(d, J = 3.0 Hz, 1H, Ar), 6.70 (dd, J = 8.8 Hz, J =3.0 Hz, 1H, Ar), 3.96 (t, J = 6.5 Hz, 2H, CH2-), 3.71 (s, 3H, -OCH3), 2.72 (t, J = 6.5 Hz, 2H, -CH2-), 2.58 (s, 3H, 2-CH3), 1.98-1.90
(m, 2H, -CH2-), 1.54 (s, 3H, 5-CH3). Anal. Calcd. for C18H19N3OS: C, 66.43; H, 5.88; N,
12.91; S, 9.85. Found: C, 66.37; H, 5.98; N, 13.00; S, 9.68.

2-chloro-N-(4-methoxyphenyl)-N,5-dimethylthieno[2,3-d]pyrimidin-4-amine (219)
Commercially available 2,4-dichloro-5-methylthieno[2,3-d]pyrimidine 315b (300 mg, 1.37
mmol) was dissolved in isopropanol (10 mL) at room temperature followed by addition of 1
drop of HCl and 4-methoxy-N-methylaniline (187.85 mg, 1.37 mmol) and reacted for 18 hours
at room temperature. Silica gel was added to the solvent mixture and plug was prepared. A
flash column chromatographic separation was performed using ethyl acetate-hexane as eluent
to afford intermediate 219 as light yellow solid (210 mg, 48% yield); TLC Rf = 0.65 (Hexane:
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EtOAc, 3:1) ); mp, 216-217.5 oC; 1H NMR (400 MHz, DMSO-d6) δ 7.14 (s, 1H, Ar), 7.10 (d,
J = 9.0 Hz, 2H, Ar), 6.90 (d, J = 9.0 Hz, 2H, Ar), 3.74 (s, 3H, -OCH3), 3.46 (s, 3H, -N4CH3),
1.45 (s, 3H, 5-CH3). Anal. Calcd. for C15H14ClN3OS 0.16 (CH3)2CHOH: C, 56.43; H, 4.67;
Cl, 10.76; N, 12.76; S, 9.73. Found: C, 56.10; H, 4.78; Cl, 10.64; N, 12.90; S, 9.65.

N4-(4-methoxyphenyl)-N4,5-dimethylthieno[2,3-d]pyrimidine-2,4-diamine (220)
Commercially available 4-chloro-5-methylthieno[2,3-d]pyrimidin-2-amine 315c (250 mg,
1.14 mmol) was dissolved in isopropanol (10 mL) at r.t. followed by addition of 1 drop of
HCl and 4-methoxy-N-methylaniline (156.5 mg, 1.14 mmol) for 24 hours at room
temperature. Silica gel was added to the solvent mixture and plug was prepared. A flash
column chromatographic separation was performed using methanol-dichloromethane as
eluent to afford intermediate 220 as light yellow solid (164 mg, 45% yield); TLC Rf = 0.20
(MeOH:CH2Cl2:NH4OH, 1:20:0.5); mp, 209.5-211 oC 1H NMR (400 MHz, DMSO-d6) δ 7.02
(s, 1H, Ar), 7.10 (d, J = 8.9 Hz, 2H, Ar), 6.98 (d, J = 8.9 Hz, 2H, Ar), 5.96 (s, br, 2H, exch,.
2-NH2), 3.81 (s, 3H, -OCH3), 3.42 (s, 3H, -N4CH3), 1.58 (s, 3H, 5-CH3). Anal. Calcd. for
C15H16N4OS 0.44 CH2Cl2: C, 54.88; H, 5.04; N, 16.58; S, 9.48. Found: C, 54.82; H, 5.36; N,
16.71; S, 9.44.

2-chloro-4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)-5-methylthieno[2,3-d]pyrimidine
(222)
Commercially available 2,4-dichloro-5-methylthieno[2,3-d]pyrimidine 315b (200 mg, 0.91
mmol) was dissolved in isopropanol (10 mL) at r.t. followed by addition of 1 drop of HCl and
6-methoxy-1,2,3,4-tetrahydroquinoline (149 mg, 0.91 mmol) for 18 hours at room
temperature. Silica gel was added to the solvent mixture and plug was prepared. A flash
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column chromatographic separation was performed using ethyl acetate-hexane as eluent to
afford intermediate 222 as yellow solid (142 mg, 45% yield). TLC Rf = 0.47 (Hexane: EtOAc,
3:1); mp, 220-222.8 oC; 1H NMR (400 MHz, DMSO-d6) δ 7.25 (s, 1H, Ar), 6.81 (J = 8.8 Hz,
1H, Ar), 6.60 (d, J = 2.9 Hz, 1H, Ar), 6.53 (dd, J = 8.8 Hz, J =2.9 Hz, 1H, Ar), 3.81 (t, J = 6.4
Hz, 2H, -CH2-), 3.72 (s, 3H, -OCH3), 2.79 (t, J = 6.4 Hz, 2H, -CH2-), 1.74-1.80 (m, 2H, -CH2) 1.64 (s, 3H, 5-CH3). Anal. Calcd. for C17H16ClN3OS 0.29 CH3(CH2)4CH3 0.19 HCl: C,
59.51; H, 5.39; Cl, 11.24; N, 11.13; S, 8.49. Found: C, 59.80; H, 5.44; Cl, 11.50; N, 11.51; S,
8.50.

4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)-5-methylthieno[2,3-d]pyrimidin-2-amine
(223)
Commercially available 4-chloro-5-methylthieno[2,3-d]pyrimidin-2-amine 315c (220 mg, 1.0
mmol) was dissolved in isopropanol (10 mL) at r.t. followed by addition of 1 drop of HCl and
6-methoxy-1,2,3,4-tetrahydroquinoline (137.8 mg, 1.0 mmol) for 24 hours at room
temperature. Silica gel was added to the solvent mixture and plug was prepared. A flash
column chromatographic separation was performed using methanol-dichloromethane as
eluent to afford intermediate 223 as light yellow solid (128.5 mg, 40% yield); TLC Rf = 0.24
(MeOH:CH2Cl2:NH4OH, 1:20:0.5); mp, 218-220.2 oC; 1H NMR (400 MHz, DMSO-d6) δ 7.15
(s, 1H, Ar), 6.84 (J = 8.9 Hz, 1H, Ar), 6.62 (d, J = 3.0 Hz, 1H, Ar), 6.56 (dd, J = 8.9 Hz, J =
3.0 Hz, 1H, Ar), 5.92 (s, br, 2 H, exch., 2-NH2), 3.78 (t, J = 6.3 Hz, 2H, -CH2-), 3.70 (s, 3H,
-OCH3), 2.76 (t, J = 6.3 Hz, 2H, -CH2-), 1.70-1.78 (m, 2H, -CH2-), 1.60 (s, 3H, 5-CH3). Anal.
Calcd. for C17H18N4OS: C, 62.55; H, 5.55; N, 17.16; S, 9.82. Found: C, 62.29; H, 5.69; N,
16.88; S, 9.62.
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4-chloro-2,5,6-trimethylthieno[2,3-d]pyrimidine (318)
To a 50 mL flask were added commercially available ethyl 2-amino-4,5-dimethylthiophene3-carboxylate 316 (6.0 g, 30.11 mmol) and acetonitrile (20 mL). The resulting mixture was
stirred to afford a clear solution. Anhydrous HCl gas was bubbled into the solution for 30
mins until there was no further precipitation. The mixture was stirred for an additional hour
at room temperature. The residue was dried and dissolved in 10 mL distilled water and treated
with ammonia in water solution to generate precipitate. The white precipitate was collected
through filtration and washed with ether then dried over P 2O5 to afford 3.80 g of yellow solid
of 317 (65% yield). TLC Rf = 0.38 (CHCl3: MeOH, 20:1); mp >250 °C (lit.404 266 oC) 1H
NMR (400 MHz, DMSO-d6): δ 11.98 (s, 1H, exch., -NH), 2.41 (s, 3H, -CH 3), 2.36 (s, 3H, CH3), 2.30 (s, 3H, -CH3). Crude 317 (3.50 g, 18.02 mmol) without further characterization
was dissolved in toluene (20 mL), POCl3 (1.68 mL, 18.02 mmol) and pyridine (1.45 mL, 18.02
mmol). The resulting mixture was refluxed for 12 hours, and the solvent was removed under
reduced pressure and neutralized with ammonia in water solution to generate light-yellow
precipitate. The precipitate was collected by filtration to afford crude 318. Silica gel column
chromatography using hexane and EtOAc (10:1) as the eluent was used to separate 318.
Fractions containing the product (TLC) were combined and evaporated to afford 318 as a
light-yellow solid (1.92 g, 50% yield). TLC Rf = 0.57 (Hexane: EtOAc 3:1); mp 116.8-118
°C (lit.429116-117 oC) 1H NMR (400 MHz, DMSO-d6): δ 2.47 (s, 3H, -CH3), 2.38 (s, 3H, CH3), 2.32 (s, 3H, -CH3). Anal. Calcd. for C9H9ClN2S: C, 50.82; H, 4.26; Cl, 16.67; N, 13.17;
S, 15.08. Found: C, 50.75; H, 4.56; Cl, 16.53; N, 13.19; S, 14.99.
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N-(4-methoxyphenyl)-2,5,6-trimethylthieno[2,3-d]pyrimidin-4-amine (227)
In a solution of isopropanol (10 mL), 318 (300 mg, 1.41 mmol) were added 1 drop of HCl and
4-methoxyaniline (191.08 mg, 1.55 mmol) and refluxed for 12 hours. The reaction mixture
was cooled, and silica gel was added to the solvent mixture and plug was prepared. A flash
column chromatographic separation was performed using ethyl acetate-hexane as eluent to
afford 227 as a white solid (253 mg, 60% yield). TLC Rf = 0.44 (Hexane: EtOAc, 3:1) ); mp,
176.3-178 oC; 1H NMR (400 MHz, DMSO-d6) δ 8.04 (s, 1H, exch., N4-H), 7.58 (d, J = 8.6
Hz, 2H, Ar), 6.94 (d, J = 8.6 Hz, 2H, Ar), 3.76 (s, 3H, -OCH3), 2.56 (s, 3H, 2-CH3), 2.42 (s,
3H, -CH3), 2.40 (s, 3H, -CH3). Anal. Calcd. for C16H17N3OS: C, 64.19; H, 5.72; N, 14.03; S,
10.71. Found: C, 64.41; H, 5.91; N, 13.80; S, 10.43.

N-(4-methoxyphenyl)-N,2,5,6-tetramethylthieno[2,3-d]pyrimidin-4-amine (225)
In a solution of DMF (10 ml), 227 (200 mg, 0.668 mmol) was added portion wise sodium
hydride (60% dispersed in mineral oil) (26.72 mg, 0.668 mmol). The reaction was stirred at
room temperature for 10 mins and then iodomethane (0.5 mL, 0.808 mmol) dissolved in 5 mL
of DMF was added drop wise to the suspension. The reaction was stirred for 2 hours at room
temperature. Silica gel was added to the solvent mixture and plug was prepared. A flash
column chromatographic separation was performed using ethyl acetate hexane as eluent to
afford 225 as a light yellow solid (144.5 mg, 69% yield); TLC Rf = 0.63 (Hexane: EtOAc,
3:1); mp, 187-189.6 oC; 1H NMR (400 MHz, DMSO-d6) δ 6.89 (d, J = 9.1 Hz, 2H, Ar), 6.84
(d, J = 9.1 Hz, 2H, Ar), 3.71 (s, 3H, -OCH3), 3.43 (s, 3H, -N4CH3), 2.57 (s, 3H, 2-CH3), 2.25
(s, 3H, 6-CH3), 1.53 (s, 3H, 5-CH3). Anal. Calcd. for C15H15N3S2 C, 59.77; H, 5.02; N, 13.94;
S, 21.27. Found: C, 59.69; H, 5.00; N, 14.15; S, 21.33.
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2,5,6-trimethyl-N-(4-(methylthio)phenyl)thieno[2,3-d]pyrimidin-4-amine (228)
In a solution of isopropanol (10 mL), 318 (250 mg, 1.18 mmol) were added 1 drop of HCl and
4-(methylthio)aniline (0.16 mL, 1.29 mmol) and refluxed for 12 hours. The reaction mixture
was cooled, and silica gel was added to the solvent mixture and plug was prepared. A flash
column chromatographic separation was performed using ethyl acetate-hexane as eluent to
afford 228 as a white solid (252 mg, 68% yield). TLC Rf = 0.32 (Hexane: EtOAc, 3:1) ); mp,
178-179.6 oC; 1H NMR (500 MHz, DMSO-d6) δ 8.12 (s, 1H, exch., -N4H), 7.62 (d, J = 8.6
Hz, 2H, Ar), 7.22 (d, J = 8.6 Hz, 2H, Ar), 2.45 (s, 3H, -CH3), 2.43 (s, 3H, -CH3), 2.39 (s, 3H,
-CH3), 2.37 (s, 3H, -CH3). Anal. Calcd. for C16H17N3S2: C, 60.92; H, 5.43; N, 13.32; S, 20.33.
Found: C, 60.71; H, 5.63; N, 13.19; S, 20.19.

N,2,5,6-tetramethyl-N-(4-(methylthio)phenyl)thieno[2,3-d]pyrimidin-4-amine (226)
Compound 228 (220 mg, 0.734 mmol) was dissolved in DMF (10 ml) followed by portion
wise addition of sodium hydride (60% dispersed in mineral oil) (29.4 mg, 0.734 mmol). The
reaction was stirred at room temperature for 10 mins and then iodomethane (0.55 mL, 0.881
mmol) dissolved in 5 mL of DMF was added drop wise to the suspension. The reaction was
stirred for 2 hours at room temperature. Silica gel was added to the solvent mixture and plug
was prepared. A flash column chromatographic separation was performed using ethyl acetate
hexane. The compound was triturated in diethyl ether to further purify and afford 226 as a
yellow solid (83 mg, 36% yield). TLC Rf = 0.55 (Hexane: EtOAc, 3:1); mp, 190-193 oC; 1H
NMR (400 MHz, DMSO-d6) δ 7.17 (d, J = 8.3 Hz, 2H, Ar), 6.86 (d, J = 8.3 Hz, 2H, Ar), 3.46
(s, 3H, -N4CH3), 2.59 (s, 3H, S-CH3), 2.43 (s, 3H, 2-CH3), 2.29 (s, 3H, 6-CH3), 1.62 (s, 3H,
5-CH3). Anal. Calcd. for C17H19N3S2 0.22 (C2H5)2O: C, 62.11; H, 6.18; N, 12.14; S, 18.53.
Found: C, 62.16; H, 5.80; N, 12.18; S, 18.35.
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7-methoxy-4-(2,5,6-trimethylthieno[2,3-d]pyrimidin-4-yl)-3,4-dihydro-2Hbenzo[b][1,4]oxazine (229)
To a solution of 318 (200 mg, 0.940 mmol) in isopropanol (10 mL), 1 drop of HCl was added,
followed by addition of 7-methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazine (170.87 mg, 1.03
mmol) and refluxed for 8 hours. The reaction mixture was cooled to room temperature, silica gel
was added, and the solvent was removed under reduced pressure. Purification was performed by
column chromatography using hexane and ethyl acetate (10:1) to give an off-white solid as 229
(186 mg, 58% yield). TLC Rf = 0.20 (Hexane: EtOAC, 3:1); mp, 210-211.8 oC; 1H NMR (400
MHz, DMSO-d6) δ 6.98 (d, J = 3.1 Hz, 1H, Ar), 6.79 (dd, J = 8.9 Hz, J = 3.1 Hz, 1H, Ar), 6.32 (d,
J = 8.9 Hz, 1H, Ar), 3.99 (t, J = 6.5 Hz, 2H, -CH2-), 3.87 (t, J = 6.5 Hz, 2H, -CH2-), 3.82 (s, 3H, OCH3), 2.57 (s, 3H, 2-CH3), 2.31 (s, 3H, 6-CH3), 1.65 (s, 3H, 5-CH3). Anal. Calcd. for
C18H19N3O2S: C, 63.32; H, 5.61; N, 12.30; S, 9.39. Found: C, 63.30; H, 5.71; N, 12.22; S, 9.22.

2-Cyano-3-phenylpropenal (321)
Benzaldehyde 319 (5.0 g, 0.047 mmol) and 3,3-dimethoxypropanenitrile (7.23 g, 0.062 mmol)
were mixed together and added to a solution of NaOMe (3.39 g, 0.062 mmol) in MeOH (15 mL)
during 15 min. The mixture was stirred at room temperature overnight. Most of the MeOH was
removed in vacuo, and the residue was partitioned between EtOAc (50 mL) and water (50 mL).
The organic layer was separated, washed with brine (40 mL), and dried (MgSO 4) and the solvent
evaporated in vacuo. The residual oil was distilled to give 320 (8.43 g, 66% yield) as a colorless
oil. The residual oil (8.43 g, 0.041 mmol) without further purification and characterization was
treated cautiously with 6 N HCl (5.7 mL), and the mixture was stirred at room temperature for 30
mins. The solid was filtered off, washed well with water, and dried in vacuo to give 321 as an offwhite powder (3.65 g, 56% yield). TLC Rf = 0.20 (Hexane: EtOAC, 3:1); mp, 98 °C (lit.240 96-97
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C); 1H NMR (400 MHz, DMSO-d6) δ 9.62 (s, 1H, -CHO), 8.53 (s, 1H, -CH), 8.05 (d, J = 9.4 Hz,

2H, Ar), 7.78 – 7.61 (m, 3H, Ar). Anal. Calcd. for C10H7NO: C, 76.42; H, 4.49; N, 8.91. Found C,
76.03; H, 4.73; N, 8.78.

Methyl 3-amino-4-benzyl-1H-pyrrole-2-carboxylate (323)
Synthesis of 323 was initiated by reacting 321 (3.50 g, 22.27 mmol) in methanol with 10% Pd/C
under 50 psi H2 in a hydrogenation bottle for 3 hours at room temperature. The catalyst was
removed by filtration to obtain crude 322. Crude 322 (2.8 g, 17.6 mmol) was added with diethyl
aminomalonate (5.67 g, 0.03 mmol) and sodium acetate (2.19 g, 0.03 mmol) and water (5 mL)
was added, and the mixture was stirred at room temperature for 16 hours. Most of the solvent was
removed in vacuo, and the residue was partitioned between EtOAc (25 mL) and water (20 mL).
The organic layer was separated and dried over sodium sulphate and evaporated in vacuo. The
residual yellow oil was dissolved in methanol containing sodium methoxide (0.48 g, 0.01 mmol),
stirred at room temperature for 12 hours and then heated to reflux for 3 hours. Most of the solvent
was evaporated in vacuo, and the residue was treated with water (20 mL) and was flash
chromatographed with 1% (v/v) CH3OH in CHCl3 to give 323 as a light-yellow solid (1.38 g, 34%
over 3 steps). TLC Rf = 0.65 (CHCl3: CH3OH, 10:1); mp, 121-123.2 oC (lit.240 120-122 °C); 1H
NMR (400 MHz, DMSO-d6)  10.47 (br, 1H, exch., NH), 7.19 - 7.27 (m, 4 H, Ar), 7.11 - 7.16 (m,
1 H, Ar), 6.46 (d, J = 3.51 Hz, 1 H, 6-H), 4.84 (br, 2H, exch., NH2), 3.68 (s, 3 H, -CH3), 3.62 (s,
2H, -CH2). This compound was used for the next reaction without further characterization.

230

7-benzyl-N-(4-methoxyphenyl)-N-methyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine (232)
Treatment 323 (1.0 g, 4.34 mmol) with 3.46 mL (86.86 mmol) formamide was carried out in
microwave vessel at 170 oC for 12 hours. The reaction was cooled to room temperature and to the
mixture, 50 mL water was added, and the precipitate was collected and dried under high vacuum
to afford 324 as white solid. (636 mg, 65 % yield). The product 324 was not subjected to separation
efforts and taken to the next step without any characterization. Chlorination of 324 (600 mg, 2.66
mmol) was performed using POCl3 (0.25 mL, 2.66 mmol) and pyridine (0.2 mL, 2.66 mmol) in
toluene and refluxed for 4 hours. The solvent was evaporated and neutralized with ammonia in
water solution to generated pale-yellow precipitate. The precipitate was collected by filtration. To
the precipitate, was added methanol and 2.0 g of silica gel. The solvent was reduced under pressure
and silica plug was prepared. A flash column chromatographic separation was performed using
ethyl acetate-hexane as eluent to afford 325 as a white solid (440 mg, 68% yield). It was used in
the next reaction, without further separation or characterization efforts. Compound 325 (150 mg,
0.615 mmol) was dissolved in isopropanol (15 mL) followed by addition of 1 drop of HCl and 4methoxy-N-methylaniline (93 mg, 0.677 mmol) refluxed for 3 hours. The solvent was evaporated
in vacuo and silica gel and methanol were added after that the solvent was evaporated to afford a
plug. The silica gel plug obtained was loaded onto a silica gel column and eluted with 1% (v/v)
CH3OH/CHCl3. Fractions containing the product (TLC) were pooled, and the solvent was
evaporated to afford 232 (152.5 mg, 72% yield). TLC Rf 0.39 (CHCl3:CH3OH:NH4OH; 20:1:0.5);
mp, 196-198.2 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.57 (br, 1H, exch, NH), 8.34 (s, 1H, Ar),
7.4 (d, 2H, J = 8.72, Ar), 7.17 – 7.26 (m, 6H, Ar and 6-CH), 7.08 (d, 2H, J = 8.72 Hz, Ar), 3.95
(s, 2H, -CH2-), 3.80 (s, 3H, -OCH3), 3.45 (s, 3H, -N4CH3). Anal. Calcd. for C21H20N4O 0.09
(CH3)2CHOH 0.03 HCl: C, 72.77; H, 5.97; N, 15.94. Found C, 72.76; H, 6.03; N, 15.98.
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Ethyl 2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate
(330)
4-Cyclohexanone 331 derivatives (5.27 mL, 50.95 mmol) and morpholine (4.39 mL, 50.95
mmol) were added to the mixture of ethyl cyanoacetate (5.42 mL, 50.95 mmol) and sulfur
(13.07 g, 50.95 mmol) in ethanol (25 mL). Then the mixture was stirred at room temperature
for 1h then stirred at 60 °C for 12 h. The reaction mixture was cooled to room temperature
and the solvent was removed in vacuo. The crude product was purified by flash column
chromatography on a silica column using hexane/ethyl acetate (10:1) as the eluent to get
compound 330 (7.81 g, 68% yield) as a light-yellow solid. TLC Rf = 0.67 (Hexane: EtOAc,
3:1); mp, 194-195.7 oC (lit.237192-193 °C); 1H NMR (400 MHz, DMSO-d6) δ 6.66 (s, 2H, br,
exch., NH2), 4.36 (q, J = 7.0 Hz, 2H, -CH2CH3), 2.60 (m, 2H, -CH2), 2.41 (m, 2H, -CH2),
1.68-1.65 (m, 4H, -CH2), 1.42 (t, J = 7.0 Hz, 3H, -CH2CH3). The 1H-NMR matches the 1HNMR of the reported compounds in the literature.237 This compound was used for the next
reaction without further characterization.

2-methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one (329)
Compound 330 (2.5 g, 11.10 mmol) was dissolved in 20 mL of acetonitrile and hydrogen
chloride gas was bubbled through for 30 mins. The mixture was stirred at room temperature
overnight. The residue was dried and dissolved in 10 mL distilled water and then treated with
ammonia in water solution to generated white precipitate. The precipitate was collected by
filtration to afford 1.27 g (52% yield) of 329 as a white solid. TLC Rf = 0.11 (Hexane: EtOAc,
3:1) ; mp >250 oC (lit. >250 oC)404 1H NMR (400 MHz, DMSO-d6): δ 12.10 (s, 1H, exch., NH), 3.02-2.95 (m, 2H, -CH2-), 2.87-2.84 (m, 2H, -CH2-), 2.66 (s, 3H, 2-CH3), 1.84 (t, J=
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3.1 Hz, 4H, -CH2-). This compound was used for the next reaction without further
characterization.

4-chloro-2-methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine (328)
Chlorination of 329 (1.0 g, 4.54 mmol) was carried out using POCl3 (0.4 mL, 4.54 mmol),
pyridine (0.37 mL, 4.54 mmol) in toluene in reflux condition for 6 hours. The solvent was
evaporated and neutralized with ammonia in water solution to generated light-yellow
precipitate. The precipitate was collected by filtration to afford 328 as light-yellow solid.
(704.42 mg, 65% yield). TLC Rf = 0.83 (Hexane: EtOAc, 3:1); mp, 228-230 oC; 1H NMR
(400 Hz) (Me2SO-d6) δ 2.79-2.85 (m, 2H, -CH2-), 2.84-2.80 (m, 2H, -CH2-), 2.58 (s, 3H, -2CH3), 1.81-1.77 (m, 4H, -CH2-). This compound was used for the next reaction without further
characterization.

General procedure for synthesis of 234, 236, 238, 239 and 240
Compound 328 was dissolved in isopropanol followed by adding 1-2 drops of HCl and appropriate
anilines. The reaction mixture was stirred for 4-8 hours at reflux. The reaction mixture was cooled,
and silica gel was added to the solvent mixture and plug was prepared. A flash column
chromatographic separation was performed using ethyl acetate-hexane as eluent to afford 234,
236, 238, 239 and 240 (yields: 55-71%).
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N-(4-methoxyphenyl)-N,2-dimethyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3d]pyrimidin-4-amine (234)
Compound 328 (250 mg, 1.05 mmol) was dissolved in isopropanol (10 mL) followed by
addition of 1-2 drops of HCl and reacted with p-anisidine (0.2 mL, 1.36 mmol) for 4 hours at
reflux conditions. The reaction mixture was cooled, and silica gel was added to the solvent
mixture and plug was prepared. A flash column chromatographic separation was performed
using ethyl acetate-hexane as eluent to afford intermediate 334 as a white solid (151 mg, 40%
yield); TLC Rf = 0.22 (Hexane: EtOAc, 1:1). Crude 334 (220 mg, 0.676 mmol) without
further characterization was dissolved in DMF (10 ml) followed by portion wise addition of
sodium hydride (60% in dispersion, 27.04 mg, 0.676 mmol). Iodomethane (0.04 mL, 0.676
mmol) dissolved in 5 mL of DMF was added drop wise to the suspension. The reaction was
stirred for 2 hours at room temperature. Silica gel was added to the solvent mixture and plug
was prepared. A flash column chromatographic separation was performed using ethyl acetate
hexane as eluent to afford 234 as a white solid (156 mg, 68% yield); TLC Rf = 0.41 (Hexane:
EtOAc, 3:1); mp, 198-199.6 oC; 1H NMR (400 MHz, DMSO-d6) δ 6.92 (d, J = 9.1 Hz, 2H,
Ar), 6.86 (d, J = 9.1 Hz, 2H, Ar), 3.72 (s, 3H, -OCH3), 3.42 (s, 3H, -N4CH3), 2.70 (m, 2H,CH2), 2.56 (s, 3H, 2-CH3), 1.72 (m, 2H, -CH2), 1.60 – 1.52 (m, 2H, -CH2), 1.46 – 1.34 (m,
2H, -CH2). Anal. Calcd. for C19H21N3OS: C, 67.22; H, 6.24; N, 12.37; S, 9.45. Found: C,
67.38; H, 6.23; N, 12.31; S, 9.44.
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N,2-dimethyl-N-(4-(methylthio)phenyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3d]pyrimidin-4-amine (236)
Compound 328 (300 mg, 1.26 mmol) was dissolved in isopropanol followed by addition of 1-2
drops of HCl and reacted with 4-(methylthio)aniline (0.2 mL, 1.63 mmol) for 6 hours at reflux
condition. The reaction mixture was cooled down and silica gel was added to the solvent mixture
and plug was prepared. A flash column chromatographic separation was performed using ethyl
acetate-hexane as eluent to afford intermediate 335 as a pale-yellow solid (186 mg, 41% yield);
TLC Rf = 0.20 (Hexane: EtOAc, 1:1). Crude 335 (150 mg, 0.439 mmol) without further
characterization was dissolved in DMF (10 mL) followed by portion wise addition of sodium
hydride (17.6 mg, 0.439 mmol). Iodomethane (0.03 mL, 0.439 mmol) dissolved in 5 mL of DMF
was added drop wise to the suspension. The reaction was stirred for 2 hours at room temperature.
Silica gel was added to the solvent mixture and plug was prepared. A flash column
chromatographic separation was performed using ethyl acetate hexane as eluent to afford 236 as a
yellow solid (109 mg, 70% yield); TLC Rf = 0.45 (Hexane: EtOAc, 3:1); mp, 189-191 oC;
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NMR (500 MHz, DMSO-d6) δ 7.16 (d, J = 8.8 Hz, 2H, Ar), 6.85 (d, J = 8.8 Hz, 2H, Ar), 3.41 (s,
3H, -N4CH3), 2.69 (m, 2H, -CH2), 2.55 (s, 3H, 2-CH3), 2.41 (s, 3H, -SCH3), 1.83 (m, 2H, -CH2),
1.62 – 1.50 (m, 2H, -CH2), 1.46 – 1.37 (m, 2H, -CH2). Anal. Calcd. for C19H21N3S2: C, 64.19; H,
5.95; N, 11.82; S, 18.04. Found: C, 64.44; H, 5.99; N, 11.70; S, 17.78.
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4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)-2-methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno
[2,3-d]pyrimidine (238)
Compound 328 (250 mg, 1.05 mmol) was dissolved in isopropanol (15 mL) followed by adding
1-2 drops of HCl and 6-methoxy-1,2,3,4-tetrahydroquinoline (192 mg, 1.20 mmol). The reaction
mixture was stirred for 8 hours at reflux condition. The reaction mixture was cooled, and silica gel
was added to the solvent mixture and plug was prepared. A flash column chromatographic
separation was performed using hexane and EtOAc as eluent to afford 238 as a yellow solid (209
mg, 55% yield); TLC Rf = 0.53 (Hexane: EtOAc, 3:1); mp, 199-201 oC; 1H NMR (400 MHz,
DMSO-d6) δ 6.78 (d, J = 3.1 Hz, 1H, Ar), 6.54 (dd, J = 8.8 Hz, J = 3.1 Hz, 1H, Ar), 6.34 (d, J =
8.8 Hz, 1H, Ar), 3.80-3.71 (m, 2H, -CH2), 3.69 (s, 3H, -OCH3), 3.48-3.42 (m, 2H, -CH2), 2.822.70 (m, 4H, -CH2), 2.54 (s, 3H, 2-CH3), 1.99-1.92 (m, 2H, -CH2), 1.68-1.58 (m, 2H, -CH2), 1.511.40 (m, 2H, -CH2). Anal. Calcd. for C21H23N3OS 0.39 (CH3)2CHOH: C, 68.46; H, 6.77; N, 10.79;
S, 8.24. Found: C, 68.78; H, 6.39; N, 10.52; S, 7.91.

N-(5-methoxynaphthalen-2-yl)-N,2-dimethyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3d]pyrimidin-4-amine (239)
Compound 328 (300 mg, 1.26 mmol) was dissolved in isopropanol followed by addition of 1-2
drops of HCl and reacted with 6-aminonaphthalen-1-ol (220 mg, 1.38 mmol) for 6 hours at reflux
condition. The reaction mixture was cooled down and silica gel was added to the solvent mixture
and plug was prepared. A flash column chromatographic separation was performed using ethyl
acetate-hexane as eluent to afford intermediate 240 as a pale-yellow solid (322.5 mg, 71% yield);
TLC Rf = 0.21 (Hexane: EtOAc, 3:1); mp, 214 oC. Without further characterization compound
240 (250 mg, 0.691 mmol) was dissolved in DMF (12 mL) followed by portion wise addition of
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sodium hydride (60% in dispersion, 27.6 mg, 0.691 mmol). Iodomethane (0.04 mL, 0.691 mmol)
dissolved in 5 mL of DMF was added drop wise to the suspension. The reaction was stirred for 2
hours at room temperature. Silica gel was added to the solvent mixture and plug was prepared. A
flash column chromatographic separation was performed using ethyl acetate hexane as eluent to
afford 239 as a yellow solid (153.5 mg, 57% yield); TLC Rf = 0.46 (Hexane: EtOAc, 3:1); mp,
205-208 oC; 1H NMR (400 MHz, DMSO-d6) δ 7.99 (d, J = 9.2 Hz, 1H, Ar), 7.32 (d, J = 7.8 Hz,
1H, Ar), 7.29 – 7.24 (m, 2H, Ar), 7.09 (dd, J = 9.2 Hz, J = 2.4 Hz, 1H, Ar), 6.82 (dd, J = 7.8 Hz,
J = 3.0 Hz, 1H, Ar), 3.92 (s, 3H, -OCH3), 3.53 (s, 3H, -N4CH3), 2.69 (t, J = 6.08 Hz, 2H, -CH2),
2.61 (s, 3H, 2-CH3), 1.87 (t, J = 6.08 Hz, 2H, -CH2), 1.51 – 1.45 (m, 2H, -CH2), 1.40 – 1.32 (m,
2H, -CH2). Anal. Calcd. for C23H23N3OS: C, 70.92; H, 5.95; N, 10.78; S, 8.23. Found: C, 70.75;
H, 6.11; N, 10.53; S, 7.95.

2-amino-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one (336)
Methyl sulfone (15 g), compound 330 (5.0 g, 22.19 mmol) and chloroformamidine hydrochloride
(5.10 g, 44.38 mmol) were taken in a round bottom flask. The reaction mixture was stirred at 140
°C for 4 hours. The reaction was quenched with 100 mL water, cooled in an ice bath and was
basified to pH 8.0 using an aqueous NH4OH solution. The precipitate was collected by filtration,
dried (using Na2SO4) and afforded 3.24 g (66%) of 336 as a brown solid. TLC Rf = 0.60 (CHCl3:
MeOH, 5:1); The product 336 was not subjected to separation efforts and taken to the next step
without any characterization.
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N-(4-chloro-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-2-yl)pivalamide (338)
To a 250 mL round bottom flask were added 336 (3.0 g, 13.56 mmol) and Piv2O (25 mL, 135.58
mmol) and the reaction mixture was vigorously stirred at reflux condition. After 20 min, the
reactant was completely dissolved, and, after 1 h, the product precipitated. After 2 h, TLC indicated
complete disappearance of 336. The reaction mixture was cooled to room temperature, and the
solid was collected by filtration, washed with hexane and dried to give 2.90 g (70% yield) of 337
as a brown solid. TLC Rf = 0.38 (Hexane: EtOAc, 3:1); mp 256-258 oC; This compound was used
for the next reaction without further characterization. Crude 337 (2.70 g, 8.84 mmol) was
chlorinated with phosphorus oxychloride (0.8 mL, 8.84 mml) and pyridine (0.7 mL, 8.84 mmol)
in toluene (15 mL). The reaction was refluxed for 4 hours The POCl 3 was evaporated, and the
mixture was cooled in ice bath. The mixture was neutralized using an aqueous NH 4OH solution to
yield a precipitate. The precipitate was collected by filtration, washed with water, dried and then
dissolved in MeOH. To the solution was added silica gel (1 g), and the solvent was removed under
reduced pressure to provide a silica gel plug. Column chromatography was performed with hexane
and ethyl acetate (10:1) to generate 338 (1.49 g, 52%) as a brown solid. TLC Rf = 0.68 (Hexane:
EtOAc, 3:1); mp 234-235.6 oC; 1H NMR (400 MHz, DMSO-d6):  2.85-2.80 (m, 2H, -CH2), 2.712.65 (m, 2H, -CH2), 1.80 – 1.71 (m, 4H, -CH2), 1.24 (s, 9H, -Piv). This compound was used for
the next reaction without further characterization.
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N4-(4-methoxyphenyl)-N4-methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine-2,4diamine (244)
To a solution of 338 (250 mg, 0.771 mmol) in isopropanol (20 mL), 1 drop of HCl was added,
followed by addition of 4-methoxy-N-methylaniline (116.5 mg, 0.849 mmol) under reflux
condition for 6 hours. After cooling to room temperature, 1 N NaOH solution (2 mL) was added
and heated to reflux for 2 h. The reaction mixture was cooled to rt, silica gel was added, and the
solvent was removed under reduced pressure. Purification was performed by flash column
chromatography using 1% MeOH in CHCl3 as the eluent, and the fractions containing the product
(TLC) were pooled, evaporated to give a solid which was then washed with CHCl 3 to afford 147
mg (56% in two steps) of 244 as white solid. TLC Rf = 0.40 (CHCl3: MeOH, 20:1); mp 167 oC; 1H
NMR (400 MHz, DMSO-d6) δ 6.93 (d, J = 9.0 Hz, 2H, Ar), 6.82 (d, J = 9.0 Hz, 2H, Ar), 5.19 (s,
br, 2H, exch., 2-NH2), 3.81 (s, 3H, -OCH3), 3.46 (s, 3H, -N4CH3), 2.67-2.63 (m, 2H, -CH2), 1.661.60 (m, 4H, -CH2CH2), 1.49-1.45 (m, 2H, -CH2). Anal. Calcd. for C18H20N4OS 0.29 H2O: C,
62.54; H, 6.00; N, 16.20; S, 9.27. Found: C, 62.58; H, 6.03; N, 16.10; S, 9.21.

N4-methyl-N4-(4-(methylthio)phenyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]
pyrimidine-2,4-diamine (245)
To a solution of 338 (220 mg, 0.679 mmol) in isopropanol (20 mL), 1 drop of HCl was added,
followed by addition of N-methyl-4-(methylthio)aniline (114.5 mg, 0.747 mmol) under reflux
condition for 6 hours. After cooling to room temperature, 1 N NaOH solution (2 mL) was added
and heated to reflux for 2 h. The reaction mixture was cooled to room temperature, silica gel was
added, and the solvent was removed under reduced pressure. Purification was performed by
column chromatography using 1% MeOH in CHCl 3 as the eluent, and the fractions containing the
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product (TLC) were pooled, evaporated to give a solid which was then washed with CHCl 3 to
afford 116 mg (48% in two steps) of 245 as pale yellow solid. TLC Rf = 0.35 (CHCl3: MeOH,
20:1); mp 172-173.5 oC; 1H NMR (400 MHz, DMSO-d6) δ 7.12 (d, J = 9.0 Hz, 2H, Ar), 6.97 (d,
J = 9.0 Hz, 2H, Ar), 5.53 (s, br, 2H, exch., 2-NH2), 3.51 (s, 3H, -N4CH3), 2.39 (s, 3H, -SCH3),
2.68-2.64 (m, 2H, -CH2-), 1.67-1.59 (m, 4H, -CH2), 1.48 – 1.44 (m, 2H, -CH2). Anal. Calcd. for
C18H20N4S2 0.18 CH3OH: C, 60.26; H, 5.77; N, 15.46; S, 17.69. Found: C, 60.24; H, 5.82; N,
15.47; S, 17.72.

4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)-5,6,7,8- tetrahydrobenzo [4,5]thieno[2,3-d]
pyrimidin-2-amine (246)
To a solution of 338 (300 mg, 0.926 mmol) in isopropanol (20 mL), 1-2 drops of HCl was added,
followed by addition of 6-methoxy-1,2,3,4-tetrahydroquinoline (166.3 mg, 1.02 mmol) under
reflux condition for 8 hours. After cooling to room temperature, 1 N NaOH solution (2 mL) was
added and heated to reflux for 2 h. The reaction mixture was cooled to room temperature, silica
gel (500 mg) was added, and the solvent was removed under reduced pressure. Purification was
performed by column chromatography using 1% MeOH in CHCl 3 as the eluent, and the fractions
containing the product (TLC) were pooled, evaporated to give a solid which was then washed with
CHCl3 to afford 142.6 mg (42% in two steps) of 246 as an off-white solid. TLC Rf = 0.32 (CHCl3:
MeOH, 20:1); mp 190-191.8 oC; 1H NMR (500 MHz, DMSO-d6) δ 6.79 (d, J = 3.0 Hz, 1H, Ar),
6.56 (dd, J = 8.9 Hz, J = 3.0 Hz, 1H, Ar), 6.39 (d, J = 8.9 Hz, 1H, Ar), 5.18 (s, br, 2H, exch., 2NH2), 3.95-3.88 (m, 2H, -CH2), 3.82 (s, 3H, -OCH3), 2.75 (m, 2H, -CH2), 2.68-2.64 (m, 2H, -CH2),
1.94-188 (m, 2H, -CH2), 1.68-1.61 (m, 4H, -CH2), 1.49-1.45 (m, 2H, -CH2). MS (ESI) m/z
calculated for C20H22N4OS [M+H]+, 367.48. Found: 366.8. HPLC analysis: retention time, 13.63
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min; peak area, 95.51%; eluent A, H2O: eluent B, ACN; gradient elution (100% H2O to 10% H2O)
over 60 min with flow rate of 0.5 mL/min and detection at 245 nm; column temperature, rt.

4-chloro-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine (340)
Treatment 330 (5.0 g, 22.19 mmol) with formamide (4.42 mL, 110.96 mmol) was carried out in
microwave vessel at 180 oC for12 hours. The reaction was cooled to room temperature and to the
mixture, 50 mL water was added, and the precipitate was collected and dried under high vacuum
to afford 339 as white solid in 72% yield (3.30 g). The product 339 was not subjected to separation
efforts and taken to the next step without any characterization. Chlorination of 339 (3.0 g, 14.54
mmol) was performed using POCl3 (1.4 mL, 14.54 mmol) and pyridine (1.17 mL, 14.54 mmol)
and refluxed for 8 hours. The solvent was evaporated and neutralized with ammonia in water
solution to generated pale-yellow precipitate. The precipitate was collected by filtration. To the
precipitate, was added methanol and silica gel. The solvent was reduced under pressure and silica
plug was prepared. A flash column chromatographic separation was performed using ethyl acetatehexane as eluent to afford 1.96 g of 340 (60% yield) as pale-yellow solid. TLC Rf = 0.77 (Hexane:
EtOAc, 3:1); mp, 210-112 oC; 1H NMR (400 Hz) (Me2SO-d6) δ 8.51 (s, 1H, Ar), 2.78-2.84 (m,
2H, -CH2), 2.86-2.82 (m, 2H, -CH2), 1.84-1.78 (m, 4H, -CH2). Anal. Calcd. for C10H9ClN2S: C,
53.45; H, 4.04; Cl, 15.78, N, 12.47; S, 14.27. Found: C, 53.58; H, 4.07; Cl, 15.57, N, 12.37; S,
14.12.
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N-(4-methoxyphenyl)-N-methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4amine (247)
To a solution of 340 (200 mg, 0.890 mmol) in isopropanol (15 mL), 1-2 drops of HCl was added,
followed by addition of 4-methoxy-N-methylaniline (134.3 mg, 0.979 mmol) under reflux
condition for 6 hours. The reaction mixture was cooled to room temperature, silica gel was added,
and the solvent was removed under reduced pressure. Purification was performed by flash column
chromatography using hexane and ethyl acetate (10:1) to give 247 as white solid (197 mg, 68%
yield). TLC Rf = 0.48 (Hexane: EtOAc, 3:1); mp 186-188 oC; 1H NMR (400 MHz, DMSO-d6) δ
8.58 (s, 1H, Ar), 6.93 (d, J = 9.1 Hz, 2H, Ar), 6.86 (d, J = 9.1 Hz, 2H, Ar), 3.71 (s, 3H, -OCH3),
3.42 (s, 3H, -N4CH3), 2.72 (m, 2H, -CH2), 1.74 (m, 2H, -CH2), 1.61 – 1.50 (m, 2H, -CH2), 1.46 –
1.35 (m, 2H, -CH2). Anal. Calcd. for C18H19N3OS: C, 66.43; H, 5.88; N, 12.91; S, 9.85. Found: C,
66.72; H, 5.79; N, 12.88; S, 9.66.

N-methyl-N-(4-(methylthio)phenyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4amine (248)
To a solution of 340 (150 mg, 0.667 mmol) in isopropanol (12 mL), 1-2 drops of HCl was added,
followed by addition of N-methyl-4-(methylthio)aniline (112.5 mg, 0.734 mmol) under reflux
condition for 6 hours. The reaction mixture was cooled to room temperature, silica gel was added,
and the solvent was removed under reduced pressure. Purification was performed by column
chromatography using hexane and ethyl acetate (10:1) to give 248 as light-yellow solid (160 mg,
70% yield). TLC Rf = 0.40 (Hexane: EtOAc, 3:1); mp, 192-193.6 oC; 1H NMR (400 MHz, DMSOd6) δ 8.55 (s, 1H, Ar), 6.91 (d, J = 9.1 Hz, 2H, Ar), 6.82 (d, J = 9.1 Hz, 2H, Ar), 3.51 (s, 3H, N4CH3), 2.40 (s, 3H, -SCH3), 2.74 (m, 2H, -CH2), 1.76 (m, 2H, -CH2), 1.60 – 1.54 (m, 2H, -CH2),
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1.46 – 1.39 (m, 2H, -CH2). Anal. Calcd. for C18H19N3S2 0.32 (CH3)2CHOH 0.05 HCl: C, 62.84; H,
6.02; N, 11.59; S, 17.68. Found: C, 62.68; H, 5.79; N, 11.72; S, 17.49.

Methyl 1-methyl-4-nitro-1H-pyrazole-5-carboxylate (342a)
In a solution of DMF (25 mL) commercially available methyl 4-nitro-1H-pyrazole-5-carboxylate
341 (10 g, 58.44 mmol) was reacted with K2CO3 and methyl iodide (5.5 mL, 87.66 mmol) at room
temperature for 12 hours. A flash column chromatography using ethyl acetate-hexane afforded
two regioisomers: methyl 1-methyl-4-nitro-1H-pyrazole-5-carboxylate (342a) in 35% (3.8 g) as
colorless semi solid and methyl 1-methyl-4-nitro-1H-pyrazole-3-carboxylate (342b) in 55% (6.0
g) yield as white solid. The structures of the isomers (342a and 342b) were determined by NOESY
analysis: a NOESY correlation was observed between H-5 and N-1 alkyl protons in 342b which
was absent in 342a. TLC Rf = 0.40 (Hexane: EtOAc, 3:1); 1H NMR (400 MHz, DMSO-d6) δ 8.36
(s, 1H, Ar), 4.02 (s, 3H, N1-CH3), 3.98 (s, 3H, -OCH3). The 1H-NMR matches the 1H-NMR of the
reported compounds in the literature.246 This compound was used for the next reaction without
further characterization.

Methyl 1-methyl-4-nitro-1H-pyrazole-3-carboxylate (342b)
Methyl 1-methyl-4-nitro-1H-pyrazole-3-carboxylate 342b was isolated as white solid in 55% yield
as white solid. TLC Rf = 0.50 (Hexane: EtOAc, 3:1); mp, 128.1-129.2 °C; 1H NMR (400 MHz,
DMSO-d6) δ 8.95 (s, 1H, Ar), 3.95 (s, 3H, N1-CH3), 3.89 (s, 3H, -OCH3). The 1H-NMR matches
the 1H-NMR of the reported compounds in the literature.246 Anal. Calcd. for C6H7N3O4: C, 38.92;
H, 3.81; N, 22.69. Found: C, 39.04; H, 3.79; N, 22.51.
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5,7-dichloro-1-methyl-1H-pyrazolo[4,3-d]pyrimidine (344)
Reduction of 342a (2.7 g, 14.58 mmol) using 10% Pd/C in EtOH produced 343 (1.63 g, 72% yield)
which was finely mixed with urea (2.52 g, 42.02 mmol) without solvent in a microwave vial and
heated at 180°C for 2 hours. During the reaction course, complete fusion followed by resolidification was observed. The crude product was purified by crystallization from 10% NaOH
and was carried out to next step without any column separation and further characterization.
Chlorination of crude (1.47 g, 8.85 mmol) was carried out using POCl 3 (0.8 mL, 8.85 mmol) in
toluene (20 mL) and pyridine (0.7 mL, 8.85 mmol) and refluxed for 4 hours. The solvent was
evaporated and cooled in an ice bath followed by neutralization with ammonia in water solution.
White precipitate was formed. The resulting precipitate was filtered and purified by column
chromatography to afford 344 as pale-yellow solid. (880 mg, 42% in two steps). TLC Rf = 0.62
(Hexane: EtOAc, 3:1); mp, 168-169 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.46 (s, 1H, Ar), 4.33
(s, 3H, N1-CH3). The 1H-NMR matches the 1H-NMR of the reported compounds in the
literature.246 This compound was used for the next reaction without further characterization.

5-chloro-N-(4-methoxyphenyl)-N,1-dimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-amine (251)
To a solution of 344 (0.2 g, 0.985 mmol) in acetonitrile (15 mL) was added 4-methoxy-Nmethylaniline (162.16 mg, 1.18 mmol) and the resulting mixture was refluxed for 12 hours. The
solvent was removed under reduced pressure to obtain a crude solid that was purified via column
chromatography eluting with a mixture of hexane and EtOAc (10:1) to give white solid 251 (113
mg, 38%). TLC Rf = 0.20 (Hexane: EtOAc, 3:1); mp, 123.5-124.6 oC;

1

H NMR (400 MHz,

DMSO-d6) δ 8.05 (s, 1H, Ar), 7.25 (d, J = 8.9 Hz, 2H, Ar), 7.00 (d, J = 8.9 Hz, 2H, Ar), 3.79 (s,
3H, -OCH3), 3.49 (s, 3H, N7-CH3), 3.04 (s, 3H, N1-CH3). Anal. Calcd. for C14H14ClN5O 0.05
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CH3(CH2)4CH3: C, 55.73; H, 4.79; Cl, 11.52; N, 22.76. Found: C, 55.84; H, 4.77; Cl, 11.28; N,
23.00.

5-chloro-N-(4-methoxyphenyl)-1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-amine (252)
To a solution of 344 (0.2 g, 0.985 mmol) in acetonitrile (15 mL) was added 4-methoxyaniline
(145.58 mg, 1.18 mmol) and the resulting mixture refluxed for 8 hours. The solvent was removed
under reduced pressure to obtain a crude solid that was purified via column chromatography
eluting with a mixture of hexane and EtOAc 4:1 to give a white solid 252 (128 mg, 45%). TLC Rf
= 0.25 (Hexane: EtOAc, 1:1); mp, 118-120.2 oC; 1H NMR (500 MHz, DMSO-d6) δ 9.08 (s, 1H,
exch., N7-H), 8.02 (s, 1H, Ar), 7.50 (d, J = 9.3 Hz, 2H, Ar), 7.02 (d, 2H J = 9.3 Hz, Ar), 4.35 (s,
3H, N1-CH3), 3.79 (s, 3H, -OCH3). Anal. Calcd. for C13H12ClN5O: C, 53.89; H, 4.18; Cl, 12.24;
N, 24.17. Found: C, 53.80; H, 4.16; Cl, 12.31; N, 24.23.

1-(5-chloro-1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-6-methoxy-1,2,3,4tetrahydroquinoline (253)
To a solution of 344 (0.25 g, 1.23 mmol) in acetonitrile (15 mL) was added 6-methoxy-1,2,3,4tetrahydroquinoline (241.18 mg, 1.48 mmol) and the resulting mixture was refluxed for 12 hours.
The solvent was removed under reduced pressure to obtain a crude solid that was purified via
column chromatography eluting with a mixture of hexane and EtOAc to give an off-white solid
253 (162 mg, 40%). TLC Rf = 0.28 (Hexane: EtOAc, 3:1); mp, 162.4-164.3 °C, 1H NMR (400
MHz, DMSO-d6) δ 8.12 (s, 1H, Ar), 6.93 (d, J = 3.0 Hz, 1H, Ar), 6.74 (dd, J = 8.2 Hz, J = 3.0 Hz
1H, Ar), 6.70 (d, J = 8.2 Hz, 1H, Ar), 3.94-3.83 (m, 2H, -CH2), 3.75 (s, 3H, -OCH3), 3.21 (s, 3H,
N1-CH3), 2.85 – 2.78 (m, 2H, -CH2), 2.08 – 1.99 (m, 2H, -CH2). Anal. Calcd. for C16H16ClN5O
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0.11 CH3(CH2)4CH3: C, 58.99; H, 5.22; Cl, 10.44; N, 20.63. Found: C, 58.95; H, 5.07; Cl, 10.24;
N, 20.60.
5-chloro-N-(4-ethoxyphenyl)-N,1-dimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-amine (257)
To a solution of 344 (0.2 g, 0.985 mmol) in acetonitrile (15 mL) was added 4-ethoxy-Nmethylaniline (178.75 mg, 1.18 mmol) and the resulting mixture was refluxed for 10 hours. The
solvent was removed under reduced pressure to obtain a crude solid that was purified via column
chromatography eluting with a mixture of hexane and EtOAc to give off white solid 257 (131.5
mg, 42%). TLC Rf = 0.55 (Hexane: EtOAc, 3:1); mp, 144-146 °C; 1H NMR (500 MHz, DMSOd6) δ 8.04 (s, 1H, Ar), 7.21(d, J= 9.0 Hz, 2H. Ar), 6.98 (d, J= 9.0 Hz, 2H, Ar), 4.04 (q, J = 6.9 Hz,
2H, -OCH2CH3), 3.48 (s, 3H, N7-CH3), 3.03 (s, 3H, N1-CH3), 1.32 (t, J = 6.9 Hz, 3H, -OCH2CH3).
Anal. Calcd. for C15H16ClN5O: C, 56.69; H, 5.08; Cl, 11.16; N, 22.04. Found: C, 56.76; H, 5.18;
Cl, 11.07; N, 21.91.

5-chloro-N-(4-isopropoxyphenyl)-N,1-dimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-amine (258)
TLC Rf = 0.42 (Hexane: EtOAc, 3:1); mp, 162-163.8 °C; 1H NMR (500 MHz, DMSO-d6) δ 8.05
(s, 1H, Ar), 7.21 (d, J = 9.0 Hz, 2H, Ar), 6.98 (d, J = 9.0 Hz, 2H, Ar), 4.76 – 4.51 (m, 1H, OCH(CH3)2), 3.49 (s, 3H, N7-CH3), 3.05 (s, 3H, N1-CH3), 1.27 (d, J = 7.4 Hz, 6H, -OCH(CH3)2).
Anal. Calcd. for C16H18ClN5O 0.11 CH3(CH2)4CH3: C, 58.61; H, 5.76; Cl, 10.39; N, 20.54. Found:
C, 58.36; H, 5.70; Cl, 10.13; N, 20.34.
5-chloro-N-(5-methoxynaphthalen-2-yl)-N,1-dimethyl-1H-pyrazolo[4,3-d]pyrimidin-7amine (261)
To a solution of 344 (0.15 g, 0.738 mmol) in acetonitrile (12 mL) was added 5-methoxy-Nmethylnaphthalen-2-amine (166 mg, 0.886 mmol) was and the resulting mixture was refluxed for
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12 hours. The solvent was removed under reduced pressure to obtain a crude solid that was purified
via column chromatography eluting with a mixture of hexane and EtOAc to give pale yellow solid
261 (104 mg, 40%). TLC Rf = 0.50 (Hexane: EtOAc, 3:1); mp, 178-180.2 °C, 1H NMR (500 MHz,
DMSO-d6) δ 8.20 (d, J = 9.0 Hz, 1H, Ar), 8.10 (s, 1H, Ar), 7.68 (d, J = 2.3 Hz, 1H, Ar), 7.51 (dd,
J = 9.0, 2.3 Hz, 1H, Ar), 7.43 (d, J = 7.8 Hz, 1H, Ar), 7.40 – 7.27 (m, 1H, Ar), 6.98 (d, J = 7.8 Hz,
1H, Ar), 3.97 (s, 3H, -OCH3), 3.63 (s, 3H, N7-CH3), 2.92 (s, 3H, N1-CH3). Anal. Calcd. for
C18H16ClN5O: C, 61.11; H, 4.56; Cl, 10.02; N, 19.79. Found: C, 61.19; H, 4.53; Cl, 9.89; N, 19.53.

5-chloro-N,1-dimethyl-N-(4-(methylthio)phenyl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine
(262)
To a solution of 344 (0.15 g, 0.738 mmol) in acetonitrile (15 mL) was added N-methyl-4(methylthio)aniline (135.86 mg, 0.886 mmol) and the resulting mixture was refluxed for 12 hours.
The solvent was removed under reduced pressure to obtain a crude solid that was purified via
column chromatography eluting with a mixture of hexane and EtOAc to give yellow solid 262 (85
mg, 36%). TLC Rf = 0.40 (Hexane: EtOAc, 3:1); mp, 140 °C; 1H NMR (400 MHz, DMSO-d6) δ
8.09 (s, 1H, Ar), 7.31 (d, J = 8.5 Hz, 2H, Ar), 7.24 (d, J = 8.5 Hz, 2H, Ar), 3.52 (s, 3H, N7-CH3),
3.09 (s, 3H, N1-CH3), 2.49 (s, 3H, -SCH3). Anal. Calcd. for C14H14ClN5S 0.06 CH3(CH2)4CH3:
C, 53.11; H, 4.62; Cl, 10.89; N, 21.52, S, 9.85. Found: C, 53.21; H, 4.52; Cl, 10.81; N, 21.67, S,
9.79.
5-chloro-N-(3-fluoro-4-methoxyphenyl)-N,1-dimethyl-1H-pyrazolo[4,3-d]pyrimidin-7amine (263)
To a solution of 344 (0.2 g, 0.985 mmol) in acetonitrile (15 mL) was added 3-fluoro-4-methoxyN-methylaniline (183.43 mg, 1.18 mmol) and the resulting mixture was refluxed for 12 hours. The

247

solvent was removed under reduced pressure to obtain a crude solid that was purified via column
chromatography eluting with a mixture of hexane and EtOAc (10:1) to give pale yellow solid 263
(146 mg, 46%). TLC Rf = 0. 5 (Hexane: EtOAc, 3:1); mp, 172-173.7 °C; 1H NMR (400 MHz,
DMSO-d6) δ 6.94 (d, J=3.0 Hz, 1H, Ar), 6.38-6.26 (m, 2H, Ar), 5.50 (s, 1H, Ar), 3.70 (s, 3H, OCH3), 3.48 (s, 3H, N7-CH3), 2.61 (s, 3H, N1-CH3). The compound was not sent for biological
evaluation and requires further characterization.

2-amino-5-iodonicotinonitrile (353)
To a stirred solution of 2-aminonicotinonitrile 345 (2.0 g, 16.79 mmol) in acetonitrile (15 mL) and
acetic acid (10 mL), N-Iodosuccinimide (NIS) (3.78 g, 16.79 mmol) was added. The mixture was
heated overnight to 80 °C. Sodium sulfite (4.23 g, 33.58 mmol) was added at room temperature
and then the solution was heated to 80°C for 1 h. The crude mixture was diluted in CH 2Cl2, then
washed with water and the organic layer was basified to pH 10 with NaOH 6N and dried over
Na2SO4. The solvent was removed under pressure and the residue was purified by chromatography
(CHCl3: MeOH 40:1) to yield 353 as yellow orange solid (2.96 g, 72%). TLC Rf = 0. 76 (CHCl3:
MeOH, 20:1); mp, 99-101.5°C; 1H NMR (400 MHz, DMSO-d6) δ 8.35 (d, J = 2.3 Hz, 1H, Ar),
8.19 (d, J = 2.3 Hz, 1H, Ar), 7.11 (s, 2H, exch., -NH2). Anal. Calcd. for C12H9N3S: C, 63.41; H,
3.99; N, 18.49; S, 14.11. Found: C, 63.19; H, 4.02; N, 18.47; S, 13.87.

General Procedure for the Synthesis of Compounds 282-289
To a stirred solution of Cs2CO3 (1.1 eq.) in DMF were added 2-amino-5-iodonicotinonitrile (1 eq.),
thiols (1.2 eq.), CuI (0.5 eq.) and picolinic acid (0.1 eq.). The mixture was heated 12-24 hours to
100°C and monitored by TLC until reaction was completed. The crude mixture was cooled to room
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temperature and copper salts were filtered on celite. The filtrate was diluted in CH 2Cl2 and washed
three times with a saturated solution of LiCl and the organic layer was dried over Na 2SO4. The
solvent was removed under pressure and the residue was purified by chromatography to yield 348
and 354-360 in 58-70% yield. Without further characterization 348 and 354-360,
chloroformamidine hydrochloride (1 g), and dimethyl sulfone (4.0 g) were heated in an oil bath at
140 °C under nitrogen for 2-4 hours. The reaction was cooled to room temperature, and water (10
mL) was added slowly to the reaction mixture. The aqueous phase was made basic to pH 10 with
ammonium hydroxide, followed by extraction with chloroform (3 × 5 mL). The chloroform extract
was dried overnight with Na2SO4 and reduced under pressure. The residue was dissolved in a
mixture of 50:50 methanol-acetone (v/v), and silica gel was added (3.0 g). After the removal of
solvent with a rotary evaporator, the silica gel plug was loaded onto a column and eluted with 10:1
CHCl3-MeOH (v/v). The fractions containing the required compound were evaporated under
reduced pressure to afford the targeted compounds 282-289 in 36-64% yield.

6-(phenylthio)pyrido[2,3-d]pyrimidine-2,4-diamine (282)
To a stirred solution of Cs2CO3 (731.36 mg, 2.24 mmol) in DMF were added 2-amino-5iodonicotinonitrile (500 mg, 2.04 mmol), thiophenol (269.79 mg, 2.45 mmol), picolinic acid
(25.12 mg, 0.204 mmol), and copper iodide (194.32 mg, 1.02 mmol). The mixture was heated
overnight to 100 °C. General procedure was followed for workup procedure to yield 348 as light
orange solid (260 mg, 56%). TLC Rf = 0.36 (hexane: EtOAc, 3:1). Compound 348 was used in
the next reaction, without further separation or characterization efforts. Compound 348 (200 mg,
0.879 mmol) was heated at 140 oC with chlorformamidine hydrochloride (405 mg, 3.52 mmol), and
dimethyl sulfone (2.0 g) for 2 hours to yield 282 as yellow solid (95 mg, 40% yield). TLC Rf = 0.36
(CHCl3: MeOH: NH4OH 20: 1: 1); mp, 174.5-178.2 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.68 (d, J
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= 2.4 Hz, 1H, Ar), 8.64 (d, J = 2.4 Hz, 1H, Ar), 7.68 (s, 2H, exch., -NH2), 7.32 (t, J= 7.3 Hz, 2H, Ar),
7.21 (t, J= 7.3 Hz, 1H, Ar), 7.18 – 7.13 (m, 2H, Ar), 6.65 (s, 2H, exch., -NH2). Anal. Calcd. for
C13H11N5S 0.24 H2O: C, 57.04; H, 4.23; N, 25.59, S, 11.71. Found: C, 57.17; H, 4.24; N, 25.38, S,
11.54.

6-((3-methoxyphenyl)thio)pyrido[2,3-d]pyrimidine-2,4-diamine (283)
To a stirred solution of Cs2CO3 (585.09 mg, 1.80 mmol) in DMF were added 2-amino-5iodonicotinonitrile (400 mg, 1.63 mmol), 3-methoxybenzenethiol (274.65 mg, 1.96 mmol),
picolinic acid (20.10 mg, 0.163 mmol), and copper iodide (155.45 mg, 0.816 mmol). The mixture
was heated overnight to 100 °C. General procedure was followed for workup procedure to yield
354 as yellow solid (260 mg, 62%). TLC Rf = 0.63 (hexane: EtOAc, 1:1). Compound 354 was
used in the next reaction, without further separation or characterization efforts. Compound 354 (250
mg, 0.971 mmol) was heated at 140 oC with chlorformamidine hydrochloride (446 mg, 3.89 mmol),
and dimethyl sulfone (2 g) for 4 hours to yield 283 as a yellow solid (119 mg, 41%). TLC Rf = 0.30
(CHCl3:MeOH: NH4OH 10:1:1 ); mp, 167-169.8 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.68 (d, J =
2.6 Hz, 1H, Ar), 8.65 (d, J = 2.6 Hz, 1H, Ar), 7.68 (s, 2H, exch., -NH2), 7.25-7.20 (m, 1H, Ar), 6.75
(s, 2H, exch., -NH2), 6.78-6.75 (m, 1H, Ar), 6.70-6.68 (m, 1H, Ar), 6.67-6.65 (m, 1H, Ar), 3.76 (s, 3H,
-OCH3). Anal. Calcd. for C14H13N5OS 0.52 H2O: C, 54.46; H, 4.56; N, 22.68; S, 10.38. Found: C,
54.61 H, 4.38; N, 22.30; S, 10.27.

6-((4-methoxyphenyl)thio)pyrido[2,3-d]pyrimidine-2,4-diamine (284)
To a stirred solution of Cs2CO3 (511.95 mg, 1.57 mmol) in DMF were added 2-amino-5iodonicotinonitrile (350 mg, 1.43 mmol), 4-methoxybenzenethiol (240.32 mg, 1.71 mmol),
picolinic acid (17.6 mg, 0.142 mmol), and copper iodide (136 mg, 0.714 mmol). The mixture was
heated overnight to 100°C. General procedure was followed for workup procedure to yield 355 as
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yellow solid (235 mg, 64%). TLC Rf = 0.61 (hexane: EtOAc, 1:1). Compound 355 was used in
the next reaction, without further separation or characterization efforts. Compound 355 (200 mg,
0.777 mmol) was heated at 140 oC with chlorformamidine hydrochloride (357.41 mg, 3.11 mmol), and
dimethyl sulfone (2 g) for 4 hours to yield 284 as yellow solid (93 mg, 40%). TLC Rf = 0.35
(CHCl3:MeOH: NH4OH 10:1:1 ); mp, 170-172 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.26 (d, J= 2.4
Hz,1H, Ar), 8.02 (d, J= 2.4 Hz,1H, Ar), 7.65 (s, 2H, exch., -NH2), 7.27 (d, J= 8.8 Hz, 2H, Ar), 6.93 (d,
J= 8.8 Hz, 2H, Ar), 6.59 (s, 2H, exch., -NH2), 3.80 (s, 3H, -OCH3). Anal. Calcd. for C14H13N5OS 0.09
CHCl3: C, 54.58; H, 4.26; N, 22.59; S, 10.34. Found: C, 54.56 H, 4.40; N, 22.60; S, 10.34.

6-((3,4-dimethoxyphenyl)thio)pyrido[2,3-d]pyrimidine-2,4-diamine (285)
To a stirred solution of Cs2CO3 (585.09 mg, 1.80 mmol) in DMF were added 2-amino-5iodonicotinonitrile (400 mg, 1.63 mmol), 3,4-dimethoxybenzenethiol (333.47 mg, 1.96 mmol),
picolinic acid (20.10 mg, 0.163 mmol), and copper iodide (155.45 mg, 0.816 mmol). The mixture
was heated overnight to 100°C. General procedure was followed for workup procedure to yield
356 as yellow solid (272 mg, 58%). TLC Rf = 0.45 (hexane: EtOAc, 1:1). Compound 356 was
used in the next reaction, without further separation or characterization efforts. Compound 356
(220 mg, 0.765 mmol) was heated at 140 oC with chlorformamidine hydrochloride (352 mg, 3.06
mmol), and dimethyl sulfone (2 g) for 4 hours to yield 285 as yellow solid (90 mg, 36%). TLC Rf

=

0.55 (CHCl3:MeOH: NH4OH 10:1:1 ); mp, 186 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.65-8.59 (m,
2H, Ar), 7.66 (s, 2H, exch., -NH2), 7.02-6.92 (m, 2H, Ar), 6.87-6.78 (m, 1H, Ar), 6.59 (s, 2H, exch., NH2), 3.74 (s, 6H, -OCH3). Anal. Calcd. for C15H15N5O2S 0.17 CHCl3: C, 52.05; H, 4.37; N, 20.00; S,
9.16. Found: C, 52.06; H, 4.41; N, 19.96; S, 9.17.
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6-((4-fluorophenyl)thio)pyrido[2,3-d]pyrimidine-2,4-diamine (286)
To a stirred solution of Cs2CO3 (511.95 mg, 1.57 mmol) in DMF were added 2-amino-5iodonicotinonitrile (350 mg, 1.43 mmol), 4-fluorobenzenethiol (219.69 mg, 1.71 mmol), picolinic
acid (17.6 mg, 0.143 mmol), and copper iodide (136 mg, 0.714 mmol). The mixture was heated
overnight to 100°C. General procedure was followed for workup procedure to yield 357 as yellow
solid (227 mg, 65%). TLC Rf = 0.34 (hexane: EtOAc, 3:1). Compound 357 was used in the next
reaction, without further separation or characterization efforts. Compound 357 (200 mg, 0.815
mmol) was heated at 140 oC with chlorformamidine hydrochloride (374.95 mg, 3.26 mmol), and
dimethyl sulfone (2 g) for 4 hours to yield 286 as yellow solid (138 mg, 59%). TLC Rf = 0.22 (CHCl3:
MeOH: NH4OH 20:1:1); mp, 189.2-192.1 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.72 (d, J = 2.6 Hz,
1H, Ar), 8.62 (d, J = 2.6 Hz, 1H, Ar), 7.73 (s, 2H, exch., -NH2), 7.29 – 7.25 (m, 2H, Ar), 7.20-7.16 (m,
2H, Ar), 6.62 (s, 2H, exch., -NH2). Anal. Calcd. for C13H10FN5S 0.03 CHCl3: C, 53.72; H, 3.47; F,
6.52; N, 24.03; S, 11.00. Found: C, 53.83; H, 3.48; F, 6.35; N, 23.85; S, 11.03.

6-((4-(trifluoromethoxy)phenyl)thio) pyrido[2,3-d]pyrimidine-2,4-diamine (287)
To a stirred solution of Cs2CO3 (585 mg, 1.80 mmol)

in DMF were added 2-amino-5-

iodonicotinonitrile (400 mg, 1.63 mmol), 4-(trifluoromethoxy)benzenethiol (380.38 mg, 1.96
mmol), picolinic acid (20.10 mg, 0.163 mmol), and copper iodide (155.45 mg, 0.816 mmol). The
mixture was heated overnight to 100°C. General procedure was followed for workup procedure to
yield 358 as pale-yellow solid (350 mg, 69%). TLC Rf = 0.32 (hexane: EtOAc, 3:1). Compound
358 was used in the next reaction, without further separation or characterization efforts. Compound
358 (150 mg, 0.481 mmol) was heated at 140 oC with chlorformamidine hydrochloride (221.58
mg, 1.93 mmol), and dimethyl sulfone (2.0 g) for 4 hours to yield 287 as a light yellow solid (108
mg, 64%). TLC Rf = 0.63 (CHCl3: MeOH: NH4OH 20:1:1); mp, 191 °C; 1H NMR (400 MHz,
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DMSO-d6) δ 8.70 (d, J = 2.5 Hz, 1H, Ar), 8.67 (d, J = 2.5 Hz, 1H, Ar), 7.68 (s, 2H, exch., -NH2),
7.33 (d, J = 8.5 Hz, 2H, Ar), 7.26 (d, J = 8.5 Hz, 2H, Ar), 6.67 (s, 2H, exch., -NH2). Anal. Calcd.
for C14H10F3N5OS 0.17 CH3OH 0.06 HCl: C, 47.11; H, 3.00; F, 15.77; N, 19.38, S, 8.87. Found:
C, 47.11; H, 3.02; F, 15.78; N, 19.38, S, 8.89.

6-(naphthalen-1-ylthio)pyrido[2,3-d]pyrimidine-2,4-diamine (288)
To a stirred solution of Cs2CO3 (365.68 mg, 1.12 mmol) in DMF were added 2-amino-5iodonicotinonitrile (250 mg, 1.02 mmol), naphthalene-1-thiol (196.19 mg, 1.22 mmol), picolinic
acid (12.56 mg, 0.102 mmol), and copper iodide (97.16 mg, 0.510 mmol). The mixture was heated
overnight to 100°C. General procedure was followed for workup procedure to yield 359 as offwhite solid (198 mg, 70%). TLC Rf = 0.4 (hexane: EtOAc, 3:1). Compound 359 was used in the
next reaction, without further separation or characterization efforts. Compound 359 (150 mg, 0.504
mmol) was heated at 140 oC with chlorformamidine hydrochloride (249 mg, 2.16 mmol), and
dimethyl sulfone (2.0 g) for 4 hours to yield 288 as off-white solid (105 mg, 61%). TLC Rf = 0.20
(CHCl3: MeOH: NH4OH 20:1:1); mp, 226.5-228 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.70 (d, J
= 2.3 Hz, 1H, Ar), 8.63 (d, J = 2.3 Hz, 1H, Ar), 8.33 (d, J = 8.3 Hz, 1H, Ar), 8.06 – 7.94 (m, 1H,
Ar), 7.85 (d, J = 8.3 Hz, 1H, Ar), 7.69 – 7.64 (m, 2H, Ar), 7.61 (s, 2H, exch., -NH2), 7.44 (t, J =
7.8 Hz, 1H, Ar), 7.30 – 7.13 (m, 1H, Ar), 6.62 (s, 2H, exch., -NH 2). Anal. Calcd. for C17H13N5S
0.68 CH3OH: C, 62.25; H, 4.64; N, 20.54; S, 9.40. Found: C, 61.98; H, 4.35; N, 20.70; S, 9.49.

6-(naphthalen-2-ylthio)pyrido[2,3-d]pyrimidine-2,4-diamine (289)
To a stirred solution of Cs2CO3 (321.80 mg, 0.987 mmol) in DMF were added 2-amino-5iodonicotinonitrile (220 mg, 0.897 mmol), naphthalene-2-thiol (172.64 mg, 1.08 mmol), picolinic
acid (11.05 mg, 0.089 mmol), and copper iodide (85.5 mg, 0.449 mmol). The mixture was heated
253

overnight to 100°C. General procedure was followed for workup procedure to yield 360 as offwhite solid (169 mg, 68%). TLC Rf = 0.41 (hexane: EtOAc, 3:1). Compound 360 was used in the
next reaction, without further separation or characterization efforts. Compound 360 (120 mg, 0.432
mmol) was heated at 140 oC with chlorformamidine hydrochloride (200 mg, 1.74 mmol), and
dimethyl sulfone (2.0 g) for 4 hours to yield 289 as off-white solid (82 mg, 60%). TLC Rf = 0.18
(CHCl3: MeOH: NH4OH 20:1:1); mp, 220-221.8 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.72 (d, J
= 2.3 Hz, 1H, Ar), 8.70 (d, J = 2.3 Hz, 1H, Ar) 7.88 (d, J = 8.7 Hz, 2H, Ar), 7.84 – 7.77 (m, 1H,
Ar), 7.69 (s, 2H, exch., -NH2), 7.66 (d, J= 1.9 Hz, 1H, Ar), 7.53 – 7.44 (m, 2H, Ar), 7.32 (dd, J =
8.7, 1.9 Hz, 1H, Ar), 6.66 (s, 2H, exch., -NH2). Anal. Calcd. for C17H13N5S 0.06 CHCl3: C, 62.75;
H, 4.03; N, 21.45; S, 9.82. Found: C, 62.70; H, 4.22; N, 21.55; S, 9.82.

General procedure for synthesis of 364-365
In a 20 mL vial for microwave reaction were added a mixture of palladium chloride
triphenylphosphine, triethylamine, methyl 4-iodobenzoate 361, and anhydrous acetonitrile. To the
stirred mixture were added copper(I) iodide and appropriate alkyne alcohols 362-363 and the vial
was sealed and put into the microwave reactor at 100 oC for 10 min. Silica gel (5 g) was added,
and the solvent was evaporated under reduced pressure. The resulting plug was loaded on to a
silica gel column and eluted with Hexane followed by 20% EtOAc in Hexane. The desired fraction
(TLC) was collected, and the solvent was evaporated under reduced pressure to afford the target
compounds.
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Methyl 4-(3-hydroxyprop-1-yn-1-yl)benzoate (364)
Compound 364 was synthesized using the general method described for the preparation of 364365. Methyl 4-iodobenzoate 361 (2.8 g, 10.69 mmol) in a solution of acetonitrile (5 mL) in a
microwave reactor (10 mL) were mixed with PdCl 2 (75.8 mg, 0.427 mmol) and Ph3P (112.10 mg,
0.427 mmol) and stirred for 10 mins. Copper iodide (325.6 mg, 1.71 mmol), propargyl alcohol 362
(0.67 mL, 11.75 mmol) and Et3N (4.5 mL, 32.06 mmol) were added to the microwave vial and
reacted for 1h at 100 oC to give 364 as a yellow solid (1.83 g, 84%). TLC Rf = 0.36 (Hexane:
EtOAc, 3:1); mp, 90-91.6 ⁰C; 1H-NMR (400 MHz) (Me2SO-d6) δ 7.95 (d, J = 8.4 Hz, 2H, Ar),
7.57 (d, J = 8.4 Hz, 2H, Ar), 5.42 (s,1H, exch., -OH), 4.34 (s, 2H, -CH 2-), 3.86 (s, 3 H, -OCH3).
The 1H-NMR matched the 1H-NMR reported in the literature.230 Anal. Calcd. for C11H10O3: C,
69.46; H, 5.30. Found: C, 69.43; H, 5.28.

Methyl 4-(4-hydroxybut-1-yn-1-yl)benzoate (365)
Compound 365 was synthesized using the general method described for the preparation of 364365. Methyl 4-iodobenzoate 361 (2.5 g, 9.54 mmol) in a solution of acetonitrile in a microwave
reactor (10 mL) were mixed with PdCl2 (67.6 mg, 0.381 mmol) and Ph3P (100.09 mg, 0.381 mmol)
stirred for 10 mins. Copper iodide (290.7 mg, 1.53 mmol), but-3-yn-1-ol (0.8 mL, 10.49 mmol)
and Et3N ( 4.0 mL, 28.62 mmol) were added to the microwave vial and reacted for 1 hour at 100
o

C to give 365 as a yellow solid (1.68 g, 86%); TLC Rf = 0.45 (Hexane: EtOAc, 3:1); mp, 92-94.8

⁰C; 1H NMR (400 MHz, DMSO-d6) δ 7.87 (d, J = 8.3 Hz, 2H, Ar), 7.42 (d, J = 8.3 Hz, 2H, Ar),
4.44 (t, J = 4.79 Hz, 1H, exch., -OH), 3.83 (s, 3H, -OCH 3), 2.64 (t, J = 7.7 Hz, 2H, -CH2-), 1.67 –
1.54 (m, 2H, -CH2-). The 1H-NMR matched the 1H-NMR reported in the literature.230 Anal. Calcd.
for C12H12O3: C, 70.58; H, 5.92. Found: C, 70.31; H, 5.95.
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General procedure for synthesis of 366-367
To a Parr flask was added 364-365 10% palladium on activated carbon (50% w/w), and MeOH
(100 mL). Hydrogenation was carried out at 55 psi of H2 for 12 h. The reaction mixture was filtered
through Celite, washed with MeOH (100 mL), and concentrated under reduced pressure to give
crude mixture containing 366-367 as colorless liquid. Without chromatographic separation, these
compounds were used for the next reaction.

Methyl 4-(3-hydroxypropyl)benzoate (366)
Compound 366 was prepared using the general method described, from 364 (1.60 g, 8.41 mmol)
to give 1.32 g (81% yield) of 366 as a clear oil; TLC Rf = 0.15 (Hexane: EtOAc, 3:1); 1H-NMR
(400 MHz) (Me2SO-d6) 7.87 (d, J = 8.0 Hz, 2H, Ar), 7.35 (d, J = 8.0 Hz, 2H, Ar), 4.52 (s, 1H,
exch., -OH), 3.82 (s, 3 H, -OCH3), 3.42 (t, J = 6.44 Hz, 2H, -CH2-), 2.71-2.65 (m, 2H, -CH2-),
1.76-1.70 (m, 2H, -CH2-). This compound was used for the next reaction without further
characterization.

Methyl 4-(4-hydroxybutyl)benzoate (367)
Compound 367 was prepared using the general method described, from 365 (1.60 g, 7.83 mmol)
to give 1.26 g (83%) of 367 as a clear oil; TLC Rf = 0.20 (Hexane: EtOAc, 3:1); 1H-NMR (400
MHz) (Me2SO-d6) 7.94 (d, J = 8.0 Hz, 2H, Ar), 7.56 (d, J = 8.0 Hz, 2H, Ar), 4.41 (t, J = 4.79 Hz,
1H, exch., -OH), 3.85 (s, 3 H, -OCH3), 3.44-3.38 (m, 2H, -CH2), 2.65 (t, J =7.7 Hz, 2H, -CH2-),
1.66-1.56 (m, 2H, -CH2-), 1.46-1.38 (m, 2H, -CH2-). This compound was used for the next reaction
without further characterization.
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General procedure for synthesis of 368-369
To the alcohols 366-367 was added triethylamine (1 equivalent) and dichloromethane (25 mL).
The reaction was cooled to 0 ⁰C and purged with nitrogen gas. Under anhydrous conditions,
methanesulfonyl chloride (1.05 equivalent) was added dropwise over 30 minutes. The reaction
was stirred at room temperature for 2 hours and the reaction was added into sodium bicarbonate
solution (25 mL). The water layer was washed thrice with dichloromethane (100 mL). The
dichloromethane was evaporated to obtain a colorless liquid product. To the intermediate in
acetone, sodium iodide (1 equivalent) was added and refluxed for 8 hours. The reaction mixture
was filtered. The filtrate was evaporated to obtain 368-369.

Methyl 4-(3-iodopropyl)benzoate (368)
Compound 368 was prepared using the general method described from 366 (1 g, 5.15 mmol),
methanesulfonyl chloride (0.8 mL, 10.30 mmol) and triethylamine (1.65 mL, 11.84 mmol) to form
the intermediate. To this solution mixture sodium iodide (2.89 g, 19.28 mmol) was added and the
procedure was followed to give 1.0 g (64% yield in two steps) of 368 as a clear oil; TLC Rf = 0.60
(Hexane: EtOAc, 2:1); 1H-NMR (400 MHz) (Me2SO-d6) δ 7.90 (d, J = 8.0 Hz, 2H, Ar), 7.36 (d,
J = 8.0 Hz, 2H, Ar), 3.84 (s, 3 H, -OCH3), 3.24 (t, J = 6.4 Hz, 2H, -CH2-), 2.73 (t, J = 7.5 Hz, 2H,
-CH2-), 2.11-2.07 (m, 2H, -CH2-). This compound was used for the next reaction without further
characterization.

Methyl 4-(4-iodobutyl)benzoate (369)
Compound 369 was prepared using the general method described from 367 (1 g, 4.8 mmol),
methanesulfonyl chloride (0.74 mL, 9.60 mmol) and triethylamine (1.54 mL, 11.04 mmol) to form
the intermediate. To this sodium iodide (2.52 g, 16.80 mmol) was added and the procedure was
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followed to give 0.9 g (60% in two steps) of 369 as a clear oil; TLC Rf = 0.50 (Hexane: EtOAc,
2:1); 1H-NMR (500 MHz) (Me2SO-d6) δ 7.88 (d, J = 8.2 Hz, 2H, Ar), 7.34 (d, J = 8.2 Hz, 2H,
Ar), 3.83 (s, 3H, -OCH3), 3.30 (t, J = 6.7 Hz, 2H, -CH2-), 2.68 (t, J = 7.5 Hz, 2H, -CH2-), 1.81 –
1.73 (m, 2H, -CH2-), 1.72-1.64 (m, 2H, -CH2). This compound was used for the next reaction
without further characterization.

General procedure for synthesis of 370-373
In a solution of DMF or acetonitrile, Methyl 4-nitro-1H-pyrazole-5-carboxylate 374 was alkylated
using K2CO3 or Cs2CO3 with compound 368 and 369, respectively. The reaction was stirred for 12
hours at room temperature. The solvent was removed under vacuum and a silica gel plug was
made, and the crude material was purified by column chromatography using chloroform methanol
system to give 370-373. Structure of compound 371 was confirmed by x-ray crystallography which
finally allowed full assignment of the structures for both regioisomers 370 and 371.

Methyl 1-(3-(4-(methoxycarbonyl)phenyl)propyl)-4-nitro-1H-pyrazole-5-carboxylate (372)
Compound 372 was prepared using the general method described from 374 (2.0 g, 11.69 mmol)
and 368 (9.48 g, 31.17 mmol). A flash column chromatographic separation was performed using
chloroform methanol as eluent to afford intermediate 372 (1.18 g, 35% yield) as a white semisolid.; TLC Rf = 0.27 (CHCl3: MeOH: NH4OH, 20:1:0.05); 1H NMR (400 MHz, DMSO-d6) δ
8.42 (s, 1H, Ar), 7.89 (d, J = 8.20 Hz, 2H, Ar), 7.36 (d, J = 8.20 Hz, 2H, Ar), 4.29 (t, J = 6.6 Hz,
2H, -CH2-), 3.94 (s, 3H, -OCH3), 3.84 (s, 3H, -OCH3), 2.67 (t, J = 7.5 Hz, 2H, -CH2-), 2.20 – 2.11
(m, 2H, -CH2-). This compound was used for the next reaction without further characterization.
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Methyl 1-(3-(4-(methoxycarbonyl)phenyl)propyl)-4-nitro-1H-pyrazole-3-carboxylate (373)
Compound 373 was prepared using the general method described from 374 (2.0 g, 11.69 mmol)
and 368 (9.48 g, 31.17 mmol). A flash column chromatographic separation was performed using
chloroform methanol as eluent to afford intermediate 373 (2.23 g, 66% yield). TLC Rf = 0.12
(CHCl3: MeOH: NH4OH, 20:1:0.05); mp, 112-114 ⁰C; 1H NMR (400 MHz, DMSO-d6) δ 9.00 (s,
1H, Ar), 7.87 (d, J = 8.30 Hz, 2H, Ar), 7.35 (d, J = 8.30 Hz, 2H, Ar), 4.24 (t, J = 7.0 Hz, 2H, CH2-), 3.88 (s, 2H, -OCH3), 3.83 (s, 3H, -OCH3), 2.67 (t, J = 7.5 Hz, 2H, -CH2-), 2.21 – 2.14 (p,
J = 7.5 Hz, 2H, -CH2-). Anal. Calcd. for C17H19N3O6: C, 70.58; H, 5.92. Found: C, 70.31; H, 5.95.

Methyl 1-(4-(4-(methoxycarbonyl)phenyl)butyl)-4-nitro-1H-pyrazole-5-carboxylate (370)
Compound 370 was prepared using the general method described from 374 (2.5 g, 14.61 mmol)
and 369 (12.40 g, 38.96 mmol). A flash column chromatographic separation was performed using
chloroform methanol as eluent to afford intermediate 370 (1.4 g, 32% yield) as a white semi-solid.
TLC Rf = 0.32 (CHCl3: MeOH: NH4OH, 20:1:0.05); 1H NMR (400 MHz, DMSO-d6) δ 8.41 (s,
1H, Ar), 7.87 (d, J = 8.0 Hz, 2H, Ar), 7.33 (d, J = 8.0 Hz, 2H, Ar), 4.28 (t, J = 7.0 Hz, 2H, -CH2), 3.96 (s, 3H, -OCH3), 3.84 (s, 3H, -OCH3), 2.69 (t, J = 7.6 Hz, 2H, -CH2-), 1.81 (p, J = 7.4 Hz,
2H, -CH2-), 1.56 (p, J = 7.4 Hz, 2H, -CH2-). This compound was used for the next reaction without
further characterization.

Methyl 1-(4-(4-(methoxycarbonyl)phenyl)butyl)-4-nitro-1H-pyrazole-3-carboxylate (371)
Compound 371 was prepared using the general method described from 374 (2.5 g, 14.61 mmol)
and 369 (12.40 g, 38.96 mmol). A flash column chromatographic separation was performed using
chloroform methanol as eluent to afford intermediate 371 (2.8 g, 64% yield); TLC Rf = 0.16
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(CHCl3: MeOH, 20:1); mp, 136-137.8 ⁰C; 1H NMR (400 MHz, DMSO-d6) δ 9.02 (s, 1H, Ar), 7.88
(d, J = 8.0 Hz, 2H, Ar), 7.34 (d, J = 8.0 Hz, 2H, Ar), 4.24 (t, J = 6.8 Hz, 2H, -CH2-), 3.88 (s, 3H,
-OCH3), 3.84 (s, 3H, -OCH3), 2.65 (t, J = 7.5 Hz, 2H, -CH2-), 1.83 (p, J = 7.0 Hz, 2H, -CH2-), 1.56
(t, J = 7.5 Hz, 2H, -CH2-). Anal. Calcd. for C17H19N3O6 0.047 CHCl3: C, 55.79; H, 5.23; N, 11.45.
Found: C, 55.82; H, 5.38; N, 11.28.

General procedure for synthesis of 375-376 and 381-382
Compounds 375-376 and 381-382 were generated using general method. To a Parr flask was added
370-373, 10% palladium on activated carbon (50% w/w), and MeOH (100 mL). Hydrogenation
was carried out at 40 psi of H2 for 30 min. The reaction mixture was filtered through Celite, washed
with MeOH (40 mL) and chloroform (20 mL), and concentrated under reduced pressure to give
crude mixture containing 375-376 and 381-382. Without chromatographic separation, these
compounds were used for the next reaction.

Methyl 4-amino-1-(3-(4-(methoxycarbonyl)phenyl)propyl)-1H-pyrazole-5-carboxylate (375)
Compound 375 was prepared using the general method described from 372 (1.0 g, 2.88 mmol) by
catalytic reduction by H2 in MeOH at 40 psi. Intermediate 375 appeared as a yellow liquid (676
mg, 74% yield). TLC Rf = 0.25 (CHCl3: MeOH, 10:1); 1H NMR (400 MHz, DMSO-d6) δ 7.87 (d,
J = 8.3 Hz, 2H, Ar), 7.34 (d, J = 8.3 Hz, 2H, Ar), 7.05 (s, 1H, Ar), 5.04 (s, br, 2H, exch., -NH 2),
4.30 (t, J = 7.0 Hz, 2H, -CH2-), 3.83 (s, 3H, -OCH3), 3.76 (s, 3H, -OCH3), 2.59 (t, J = 7.7 Hz, 2H,
-CH2-), 2.01 – 1.86 (m, 2H, -CH2-). This compound was used for the next reaction without further
characterization.
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Methyl 4-amino-1-(3-(4-(methoxycarbonyl)phenyl)propyl)-1H-pyrazole-3-carboxylate (381)
Compound 381 was prepared using the general method described from 373 (2.0 g, 5.76 mmol) by
catalytic reduction by H2 in MeOH at 40 psi. Intermediate 381 appeared as a yellow liquid (1.33
g, 73% yield); TLC Rf = 0.24 (CHCl3: MeOH, 10:1); 1H NMR (400 MHz, DMSO-d6) δ 7.85 (d,
J = 8.4 Hz, 2H, Ar), 7.33 (d, J = 8.4 Hz, 2H, Ar), 7.62 (s, 1H, Ar), 5.01 (s, br, 2H, exch., -NH 2),
4.26 (t, J = 7.0 Hz, 2H, -CH2-), 3.81 (s, 3H, -OCH3), 3.75 (s, 3H, -OCH3), 2.58 (t, J = 7.6 Hz, 2H,
-CH2-), 2.00 – 1.85 (m, 2H, -CH2-). This compound was used for the next reaction without further
characterization.

Methyl 4-amino-1-(4-(4-(methoxycarbonyl)phenyl)butyl)-1H-pyrazole-5-carboxylate (376)
Compound 376 was prepared using the general method described from 370 (1.2 g, 3.32 mmol) by
catalytic reduction with H2 in MeOH at 40 psi. Intermediate 376 appeared as a yellow liquid (858
mg, 78% yield); TLC Rf = 0.32 (CHCl3: MeOH, 10:1); 1H NMR (500 MHz, DMSO-d6) δ 7.87
(d, J= 8.3, 2H, Ar), 7.29 (d, J= 8.3, 2H, Ar), 7.02 (s, 1H, Ar), 4.96 (s, br, 2H, exch., -NH2), 4.30
(t, J = 6.9 Hz, 2H, -CH2-), 3.82 (s, 3H, -OCH3), 3.77 (s, 3H, -OCH3), 2.64 (t, J = 7.5 Hz, 2H, CH2-), 1.72-1.60 (m, 2H, -CH2-), 1.54-1.41 (m, 2H, -CH2-). This compound was used for the next
reaction without further characterization.

Methyl 4-amino-1-(4-(4-(methoxycarbonyl)phenyl)butyl)-1H-pyrazole-3-carboxylate (382)
Compound 382 was prepared using the general method described from 371 (2.5 g, 6.92 mmol) by
catalytic reduction with H2 in MeOH at 40 psi. Intermediate 382 appeared as a yellow liquid (1.74
g, 76% yield). TLC Rf = 0.31 (CHCl3: MeOH, 10:1); 1H NMR (400 MHz, DMSO-d6) δ 7.87 (d,
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J = 8.2 Hz, 2H, Ar), 7.33 (d, J = 8.2 Hz, 2H, Ar), 7.17 (s, 1H, Ar), 4.70 (s, br, 2H, exch., -NH 2),
4.03 (t, J = 7.0 Hz, 2H, -CH2-), 3.83 (s, 3H, -OCH3), 3.75 (s, 3H, -OCH3), 2.65 (t, J = 7.7 Hz, 2H,
-CH2-), 1.74 (p, J = 7.6 Hz, 2H, -CH2-), 1.51 (p, J = 7.0, Hz, 2H, -CH2-). Anal. Calcd. for
C17H21N3O4 0.35 CHCl3: C, 55.75; H, 5.76; N, 11.25. Found: C, 55.72; H, 6.04; N, 11.43.

General procedure for synthesis of 377-378 and 383-384.
Compounds 377-378 and 383-384 were dissolved in MeOH (10 mL), and 1,3bis(methoxycarbonyl)-2-methyl-2-thiopseudourea (3.3 mmol) was added followed by AcOH (15
mmol). The mixture was stirred at room temperature overnight and became a thick paste. NaOMe
in MeOH (25%) (22 mmol) was added, and stirring was continued at room temperature overnight.
Column chromatography was performed to finally get the compounds 378 and 383-384.
Compound 377 was not characterized and requires further characterization.

Methyl 4-(4-(5-((methoxycarbonyl)amino)-7-oxo-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin1-yl)butyl)benzoate (378)
Compound 378 was prepared using the general method described from 376 (400 mg, 1.21 mmol)
and 375 appeared as yellow solid (255.8 mg, 48% yield in two steps); TLC Rf = 0.41 (CHCl3:
MeOH, 20:1); mp, 223-224.6 ⁰C; 1H NMR (500 MHz, DMSO-d6) δ 11.56 (s, br, 1H, exch., -NH),
10.81 (s, br, 1H, exch., -NH), 7.88 (d, J=8.2 Hz, 2H, Ar), 7.80 (s, 1H, Ar), 7.31 (d, J=8.2 Hz, 2H,
Ar), 4.31 (t, J = 6.9 Hz, 2H, -CH2-), 2.63 (t, J = 7.5 Hz, 2H, -CH2-), 3.82 (s, 3H, -OCH3), 1.861.77 (m, 2H, -CH2-), 1.69-1.60 (m, 2H, -CH2-), 1.49 (s, 9H, -CH3). Anal. Calcd. for C22H27N5O5
0.10 CH3(CH2)4CH3 0.23 CH3COOH: C, 59.70; H, 6.37; N, 15.08. Found: C, 59.71; H, 6.33; N,
15.07
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Methyl 4-(4-(5-((methoxycarbonyl)amino)-7-oxo-6,7-dihydro-2H-pyrazolo[4,3-d]pyrimidin2-yl)butyl)benzoate (383)
Compound 383 was prepared using the general method described from 381 (1 g, 3.15 mmol) and
383 appeared as light yellow solid (565.7 mg, 42% yield in two steps); TLC Rf = 0.38 (CHCl3:
MeOH, 20:1); mp, 210-212.1⁰C; 1H NMR (500 MHz, DMSO-d6) δ 7.96 (s, 1H, Ar), 7.88 (d, J =
8.3 Hz, 2H, Ar), 7.37 (d, J = 8.3 Hz, 2H, Ar), 4.27 (t, J = 6.9 Hz, 2H, -CH2-), 3.84 (s, 3H, -OCH3),
2.64 (t, J = 7.5 Hz, 2H, -CH2-), 2.22-2.12 (m, 2H, -CH2-), 1.68 (s, 9H, -CH3). This compound was
used for the next reaction without further characterization.

Methyl 4-(4-(5-((methoxycarbonyl)amino)-7-oxo-6,7-dihydro-2H-pyrazolo[4,3-d]pyrimidin2-yl)butyl)benzoate (384)
Compound 384 was prepared using the general method described from 382 (800 mg, 2.41 mmol)
and 384 appeared as yellow solid (522.2 mg, 49% yield in two steps); TLC Rf = 0.46 (CHCl 3:
MeOH, 20:1); mp, 218-219 ⁰C; 1H NMR (400 MHz, DMSO-d6) δ 11.30 (s, br, 1H, exch., -NH),
10.68 (s, br, 1H, exch., -NH), 8.15 (s, 1H, Ar), 7.87 (d, J=8.20 Hz, 2H, Ar), 7.34 (d, J=8.20 Hz,
2H, Ar), 4.32 (t, J = 6.9 Hz, 2H, -CH2-), 3.83 (s, 3H, -OCH3), 2.69 (t, J = 7.5 Hz, 2H, -CH2-), 1.87
(p, J = 7.2 Hz, 2H, -CH2-), 1.49 (p, J = 7.9 Hz, 2H, -CH2-), 1.51 (s, 9H, -CH3). Anal. Calcd. for
C22H27N5O5 0.97 CH3COOH: C, 57.53; H, 6.23; N, 14.01. Found: C, 57.46; H, 6.30; N, 14.10.
General procedure for synthesis of 379-380 and 385-386
The compounds of 379-380 and 385-386 from previous steps was added to 1 N NaOH (2 mL), and
the mixture was heated at 55 °C for 3 h. The mixture was cooled and acidified using 1 N
hydrochloric acid. The precipitate was collected and dried under. These acids were used for the
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next reaction without further characterization where in anhydrous DMF (10 mL) with the acid
intermediates were added N-methylmorpholine and 2-chloro-4,6-dimethoxy-1,3,5-triazine. The
resulting mixtures were stirred at room temperature for 2 h. To this mixture were added Nmethylmorpholine and L-glutamate diethyl ester hydrochloride. The reaction mixtures were stirred
for an additional 4 h at room temperature. Silica gel (400 mg) was then added, and the solvent was
evaporated under reduced pressure. The resulting plug was loaded on to a silica gel column with
5% MeOH in CHCl3 as the eluent. Fractions that showed the desired spot (TLC) were pooled and
the solvent evaporated to dryness to afford compounds 380 and 385-386. Compound 379 was not
characterized and requires further characterization.

Diethyl (4-(4-(5-amino-7-oxo-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-1-yl)butyl)benzoyl)L-glutamate (380)
Crude acid (220 mg, 0.672 mmol), were used for the next reaction without further characterization
where in anhydrous DMF (10 mL) with the acid intermediates were added N-methylmorpholine
(0.13 mL, 1.21 mmol), and 2-chloro-4,6-dimethoxy-1,3,5-triazine (212.40 mg, 1.21 mml). The
resulting mixtures were stirred at room temperature for 2 h. To this mixture were added Nmethylmorpholine (0.13 mL, 1.21 mmol), and L-glutamate diethyl ester hydrochloride (191.23
mg. 0.940 mmol). The reaction mixtures were stirred for an additional 4 h at room temperature to
get 380 in 68% yield (234.25 mg); mp: 238-240.1 oC; 1H NMR (400 MHz, DMSO-d6) δ 10.92 (s,
1H, exch., -NH), 8.66 (d, J = 7.5 Hz, 1H, exch., -NH), 7.78 (d, J = 8.1 Hz, 2H, Ar), 7.50 (s, 1H,
Ar), 7.26 (d, J = 8.1 Hz, 2H, Ar), 6.04 (s, 2H, exch., -NH2), 4.43-4.39 (m, 1H, α-CH), 4.45 (t, J =
6.9 Hz, 2H, -CH2-), 4.14 – 4.01 (m, 4H, -COOCH2CH3), 2.63 (t, J = 7.5 Hz, 2H, -CH2-), 2.44 (t, J
= 7.5 Hz, 2H, γ-CH2-), 2.13-1.97 (m, 2H, β-CH2-), 1.78 (p, J = 7.5 Hz, 2H, -CH2-), 1.49 (p, J = 7.9
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Hz, 2H, -CH2-), 1.26-1.12 (m, 6H, -COOCH2CH3). Anal. Calcd. for C25H32N6O6 0.57 CH3OH: C,
57.85; H, 6.51; N, 15.83. Found: C, 57.52; H, 6.47; N, 16.22.

Methyl 4-(4-(5-((methoxycarbonyl)amino)-7-oxo-6,7-dihydro-2H-pyrazolo[4,3-d]pyrimidin2-yl)butyl)benzoate (385)
Crude acid (250 mg, 0.797 mmol), were used for the next reaction without further characterization
where in anhydrous DMF (10 mL) with the acid intermediates were added N-methylmorpholine
(0.16 mL, 1.44 mmol), and 2-chloro-4,6-dimethoxy-1,3,5-triazine (252.6 mg, 1.44 mml). The
resulting mixtures were stirred at room temperature for 2 h. To this mixture were added Nmethylmorpholine (0.16 mL, 1.44 mmol), and L-glutamate diethyl ester hydrochloride (227.03
mg. 1.21 mmol). The reaction mixtures were stirred for an additional 4 h at room temperature to
get 385 in 62% yield (246.6 mg); mp: 228-230 oC; 1H NMR (400 MHz, DMSO-d6) δ 10.55 (s,
1H, exch., -NH), 8.68 (d, J = 7.5 Hz, 1H, exch., -NH), 7.88 (d, J = 8.2 Hz, 2H, Ar), 7.79 (s, 1H,
Ar), 7.34 (d, J = 8.2 Hz, 2H, Ar), 5.90 (s, 2H, exch., -NH2), 4.44-4.38 (m, 1H, α-CH), 4.23 (t, J =
6.9 Hz, 2H, -CH2-), 4.13-4.01 (m, 4H, -OCH2CH3), 2.68-2.64 (m, 2H, -CH2-), 2.61-2.55 (m, 2H,
-CH2-), 2.44 (t, J = 7.6 Hz, 2H, γ-CH2-), 2.20-2.13 (m, 2H, β-CH2-), 1.24-1.15 (m, 6H, -OCH2CH3).
MS (ESI) m/z calculated for C24H30N6O6 [M+H]+, 499.22. Found: 498.9. HPLC analysis: retention
time, 12.4 min; peak area, 95.68%; eluent A, H2O: eluent B, ACN; gradient elution (100% H2O to
10% H2O) over 60 min with flow rate of 0.5 mL/min and detection at 245 nm; column temperature,
rt.
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Methyl 4-(4-(5-((methoxycarbonyl)amino)-7-oxo-6,7-dihydro-2H-pyrazolo[4,3-d]pyrimidin2-yl)butyl)benzoate (386)
Crude acid (300 mg, 0.916 mmol), were used for the next reaction without further characterization
where in anhydrous DMF (10 mL) with the acid intermediates were added N-methylmorpholine
(0.18 mL, 1.65 mmol), and 2-chloro-4,6-dimethoxy-1,3,5-triazine (289.63 mg, 1.65 mml). The
resulting mixtures were stirred at room temperature for 2 h. To this mixture were added Nmethylmorpholine (0.18 mL, 1.65 mmol), and L-glutamate diethyl ester hydrochloride (260.77
mg. 1.28 mmol). The reaction mixtures were stirred for an additional 4 h at room temperature to
get 386 in 64% yield (300.6 mg); mp: 219-220.8 oC; 1H NMR (400 MHz, DMSO-d6) δ 10.56 (s,
1H, exch., -NH), 8.66 (d, J = 7.5 Hz, 1H, exch., -NH), 7.80 (d, J = 8.2 Hz, 2H, Ar), 7.77 (s, 1H,
Ar), 7.29 (d, J = 8.2 Hz, 2H, Ar), 5.91 (s, 2H, exch., -NH2), 4.45-4.38 (m, 1 H, α-CH), 4.23 (t, J =
6.9 Hz, 2H, -CH2-), 4.13-4.02 (m, 4H, -OCH2CH3), 2.66 (t, J = 7.5 Hz, 2H, -CH2-), 2.44 (t, J = 7.5
Hz, 2H, γ-CH2-), 2.13 – 1.96 (m, 2H, β-CH2-), 1.85-1.79 (p, J = 7.5 Hz, 2H, -CH2-), 1.57-1.48 (p,
J = 7.7 Hz, 2H, -CH2-), 1.20-1.15 (m, 6H, -OCH2CH3). Anal. Calcd. for C25H32N6O6 0.88 CH3OH:
C, 57.47; H, 6.62; N, 15.53. Found: C, 57.70; H, 6.41; N, 15.15.

General procedure for synthesis of 297-298 and 301-302.
The compounds 298 and 301-302 from previous steps was added to 1 N NaOH (2 mL), and the
hydrolyzed at room temperature for an hour. The mixture was cooled and acidified using 1 N
hydrochloric acid. The precipitate was collected and dried under vacuum. Compound 297 and 301
was not sent for biological evaluation and requires further characterization.
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(4-(4-(5-amino-7-oxo-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-1-yl)butyl)benzoyl)-Lglutamic acid (298)
Compound 380 (100 mg, 0.19 mmol) was dissolved in MeOH (2 mL) added 1N NaOH (2 mL)
and the mixture was stirred under N2 at room temperature for 10 h. TLC showed the disappearance
of the starting material and one major spot at the origin (CHCl 3:MeOH 5:1). The reaction mixture
was dissolved in water (10 mL), the resulting solution was cooled in an ice bath, and the pH was
adjusted to 3-4 with dropwise addition of 1N HCl. The resulting suspension was frozen in dry iceacetone bath, thawed to 4-5 °C in the refrigerator, and filtered. The residue was washed with a
small amount of cold water and dried in vacuum using P 2O5 to afford the target compound 298
(41.3 mg, yield 52%) as a white powder, Rf 0.18 (CHCl3:MeOH: NH4OH 5:1:0.5); mp, 182 °C;
1

H NMR (400 MHz, DMSO-d6) δ 12.46 (s, 2H, br., exch., -COOH), 8.53 (d, J = 8.2 Hz, 1H, exch.,

-NH), 7.78 (d, J = 8.2 Hz, 2H, Ar), 7.55 (s, 1H, Ar), 7.27 (d, J = 8.2 Hz, 2H, Ar), 6.62 (s, 2H,
exch., -NH2), 4.46 (t, J = 6.9 Hz, 2H, -CH2), 4.41-4.36 (m, 1 H, α-CH), 2.64 (t, J = 7.5 Hz, 2H, CH2-), 2.34 (t, J = 7.5 Hz, 2H, γ-CH2-), 2.12 – 1.90 (m, 2H, β-CH2-), 1.79 (p, J = 7.5 Hz, 2H, CH2-), 1.49 (p, J = 7.9 Hz, 2H, -CH2-). Anal. Calcd. for C21H24N6O6 0.41 CH3OH 0.37 HCl: C,
53.23; H, 5.43; N, 17.39. Found: C, 53.20; H, 5.55; N, 17.47.

(4-(4-(5-amino-7-oxo-6,7-dihydro-2H-pyrazolo[4,3-d]pyrimidin-2-yl)butyl)benzoyl)-Lglutamic acid (302)
Compound 386 (150 mg, 0.29 mmol) was dissolved in MeOH (2 mL) added 1N NaOH (2 mL)
and the mixture was stirred under N2 at room temperature for 10 h. TLC showed the disappearance
of the starting material and one major spot at the origin (CHCl 3:MeOH 5:1). The reaction mixture
was dissolved in water (10 mL), the resulting solution was cooled in an ice bath, and the pH was
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adjusted to 3-4 with dropwise addition of 1N HCl. The resulting suspension was frozen in dry iceacetone bath, thawed to 4-5 °C in the refrigerator, and filtered. The residue was washed with a
small amount of cold water and dried in vacuum using P 2O5 to afford the target compound 302
(82.8 mg, yield 62%) as a white powder, Rf 0.21 (CHCl3:MeOH 5:1); mp, 172 °C; 1H NMR (400
MHz, DMSO-d6) δ 12.72 (s, 2H, br., exch., -COOH), 10.63 (s, 1H, exch., -NH), 8.54 (d, J = 8.2
Hz, 1H, exch., -NH), 7.81 (d, J = 8.2 Hz, 2H, Ar), 7.76 (s, 1H, Ar), 7.28 (d, J = 8.2 Hz, 2H, Ar),
6.01 (s, 2H, exch., -NH2), 4.40-4.32 (m, 1 H, α-CH), 4.23 (t, J = 6.9 Hz, 2H, -CH2-), 2.65 (t, J =
7.5 Hz, 2H, -CH2-), 2.34 (t, J = 7.5 Hz, 2H, γ-CH2-), 2.10 – 1.90 (m, 2H, β-CH2-), 1.86-1.75 (m,
2H, -CH2-), 1.59-1.46 (m, 2H, -CH2-). Anal. Calcd. for C21H24N6O6 0.76 HCl: C, 52.08; H, 5.15;
N, 17.35. Found: C, 52.07; H, 5.41; N, 17.33.

4-(3-fluoro-4-(methoxycarbonyl)phenoxy)butanoic acid (398)
To 100 mL round bottom flask was added a mixture of compound 399 (3.0 g, 13.45 mmol), cesium
carbonate (6.41 g, 19.67 mmol), TBAI (8.23 g, 22.28 mmol) and anhydrous DMF (20 mL).
Compound 390 (1.71 g, 10.03 mmol) was added dropwise to the mixture. The reaction mixture
was then stirred at room temperature for 2 h at 100 oC. Ethyl acetate was added into the reaction
mixture. Combined mixture was washed with two portions of water. After evaporation of solvent
under reduced pressure MeOH (20 mL) was added followed by silica gel (1 g). The resulting plug
was loaded on to a silica gel column and eluted with 1:10 (ethylacetate:hexane). Fractions with
and Rf =0.91 (TLC) (hexane:ethylacetate, 1:1) were pooled and evaporated to afford tert-butyl
ester 400 (2.07 g, yield; 66%) as a colorless liquid. 1H NMR (500 MHz, DMSO-d6) δ 7.83 (t, J =
8.8 Hz, 1H, Ar), 6.92 (dd, J = 13.2, 2.5 Hz, 1H, Ar), 6.87 (dd, J = 8.8, 2.5 Hz, 1H, Ar), 4.07 (t, J
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= 6.4 Hz, 2H, -CH2-), 3.81 (s, 3H, -OCH3), 2.36 (t, J = 7.4 Hz, 2H, -CH2-), 1.94 (p, J= 7.0 Hz, 2H,
-CH2-), 1.40 (s, 9H, -CH3). Without further characterization trifluoroacetic acid was then added
into 400 and mixture was stirred at room temperature in DCM. Excess of trifluoroacetic acid was
evaporated and MeOH (20 mL) was added followed by silica gel (1 g). The resulting plug was
loaded on to a silica gel column and eluted with 1:10 (ethylacetate:hexane). Fractions with and Rf
= 0.48 (TLC) (Hexane:ethylacetate, 1:1) were pooled and evaporated to afford 398 (1.36 g, yield
80%) as white solid, Rf = 0.45 (Hexane:EtOAc, 1:1); mp, 118 C; 1H NMR (400 MHz, DMSO-d6)
δ 12.19 (s, 1H, exch., COOH), 7.84 (t, J = 8.8 Hz, 1H, Ar), 6.94 (dd, J = 13.2, 2.4 Hz, 1H, Ar),
6.88 (dd, J = 8.8, 2.4 Hz, 1H, Ar), 4.08 (t, J = 6.4 Hz, 2H, -CH2-), 3.81 (s, 3H, -OCH3), 2.38 (t, J
= 7.3 Hz, 2H, -CH2-), 1.96 (p, J = 7.0 Hz, 2H, -CH2-). This compound was used for the next
reaction without further characterization.

Methyl 4-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)propoxy)-2fluorobenzoate (389)
To 398 (3.20 g, 12.49 mmol) in a 250 mL flask was added oxalyl chloride (9.51 g, 74.93 mmol)
and anhydrous CH2Cl2 (20 mL). The resulting solution was refluxed for 1 hour and then cooled to
room temperature. After the solvent was evaporated under reduced pressure, the residue was
dissolved in 20 mL of Et2O. The resulting solution was added dropwise to an ice cooled
diazomethane (generated in situ from 10 g of Diazald® by using Aldrich Mini Diazald® apparatus)
in an ice bath over 10 min. The resulting mixture was allowed to stand for 30 min and then stirred
for an additional 1 hour. To this solution was added 48% HBr (20 mL). The resulting mixture was
refluxed for 1.5 h. After the mixture was cooled to room temperature, the organic layer was
separated, and the aqueous layer was extracted with Et 2O (2 X 200 mL). The combined organic
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layer and Et2O extract was washed with two portions of 10% Na2CO3 solution and dried over
Na2SO4. Evaporation of the solvent afforded 403 in 92% yield (2.70 g). To a suspension of 2,6diaminopyrimidin-4-one 393 (1.11 g, 10 mmol) in anhydrous DMF (25 mL) was added 403 (8.46
mmol). The resulting mixture was stirred under N2 at room temperature for 3 days. After
evaporation of solvent under reduced pressure, MeOH (20 mL) was added followed by silica gel
(5 g). The resulting plug was loaded on to a silica gel column and eluted with CHCl 3 followed by
3% MeOH in CHCl3 and then 5% MeOH in CHCl3. Fractions (CHCl3:CH3OH, 5:1) were pooled
and evaporated to afford 389 (640 mg, yield 21%) as light orange solid. TLC Rf = 0.40
(CHCl3:MeOH: NH4OH, 5:1:0.5); mp, 175-176 °C 1H NMR (500 MHz, DMSO-d6) δ 10.91 (s,
1H, exch., 7-NH), 10.19 (s, 1H, exch., 3-NH), 7.86 (t, J = 8.8 Hz, 1H, Ar), 6.95 (dd, J = 13.1, 2.5
Hz, 1H, Ar), 6.89 (dd, J = 8.8, 2.5 Hz, 1H, Ar), 6.02 (s, 2H, exch., -NH2), 5.91 (s, 1H, C5-CH, Ar),
4.07 (t, J = 6.4 Hz, 2H, -CH2-), 3.81 (s, 3H, -OCH3), 2.65 (t, J = 7.4 Hz, 2H, -CH2-), 2.04 (p, J =
7.0 Hz, 2H, -CH2-). This compound was used for the next reaction without further characterization.

(4-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)propoxy)-2fluorobenzoyl)-L-glutamic acid (305)
Compound 389 (300 mg, 0.86 mmol) was dissolved in MeOH (10 mL) added 1N NaOH (10 mL)
and the mixture was stirred under N2 at room temperature for 10 h. TLC showed disappearance of
the starting material and one major spot at the origin (CHCl 3:MeOH 5:1). The reaction mixture
was dissolved in water (10 mL), the resulting solution was cooled in an ice bath, and the pH was
adjusted to 3-4 with drop wise addition of 1N HCl. The resulting suspension was frozen in dry iceacetone bath, thawed to 4-5 °C in the refrigerator, and filtered. The residue was washed with a
small amount of cold water and dried in vacuum using P 2O5 to afford the compound 387 (173 mg,
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yield 60%) as yellow solid, Rf 0.20 (5:1 CHCl3: MeOH). This compound was used for the next
reaction without further characterization. To a 250 mL round bottom flask, was added a mixture
of compound 387 (150 mg, 0.43 mmol), N-methylmorpholine (0.78 mmol), 2-chloro-4,6dimethoxy-1,3,5-triazine (0.79 mmol) and anhydrous DMF (10 mL). The resulting mixture was
stirred at room temperature under anhydrous condition for 1.5 h. N-methylmorpholine (0.79 mmol)
and L-glutamate di-tert-butyl hydrochloride 388 (123.24 mg, 0.61 mmol) were added in reaction
mixture. The resulting mixture was then stirred at room temperature under anhydrous condition
for 12 h. After evaporation of solvent under reduced pressure, MeOH (20 mL) was added followed
by silica gel (1 g). The resulting plug was loaded on to a silica gel column and eluted with CHCl3
followed by 1% MeOH in CHCl3. Fractions with Rf = 0.60 (CHCl3:CH3OH, NH4OH, 5:1:0.5)
were pooled and evaporated to afford 404 (142 mg, yield 62%) as a brown sticky solid. Compound
404 (120 mg, 0.22 mmol) was dissolved in MeOH (10 mL) added 1N NaOH (10 mL) and the
mixture was stirred under N2 at room temperature for 10 h. TLC showed the disappearance of the
starting material and one major spot at the origin (CHCl3:MeOH 5:1). The reaction mixture was
dissolved in water (10 mL), the resulting solution was cooled in an ice bath, and the pH was
adjusted to 3-4 with dropwise addition of 1N HCl. The resulting suspension was frozen in dry iceacetone bath, thawed to 4-5 °C in the refrigerator, and filtered. The residue was washed with a
small amount of cold water and dried in vacuum using P 2O5 to afford the target compound 305
(58.8 mg, yield 55%) as a white powder, Rf 0.15 (CHCl3:MeOH:NH4OH, 5:1:0.5); mp, 148-149.2
°C; 1H NMR (500 MHz, DMSO-d6) δ 10.89 (s, 1H, exch., 7-NH), 10.36 (s, 1H, exch., 3-NH), 7.96
(dd, J = 9.3 Hz, 6.1 Hz, 1H, exch., -CONH), 7.78 (t, J = 8.8 Hz, 1H, Ar), 6.91 (dd, J = 13.2, 2.4
Hz, 1H, Ar), 6.87 (dd, J = 8.8, 2.4 Hz, 1H, Ar), 6.10 (s, 1H, exch., -NH2), 5.90 (s, 1H, C5-CH, Ar),
4.18-4.12 (m, 1H, α-CH), 4.05 (t, J = 6.4 Hz, 2H, -CH2-), 2.65 (t, J = 7.4 Hz, 2H, -CH2-), 2.34-
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2.13 (m, 2H, γ-CH2-), 2.11-2.02 (m, 2H, β-CH2-), 2.05-1.95 (m, 2H, -CH2-). MS (ESI) m/z
calculated for C21H22FN5O7 [M+H]+, 476.15. Found: 475.6. HPLC analysis: retention time, 8.32
min; peak area, 97.57%; eluent A, H2O: eluent B, ACN; gradient elution (100% H2O to 10% H2O)
over 60 min with flow rate of 0.5 mL/min and detection at 245 nm; column temperature, rt.

Docking protocol for molecular modeling single agents with combination chemotherapy and
multiple RTK inhibitory potential:
Docking of target compounds was carried out in the published X-ray crystal structure of colchicine
in tubulin (PDB: 6BS2, 2.65 Å)327, axitinib in VEGFR-2 (PDB: 4AG8, 1.95 Å)329 gefitinib in
EGFR (PDB: 4WKQ, 1.85 Å)340, and in the homology model of PDGFR-β294 using Schrodinger
Maestro 2020-1.156 The crystal structure of tubulin, VEGFR-2 and EGFR were obtained from the
protein database and imported into Schrödinger Maestro. All the compounds were redocked with
an RMSD (root-mean-square deviation) of 0.89 and 0.91 for the best-scored pose, thus validating
the docking process. All docking procedures were performed using various modules of
Schrödinger Maestro suite (Schrödinger, LLC, New York, NY, 2020). The polypeptide structures
of in tubulin, EGFR, VEGFR-2 and the homology model of PDGFR-β were optimized and
prepared for docking using the Maestro Protein Preparation Wizard to assess bond order and
missing hydrogens, followed by energy minimization using the OPLS3e force field. Gaps in the
protein structures were not corrected as they were far from the active site. The Maestro inducedfit Grid Generation module was then used to define a 15 × 15 × 15 Å grid from the center of all
the ligands. Ligands used in the computational docking study were built using the Maestro 2D
Build module. The Maestro LigPrep module was then used to generate conformers of each
compound subjected to energy minimization using the OPLS3e force field protocol. The resulting
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compounds were docked into the prepared tubulin, EGFR, VEGFR-2 and the homology model of
PDGFR-β structures using the Maestro Induced Fit Docking. Induced Fit Docking was performed
with standard precision with flexible ligand sampling. A total of 20 initial poses were generated
for each compound. Based on the pose score, the top 4 poses were selected and subjected to energy
minimization using the OPLS3e force field. Finally, the top 2 poses per compound were generated
and ranked according to Glide score, which is an approximation of binding energy defined by
receptor-ligand complex energies. The top pose of specific compounds were analyzed and
presented in the statement of the problem. Docked scores are listed in Table 33 and Table 34.
Table 33. Docked scores of proposed compounds in colchicine site of tubulin, EGFR, VEGFR-2
and PDGFR-β for series I-VII

183
182
196
197
204
218
219
220
225
227
184
226
228
185
198
199
205
221
222
223
229
189
CA-4

Tubulin
(kcal/mol)
-10.68
-11.49
-11.32
-11.30
-11.55
-11.96
-11.94
-11.75
-12.22
-11.58
-11.62
-12.02
-11.62
-11.78
-12.05
-12.15
-12.36
-12.18
-12.32
-12.12
-11.70
-11.42
-9.18

EGFR
(kcal/mol)
-8.36
-9.15
-8.98
-8.95
-9.11
-9.16
-9.12
-9.04
-9.20
-8.81
-9.02
-9.01
-8.86
-9.28
-9.12
-9.08
-9.10
-9.18
-9.15
-9.04
-8.82
-9.05
-8.62
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VEGFR-2
(kcal/mol)
-12.25
-13.21
-13.02
-12.98
-13.20
-13.25
-13.15
-13.01
-13.46
-12.84
-13.11
-13.16
-12.75
-13.26
-13.14
-13.02
-13.21
-13.25
-13.22
-12.96
-13.45
-13.18
-12.71

PDGFR-β
(kcal/mol)
-7.91
-8.30
-8.11
-8.06
-8.31
-8.25
-8.21
-8.10
-8.38
-7.98
-8.26
-8.35
-7.94
-8.42
-8.26
-8.05
-8.50
-8.28
-8.20
-8.10
-8.02
-8.52
-7.86

Table 34. Docked scores of proposed compounds in colchicine site of tubulin for series VIII-XIV
Compounds
234
244
247
236
245
248
238
246
239
240

251
252
257
258
253
261
262
263
CA-4
Colchicine

Docked scores in tubulin
(kcal/mol)
-12.08
-12.23
-12.24
-11.97
-12.02
-11.38
-11.95
-12.05
-11.83
-11.28
-11.23
-10.74
-11.26
-11.05
-11.16
-11.02
-11.18
-9.20
-9.18
-13.28

Docking protocol for molecular modeling of selective pjDHFR inhibitors
Docking of target compounds was carried out using the published X-ray crystal structure of N6methyl-N6-(3,4,5-trifluorophenyl)pyrido[3,2-d]pyrimidine-2,4,6-triamine

in

hDHFR

(PDB:

4QJC, 1.62 Å)362 and in the homology model of pjDHFR362 using Schrödinger Maestro suite
(Schrödinger, LLC, New York, NY, 2020).156 The crystal structure of hDHFR (PDB: 4QJC, 1.62
Å) was obtained from the protein database and imported into Schrodinger Maestro. All the
compounds were redocked with an RMSD (root-mean-square deviation) of 0.89 and 0.91 for the
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best-scored pose, thus validating the docking process. All docking procedures were performed
using various modules of Schrödinger Maestro suite. The polypeptide structures hDHFR and the
homology model of pjDHFR were optimized and prepared for docking using the Maestro Protein
Preparation Wizard to assess bond order and missing hydrogens, followed by energy minimization
using the OPLS3e force field. Gaps in the protein structures were not corrected as they were far
from the active site. The Maestro induced-fit Grid Generation module was then used to define a
15 × 15 × 15 Å grid from the center of all the ligands. Ligands used in the computational docking
study were built using the Maestro 2D Build module. The Maestro LigPrep module was then used
to generate conformers of each compound subjected to energy minimization using the OPLS3e
force field protocol. The resulting compounds were docked into the prepared hDHFR and the
homology model of pjDHFR structures using the Maestro Induced Fit Docking. Induced Fit
Docking was performed with standard precision with flexible ligand sampling. A total of 20 initial
poses were generated for each compound. Based on the pose score, the top 4 poses were selected
and subjected to energy minimization using the OPLS3e force field. Finally, the top 2 poses per
compound were generated and ranked according to Glide score, which is an approximation of
binding energy defined by receptor-ligand complex energies. The validation of Schrödinger
Maestro as a suitable docking system for pjDHFR and hDHFR was carried out by re-docking the
native ligands in the x-ray crystal structures of hDHFR (PDB: 4QJC) and homology model of
pjDHFR. The best docked pose of the ligands had RMSD of 0.7065 Å in pjDHFR and 0.8802 Å
in hDHFR. The top pose of specific compounds were analyzed and presented in the statement of
the problem. Docking scores are listed in Table 35.
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Table 35. Docked scores of proposed compounds in homology model of pjDHFR and X-ray
crystal structure of hDHFR
hDHFR (kcal/mol)

pjDHFR (kcal/mol)

282

-8.74

-10.35

283

-8.81

-10.45

284

-7.95

-10.64

285

-8.80

-10.85

286

-8.53

-10.55

287

-8.04

-10.32

288

-9.15

-10.72

289

-9.22

-10.86

TMP

-7.97

-8.90

PTX

-8.80

-9.36

Docking protocol for molecular modeling of single agents with tumor targeting via cellular
uptake by Folate Receptors and/or Proton-Coupled Folate Transporter and inhibition of de
novo purine nucleotide biosynthesis:
The X-ray crystal structures of human FRα bound to AGF183 (PDB: 5IZQ, 3.60 Å)190,
FRβ bound to PMX (PDB: 4KN2, 2.60 Å)388, human GARFTase bound to AGF150 (PDB: 4ZZ1,
1.35 Å)211 and human AICARFTase (PDB: 1P4R, 2.55 Å)219 were obtained from the protein
database. Docking studies were performed using Schrödinger Maestro suite 2020-1. 156 The
polypeptide structures of FRα, FRβ, GARFTase, AICARFTase and SHMT2 were optimized and
prepared for docking using the Maestro Protein Preparation Wizard to assess bond order and
missing hydrogens, followed by energy minimization using the OPLS3e force field. Gaps in the
protein structures were not corrected as they were far from the active site. The Maestro induced276

fit Grid Generation module was then used to define a 15 × 15 × 15 Å grid from the center of all
the ligands. Ligands used in the computational docking study were built using the Maestro 2D
Build module. The Maestro LigPrep module was then used to generate conformers of each
compound subjected to energy minimization using the OPLS3e force field protocol. The resulting
compounds were docked into the prepared FRα, FRβ, GARFTase, AICARFTase and SHMT2
using the Maestro Induced Fit Docking. Induced Fit Docking was performed with standard
precision with flexible ligand sampling. A total of 20 initial poses were generated for each
compound. Based on the pose score, the top 4 poses were selected and subjected to energy
minimization using the OPLS3e force field. Finally, the top 2 poses per compound were generated
and ranked according to Glide score, which is an approximation of binding energy defined by
receptor-ligand complex energies. The validation of Schrödinger Maestro as a suitable docking
system for FRα, FRβ, GARFTase, AICARFTase and SHMT2 was carried out by re-docking the
native ligands in the x-ray crystal structures of FRα, FRβ, GARFTase, AICARFTase and SHMT2.
The best pose of AGF183 in FRα had an RMSD of 0.96 Å. PMX in FRβ had an RMSD of 0.89
Å, AGF150 in the human GARFTase had an RMSD of 1.15 Å, and ((S)-(4-((2-amino-4hydroxyquinazoline)-6-sulfonamido)phenyl)(hydroxy)methyl)-L-glutamic acid in the human
AICARFTase had an RMSD of 1.10 Å. Thus, Schrödinger Maestro 2020-1 was validated for our
docking purposes in FRα, FRβ, GARFTase, AICARFTase and SHMT2. The top pose of specific
compounds were analyzed and presented in the statement of the problem. Docking scores are listed
in Table 36.
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Table 36. Docked scores of proposed compounds in crystal structures of FRα, FRβ, GARFTase
and AICARFTase
FRα

FRβ

GARFTase

AICARFTase SHMT2

(kcal/mol)

(kcal/mol)

(kcal/mol)

(kcal/mol)

(kcal/mol)

297

-14.98

-15.14

-14.02

-10.55

-10.16

298

-15.22

-15.38

-14.33

-10.68

-10.55

301

-15.14

-15.03

-14.96

-10.92

-9.35

302

-15.32

-15.11

-15.12

-11.16

-9.48

305

-15.16

-15.10

-15.38

-11.29

-9.52
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VI. SUMMARY
This dissertation describes the design and synthesis of single agents with combination
chemotherapy and multiple RTK inhibitory potential, selective pjDHFR inhibitors, and single
agents with tumor targeting via cellular uptake by Folate Receptors and Proton-Coupled
Folate Transporter and inhibition of de novo purine nucleotide biosynthesis. The novel
compounds synthesized as part of this study are listed below:
1. N-(4-methoxyphenyl)-N,2-dimethylthieno[2,3-d]pyrimidin-4-amine (182)
2. N-(4-methoxyphenyl)- 2-methylthieno[2,3-d]pyrimidin-4-amine (183)
3. N,2-dimethyl-N-(4-(methylthio) phenyl)thieno[2,3-d]pyrimidin-4-amine (184)
4. 4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)-2-methylthieno[2,3-d]pyrimidine (185):
5. N-(5-methoxynaphthalen-2-yl)-N,2-dimethylthieno[2,3-d]pyrimidin-4-amine (189)
6. N-(4-methoxyphenyl)-N-methylthieno[2,3-d]pyrimidin-4-amine (196)
7. N4-(4-methoxyphenyl)-N4-methylthieno[2,3-d]pyrimidine-2,4-diamine (197)
8. 4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)thieno[2,3-d]pyrimidine (198)
9. 4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)thieno[2,3-d]pyrimidin-2-amine (199)
10. 2-chloro-N-(4-methoxyphenyl)-N-methylthieno[2,3-d]pyrimidin-4-amine (204)
11. 2-chloro-4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)thieno[2,3-d]pyrimidine (205)
12. N-(4-methoxyphenyl)-N,2,5- trimethylthieno[2,3-d]pyrimidin-4-amine (218)
13. 2-chloro-N-(4-methoxyphenyl)-N,5-dimethylthieno[2,3-d]pyrimidin-4-amine (219)
14. N4-(4-methoxyphenyl)-N4,5-dimethylthieno[2,3-d]pyrimidine-2,4-diamine (220)
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15. 4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl) -2,5-dimethylthieno[2,3-d]pyrimidine (221)
16. 2-chloro-4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)-5-methylthieno[2,3-d]pyrimidine
(222)
17. 4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)-5-methylthieno[2,3-d]pyrimidin-2-amine
(223)
18. N-(4-methoxyphenyl)-N,2,5,6-tetramethylthieno[2,3-d]pyrimidin-4-amine (225)
19. N,2,5,6-tetramethyl-N-(4-(methylthio)phenyl)thieno[2,3-d]pyrimidin-4-amine (226)
20. N-(4-methoxyphenyl)-2,5,6-trimethylthieno[2,3-d]pyrimidin-4-amine (227)
21. 2,5,6-trimethyl-N-(4-(methylthio)phenyl)thieno[2,3-d]pyrimidin-4-amine (228)
22. 7-methoxy-4-(2,5,6-trimethylthieno[2,3-d]pyrimidin-4-yl)-3,4-dihydro-2Hbenzo[b][1,4]oxazine (229)
23. Methyl 3-amino-4-benzyl-1H-pyrrole-2-carboxylate (323)
24. 4-chloro-2-methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine (328)
25. 2-methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one (329)
26. Ethyl 2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate (330)
27. 7-benzyl-N-(4-methoxyphenyl)-N-methyl-5H-pyrrolo[3,2-d]pyrimidin-4-amine (232)
28. N-(4-methoxyphenyl)-N,2-dimethyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin4-amine (234)
29. N,2-dimethyl-N-(4-(methylthio)phenyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3d]pyrimidin-4-amine (236)
30. 4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)-2-methyl-5,6,7,8tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine (238)
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31. N-(5-methoxynaphthalen-2-yl)-N,2-dimethyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3d]pyrimidin-4-amine (239)
32. 2-amino-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one (336)
33. N-(4-chloro-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-2-yl)pivalamide (337)
34. N4-(4-methoxyphenyl)-N4-methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine2,4-diamine (244)
35. N4-methyl-N4-(4-(methylthio)phenyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]
pyrimidine-2,4-diamine (245)
36. 4-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)-5,6,7,8- tetrahydrobenzo [4,5]thieno[2,3-d]
pyrimidin-2-amine (246)
37. N-(4-methoxyphenyl)-N-methyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4amine (247)
38. N-methyl-N-(4-(methylthio)phenyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin4-amine (248)
39. 5-chloro-N-(4-methoxyphenyl)-N,1-dimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-amine
(251)
40. 5-chloro-N-(4-methoxyphenyl)-1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-amine (252)
41. 1-(5-chloro-1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-6-methoxy-1,2,3,4tetrahydroquinoline (253)
42. 5-chloro-N-(4-ethoxyphenyl)-N,1-dimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-amine (257)
43. 5-chloro-N-(4-isopropoxyphenyl)-N,1-dimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-amine
(258)
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44. 5-chloro-N-(5-methoxynaphthalen-2-yl)-N,1-dimethyl-1H-pyrazolo[4,3-d]pyrimidin-7amine (261)
45. 5-chloro-N,1-dimethyl-N-(4-(methylthio)phenyl)-1H-pyrazolo[4,3-d]pyrimidin-7-amine
(262)
46. 5-chloro-N-(3-fluoro-4-methoxyphenyl)-N,1-dimethyl-1H-pyrazolo[4,3-d]pyrimidin-7amine (263)
47. 6-(phenylthio)pyrido[2,3-d]pyrimidine-2,4-diamine (282)
48. 6-((3-methoxyphenyl)thio)pyrido[2,3-d]pyrimidine-2,4-diamine (283)
49. 6-((4-methoxyphenyl)thio)pyrido[2,3-d]pyrimidine-2,4-diamine (284)
50. 6-((3,4-dimethoxyphenyl)thio)pyrido[2,3-d]pyrimidine-2,4-diamine (285)
51. 6-((4-fluorophenyl)thio)pyrido[2,3-d]pyrimidine-2,4-diamine (286)
52. 6-((4-(trifluoromethoxy)phenyl)thio) pyrido[2,3-d]pyrimidine-2,4-diamine (287)
53. 6-(naphthalen-1-ylthio)pyrido[2,3-d]pyrimidine-2,4-diamine (288)
54. 6-(naphthalen-2-ylthio)pyrido[2,3-d]pyrimidine-2,4-diamine (289)
55. Methyl 1-(3-(4-(methoxycarbonyl)phenyl)propyl)-4-nitro-1H-pyrazole-5-carboxylate
(372)
56. Methyl 1-(3-(4-(methoxycarbonyl)phenyl)propyl)-4-nitro-1H-pyrazole-3-carboxylate
(373)
57. Methyl 1-(4-(4-(methoxycarbonyl)phenyl)butyl)-4-nitro-1H-pyrazole-5-carboxylate
(370)
58. Methyl 1-(4-(4-(methoxycarbonyl)phenyl)butyl)-4-nitro-1H-pyrazole-3-carboxylate
(371)
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59. Methyl 4-amino-1-(3-(4-(methoxycarbonyl)phenyl)propyl)-1H-pyrazole-5-carboxylate
(375)
60. Methyl 4-amino-1-(3-(4-(methoxycarbonyl)phenyl)propyl)-1H-pyrazole-3-carboxylate
(381)
61. Methyl 4-amino-1-(4-(4-(methoxycarbonyl)phenyl)butyl)-1H-pyrazole-5-carboxylate
(376)
62. Methyl 4-amino-1-(4-(4-(methoxycarbonyl)phenyl)butyl)-1H-pyrazole-3-carboxylate
(382)
63. Methyl 4-(4-(5-((methoxycarbonyl)amino)-7-oxo-6,7-dihydro-1H-pyrazolo[4,3d]pyrimidin-1-yl)butyl)benzoate (378)
64. Methyl 4-(4-(5-((methoxycarbonyl)amino)-7-oxo-6,7-dihydro-2H-pyrazolo[4,3d]pyrimidin-2-yl)butyl)benzoate (383)
65. Methyl 4-(4-(5-((methoxycarbonyl)amino)-7-oxo-6,7-dihydro-2H-pyrazolo[4,3d]pyrimidin-2-yl)butyl)benzoate (384)
66. Diethyl (4-(4-(5-amino-7-oxo-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-1yl)butyl)benzoyl)-L-glutamate (380)
67. Methyl 4-(4-(5-((methoxycarbonyl)amino)-7-oxo-6,7-dihydro-2H-pyrazolo[4,3d]pyrimidin-2-yl)butyl)benzoate (385)
68. Methyl 4-(4-(5-((methoxycarbonyl)amino)-7-oxo-6,7-dihydro-2H-pyrazolo[4,3d]pyrimidin-2-yl)butyl)benzoate (386)
69. (4-(4-(5-amino-7-oxo-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-1-yl)butyl)benzoyl)-Lglutamic acid (298)
70. (4-(3-(5-amino-7-oxo-6,7-dihydro-2H-pyrazolo[4,3-d]pyrimidin-2-yl)propyl)benzoyl)-Lglutamic acid (301)
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71. (4-(4-(5-amino-7-oxo-6,7-dihydro-2H-pyrazolo[4,3-d]pyrimidin-2-yl)butyl)benzoyl)-Lglutamic acid (302)
72. 4-(3-fluoro-4-(methoxycarbonyl)phenoxy)butanoic acid (398)
73. Methyl 4-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)propoxy)-2fluorobenzoate (389)
74. (4-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)propoxy)-2fluorobenzoyl)-L-glutamic acid (305)
Proposed compounds from the Series I-VII were evaluated for activity against
microtubule assembly, EGFR, VEGFR-2 and PDGFR-β. The results revealed an extensive
SAR for thieno[2,3-d]pyrimidine. The SAR for 2,4,5, and 6-position of the scaffold is distinct
for thieno[2,3-d]pyrimidines and the effects of a substitution on one scaffold cannot be
extrapolated to another. Compound 185 was active across all the three angiokinases and was
comparable to erlotinib and sunitinib in inhibition of EGFR and VEGFR-2, respectively and
20-fold higher than sunitinib in inhibition of PDGFRβ. It shows an excellent inhibition of all
the four targets (microtubule assembly, EGFR, VEGFR-2 and PDGFR-β) and significant
improvement in reduction of tumor growth, compared to the positive control- gemcitabine.
Proposed compounds from the Series VIII-XI evaluated for activity against
microtubule assembly. The results revealed an extensive SAR for tricyclic thieno[2,3d]pyrimidine. The SAR for 2- and 4-position of the scaffold is distinct from bicyclic
thieno[2,3-d]pyrimidine. Compound 244 was the active most compound in anti-proliferative
assay and showed significant improvement in reduction of tumor growth, compared to the
positive control-paclitaxel.
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Proposed compounds from the Series XII-XIV evaluated for activity against
microtubule assembly. The results revealed an extensive SAR for pyrazolo[4,3-d]pyrimidine.
The SAR for 4-position of the scaffold is impressively significant. Compound 251 was one of
the active most compound in inhibition of colchicine binding and inhibition of tubulin
assembly and showed significant improvement in reduction of tumor growth, compared to the
positive control-paclitaxel.
Proposed compounds from Series XV-XVII were evaluated biologically against
pjDHFR and hDHFR enzymes. The evaluation results and hDHFR crystal structures with
some of the proposed compounds show the importance of targeting amino acid differences
between pjDHFR and hDHFR. Our attempts to obtain a compound similar in selectivity of
TMP and higher in potency than TMP led to compounds 283 and 284, 289. Based on the
medicinal chemistry approach of carrying out bioisosteric replacement and studying the active
site, compounds were obtained with significantly increased potency and/or selectivity.
Biological evaluation of proposed compounds from Series XVIII-XX were carried out
in engineered CHO cell lines overexpressing RFC, PCFT, FRα and FRβ. One of the aims for
this study was to obtain compounds with selective uptake through FRα and FRβ, compared to
RFC. Majority of the proposed compounds showed a selective transport through FRα and FRβ
over RFC. Hence, we were able to successfully incorporate selectivity for FRα and FRβ by
performing as scaffold-hopping from the pyrrolo[3,2-d]pyrimidines. The investigation of the
intracellular targets suggests that there is (are) additional intracellular target(s) than
GARFTase and/or AICARFTase that the compounds bind to and inhibit.
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VII. APPENDIX
A. Biological evaluation of Single agents with combination chemotherapy and multiple RTK
inhibitory potential
The biological evaluations reported in this section were performed by Dr. Michael Ihnat
(Department of Pharmaceutical Sciences, University of Oklahoma College of Pharmacy,
Oklahoma City, OK 73117), Dr. Ernest Hamel (Screening Technologies Branch, Developmental
Therapeutics Program, Division of Cancer Treatment and Diagnosis, Frederick National
Laboratory for Cancer Research, National Cancer Institute, Frederick, MD 21702), Dr. Susan
Mooberry (Department of Pharmacology, University of Texas Health Science Center at San
Antonio, San Antonio, TX 78229) and National Cancer Institute (Developmental Therapeutics
Program).
A1. Biological evaluation of 2, 4-substituted thieno[2,3-d]pyrimidines
(a) Activity as MTAs
The EC50 (concentration required to cause 50% loss of cellular microtubules) was
determined in A-10 cells.112 The effects of the compounds on interphase and mitotic microtubules
were evaluated using indirect immunofluorescence techniques, and the EC 50 values were
calculated from a minimum of three experiments.99 Antiproliferative effects were evaluated
against the drug sensitive MDA-MB-435 melanoma cells using sulforhodamine B assay and the
IC50 values (concentration required to cause 50% inhibition of proliferation) were calculated. 99
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Table 37. Effects in cellular assays and on purified tubulin for Series I-IV (ND= not determined)

R1

R2

R3

R4

183

CH3

H

H

H

182

CH3

H

H

196

H

H

197

NH2

204

IC50 ± SD in MDA- EC50
for
Microtubule
435 Cells (nM)
Depolymerization in A·10 Cells (nM)
ND

>10 µM

CH3

8.6 ± 1.1

15.4

H

CH3

H

H

CH3

13.1 ± 1.4
11.0 ± 1.2

80
46.8

Cl

H

H

CH3

6.3 ± 0.5

23

218

CH3

CH3

H

CH3

2.1 ± 0.2

2.5

219

Cl

CH3

H

CH3

2.0 ± 0.3

2.3

220

NH2

CH3

H

CH3

4.3 ± 0.3

7.5

225

CH3

CH3

CH3

CH3

227

CH3

CH3

CH3

H

10.7 ± 1.0
ND

18
>10 µM

184

CH3

H

H

CH3

4.0 ± 0.5

10

226

CH3

CH3

CH3

CH3

228

CH3

CH3

CH3

H

34.8 ± 3.7
ND

128
>10 µM

185

CH3

H

H

-

4.2 ± 0.3

8.0

198

H

H

H

-

14.3 ± 1.9

40

199

NH2

H

H

-

9.5 ± 0.5

15.2

205

Cl

H

H

-

1.5 ± 0.3

2.41

221

CH3

CH3

H

-

9.2 ± 1.3

12.2

222

Cl

CH3

H

-

16.8 ± 2.2

19.9

223

NH2

CH3

H

-

7.4 ± 1.0

12.9

229

CH3

CH3

CH3

-

202 ± 23

1.2 µM

189

CH3

H

H

CH3

CA-4

-

-

-

-

3.9 ± 0.2
3.4 ± 0.6

5.5
9.8
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Biological evaluation of 182-189, 196-199, 204-205, 218-223 and 225-229 enabled a SAR
on the thieno[2,3-d]pyrimidine scaffold. An electron withdrawing substituent at the 2-position
showed an improvement in inhibition of tubulin depolymerization (Table 37). The activity trend
for 2-postion was Cl>CH3>NH2> H. Varying aryl group at the 4-position on the thieno[2,3d]pyrimidine scaffold did not create a significant impact on the inhibition of tubulin assembly.
Next, the effects of methyl group at 5-poition was evaluated. The most striking effect was seen on
comparison of 5-H (182, 204, 197) and 5-CH3 (218, 219, 220) compounds. Comparing the IC50s
of 182 (2-CH3, 5-H) vs. 218 (2-CH3, 5-CH3); 204 (2-Cl, 5-H) vs. 219 (2-Cl, 5-CH3) and 197 (2NH2, 5-H) vs. 220 (2-NH2, 5-CH3), the 5-CH3 substitution exhibits an increase in IC50 values from
3- to 4-fold.

Figure 111. Possible steric clash between N4-CH3 and 5-H in 182; and N4-CH3 and 5-CH3 in 218
The improvement in the microtubule depolymerization activity of the 5-CH 3 compounds
(218, 219, 220) compared to 5-H compounds (182, 204, 197) can be explained by studying the
stable solution conformations of 218 and 183, using 1HNMR. This solution conformation of 182
is possibly due to steric clash between 5-H and N4-CH3. This clash is further reinforced in 218 by
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steric clash between 5-CH3 and N4-CH3 (Figure 111). On the other hand, 5-CH3 compounds (221,
222, 223) compared to 5-H compounds (185, 205, 199) had almost 2-fold less potency. The 5,6dimethyl substituted compounds (225-229) compared to desmethyl compounds (182-185) were
not conducive to microtubule depolymerization activity. The biological evaluation of 225 (Table
37) had comparable potency to 182, and on the other hand, compound 226 causes 8-fold decrease
in antiproliferative activity against MDA-MB-435 cells and 12-fold decrease in inhibition of
microtubule depolymerization. The SAR study from methyl group incorporation thus suggested
that, methyl groups at only 5-position improves potency on the contrary methyl groups at both the
5- and 6-postion are detrimental for anti-tubulin activity.

Figure 112. in vivo study of 225 in mice: (A) Tumor volumes during the trial on treatment with
225 (10 mg/kg), Paclitaxel (PTX) and control, dosed i.p. Arrows indicate treatment days for
compound 7 and PTX (dosed days 1, 3, 5, 8, 10, 12). n = 7-10 tumors and data points represent
mean ± SEM. (B) Change in weight of the animal on treatment with 225 (10 mg/kg), Paclitaxel
(PTX) and control.
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One of the most active compound from the thieno[2,3-d]pyrimidine series (225) was
evaluated in vivo using MDA-MB-435 model (Figure 112). The MDA-MB-435 cells were
implanted subcutaneously into both flanks of nude mice. Mice were treated with MTD and
schedule using IP injections. Tumor volume was determined using tumor length, width, and height
measured with calipers. Two-way repeated measures ANOVA with post hoc testing was used to
analyze the datasets. Compared to paclitaxel, 225 showed a significant improvement in reduction
of tumor growth. It also showed a weight loss of only 5%. Further evaluation for this compound
in other preclinical models is underway.

(b) Activity as angiokinase inhibitors
Cells used were tumor cell lines naturally expressing high levels of VEGFR-2 (U251),
PDGFR-b (SF-539) and EGFR (A431).99 Expression levels at the RNA level were derived from
the NCI Developmental Therapeutics Program (NCI-DTP) web site describing molecular target
information. Briefly, cells at 60–75% confluence were placed in serum-free medium for 18 h to
reduce background phosphorylation. Cells were always >98% viable by trypan blue exclusion.
Cells were then pretreated for 60 min to obtain dose–response data, using concentrations of 1.4–
100 µM compound, followed in ⅓log increments by 100 ng/mL VEGF, PDGF-BB or EGF for 10
min. The reaction was stopped, and cells permeabilized by quickly removing the media from the
cells and adding ice-cold Tris-buffered saline (TBS) containing 0.05% Triton X-100, protease
inhibitor cocktail and tyrosine phosphatase inhibitor cocktail. The TBS solution was then removed
and cells fixed to the plate for 30 min at 60 ⁰C with a further incubation in 70% ethanol for 30
min. Cells were exposed to a blocking solution (TBS with 1% BSA) for 1 h, washed, and then a
horseradish peroxidase (HRP)-conjugated phosphotyrosine (PY) antibody was added overnight.
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The antibody was removed, and the cells were washed again in TBS, exposed to an enhanced
luminol ELISA substrate (Pierce Chemical EMD, Rockford, IL), and light emission was measured
using a UV Products (Upland, CA) BioChemi digital darkroom. Data were graphed as a percent
of cells receiving growth factor alone and IC50 values were determined from two to three separate
experiments (n = 8–24) using non-linear regression dose–response analysis with Prism 5.0
software (GraphPad, San Diego, CA). In each case, the activity of a positive control inhibitor did
not deviate more than 10% from the IC50 values listed in the table.
Table 38. Inhibition (IC50) of cellular VEGFR-2, EGFR and PDGFRβ- RTKs. (ND= not
determined)

EGFR (nM)

.

VEGFR-2 (nM) PDGFRβ (nM)

182

18.9±1.5

59.1±5.4

41.4±10.8

184

64.9±10.3

436.2±56.1

182.1±26.2

185

12.6 ± 1.2

25.2 ± 7.2

35.2 ± 5.8

189

28.8±4.1

52.2±5.4

25.6±4.6

196

50.2±6.8

188.4±26.9

185.6±32.0

199

30.3±5.1

79.4±2

186±22.2

205

30.9±5.1

41.8±21

23.4±2.6

225

81.2±10.2

416.5±38.0

140.1±18.9

226

111.0±17.5

1636.9±206.2

490.3±66.3

sunitinib

172.1 ± 19.4

18.9 ± 2.7

83.1 ± 10.1

erlotinib

1.2 ± 0.2

124.7±18.2

1.2 ± 0.2

The most active anti-tubulin compounds (Table 37) were evaluated for activity against
VEGFR-2 (U251), PDGFR-b (SF-539) and EGFR (A431) using cellular assays (Table 38). Since
only a few compounds were evaluated, a comprehensive SAR is not possible. The 2-CH 3 of 182
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displayed an increased the potency towards all the three kinases compared to 2-H compound (196).
Comparison of 182 vs. 196 suggests that methylation at the 5-position of the thieno[2,3d]pyrimidine scaffold increases potency for all the EGFR (by 3-fold), VEGFR-2 (by 3-fold) and
PDGFR-β (by 5-fold). It also corroborates with the results of molecular modeling studies carried
out for these compounds in the colchicine site of tubulin and ATP-binding sites of EGFR, VEGFR2 and PDGFR-β.

The trend of activity in inhibition of microtubule assembly and kinases at the 2-position
was: CH3>Cl>NH2. This could be due to an increase in cLogP (measure of lipophilicity) for
CH3>Cl>NH2, which enables a higher passive diffusion of compounds into cancer cells.
Compound 185 was active across all the three angiokinases and showed an excellent inhibition of
all the four targets (microtubule assembly, EGFR, VEGFR-s and PDGFR-β). Compound 185 was
comparable to erlotinib in inhibition of EGFR and 5-fold more potent VEGFR-2. Compound 185
was 14-and 2.5-fold more potent than sunitinib, in inhibition of EGFR and PDGFRβ, respectively.
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Figure 113: Effects of 185 versus gemcitabine on primary tumor growth and animal weight in the
BxPC-3 flank xenograft model. (A) BxPC-3 tumor bearing NCr nu/nu athymic mice were treated
IP with solvent (10% Kolliphor, 10% DMSO in normal saline) or with 185 (8 mg/kg, twice weekly)
or with gemcitabine (75 mg/kg, twice weekly) and primary tumor volumes assessed. Statistical
analysis was performed with two-way ANOVA and Dunnett’s multiple comparisons test. (B)
Animal weights were graphed as percent weight change at day 35 versus the starting weight.
Statistical analysis was performed with one-way ANOVA with Tukey’s multiple comparisons test.
n =8 (4 male; 4 female); ns = not significant, *P<0.05, ** P<0.01, ***P<0.001 ***P<0.001
****P<0.0001 versus solvent (or gemcitabine, if designated) group.
One of the best compounds 185 which showed activity in all four cell lines of tubulin,
EGFR, VEGFR-2 and PDGFR-β was further carried out to in vivo animal study (Figure 113).
Compound 185 inhibited tumor growth significantly compared to control- gemcitabine.
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A2. Biological evaluation of 2- and 4-substituted 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3d]pyrimidine activity as MTAs
Table 39. Effects in cellular assays and on purified tubulin for Series VIII and XI

R1

IC50 ± SD in MDA-435 EC50 for Microtubule
Cells (nM)
Depolymerization in A·10 Cells (nM)

234

CH3

53.0 ± 0.3

52

244

NH2

9.0 ± 0.2

19.0

247

H

36.8 ± 5.2

44.8

236

CH3

87.7 ± 4.7

157

245

NH2

38.6 ± 5.6

70.3

248

H

ND

Not MT active

238

CH3

125 ± 14

150

246

NH2

59.6 ± 11.8

121

239

CH3

81.3 ± 8.4

118

240

CH3

ND

Not MT active

3.4 ± 0.6

9.8

CA-4

Biological evaluation of 234, 236, 238, 239, 240, 244-248 enabled a SAR around 2- and
4-position of tricyclic thieno[2,3-d]pyrimidine scaffold. The trend observed at the 2-postion was:
NH2>H>CH3 for 234, 244, 247 and NH2>CH3 for rest of the compounds (Table 39). This suggests
that electron donating group at 2-position is conducive to the activity towards tubulin. In the
molecular modeling studied the electron donating group at 2-position is oriented towards the
solvent and polar residues. It could also indicates increase in inhibition of tubulin
depolymerization. Compared to bicyclic thieno[2,3-d]pyrimidine scaffold, the 2-NH2 showed an
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improved activity as MTA. This suggests that similar substitutions on different scaffolds can create
varying effects on the targets. It is not therefore advisable to postulate the effect of a substituent
form one scaffold to another. Varying the aryl group at the 4-position on the tricyclic thieno[2,3d]pyrimidine scaffold did not create a significant impact on the inhibition of tubulin assembly.

Figure 114. in vivo study of 244 in mice: (a) Tumor volumes during the trial on treatment with
244 (50 mg/kg), Paclitaxel (PTX) and control, dosed i.p. Arrows indicate treatment days for
compound 2 and PTX (dosed days 1, 3, 5, 8, 10, 12). n = 7-10 tumors and data points represent
mean ± SEM. (b) Change in weight of the animal on treatment with 244 (50 mg/kg), Paclitaxel
(PTX) and control.
Based on the solubility studies of the most active compounds from the thieno[2,3d]pyrimidine series, 244 was selected for evaluation in vivo using MDA-MB-435 model (Figure
114). The MDA-MB-435 cells were implanted subcutaneously into both flanks of nude mice. Mice
were treated with MTD and schedule using IP injections. Tumor volume was determined using
tumor length, width, and height measured with calipers. Two-way repeated measures ANOVA
with post hoc testing was used to analyze the datasets. Compared to paclitaxel, 244 showed a
295

significant improvement in reduction of tumor growth. It also showed a weight loss of less than
5%. Further evaluation for his compound in other preclinical models is underway.

A3.1 Biological evaluation of 2, 4- and 5-substituted pyrazolo[4,3-d]pyrimidines
Table 40. Effects in cellular assays and on purified tubulin for Series XII-XIV

R1

R2

Inhibition of colchicine binding

5 µM inhibitor
% inhibition ± SD

0.5 µM inhibitor%
inhibition ± SD

Inhibition of tubulin
assembly IC50 (µM ±
SD

251

CH3

CH3

94 ± 3

68 ± 3

0.45 ± 0.09

252

H

CH3

7.1± 3

-

>20

257

-

CH2CH3

99 ± 0.4

88 ± 0.007

0.42 ± 0.07

258

-

CH(CH3)2 85 ± 1

-

1.1 ± 0.08

253

-

-

94 ± 0.4

68 ± 2

0.42 ± 0.07

261

-

-

91 ± 1

66 ± 0.7

0.49 ± 0.01

262

-

-

93 ± 0.5

64 ± 2

0.82 ± 0.02

263

-

-

ND*

ND*

ND*
9.8

CA-4
ND*: Not determined

Biological evaluation of 251-253, 257-258, and 261-263 enabled a SAR around 4- position
of pyrazolo[4,3-d]pyrimidine scaffold (Table 40). Except for 252, all the compounds at 5 µM
inhibited [3H]colchicine binding to the protein, and the extent of inhibition was similar to that
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obtained with CA-4. With equal or more than 94% and 68% inhibition at 5 and 0.5 μM,
respectively, compounds 251, 253, 257 and 263 showed similar potency to the lead compounds
and CA-4 (Table 36). Homologation with a single methylene at 4’-position of 151 (4’-OMe)
afforded compound 257 (4’-OEt) which was more potent (99% at 5 μM and 88% at 0.5 μM) than
compound 251 and CA-4 in the colchicine binding inhibition assay. On the other hand, branching
with isopropyl moiety yielded compound 258 which was slightly less potent than 252, with 85%
inhibition occurring at 5 μM. Introduction of fluorine atom at 3’-position of the phenyl ring of 251
yielded compound 263, which had 97 and 77% inhibition at 5 and 0.5 μM, respectively, in
colchicine binding assay. In the colchicine inhibition assay, compounds 253, 261, 257-258, 262263 at 5 µM, inhibited the binding of [3H]colchicine by 85–99%. Compound 251 was completely
inactive in inhibiting the colchicine binding. Compound 251 lacking the N7-methyl moiety did not
inhibit tubulin assembly, emphasizing the essential role of this methyl moiety at N7-position in
retaining the bioactive conformation for the anti-tubulin activity.

Figure 115: In vivo data of 251 in mice
One of the best compound from pyazolo[4,3-d]pyrimidine was evaluated for in vivo
activities in mice (Figure 115). Treatment with compound 251 decreased primary tumor growth in
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MCF-7 TUBB3 (beta III tubulin overexpressing) breast cancer cell model. * = P<0.05; ***
P<0.001 (0.0007 for control vs 251, 0.0003 for PTX vs 251). A) 1x01exp7 cells/100 uL Matrigel
implanted into fat pad #4 of 8 weeks old athymic female mice were treated with compound 251
with MTD of 30 mg/kg two times weekly, or paclitaxel at its MTD of 10 mg/kg/week and tumor
volumes were determined. Statistical analysis was performed with two-way ANOVA repeated
measures post test. Compound 251 is significantly (P<0.0001) better than paclitaxel at reducing
MCF-7 TUBB3 (beta III tubulin overexpressing). B) Animal weights were graphed as percent
weight change at day 41 over the starting weight. Statistical analysis was performed with one-way
ANOVA.
Only the control and paclitaxel mice lost weight at the end. Sample sizes are 7 for control
(lost an animal in each group toward the end) and 8 for PTX and 251. Compound 251 was selected
for an in vivo xenograft mouse study considering its nanomolar potency in vitro in the NCI cancer
cell line panel and its potent activities in inhibiting microtubule polymerization and colchicine
binding assay.

A3.2 Evaluation as pan assay interference compounds (PAINS) of 2, 4- and 5-substituted
pyrazolo[4,3-d]pyrimidines
PAINs produce often unknowingly false positives that could be a challenge in drug
discovery research.429, 430 As a result, we have carried out an analysis of PAINS and the compounds
library was submitted to https://www.cbligand.org/PAINS430 to filter out structures (molecular
weight 290-354 Da). All fragments were classified as "Accepted" due to no structural alerts and
passing through the filter. All the tested compounds showed zero PAINS alert and can be used as
drug compounds in the future. Theses chemical compounds will give less false positive results in
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high-throughput screens.430 There will be more specific binding with one desired target rather than
nonspecific binding with numerous biological targets. 431 Their identification will be helpful in
implementing the pyrazole sub structure as an important step toward the identification of future
drug candidates.

Figure 116: Pan Assay Interference Compounds (PAINS) results of compounds 251-253, 257258 and 261-263.

B. Biological evaluation of Selective pjDHFR inhibitors
All the proposed compounds were evaluated as inhibitors of recombinant pjDHFR and
recombinant hDHFR.1 Selectivity ratios were determined using recombinant hDHFR as a
mammalian DHFR. TMP and PTX were used as positive controls in the assays. 2
Assays to assess inhibitory concentrations (IC50, in nM) against recombinant DHFR from
P. jirovecii (pj) and human (h) were carried out at 37 °C under 9 µM dihydrofolic acid
concentration.2 The assay also contains 117 µM NADPH, 8.9 mM 2mercaptoethanol, 150 mM
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KCl, 41 mM Na phosphate buffer pH 7.4 and sufficient enzyme to cause a change in OD340 of
0.005/minute. The standard error of the mean for these values is 12% or less than the mean value.
The biological evaluations were performed by Dr. Sherry Queener (Indiana University
School of Medicine, Indianapolis, IN 46202), Dr. Vivian Cody (Department of Structural Biology,
Structural Biology Department, School of Medicine and Biomedical Science, Buffalo, NY 14203),
Dr. Melanie Cushion (Infectious Diseases, Department of Internal Medicine, University of
Cincinnati College of Medicine, Cincinnati, Ohio 45267 and The Cincinnati Veterans Medical
Center, Cincinnati, OH) and Dr. David Seybert (Chemistry and Biochemistry, Bayer School of
Natural and Environmental Sciences, Duquesne University, Pittsburgh PA 15282).

B1. Biological evaluation of 6-(arylthio)pyrido[2,3-d]pyrimidine-2,4-diamines as selective
pjDHFR inhibitors
Table 41 displays the IC50 of compounds 265, 267-269 and 282-289 for pjDHFR and
hDHFR. The 6-(arylthio)pyrido[3,2-d]pyrimidines 282 and 284 showed a 88- and 250-fold
improvement in selectivity than the 6- amine linked compounds 265 and 267, respectively. The
sulfur linked analogs showed a single digit nanomolar and picomolar potency for pjDHFR.
Replacement of -NH- of 269 with -S- in 289 improved potency for pjDHFR by 800-fold selectivity
ratio for pjDHFR by 28-fold. TMP is widely used because of its exceptional selectivity ratio for
pjDHFR but has a low potency for pjDHFR. Compounds with picomolar potency for pjDHFR
have not been reported in the literature, in our opinion. All the compounds tested in this series so
far have a single digit nM or a pM IC50 for pjDHFR.
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Table 41. Inhibition Concentrations (IC50) against pjDHFR and hDHFR and Selectivity Ratios for
Series XV-XVII

R

pjDHFR
(nM)

hDHFR
(nM)

Selectivity
[hDHFR/pjDHFR]

265

H

300

190

1

267

4ˊ-OCH3

400

3650

9

268

2ˊ,3ˊ-(CH)4

250

2100

8

269

3ˊ,4ˊ-(CH)4

400

2200

5

282

H

29

475

88

283

3ˊ-OCH3

12.2

335

4090

284

4ˊ-OCH3

7.5

17.4 µM

2320

285

3ˊ,4ˊ-OCH3

2.0

226

113

286

4ˊ-F

7.5

817

109

287

4ˊ-OCF3

30

2490

83

288

2ˊ,3ˊ-(CH)4

2.5

27

10.8

289

3ˊ,4ˊ-(CH)4

0.5

70

140

TMP

92

24500

266

PTX

41

2

0.05

#

301

Ratios

A

B

Figure 83: A. Docked pose of 289 (green) in the crystal structure of hDHFR (PDB: 4QJC, 1.62
Å). 83B. Docked pose of 289 (green) in the homology model of pjDHFR.

Table 42. Bond angles and bond distance for C-X-C angle and C-X bond measured with
Schrödinger Maestro.156

3

N

C-X bond distance
NH 2 5
4
6 X

2

H2 N

N
1

N

7

8 C-X-C bond angles

Entry

X

C-X Bond distance (Å)

C-X-C Bond angle (⁰)

269

NH

1.46

120

289

S

1.78

94.1

This gain in selectivity ratio in -S-linked compounds 282-289 could be explained by
studying the active sites of hDHFR and pjDHFR. The binding site where the side chain aryl group
binds contains the Met33 in pjDHFR and the Phe31 in hDHFR. The Met33/Phe31 in
pjDHFR/hDHFR can affect binding due to their distinct steric and electronic effects. Compared to
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the lead compound 269, sulfur linked analog 289 could change the bond angle, distance (Table 42)
and electronics of the naphthyl group and cause a clash with Phe31 in hDHFR, whereas
appropriately fit with Met33 in pjDHFR (Figure 83). The increased C-S bond length and reduced
C-S-C bond angle poses an increase in probability of a clash between the side chain aryl ring and
the Phe31 in hDHFR, and thus decrease binding of such compounds with hDHFR. Such a clash is
avoided in binding of 6-substituted sulfur linked pyrido[2,3-d]pyrimidines to pjDHFR active site
due to the flexible nature of the Met33 side chain.

DHFR inhibitory assays134 (performed by David W. Seybert):
For analysis of inhibitor susceptibility, DHFR was assayed using a continuous
spectrophotometric assay. The assay contains a final concentration of 9 µM dihydrofolic acid, 117
µM NADPH, and 6–8 IU of enzyme activity (1 IU D0.005 optical density units/min). The reaction
is incubated at 37 °C and change in absorbance at 340 nM, which is related to oxidation of
NADPH, is measured over 3 min. The assay under standard conditions is linear over this time span
and linear with protein concentration. KCl 150 mM is included in assays of mammalian DHFR.
The standard error of the means for these values are 12% or less than the mean value.

C. Folate receptors (FRs) and/or Proton-Coupled Folate Transporter (PCFT) targeted
(cytosolic and/or mitochondrial) one carbon (1C) metabolism inhibitors
C1. N1-substituted 5-amino-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-ones
The pyrazolo[4,3-d]pyrimidine compounds 297-298 were designed based on 5-substituted
pyrrolo[3,2-d]pyrimidines 294-295 (Table 43). The synthesized analog 298 showed a considerable
potency in FRα and FRβ assays. One of the aims for this study was to obtain compounds with
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selective uptake through FRα and FRβ, compared to RFC. Compounds 298 shows a favorable
uptake though both the FRs. For 298, no RFC uptake is observed, suggesting that the selectivity
of transport through FRα and FRβ. Hence, we have been able to incorporate selectivity for FRα
and FRβ by performing as scaffold-hopping from the pyrrolo[3,2-d]pyrimidines 295 to pyrazo[4,3d]pyrimidine 298. This compound displays can be served as a future lead candidate in designing
compounds with the novel scaffold with pyrazolo[4,3-d]pyrimidine.
Table 43. IC50s (in nM) in RFC-, PCFT- and FR-expressing cell lines and KB human tumor
cells (express RFC, FRα, and PCFT) for Series XVIII

hRFC

hFRα

hFRβ

hPCFT

hRFC/ hFRα/hPCFT

PC43-10

R2

RT16

D4

R2/hPCFT4

KB

294

43

>1000

50

1.59

25.2

6.7

295

516

>1000

2.13

1.29

309

6.8

297

ND

ND

ND

ND

ND

ND

298

>1000

>1000

6.46

5.91

>1000

42.48

894(93) 138(13)

42(9)

60(8)

13.2(2.4)

68 (12)

PMX

304

364

Relative Growth

150

100

50

Figure 117. Cell proliferation assays in MIA-PaCa-2 cells to identify intracellular targets of 298.
The intracellular targets for 294 and 295 were GARFTase and AICARFTase. To
investigate the

intracellular targets of 298, the compound was subjected to growth inhibition

studies of KB cells along with protection by excess folic acid, AICA, adenine and thymidine. To
identify the targeted pathways and the folate-dependent intracellular enzymes in KB cells treated
with 298 (1−1000 nM), cell proliferation assays were performed in the presence of 10 μM
thymidine, 60 μM adenosine, or 320 μM AICA. The results were normalized to those for untreated
cells (no drug) and for 298. The results shown are representative of triplicate experiments (Figure
117). From the protection studies performed, the inhibition of proliferation of KB cells was not
protected by thymidine suggesting it is not a TS inhibitor. The inhibition of proliferation of KB
cells was not protected by AICA alone; suggesting it is might be GARFTase inhibitor, along with
another intracellular target. The inhibition of proliferation of KB cells was protected by adenosine
at low concentrations (up to 10 nM), suggesting it could be GARFTase and/or AICARFTase
inhibitor at that low concentration. At higher concentrations (> 31.6 nM), the inhibition of
proliferation of KB cells was not protected by adenosine, suggesting that there is (are) additional
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intracellular target(s) that the compounds bind and inhibit. Further studies to investigate the
possible targets are underway.
C2. N2-substituted 5-amino-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-ones
Table 44. IC50s (in nM) in RFC-, PCFT- and FR-expressing cell lines and KB human tumor cells
(express RFC, FRα, and PCFT) for Series XIX.

hRFC

hFRα

hFRβ

hPCFT

hRFC/FRα/hPCFT

PC43-10

R2

RT16

D4

R2/hPCFT4

KB

299

649(38)

6.3(1.6)

5.6(1.2)

23.0(3.3)

141 ± 40

1.7(0.4)

300

>1000

6.3(1.6)

10(2)

213(28)

57.4 ± 21.4

1.9(0.7)

301

ND

ND

ND

ND

ND

ND

302

>1000

>1000

1.63

7.83

>1000

>1000

PMX

894(93)

138(13)

42(9)

60(8)

13.2(2.4)

68 (12)

The pyrazolo[4,3-d]pyrimidine compounds 301-302 with N2-side chain substitutions were
designed by scaffold hopping from 6-substituted pyrrolo[2,3-d]pyrimidine counterparts 299-300.
Compared to their pyrrolo[2,3-d]pyrimidine analog 300, the synthesized analog 302 improve
binding to 6- and 27-fold in FRα and Frβ, respectively (Table 44). They also have a decreased
uptake through RFC and PCFT, compared to the lead compounds 300. Except for loss in PCFT
activity of 302, this compound display the desired improvement in antiproliferative activity and
transporter selectivity through Frα and Frβ. To study the intracellular targets, detailed protection
studies of all the synthesized compounds are currently underway.
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C3. Evaluation as pan assay interference compounds (PAINS) of N1-substituted 5-amino1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-ones and N2-substituted 5-amino-2,6-dihydro7H-pyrazolo[4,3-d]pyrimidin-7-ones
The compounds library was submitted to https://www.cbligand.org/PAINS430 to filter out
structures (molecular weight 442-456 Da). All fragments were classified as "Accepted" due to no
structural alerts and passing through the filter. All the tested compounds showed zero PAINS alert
and can be used as drug compounds in the future. Theses chemical compounds will give less false
positive results in high-throughput screens.430 There will be more specific binding with one desired
target rather than nonspecific binding with numerous biological targets. 431 Their identification will
be helpful in implementing the pyrazole sub structure as an important step toward the identification
of future drug candidates.

Figure 118. Pan Assay Interference Compounds (PAINS) results of compounds 297-298 and 301302.
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C4. 6-substituted 2-amino-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-ones
Table 45. IC50s (in nM) in RFC-, PCFT- and FR-expressing cell lines and KB human tumor cells
(express RFC, FRα, and PCFT) for Series XX.

hRFC

hFRα

hFRβ

hPCFT

hRFC/FRα/hPCFT

PC43-10

R2

RT16

D4

R2/hPCFT4

KB

300

>1000

>1000

6.3(1.6)

10(2)

213(28)

1.9(0.7)

303

>1000

>1000

4.6 (1.3)

5.6(1.4)

>1000

2.5(0.64)

304

>1000

>1000

0.58(0.12) 1.6(0.44)

23(2)

0.59

305

>1000

>1000

1.92

2.73

>1000

4.08

PMX

894(93)

138(13)

42(9)

60(8)

13.2(2.4)

68 (12)

The pyrrolo[2,3-d]pyrimidine compounds 305 with 6-substitutions was designed as analog
of 303 and 305. Based on the biological evaluations of 300 and 303-304 (Table 45), compound
305 was designed to evaluate and compare the effects of replacing the benzylic 11-CH2 of 304
with an oxygen to compare its effects towards improving selectivity in FRα, FRβ and PCFT over
RFC. Compared to lead pyrrolo[2,3-d]pyrimidine analog 303, the synthesized analog 305 improve
binding to FRα and Frβ by 2.5- and 2-fold, respectively (Table 41). Compound 305 had a decreased
uptake through PCFT, compared to the lead compounds 303. Except for loss in PCFT activity of
305, this compound display the desired improvement in antiproliferative activity and transporter
selectivity through Frα and Frβ. To study the intracellular targets, detailed protection studies of all
the synthesized compounds are currently underway.
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Cell lines and assays of antitumor drug activities:190 The engineered CHO sublines including
RFC-, PCFT- and FRα-null MTXRIIOuaR2-4 (R2), and RFC- (pC43-10), PCFT- (R2/PCFT4), or
FRα- (RT16) and FRβ- (D4) expressing CHO sublines were previously described. The CHO cells
were cultured in α-minimal essential medium
(MEM) supplemented with 10% bovine calf serum (Invitrogen, Carlsbad, CA), penicillin
(1000 U/mL) streptomycin (1000 μg/mL) and 2 mM L-glutamine at 37° C with 5% CO 2.
All the R2 transfected cells (PC43-10, RT16, R2/hPCFT4) were cultured in complete αMEM
media plus 1 mg/mL G418. Prior to the cytotoxicity assays (see below), RT16 and D4 cells were
cultured for 3 days in complete folate free RPMI 1640 (without added folate), plus dialyzed fetal
bovine serum (FBS) (Sigma-Aldrich) and penicillin/streptomycin. KB human nasopharengeal
carcinoma cells were purchased from the American Type Culture Collection (Manassas, VA). KB
cells were routinely cultured in folate-free RPMI 1640 medium, supplemented with 10% FBS
(Sigma-Aldrich), penicillin-streptomycin solution, and 2 mM L-glutamine. For growth inhibition
studies, cells (CHO, KB) were plated in 96 well dishes (~2500-5000 cells/well; total volume of
200 μl medium) with a range of antifolate concentrations (0-1000 nM). The experiments with
RT16, D4, and KB cells used folate-free RPMI medium with 10% dialyzed FBS (Sigma-Aldrich),
antibiotics and L-glutamine; the medium was supplemented with 2 nM LCV. To confirm FRmediated drug uptake, 200 nM folic acid was added to parallel incubations. For experiments with
R2, PC43-10, and R2/PCFT4 cells, cells were routinely cultured in folate free RPMI 1640 (pH
7.2)/10% dialyzed FBS with antibiotics and L-glutamine, supplemented with 25 nM LCV. Cells
were incubated up to 96 h and viable cells were assayed with Cell-Titer BlueTM reagent (Promega,
Madison, WI), with fluorescence measured with a fluorescence plate reader. Fluorescence data
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were analyzed for calculations of IC50s, corresponding to the drug concentrations that resulted in
50% loss of cell proliferation.

FR binding assay:190 To measure relative binding affinities for antifolate drugs, RT16 (expresses
FRα) and D4 (FRβ) CHO cells were cultured in 60 mm dishes until they were ~80% confluent.
Cells (2-4 x 106 cells) were sequentially rinsed at 4 ⁰C with Dulbecco’s phosphate buffered saline
(DPBS) (3x), followed by acidic buffer (10 mM sodium acetate, 150 mM NaCl, pH 3.5) (2x)
(removes FR-bound folates), and finally HEPES-buffered saline (20 mM HEPES, 140 mM NaCl,
5 mM KCl, 2 mM MgCl2, 5 mM glucose, pH 7.4) (HBS). Cells were incubated with [ 3H]folic acid
(50 nM, specific activity 0.5 Ci/mmol) in HBS in the presence and absence of unlabeled folic acid,
MTX (negative control), or the synthesized antifolates (range of concentrations up to 1000 nM)
for 15 min at 0 ⁰C. Dishes were rinsed with HBS (0-4 ⁰C, 3x). Cells were solubilized with 0.5 N
NaOH, and aliquots were measured for radioactivity and protein contents. Protein concentrations
were quantified with Folin-phenol reagent. FR-bound [ 3H]folic acid was calculated as pmol/mg
protein and binding affinities were calculated as the inverse molar ratios of unlabeled ligands
required to inhibit [3H]folic acid binding by 50%. The relative affinity of folic acid was assigned
a value of 1.
Transport assays:190 R2 and R2/hPCFT4 CHO sublines were grown in suspension as spinner
cultures at densities of 2-5 x 105 cells/mL. Cells were collected by centrifugation, washed with
DPBS, and the cell pellets (~2 x 107 cells) were suspended in transport buffer (2 mL) for cellular
uptake assays. PCFT-dependent uptake of 0.5 µM [ 3H]MTX was assayed in cell suspensions over
2 min at 37° C in HBS at pH 6.8, or in 4morpholinopropane sulfonic (MES)-buffered saline (20
mM MES, 140 mM NaCl, 5 mM KCl, 2 mM MgCl 2, and 5 mM glucose) at pH 5.5 in the presence
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of 1 or 10 µM inhibitor. At the end of the incubations, transport was quenched with ice cold DPBS,
cells were washed three times with ice-cold DPBS, and cellular proteins were solubilized with 0.5
N NaOH. Levels of drug uptake were expressed as pmol/mg protein, calculated from direct
measurements of radioactivity and protein contents of the cell homogenates. Proteins were
quantified using Folin-phenol reagent. Transport results were normalized to levels in untreated
controls. Data were analyzed by Dixon plots.
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